



## STATISTICAL REPORT

**TITLE:** A prospective, multi-centre, controlled, double-blind study to evaluate the efficacy and tolerability of a steroid/antibiotic associated treatment following cataract extraction by means of phaco-emulsification

**PROTOCOL NUMBER:** 044-SI Version No

Approval date

**BIOSTATISTICIAN:** Mauro Montanari

**SPONSOR:** Study Sponsor:  
S.I.F.I. S.p.A  
Via Ercole Patti, 36  
95025 Lavinaio – Aci S. Antonio (CT) – Italy

**CRO:** Sintesi Research srl  
Via M. Bandello, 6- 20141 Milano (Italy)  
Contact Person: Paolo De Simoni

**DOCUMENT VERSION** Final No. 1

**DATE:** 29 July 2019

	Date	SignatureFirma
Mauro Montanari	29/07/2019	

## Table of contents

Table of contents .....	2
1. Study objective.....	3
2. Study endpoint .....	3
2.1 Primary endpoint.....	3
2.2 Secondary endpoints .....	3
3. Software .....	3
5. Statistical Methods .....	4
5.1 General principles .....	4
5.2 Sample Size Calculation .....	5
5.3 Handling of Missing Values .....	5
5.4 Schedule of assessment.....	5
5.5 Definition of Sets for Statistical Analysis.....	5
6. Description of analyses .....	5
6.1 Overall disposition .....	5
6.2 Sample profile at screening.....	5
6.3 Evaluations at surgery.....	6
6.4 Efficacy evaluation after surgery .....	6
6.5 Concomitant medications.....	6
6.6 Safety evaluation.....	7
7. Results.....	7
7.1 Disposition of the sample.....	7
7.2 Protocol violation.....	8
7.3 Population sets analyzed .....	8
7.4 Comparability between the two treatment groups .....	8
7.5 Baseline characteristics .....	8
7.6 Evaluation at surgery .....	9
7.7 Efficacy evaluation after surgery .....	10
7.7.1 Primary endpoint.....	10
7.7.2 Secondary endpoints .....	12

## **1. Study objective**

The objective of this study is to demonstrate the efficacy and tolerability of NETILDEX™ 3mg/ml / 1mg/ml ophthalmic gel, administered twice daily (b.i.d.), in comparison with NETILDEX™ 3mg/ml / 1mg/ml eye drops solution, administered four times a day (q.i.d.) in the prevention of post-surgery inflammation and infection after cataract extraction by means of phaco-emulsification.

## **2. Study endpoint**

### **2.1 Primary endpoint**

The primary objective of this study is to demonstrate the noninferiority of a reduced frequency of administration of Netildex gel, administered twice daily (b.i.d.), in comparison with Netildex drops solution, administered four times a day (q.i.d.), in the prevention of post-surgery inflammation and infection after cataract extraction.

For this evaluation has been adopted the responder rate (for the definition of responder see paragraph 6.4) measured in the comparison between the inflammation status 24 hours after surgery (Visit 3) and inflammation status after seven days (Visit 4).

### **2.2 Secondary endpoints**

Secondary objectives of this study are:

- to confirm the antibiotic efficacy of Netildex gel after 15 days from cataract surgery (Visit 5);
- to confirm the safety of Netildex gel in terms of:
  - Intra Ocular Pressure (IOP);
  - adverse events;
  - presence or absence of conjunctival hyperemia;
- to establish the global tolerability of Netildex gel.

## **3. Software**

Statistical calculations will be performed using SAS System, release 9.4 in Microsoft Windows 10 Pro environment. The SAS library engine is the release V9.

## **4. Data management**

The clinical data have been provided after database lock in native format SAS (sas7bdat).

To be analyzed, original datasets have been converted to derived datasets and all categorical fields formatted. In the table of the next page, the original datasets and correspondent description are reported.

*Exhibit 1: Listing of source datasets exported from SAS PheedIt database*

#	Name source dataset	Description
1	AE	Adverse event
2	AE_COD	Adverse event (medical codes)
3	AE_YN	Adverse event (n/y)
4	AMSLER	Amsler test
5	ANTI_AFTER	Antibiotics after surgery
6	ANTI_AFTER_COD	Antibiotics after surgery (medical codes)
7	ANTI_AFTER_YN	Antibiotics after surgery (n/y)
8	ANTI_BEFORE	Antibiotics before surgery
9	ANTI_BEFORE_COD	Antibiotics before surgery (medical codes)
10	ANTI_BEFORE_YN	Antibiotics before surgery (n/y)
11	ANTIBIOGRAM	Microbial load
12	BROM_TRT	Bromfenac treatment during the 3 days before surgery
13	CMED	Concomitant medications
14	CMED_COD	Concomitant medications (medical codes)
15	CMED_YN	Concomitant medications (n/y)
16	DEMOGRAPHY	Demography, Informed consent
17	EOS	End of study
18	EXCLUSION	Exclusion criteria
19	INCLUSION	Inclusion criteria
20	INTRA_PRES	Intra ocular pressure
21	MEDHIS	General medical history
22	MEDHIS_COD	General medical history (medical codes)
23	MEDHIS_YN	General medical history (n/y)
24	MICRO_LOAD	Microbial load
25	MYDIATIC_COD	Mydiatric drugs during the study (medical codes)
26	MYDIATIC	Mydiatric drugs during the study
27	MYDIATIC_YN	Mydiatric drugs during the study (n/y)
28	OCT	Optical Coherence Tomography test
29	OCULAR_INFLA	Evaluation of signs/symptoms of ocular inflammation
30	OPHHIS	Ophtalmic medical history
31	OPHHIS_COD	Ophtalmic medical history (medical codes)
32	OPHHIS_YN	Ophtalmic medical history (n/y)
33	OPHTHALMOSCOPY	Ophtalmoscopy test
34	PREGNANCY	Pregnancy test
35	RAND	Randomization
36	SLIT	SLIT lamp examination
37	SURGERY	Cataract surgery
38	TOLERABILITY	Evaluation of global tolerability by investigator
39	TREATMENT	Study treatment after surgery
40	UNS_REAS	Reason for unscheduled visit
41	VISIT	Date of visit
42	VISUAL_CONTROL	Visual acuity at control visits
43	VISUAL_SCREEN	Visual acuity at the screening visit

## 5. Statistical Methods

Planned analyses for this study have been outlined in the Statistical Analysis Plan (SAP).

### 5.1 General principles

All the variables collected have been summarized by appropriate descriptive statistics: mean, standard deviation, median, minimum and maximum for continuous variables; frequency and per cent values for categorical variables.

The primary objective has been evaluated in the Intention-To-Treat (ITT) population and one-tailed alpha level of 0.025 has been used for the statistical test.

## 5.2 Sample Size Calculation

Considering a true difference in the evaluation of the responder rate in favour of the reference treatment of 5%, then 130 Patients are required to be 90% sure that the lower limit of a one-sided 97.5% Confidence Interval will exclude a difference in favour of the reference group of more than 10%. Considering a drop-out rate of 28%, the global sample size will be at least of 180 subjects.

## 5.3 Handling of Missing Values

No missing data imputations techniques have been used.

## 5.4 Schedule of assessment

The study assessments and data collection have been performed at the following visits:

1. visit 1 (day -4/-7, before cataract surgery) - screening
2. visit 2 (day 0) - surgery
3. visit 3 (day 1) - control 1
4. visit 4 (day 7±1) - control 2
5. visit 5 (day 15±2) - end of treatment

## 5.5 Definition of Sets for Statistical Analysis

### *Intent-To-Treat (ITT) analysis population*

The Intent-To-Treat (ITT) analysis population is intended as the set of Patients who received the dose of study treatment and presence of SLIT lamp examination at baseline Visit 3 (day 1) and endpoint Visit 4 (day 7). This population is considered as primary and will be used for all efficacy analyses.

### *Per-Protocol (PP) analysis population*

The Per-Protocol (PP) population will include all ITT patients who completed regularly the study with no major violations of the eligibility criteria or during study conduction. This population will be used as a sensitivity analysis for the comparison of the results respect to the ITT analysis limited to the primary endpoint.

### *Safety Analysis Population*

The Safety Analysis Population will include all Patients registered, who received at least one dose of study treatment. This population will be used for safety analysis. Patients will be analysed according to the treatment to which they were randomised.

## 6. Description of analyses

### 6.1 Overall disposition

Descriptive tables for:

- patient accountability (treated, completers, withdrawn);
- protocol violations;
- sample disposition;
- patient stratification by Age and Sex;
- time intervals.

### 6.2 Sample profile at the screening

Descriptive assessment of:

- demography (sex, age, race);
- baseline clinical tests (IOP, SLIT lamp, Ophtalmoscopy test);
- medical and ophtalmoscopy history;
- use of antibiotics before surgery.

### 6.3 Evaluations at the surgery

Descriptive tables for:

- use of Bromfenac medication;
- sterilization;
- surgery problems;
- mydiatric and antibiotic medications.

### 6.4 Efficacy evaluation after surgery

As previously defined (see paragraph 2.1) the primary objective of this study is to demonstrate the noninferiority of the Netildex gel in comparison with Netildex drops solution.

The efficacy parameter utilized has been the combination of two clinical parameters, *Flare* and *Cellularity* after 24 hours (Visit 3) and after 7 days (Visit 4) from cataract extraction, examined with slit lamp and bio-microscopy in the anterior ocular chamber.

In relation to the above mentioned variables, a patient has been defined:

- ✓ *Full responder*: if both measurements are responder;
- ✓ *Partial responder*: if responder at least for one of the two measurements;
- ✓ *No responder*: if both measurements are not responder.

The above classification has been used for the descriptive analyses while it has been reduced to the binary outcome (*Full responder* vs *Not Full responder*) for inferential analysis.

The hypotheses for noninferiority has been stated in terms of the difference in the proportions  $D = p_{test} - p_{ctrl}$  where *test* is Netildex gel and *ctrl* is Netildex drops solution.

The null and alternative hypotheses are the following:

$$H_0: D = p_{test} - p_{ctrl} \leq -\delta$$

$$H_A: D = p_{test} - p_{ctrl} > -\delta$$

where  $\delta > 0$  is the noninferiority margin of clinical interest.

A noninferiority analysis to obtain the difference in the proportion planned has been performed using the Proc Freq in SAS v. 9.4, with one-sided 97.5% Confidence Intervals and noninferiority margin of 0.10.

A Logistic Regression analysis has been done to compare the treatment effects adjusted for the variables SEX and AGE (potential confounders).

The following descriptive tables, and inference, when planned, have been performed for:

- SLIT lamp
- overall and stratified (by sex, age and site) responder rate at endpoint visit;
- Flare;
- Cellularity;
- Flare for the sub-group of patients showing a grade greater than zero at Visit 3 (day 1);
- Cellularity for the sub-group of patients showing a grade greater than zero at Visit 3 (day 1);
- Microbial load.

### 6.5 Concomitant medications

Descriptive assessment has been prepared for concurrent medications.

## 6.6 Safety evaluation

Descriptive tables of point estimation and change from Visit 1 or Visit 3, if pertinent, for:

- IOP for treated and not-treated eye;
- IOP difference between treated and not-treated eye;
- ophthalmoscopy test;
- visual acuity;
- ocular inflammation;
- global tolerability;
- AE, drug related AE and AE requiring study discontinuation.

## 7. Results

It was screened a sample of 176 patients in 5 centres located in Italy (3 centres) and Germany (2 centres). The patients 100103, 100240 and 200201 were considered as screening failure and received no study drug. The patients 100308, 100313, 100337, randomized in the GEL group, and the patients 100306 and 200114, randomized in the DROP group, have not been treated and not considered in this analysis.

The total number of patients remaining was 168, 85 for the GEL group and 83 for the DROP group. Only two patients presented protocol violations and excluded from the Per-Protocol analyses: 100302 (GEL group) for violation of exclusion criteria 5 (suffering of type 2 Diabetes Mellitus) 100348 (GEL group) for violation of inclusion criteria 2 (age < 40 years)

### 7.1 Disposition of the sample

The percentage of premature discontinued patients was 4.2% (5.9% for GEL group and 2.4% for DROP group) where the main reason was *Withdrawal of consent* with 71.4% on total discontinued patients (80.0% for GEL group and 50.0% for DROP group).

Table 7.1-1: Subjects disposition

	GEL (N=85)		DROP (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Randomized	85	100.0	83	100.0	168	100.0
Completed study	80	94.1	81	97.6	161	95.8
Discontinued	5	5.9	2	2.4	7	4.2
Main reason for study discontinuation - (n %)						
Withdrawal of consent/Patient choice	4	80.0	1	50.0	5	71.4
Adverse event	1	20.0	1	50.0	2	28.6
Major complications during cataract surgery	0	0.0	0	0.0	0	0.0
Lack of efficacy	0	0.0	0	0.0	0	0.0
Protocol violation, including disallowed conc	0	0.0	0	0.0	0	0.0
Investigator considers it not in the patient'	0	0.0	0	0.0	0	0.0
Sponsor terminates the study	0	0.0	0	0.0	0	0.0
Total	5	100.0	2	100.0	7	100.0

Source table(s): 1.2

## 7.2 Protocol violation

Only two patients (1.5% on total), both belonging to GEL group, were classified as violators. See the listing below.

Table 7.2-1: Protocol violation patients

Age			
Pat.ID	(yrs)	Sex	Violation reported on database
100302	61	male	Patient suffering of type 2 Diabetes Mellitus (exclusion criteria 5)
100348	38	female	Patient age < 40 years old (inclusion criteria 2)

Source table(s): 1.3

## 7.3 Population sets analyzed

The two treatment groups are well balanced, see Table 7.3-1. The listing of not-regular patients is depicted in Appendix 1 on page 11.

Table 7.3-1: Summary of patient sets disposition

	GEL (N=88)		DROP (N=85)		ALL (N=173)	
	n	%	n	%	n	%
No. of patients						
Screened					176	100.0
Screening failure					3	1.7
Randomized	88	100.0	85	100.0	173	100.0
Non treated patients	3	3.4	2	2.4	5	2.9
Treated patients	85	96.6	83	97.6	168	97.1
Treated patients	85	100.0	83	100.0	168	100.0
Safety population	85	100.0	83	100.0	168	100.0
ITT population	80	94.1	80	96.4	160	95.2
PP population	78	91.8	80	96.4	158	64.0

Source table(s): 1.4

See Table 1.5 of Appendix 1 for the sample disposition when stratified by Sex and Age.

## 7.4 Comparability between the two treatment groups

The two groups do not show significant differences.

## 7.5 Baseline characteristics

A preponderance of females (62.5% on total) but not statistically significative.  
See Table 7.5-1 on the next page.



Table 7.5-1: Demographic characteristics

Variable	GEL (N=85)		DROP (N=83)		ALL (N=168)		Difference between study drugs	95% CI of difference	
	n	%	n	%	n	%			
Age (years)							-0.9931	-3.6090	1.6229
N	85		83		168				
Mean	72.2		73.2		72.7				
SD	8.8		8.3		8.6				
Median	74.0		74.0		74.0				
Range	38.0	89.0	48.0	89.0	38.0	89.0			
Age frequency - (n %)									
<=65	16	18.8	15	18.1	31	18.5			
66-74	37	43.5	28	33.7	65	38.7			
>=75	32	37.6	40	48.2	72	42.9			
Total	85	100.0	83	100.0	168	100.0			
Sex - (n %)							12.2000	-2.3100	26.7200
Male	37	43.5	26	31.3	63	37.5			
Female	48	56.5	57	68.7	105	62.5			
Total	85	100.0	83	100.0	168	100.0			
Race - (n %)									
White	84	98.8	81	97.6	165	98.2			
Black	1	1.2	2	2.4	3	1.8			
Asian	0	0.0	0	0.0	0	0.0			
Middle-eastern	0	0.0	0	0.0	0	0.0			
Other	0	0.0	0	0.0	0	0.0			
Total	85	100.0	83	100.0	168	100.0			

Source table(s): 2.1

All the patients performed AMSLER and OCT test, with negative results. No significant difference between groups about the variables Visual acuity, IOP and SLIT lamp.  
See Table 2.2 of Appendix 1.

No relevant abnormalities percentages for the variable Ophtalmoscopy test were noted, only 2.4% for Retina and 1.8% for Choroid of the whole sample, showed an abnormality.  
See Table 2.3 of Appendix 1.

About 71.4% of the total of the sample (69.4% for GEL group and 73.5% for DROP group) showed a relevant Medical history.  
See Table 2.4 of Appendix 1.

About 20.8% of the total of the sample (21.2% for GEL group and 20.5% for DROP group) showed a relevant Ophtalmoscopy history.  
See Table 2.5 of Appendix 1.

About 55.4% of the total of the sample (54.1% for GEL group and 56.6% for DROP group) have assumed antibiotic medications before surgery.  
See Table 2.6 of Appendix 1.

## 7.6 Evaluation at the surgery

The whole sample, except one patient, have assumed Bromfenac medication before surgery.  
See Table 3.1 of Appendix 1.

No problem during surgery has been reported.  
See Table 3.2 of Appendix 1.

About 98.8% of the total of the sample (97.6% for GEL group and 100.0% for DROP group) have assumed mydiatric medication at the surgery, and about 24.4% (22.4% for GEL group and 26.5% for DROP group) have assumed antibiotic medications after surgery.  
See Table 3.3-1 of Appendix 1.

Regarding the evaluation of ocular inflammation at the surgery, we can see that the two treatment groups are similar. See table 7.6-1 below.

Table 7.6-1: Ocular inflammation at the surgery

Variable	GEL (N=85)		DROP (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Anterior chamber flare - (n %)						
None	57	73.1	54	71.1	111	72.1
Faint	21	26.9	22	28.9	43	27.9
Total	78	100.0	76	100.0	154	100.0
Conjunctival hyperemia - (n %)						
None	71	91.0	73	96.1	144	93.5
Mild	7	9.0	3	3.9	10	6.5
Total	78	100.0	76	100.0	154	100.0
Ocular discomfort: pain - (n %)						
None	77	98.7	76	100.0	153	99.4
Mild	1	1.3	0	0.0	1	0.6
Total	78	100.0	76	100.0	154	100.0
Ocular discomfort: photophobia - (n %)						
None	69	88.5	67	88.2	136	88.3
Mild	9	11.5	9	11.8	18	11.7
Total	78	100.0	76	100.0	154	100.0
Ocular discomfort: tearing - (n %)						
None	68	87.2	69	90.8	137	89.0
Mild	10	12.8	7	9.2	17	11.0
Total	78	100.0	76	100.0	154	100.0

Source table(s): 3.4

## 7.7 Efficacy evaluation after surgery

As previously reported (see paragraph 6.4) the objective of this study is to demonstrate the noninferiority of the Netildex gel in comparison with Netildex drops solution.

### 7.7.1 Primary endpoint

The primary endpoint was the combination of the grade of severity of two clinical parameters, *Flare* and *Cellularity* after 24 hours and after 7 days (Visit 4) from surgery.

Given the following definition:

- ✓ *Full responder*: if both measurements are responder;
- ✓ *Partial responder*: if responder at least for one of the two measurements;
- ✓ *No responder*: if both measurements are not responder.

where *responder* was the patient with a decrease of the degree at endpoint respect to baseline or absence of degree both at baseline and at endpoint visits.

Now we describe the situation of the two clinical variables separately, *Cellularity* and *Flare*, which compose the primary endpoint (see Table 7.7-1-1 in the next page).

Table 7.7-1-1: Cellularity and Flare

GEL (N=80)								DROP (N=80)		ALL (N=160)	
Variable	Visit	n	%	n	%	n	%				
Cellularity								V4 (day 7) - (n %)			
	decreased	8	10.0	8	10.0	16	10.0				
	unchanged	71	88.8	72	90.0	143	89.4				
	increased	1	1.3	0	0.0	1	0.6				
	total	80	100.0	80	100.0	160	100.0				
								V5 (day 15) - (n %)			
	decreased	10	12.5	9	11.3	19	11.9				
	unchanged	70	87.5	71	88.8	141	88.1				
	increased	0	0.0	0	0.0	0	0.0				
	total	80	100.0	80	100.0	160	100.0				
Flare								V4 (day 7) - (n %)			
	decreased	17	21.3	24	30.0	41	25.6				
	unchanged	63	78.8	56	70.0	119	74.4				
	increased	0	0.0	0	0.0	0	0.0				
	total	80	100.0	80	100.0	160	100.0				
								V5 (day 15) - (n %)			
	decreased	22	27.5	27	33.8	49	30.6				
	unchanged	58	72.5	53	66.3	111	69.4				
	increased	0	0.0	0	0.0	0	0.0				
	total	80	100.0	80	100.0	160	100.0				
Source table(s): 4.2-1 and 4.3-1											

Source table(s): 4.2-1 and 4.3-1

After 7 days, we observe a very low increase of the severity degree for both the variables while this increase is absent after 14 days.

Combining the two clinical variables Cellularity and Flare, according to the definition provided previously, we observe a full response on 90% for GEL group and 95% for DROP group. See the table below.

Table 7.7-1-2: Summary of responder rate

Efficacy						
	GEL (N=80)		DROP (N=80)		ALL (N=160)	
	n	%	n	%	n	%
full responder	72	90.0	76	95.0	148	92.5
partial responder	8	10.0	4	5.0	12	7.5
no responder	0	0.0	0	0.0	0	0.0
Total	80	100.0	80	100.0	160	100.0

Source table(s): 4.4-1

Considering the non-inferiority margin equal to 0.10, established by protocol, the test provides the following results depicted in Table 7.7-1-3.

Table 7.7-1-3: Noninferiority test on responder rate

Non inferiority margin		Observed risk difference		97.5% Confidence interval	
Source	n/N %	Test	difference	Lower	Upper
GEL	72/80 90.0	Univariate test	-0.0500	-0.0580	0.1580
DROP	76/80 95.0	Multivariate test	-0.0576	-0.0378	0.1530

Source table(s): 4.5-1

The results show that the success rate for the GEL group exceeded that of the DROP group by 0.05.

The noninferiority test results indicate that the GEL group is noninferior to the DROP group since the lower limit of the 97.5% Confidence Interval (both in unadjusted and adjusted analysis) is greater than the noninferiority limit of -0.10.

When correct, the effect of study drug by the factors Sex and Age (the factor Site was not introduced in the model due to a very small number of patients) the noninferiority is confirmed (lower 97.5% CI=-0.0597).

For details see Tables 4.5-1 and 4.5-2 of Appendix 1.

## 7.7.2 Secondary endpoints

### Evaluation of responders for the Per Protocol sample

As previously mentioned (paragraph 7.) only two patients were excluded from the PP sample (both of GEL group). The description of the two clinical variables separately, Cellularity and Flare, is reported in the Table 7.7-2-1.

No relevant differences in the results with the analysis on ITT sample.

Table 7.7-2-1: Cellularity and Flare for the PP sample

		GEL (N=78)		DROP (N=80)		ALL (N=158)	
Variable	Visit	n	%	n	%	n	%
<b>Cellularity</b>							
	V4 (day 7) - (n %)						
	decreased	8	10.3	8	10.0	16	10.1
	unchanged	69	88.5	72	90.0	141	89.2
	increased	1	1.3	0	0.0	1	0.6
	total	78	100.0	80	100.0	158	100.0
	V5 (day 15) - (n %)						
	decreased	10	12.8	9	11.3	19	12.0
	unchanged	68	87.2	71	88.8	139	88.0
	increased	0	0.0	0	0.0	0	0.0
	total	78	100.0	80	100.0	158	100.0
<b>Flare</b>							
	V4 (day 7) - (n %)						
	decreased	17	21.8	24	30.0	41	25.0
	unchanged	61	78.2	56	70.0	117	74.1
	increased	0	0.0	0	0.0	0	0.0
	total	78	100.0	80	100.0	158	100.0
	V5 (day 15) - (n %)						
	decreased	22	28.2	27	33.8	49	31.0
	unchanged	56	71.8	53	66.3	109	69.0
	increased	0	0.0	0	0.0	0	0.0
	total	78	100.0	80	100.0	158	100.0

Source table(s): 4.2-2 and 4.3-2

Table 7.7-2-2: Summary of responder rate for the PP sample

		GEL (N=78)		DROP (N=80)		ALL (N=158)	
		n	%	n	%	n	%
full responder		70	89.7	76	95.0	146	92.4
partial responder		8	10.3	4	5.0	12	7.6
no responder		0	0.0	0	0.0	0	0.0
Total		78	100.0	80	100.0	158	100.0

Source table(s): 4.4-2

Table 7.7-2-3: Noninferiority test on responder rate for the PP sample

		Non inferiority margin	Observed risk difference	97.5% Confidence interval		
Source	n/N %			Lower Upper		

GEL 70/80 89.7 -0.10 -0.0526 -0.0562 0.1613  
DROP 76/80 95.0  
Source table(s): 4.5-2

### Evaluation of responders at Visit 5 (day 15)

Because the responder rate is 100% for both treatment groups, no computation/estimation is possible. See tables 4.6-1 and 4.6.2 of Appendix 1.

### Description of responders for the sub-group

As previously defined (see paragraph 6.4), the description of the subset of patients with Cellularity and/or Flare degree greater than zero at Visit 3 (day 1) is summarized in the below table.

Table 7.7-2-4: Grade of Flare and Cellularity for the patients showing severity degree greater than zero at Visit 3

		GEL (N=22/80)		DROP (N=27/80)		ALL (N=49/160)	
Visit		n	%	n	%	n	%
<b>Flare</b>							
V4 - (n %)							
None		17	77.3	24	88.9	41	83.7
Faint		5	22.7	3	11.1	8	16.3
Total		22	100.0	27	100.0	49	100.0
V5 - (n %)							
None		22	100.0	27	100.0	49	100.0
Total		22	100.0	27	100.0	49	100.0
<b>Cellularity</b>							
V4 - (n %)							
0 grade		6	60.0	7	77.8	13	68.4
0.5 grade		4	40.0	2	22.2	6	31.6
Total		10	100.0	9	100.0	19	100.0
V5 - (n %)							
0 grade		10	100.0	8	88.9	18	94.7
0.5 grade		0	0.0	1	11.1	1	5.3
Total		10	100.0	9	100.0	19	100.0

Source table(s): 4.7-1, 4.8-1

### Evaluation of antibiotic efficacy at Visit 3 (Day 1)

No patients have showed microbial load. See Table 4.9 of Appendix 1.

### Evaluation of Intra-Ocular Pressure (IOP)

The values of IOP for treated and no-treated eye are within the normal range (12-22 mmHg) except for patient 200101 who showed an IOP of 34 mmHg on the treated eye at Visit 3 (day 1) decreased to 16 mmHg at Visit 4 (day 7).

The point estimation description and change with values at Visit 1 (screening ) of IOP are reported in the Tables 6.1-1 and 6.1-2 and the difference between treated vs no-treated eye at Table 6.1-3 of Appendix 1.

## Evaluation of Visual acuity

No relevant difference in the study and between treatment groups are present.  
See Table 6.3-1 of Appendix 1.

## Evaluation of Ophtalmoscopy test

No relevant difference in the study and between treatment groups are present. See the table below.

Table 7.7-2-5: Abnormality frequency recorded with Ophtalmoscopy test

		GEL (N=85)		DROP (N=83)		ALL (N=168)	
Variable	Visit	n	%	n	%	n	%
Vitreous							
	V1	0	0.0	0	0.0	0	0.0
	V3	0	0.0	0	0.0	0	0.0
	V4	0	0.0	0	0.0	0	0.0
	V5	0	0.0	0	0.0	0	0.0
Retina							
	V1	2	2.4	2	2.4	4	2.4
	V3	2	2.4	2	2.5	4	2.5
	V4	2	2.5	2	2.5	4	2.5
	V5	2	2.5	2	2.5	4	2.5
Macula							
	V1	0	0.0	0	0.0	0	0.0
	V3	0	0.0	0	0.0	0	0.0
	V4	0	0.0	0	0.0	0	0.0
	V5	0	0.0	0	0.0	0	0.0
Choroid							
	V1	1	1.2	2	2.4	3	1.8
	V3	0	0.0	2	2.5	2	1.2
	V4	0	0.0	2	2.5	2	1.3
	V5	0	0.0	2	2.5	2	1.3

Source table(s): from 6.2-2-1 to 6.2-5-2

## Evaluation of Ophthalmoscopy test

No relevant difference in the study and between treatment groups are present. See the table below.

Table 7.7-2-6 (1 of 2): Ocular inflammation signs/symptoms change from Visit 3 (day 1)

		GEL (N=85)		DROP (N=83)		ALL (N=168)	
Visit		n	%	n	%	n	%
Anterior chamber flare							
V4	decreased	17	20.7	24	29.3	41	25.0
	unchanged	65	79.3	58	70.7	123	75.0
	increased	0	0.0	0	0.0	0	0.0
	total	82	100.0	82	100.0	164	100.0
V5	decreased	21	25.9	27	33.3	48	29.6
	unchanged	60	74.1	54	66.7	114	70.4
	increased	0	0.0	0	0.0	0	0.0
	total	81	100.0	81	100.0	162	100.0
Anterior chamber cells							
V4	decreased	6	7.3	4	4.9	10	6.1
	unchanged	76	92.7	77	93.9	153	93.3
	increased	0	0.0	1	1.2	1	0.6
	total	82	100.0	82	100.0	164	100.0
V5	decreased	7	8.6	4	4.9	11	6.8
	unchanged	74	91.4	77	95.1	151	93.2
	increased	0	0.0	0	0.0	0	0.0
	total	81	100.0	81	100.0	162	100.0
Conjunctival hyperemia							
V4	decreased	6	7.3	7	8.5	13	7.9
	unchanged	74	90.2	75	91.5	149	90.9
	increased	2	2.4	0	0.0	2	1.2
	total	82	100.0	82	100.0	164	100.0
V5	decreased	7	8.6	7	8.6	14	8.6
	unchanged	72	88.9	73	90.1	145	89.5
	increased	2	2.5	1	1.2	3	1.9
	total	81	100.0	81	100.0	162	100.0
Lid edema							
V4	decreased	0	0.0	0	0.0	0	0.0
	unchanged	82	100.0	82	100.0	164	100.0
	increased	0	0.0	0	0.0	0	0.0
	total	82	100.0	82	100.0	164	100.0
V5	decreased	0	0.0	0	0.0	0	0.0
	unchanged	81	100.0	81	100.0	162	100.0
	increased	0	0.0	0	0.0	0	0.0
	total	81	100.0	81	100.0	162	100.0
Corneal edema							
V4	decreased	3	3.7	1	1.2	4	2.4
	unchanged	79	96.3	81	98.8	160	97.6
	increased	0	0.0	0	0.0	0	0.0
	total	82	100.0	82	100.0	164	100.0
V5	decreased	2	2.5	1	1.2	3	1.9
	unchanged	79	97.5	80	98.8	159	98.1
	increased	0	0.0	0	0.0	0	0.0
	total	81	100.0	81	100.0	162	100.0
Ocular discomfort - Pain							
V4	decreased	1	1.2	1	1.2	2	1.2
	unchanged	81	98.8	81	98.8	162	98.8
	increased	0	0.0	0	0.0	0	0.0
	total	82	100.0	82	100.0	164	100.0
V5	decreased	1	1.2	1	1.2	2	1.2
	unchanged	80	98.8	80	98.8	160	98.8
	increased	0	0.0	0	0.0	0	0.0
	total	81	100.0	81	100.0	162	100.0

Table 7.7-2-6 (2 of 2): Ocular inflammation signs/symptoms change from Visit 3 (day 1)

		GEL (N=85)		DROP (N=83)		ALL (N=168)	
Visit		n	%	n	%	n	%
<b>Ocular discomfort - Photophobia</b>							
V4	decreased	7	8.5	4	4.9	11	6.7
	unchanged	74	90.2	77	93.9	151	92.1
	increased	1	1.2	1	1.2	2	1.2
	total	82	100.0	82	100.0	164	100.0
V5	decreased	8	9.9	3	3.7	11	6.8
	unchanged	72	88.9	77	95.1	149	92.0
	increased	1	1.2	1	1.2	2	1.2
	total	81	100.0	81	100.0	162	100.0
<b>Tearing</b>							
V4	decreased	7	8.5	4	4.9	11	6.7
	unchanged	73	89.0	76	92.7	149	90.9
	increased	2	2.4	2	2.4	4	2.4
	total	82	100.0	82	100.0	164	100.0
V5	decreased	9	11.1	4	4.9	13	8.0
	unchanged	68	84.0	75	92.6	143	88.3
	increased	4	4.9	2	2.5	6	3.7
	total	81	100.0	81	100.0	162	100.0

Source table(s): from 6.4-2 to 6.4-9

### Evaluation of Global tolerability

No relevant difference in the study and between treatment groups are present. See the table below.

Table 7.7-2-7 (1 of 2): Global tolerability by Investigator change from Visit 3 (day 1)

		GEL (N=85)		DROP (N=83)		ALL (N=168)	
Visit		n	%	n	%	n	%
<b>Burning</b>							
V4	decreased	6	7.3	4	4.9	10	6.1
	unchanged	76	92.7	77	93.9	153	93.3
	increased	0	0.0	1	1.2	1	0.6
	total	82	100.0	82	100.0	164	100.0
V5	decreased	7	8.6	4	4.9	11	6.8
	unchanged	74	91.4	77	95.1	151	93.2
	increased	0	0.0	0	0.0	0	0.0
	total	81	100.0	81	100.0	162	100.0
<b>Stinging</b>							
V4	decreased	4	4.9	3	3.7	7	4.3
	unchanged	77	93.9	76	93.8	153	93.9
	increased	1	1.2	2	2.5	3	1.8
	total	82	100.0	81	100.0	163	100.0
V5	decreased	5	6.3	3	3.8	8	5.0
	unchanged	73	91.3	76	95.0	149	93.1
	increased	2	2.5	1	1.3	3	1.9
	total	80	100.0	80	100.0	160	100.0
<b>Blurred vision</b>							
V4	decreased	1	1.2	0	0.0	1	0.6
	unchanged	78	95.1	79	97.5	157	96.3
	increased	3	3.7	2	2.5	5	3.1
	total	82	100.0	81	100.0	163	100.0
V5	decreased	2	2.5	0	0.0	2	1.3
	unchanged	76	95.0	77	96.3	153	95.6
	increased	2	2.5	3	3.8	5	3.1
	total	80	100.0	80	100.0	160	100.0



[illegible][illegible]

```
Source table(s): from 6.5-2 to 6.5-5
```

## Table 7.7-2-8: Main ATC class of concomitant medications (numeric descending order)

Table 1.1: 2-3: Main PPK class of concomitant medications (numeric descending order)

ATC Class Preferred term	GEL (N=85)		DROP (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one concomitant medication	61	71.8	55	66.3	116	69.0
CARDIOVASCULAR SYSTEM	49	57.6	46	55.4	95	56.5
BLOOD AND BLOOD FORMING ORGANS	16	18.8	17	20.5	33	19.6
NERVOUS SYSTEM	16	18.8	8	9.6	24	14.3
ALIMENTARY TRACT AND METABOLISM	14	16.5	8	9.6	22	13.1
SENSORY ORGANS	8	9.4	8	9.6	16	9.5
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES	6	7.1	10	12.0	16	9.5
ANTIINFECTIVES FOR SYSTEMIC USE	7	8.2	6	7.2	13	7.7
MUSCULO-SKELETAL SYSTEM	7	8.2	3	3.6	10	6.0
GENITO URINARY SYSTEM AND SEX HORMONES	2	2.4	3	3.6	5	3.0
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	1	1.2	1	1.2	2	1.2
RESPIRATORY SYSTEM	.	.	2	2.4	2	1.2
VARIOUS	1	1.2	1	1.2	2	1.2
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENT	.	.	1	1.2	1	0.6

```

Source table(s): 5.1

```

## Adverse events

The total number of patients with adverse events is 10, 4 for GEL group (4.7%) and 6 for DROP group (7.2%) while the total number of patients with SAE is 2, all for DROP group.

Only 1 patient, of GEL group, showed a relation with study drug.

In the table below, the frequency of patients with AE.

Table 7.7-2-8: Summary of all Adverse Events by MedDRA System Organ Class (numeric descending order)

System Organ Class Preferred term	GEL (N=85)		DROP (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one event	4	4.7	6	7.2	10	6.0
Eye disorders	1	1.2	3	3.6	4	2.4
Investigations	3	3.5	.	.	3	1.8
Gastrointestinal disorders	1	1.2	.	.	1	0.6
Immune system disorders	.	.	1	1.2	1	0.6
Infections and infestations	.	.	1	1.2	1	0.6
Injury, poisoning and procedural complications	1	1.2	.	.	1	0.6
Vascular disorders	.	.	1	1.2	1	0.6

For the details, see Tables from 6.6-1 to 6.6-5 of Appendix 1 and Listing 17 of Appendix 2.

## APPENDIX 1: Statistical tables

	<b>Page</b>
<b>Study flow-chart</b>	<b>5</b>
<b>1. Patient accountability.....</b>	<b>6</b>
Table 1.1 Number of subjects treated (randomized), completed the study and discontinued by center - Randomized sample.....	7
Table 1.2 Summary of Subjects disposition - Randomized sample.....	8
Table 1.3 Number of subjects with protocol violations - Randomized sample.....	10
Table 1.4 Summary of patient sets disposition - Randomized sample.....	11
Table 1.5 Patient accountability - Summary of demographic characteristics, by population and study drug.....	12
Table 1.6 Summary of time interval (days) among visits - Safety sample.....	13
Table 1.7 Summary of time interval (days) between post-surgery visits vs. surgery visit - Safety sample.....	14
<b>2. Demographic and baseline characteristics.....</b>	<b>15</b>
Table 2.1 Demographic characteristics and pregnancy test at study entry - Safety sample.....	16
Table 2.2 Clinical tests at study entry - Safety sample.....	17
Table 2.3 Ophthalmoscopy test at study entry - Safety sample.....	20
Table 2.4 General medical history before surgery, by primary system organ class and preferred term Safety sample.....	21
Table 2.5 Ophthalmic medical history before surgery, by primary system organ class and preferred term - Safety sample.....	25
Table 2.6 Antibiotics before surgery, by primary system organ class and preferred term Safety sample.....	29
<b>3. Evaluation at surgery day.....</b>	<b>30</b>
Table 3.1 Examinations at day of surgery - Safety sample.....	31
Table 3.2 Surgery problems - Safety sample.....	32
Table 3.3-1 Mydriatic and Antibiotic drugs at surgery - Safety sample.....	33
Table 3.3-2 Study treatment administration during the study - Safety sample.....	34
Table 3.4 Evaluation of ocular inflammation signs/symptoms at surgery - Safety sample.....	35
<b>4. Efficacy evaluation after surgery.....</b>	<b>37</b>
Table 4.1-1 Slit lamp evaluation during the study - Frequency of test execution - ITT sample.....	38
Table 4.1-2 Slit lamp evaluation during the study - Frequency of test execution - PP sample.....	39
Table 4.2-1 Slit lamp evaluation during the study - Grade of CELLULARITY of the treated eye during the study and change from Day 1 - ITT sample.....	40

## APPENDIX 1 (cont.d)

		<b>Page</b>
Table 4.2-2	Slit lamp evaluation during the study - Grade of CELLULARITY of the treated eye during the study and change from Day 1 - PP sample.....	41
Table 4.3-1	Slit lamp evaluation during the study - Grade of FLARE of the treated eye during the study and change from Day 1- ITT sample.....	42
Table 4.3-2	Slit lamp evaluation during the study - Grade of FLARE of the treated eye during the study and change from Day 1 - PP sample.....	43
Table 4.4-1	Slit lamp evaluation during the study - Summary of study drug response at endpoint stratified by sex, age and centre - ITT sample.....	44
Table 4.4-2	Slit lamp evaluation during the study - Summary of study drug response at endpoint stratified by sex, age and centre - PP sample.....	46
Table 4.5-1	Slit lamp evaluation during the study Analysis to test the noninferiority of GEL group (test) vs. EYE DROPS group (control) on occurrence of full-responder at endpoint - ITT sample.....	48
Table 4.5-2	Slit lamp evaluation during the study Analysis to test the noninferiority of GEL group (test) vs. EYE DROPS group (control) on occurrence of full-responder at endpoint - PP sample.....	49
Table 4.6-1	Slit lamp evaluation during the study Analysis to test the noninferiority of GEL group (test) vs. EYE DROPS group (control) on occurrence of full-responder at Visit 5 (Day 15) - ITT sample.....	50
Table 4.6-2	Slit lamp evaluation during the study Analysis to test the noninferiority of GEL group (test) vs. EYE DROPS group (control) on occurrence of full-responder at Visit 5 (Day 15) - PP sample.....	51
Table 4.7-1	Slit lamp evaluation during the study Grade of FLARE of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7) - ITT sample.....	52
Table 4.7-2	Slit lamp evaluation during the study Grade of FLARE of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7) - PP sample.....	53
Table 4.8-1	Slit lamp evaluation during the study Grade of CELLULARITY of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7) - ITT sample.....	54
Table 4.8-2	Slit lamp evaluation during the study Grade of CELLULARITY of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7) - PP sample.....	55
Table 4.9	Microbial load during the study - Frequency of test execution - ITT sample.....	56
<b>5.</b>	<b>Medications.....</b>	<b>57</b>
Table 5.1	Number of patients with concomitant medications, by ATC therapeutic class and preferred term - Safety sample.....	58
Table 5.2	Number of patients assuming study drugs during the study - Safety sample.....	59


## APPENDIX 1 (cont.d)

		<b>Page</b>
<b>6.</b>	<b>Safety evaluation.....</b>	<b>65</b>
<b>6.1</b>	<b>Intra Ocular Pressure.....</b>	<b>66</b>
Table 6.1-1	Intra ocular pressure on treated eye - Point estimate of IOP and change from baseline visite - Safety sample.....	67
Table 6.1-2	Intra ocular pressure on non-treated eye - Point estimate of IOP and change from baseline visite - Safety sample.....	69
Table 6.1-3	Intra ocular pressure - Point estimate of the difference between Treated vs. Non-treated eye - Safety sample.....	70
<b>6.2</b>	<b>Ophthalmoscopy test.....</b>	<b>71</b>
Table 6.2-1	Ophthalmoscopy test during the study - Frequency of test execution during the study - Safety sample.....	72
Table 6.2-2-1	Ophthalmoscopy test during the study - Frequency for Vitreous- Safety sample.....	73
Table 6.2-2-2	Ophthalmoscopy test during the study - Shift table for Vitreous - Safety sample.....	74
Table 6.2-3-1	Ophthalmoscopy test during the study - Frequency for Retina - Safety sample.....	75
Table 6.2-3-2	Ophthalmoscopy test during the study - Shift table for Retina - Safety sample.....	76
Table 6.2-4-1	Ophthalmoscopy test during the study - Frequency for Macula - Safety sample.....	77
Table 6.2-4-2	Ophthalmoscopy test during the study - Shift table for Macula- Safety sample.....	78
Table 6.2-5-1	Ophthalmoscopy test during the study - Frequency for Choroid- Safety sample.....	79
Table 6.2-5-2	Ophthalmoscopy test during the study - Shift table for Choroid - Safety sample.....	80
<b>6.3</b>	<b>Visual acuity.....</b>	<b>81</b>
Table 6.3-1	Visual acuity during the study for the treated eye - Safety sample.....	82
<b>6.4</b>	<b>Ocular inflammation evalution.....</b>	<b>83</b>
Table 6.4-1	Signs/Symptoms of ocular inflammation evaluation during the study - Frequency of test execution - Safety sample.....	84
Table 6.4-2	Evaluation of ocular inflammation signs/symptoms during the study - Anterior chamber flare - Safety sample.....	85
Table 6.4-3	Evaluation of ocular inflammation signs/symptoms during the study - Anterior chamber cells - Safety sample.....	86
Table 6.4-4	Evaluation of ocular inflammation signs/symptoms during the study - Conjunctival hyperemia - Safety sample.....	87

## APPENDIX 1 (cont.d)

		<b>Page</b>
Table 6.4-5	Evaluation of ocular inflammation signs/symptoms during the study - Lid edema - Safety sample.....	88
Table 6.4-6	Evaluation of ocular inflammation signs/symptoms during the study - Corneal edema - Safety sample.....	89
Table 6.4-7	Evaluation of ocular inflammation signs/symptoms during the study - Ocular discomfort - Pain - Safety sample.....	90
Table 6.4-8	Evaluation of ocular inflammation signs/symptoms during the study - Ocular discomfort - Photophobia - Safety sample.....	91
Table 6.4-9	Evaluation of ocular inflammation signs/symptoms during the study - Ocular discomfort - Tearing - Safety sample.....	92
Table 6.4-10	Evaluation of ocular inflammation signs/symptoms during the study - Total score - Safety sample.....	93
<b>6.5</b>	<b>Global tolerability.....</b>	<b>94</b>
Table 6.5-1	Evaluation of global tolerability by the investigator during the study - Frequency of test execution - Safety sample.....	95
Table 6.5-2	Evaluation of global tolerability by the investigator during the study - Burning - Safety sample.....	96
Table 6.5-3	Evaluation of global tolerability by the investigator during the study - Stinging - Safety sample.....	97
Table 6.5-4	Evaluation of global tolerability by the investigator during the study - Blurred vision Safety sample.....	98
Table 6.5-5	Evaluation of global tolerability by the investigator during the study - Global subjective tolerability - Safety sample.....	99
<b>6.6</b>	<b>Adverse events.....</b>	<b>100</b>
Table 6.6-1	Overview of Adverse Events - Safety sample.....	101
Table 6.6-2	Summary of all Adverse Events by MedDRA System Organ Class and Preferred Term - Safety sample.....	102
Table 6.6-3	Summary of Serious Adverse Events, by MedDRA System Organ Class and Preferred Term - Safety sample.....	104
Table 6.6-4	Summary of Related Adverse Events, by MedDRA System Organ Class and Preferred Term - Safety sample.....	105
Table 6.6-5	Summary of Adverse Events leading to discontinuation, by MedDRA System Organ Class and Preferred Term - Safety sample.....	106

# Study flow-chart



GEL: NETILDEX 3mg/mL / 1mg/mL ophthalmic gel  
EYE DROPS: NETILDEX 3mg/mL / 1mg/mL eye drops solutions

## **1. Patient accountability**



**Table 1.1 (1 of 1): Number of subjects treated (randomized), completed the study and discontinued by center**  
**Randomized sample**

Center Code	Name	GEL (N=85)						EYE DROPS (N=83)						ALL (N=168)					
		Trt		Compl.		Discont.		Trt		Compl.		Discont.		Trt		Compl.		Discont.	
		n	n	%	n	%	n	n	n	%	n	%	n	n	%	n	%	n	%
1001	IT01 - Rome	28	27	96.4	1	3.6	27	26	96.3	1	3.7	55	53	96.4	2	3.6			
1002	IT02 - Florence	22	20	90.9	2	9.1	22	22	100.0	.	.	44	42	95.5	2	4.5			
1003	IT03 - Milan	26	25	96.2	1	3.8	26	26	100.0	.	.	52	51	98.1	1	1.9			
2001	DE01 - Potsdam	7	6	85.7	1	14.3	7	6	85.7	1	14.3	14	12	85.7	2	14.3			
2002	DE02 - Würzburg	2	2	100.0	.	.	1	1	100.0	.	.	3	3	100.0	.	.			
	Total	85	80	94.1	5	5.9	83	81	97.6	2	2.4	168	161	95.8	7	4.2			

SAS program: P03\_T01\_01.sas - SAS dataset(s): RAND,EOS

Note: - Trt=treated

- percents of Completed and Discontinued are computed on treated subjects of correspondent row

**Table 1.2 (1 of 1): Summary of Subjects disposition  
Randomized sample**

	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Randomized	85	100.0	83	100.0	168	100.0
Completed study	80	94.1	81	97.6	161	95.8
Discontinued	5	5.9	2	2.4	7	4.2
-----						
Main reason for study discontinuation - (n %)						
Withdrawal of consent/Patient choice	4	80.0	1	50.0	5	71.4
Adverse event	1	20.0	1	50.0	2	28.6
Major complications during cataract surgery	0	0.0	0	0.0	0	0.0
Lack of efficacy	0	0.0	0	0.0	0	0.0
Protocol violation, including disallowed conc	0	0.0	0	0.0	0	0.0
Investigator considers it not in the patient'	0	0.0	0	0.0	0	0.0
Sponsor terminates the study	0	0.0	0	0.0	0	0.0
Total	5	100.0	2	100.0	7	100.0

SAS program: P03\_T01\_02.sas - SAS dataset(s): RAND,EOS

**Listing of patients discontinued**

Subj. code	Reason for discontinuation
<b>GEL</b>	
100152	Withdrawal of consent/Patient choice
100209	Withdrawal of consent/Patient choice
100228	Withdrawal of consent/Patient choice
100325	Withdrawal of consent/Patient choice
200109	Adverse event
<b>EYE DROPS</b>	
100147	Withdrawal of consent/Patient choice
200107	Adverse event

**Table 1.3 (1 of 1): Number of subjects with protocol violations  
Randomized sample**

Protocol violation	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Any protocol violation	2	2.4	.	.	2	1.2
Exclusion criteria 5 (type 2 diabetes mellitus)	1	1.2	.	.	1	0.6
Inclusion criteria 2 (age <40yrs)	1	1.2	.	.	1	0.6

Source: on-line editing

#### Listing of subjects with protocol violations

Pat. ID	Age (yrs)	Sex	Violation reported on database
100302	61	male	Patient suffering of type 2 Diabetes Mellitus (exclusion criteria 5)
100348	38	female	Patient age < 40 years old (inclusion criteria 2)

**Table 1.4 (1 of 1): Summary of patient sets disposition  
Randomized sample**

No. of patients	GEL (N=88)		EYE DROPS (N=85)		ALL (N=173)	
	n	%	n	%	n	%
Screened					176	100.0
Screening failure (1)					3	1.7
Randomized	88	100.0	85	100.0	173	100.0
Non treated patients (2)	3	3.4	2	2.4	5	2.9
Treated patients	85	96.6	83	97.6	168	97.1
Treated patients	85	100.0	83	100.0	168	100.0
Safety population	85	100.0	83	100.0	168	100.0
ITT population (3)	80	94.1	80	96.4	160	95.2
PP population (4)	78	91.8	80	96.4	158	64.0

Source: on-line editing

**Listing of not regular patients regarding the disposition and details on presence of study drug assumption and SLIT lamp execution**

	Subj. cde	Study drug	Reason	-Study drug-			-----SLIT lamp-----				
				V2	V3	V4	V1	V3	V4	V5	V6
(1)	100103	No treated	Screening failure								
	100240	No treated	Screening failure								
	200201	No treated	Screening failure								
(2)	100306	EYE DROPS	no study drug intake								
	100308	GEL	no study drug intake								
	100313	GEL	no study drug intake								
	100337	GEL	no study drug intake								
	200104	EYE DROPS	no study drug intake								
(3)	100209	GEL	no study drug intake at baseline & endpoint	Yes			Yes				
	100228	GEL	no study drug intake at endpoint	Yes	Yes	No	Yes	Yes	Yes		
	100325	GEL	no study drug intake at baseline & endpoint	Yes			Yes				
	200109	GEL	no study drug intake at endpoint	Yes	Yes	No	Yes	Yes	Yes		
	100147	EYE DROPS	no study drug intake at baseline	Yes	No	Yes	Yes	Yes	Yes		
	100326	EYE DROPS	no study drug intake at baseline	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
	200107	EYE DROPS	no study drug intake at baseline	Yes	No		Yes	Yes			
(4)	100302	GEL	protocol violation (type 2 Diabetes Mellitus)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	100348	GEL	protocol violation (age < 40 years old)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Missing value when premature discontinued patient

**Table 1.5 (1 of 1): Patient accountability - Summary of demographic characteristics, by population and study drug**

Variable	-----Safety sample-----						-----ITT sample-----						-----PP sample-----					
	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)		GEL (N=80)		EYE DROPS (N=80)		ALL (N=160)		GEL (N=78)		EYE DROPS (N=80)		ALL (N=158)	
Age (years)																		
N	85		83		168		80		80		160		78		80		158	
Mean	72.2		73.2		72.7		71.8		73.7		72.8		72.4		73.7		73.0	
SD	8.8		8.3		8.6		8.9		7.6		8.3		8.0		7.6		7.8	
Median	74.0		74.0		74.0		73.0		74.0		74.0		73.5		74.0		74.0	
Range	38.0	89.0	48.0	89.0	38.0	89.0	38.0	89.0	51.0	89.0	38.0	89.0	48.0	89.0	51.0	89.0	48.0	89.0
Age class - (n %)																		
<=65	17	20.0	14	16.9	31	18.5	17	21.3	12	15.0	29	18.1	15	19.2	12	15.0	27	17.1
66-74	34	40.0	29	34.9	63	37.5	33	41.3	29	36.3	62	38.8	33	42.3	29	36.3	62	39.2
>=75	34	40.0	40	48.2	74	44.0	30	37.5	39	48.8	69	43.1	30	38.5	39	48.8	69	43.7
Total	85	100.0	83	100.0	168	100.0	80	100.0	80	100.0	160	100.0	78	100.0	80	100.0	158	100.0
Sex - (n %)																		
Male	37	43.5	26	31.3	63	37.5	37	46.3	24	30.0	61	38.1	36	46.2	24	30.0	60	38.0
Female	48	56.5	57	68.7	105	62.5	43	53.8	56	70.0	99	61.9	42	53.8	56	70.0	98	62.0
Total	85	100.0	83	100.0	168	100.0	80	100.0	80	100.0	160	100.0	78	100.0	80	100.0	158	100.0

SAS program: P03\_01\_05.sas - SAS dataset(s): \_Populations

**Table 1.6 (1 of 1): Summary of time interval (days) among visits  
Safety sample**

Interval among visits	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
V1 (screening) vs. V2 (surgery)*						
N		85		83		168
Mean		6.1		5.6		5.8
SD		5.6		1.1		4.0
Median		6.0		6.0		6.0
Range	2.0	56.0	1.0	8.0	1.0	56.0
V2 (surgery) vs. V3 (day 1)						
N		83		83		166
Mean		1.0		1.0		1.0
SD		0.1		0.1		0.1
Median		1.0		1.0		1.0
Range	1.0	2.0	1.0	2.0	1.0	2.0
V3 (day 1) vs. V4 (day 7)						
N		83		82		165
Mean		6.1		6.2		6.1
SD		1.3		2.0		1.7
Median		6.0		6.0		6.0
Range	4.0	15.0	5.0	22.0	4.0	22.0
V4 (day 7) vs. V5 (day 15 - End of treatment)						
N		81		81		162
Mean		7.4		7.1		7.2
SD		1.3		0.9		1.1
Median		7.0		7.0		7.0
Range	0.0	13.0	5.0	9.0	0.0	13.0
V5 (day 15) vs. V6 (follow-up)						
N		80		81		161
Mean		45.9		46.3		46.1
SD		6.9		4.3		5.7
Median		47.0		47.0		47.0
Range	10.0	77.0	13.0	54.0	10.0	77.0

SAS program: P03\_01\_06.sas - SAS dataset(s): RAND,VISIT

\* Patient 100205 with V1 date=14DEC2017 and V2 date=08FEB2018

**Table 1.7 (1 of 1): Summary of time interval (days) between post-surgery visits vs. surgery visit  
Safety sample**

Interval among visits	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
V2 (surgery) vs. V3 (day 1)						
N		83		83		166
Mean		1.0		1.0		1.0
SD		0.1		0.1		0.1
Median		1.0		1.0		1.0
Range	1.0	2.0	1.0	2.0	1.0	2.0
V3 (day 1) vs. V4 (day 7)						
N		83		82		165
Mean		7.1		7.2		7.1
SD		1.3		1.9		1.7
Median		7.0		7.0		7.0
Range	6.0	16.0	6.0	23.0	6.0	23.0
V4 (day 15) vs. V5 (day 15 - End of treatment)						
N		81		81		162
Mean		14.4		14.1		14.3
SD		1.1		0.9		1.0
Median		14.0		14.0		14.0
Range	13.0	20.0	12.0	16.0	12.0	20.0
V5 (day 15) vs. V6 (follow-up)						
N		80		81		161
Mean		60.3		60.4		60.3
SD		6.7		4.2		5.6
Median		61.0		61.0		61.0
Range	25.0	91.0	27.0	70.0	25.0	91.0

SAS program: P03\_01\_07.sas - SAS dataset(s): RAND,VISIT



## **2. Demographic and baseline characteristics**

**Table 2.1 (1 of 1): Demographic characteristics and pregnancy test at study entry  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)		Difference between study drugs	95% CI of difference	
	n	%	n	%	n	%			
Age (years)*							-0.9931	-3.6090	1.6229
N		85		83		168			
Mean		72.2		73.2		72.7			
SD		8.8		8.3		8.6			
Median		74.0		74.0		74.0			
Range	38.0	89.0	48.0	89.0	38.0	89.0			
Age frequency - (n %)									
<=65	16	18.8	15	18.1	31	18.5			
66-74	37	43.5	28	33.7	65	38.7			
>=75	32	37.6	40	48.2	72	42.9			
Total	85	100.0	83	100.0	168	100.0			
Sex - (n %)							12.2000	-2.3100	26.7200
Male	37	43.5	26	31.3	63	37.5			
Female	48	56.5	57	68.7	105	62.5			
Total	85	100.0	83	100.0	168	100.0			
Race - (n %)									
White	84	98.8	81	97.6	165	98.2			
Black	1	1.2	2	2.4	3	1.8			
Asian	0	0.0	0	0.0	0	0.0			
Middle-eastern	0	0.0	0	0.0	0	0.0			
Other	0	0.0	0	0.0	0	0.0			
Total	85	100.0	83	100.0	168	100.0			
Pregnancy - (n %)									
No	1	1.2	0	0.0	1	0.6			
Yes	0	0.0	0	0.0	0	0.0			
NA (male)	36	42.4	26	31.3	62	36.9			
NA (out of childbearing age)	48	56.5	56	67.5	104	61.9			
Total	85	100.0	83	100.0	168	100.0			
Result of pregnancy test - (n %)									
Positive	0	0.0	0	0.0	0	0.0			
Negative	0	0.0	0	0.0	0	0.0			
Total	0	100.0	0	100.0	0	100.0			

SAS program: P03\_T02\_01.sas - SAS dataset(s): RAND,DEMOGRAPHY,PREGNANCY

\* Age was computed from date of birth and date of informed consent

**Table 2.2 (1 of 3): Clinical tests at study entry  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
AMSLER test performed - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
If YES, result of AMSLER test - (n %)						
Positive	0	0.0	0	0.0	0	0.0
Negative	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
OCT test performed - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
If YES, result of OCT test - (n %)						
Positive	0	0.0	0	0.0	0	0.0
Negative	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
Visual acuity - Treated eye (fraction)						
N		85		83		168
Mean		0.5		0.5		0.5
SD		0.2		0.2		0.2
Median		0.5		0.5		0.5
Range	0.0	1.0	0.0	1.0	0.0	1.0
Visual acuity - Non-treated eye (fraction)						
N		85		83		168
Mean		0.7		0.6		0.7
SD		0.3		0.3		0.3
Median		0.7		0.7		0.7
Range	0.0	1.3	0.0	1.0	0.0	1.3
Visual acuity - Difference between Treated and Non-treated eye (fraction)						
N		85		83		168
Mean		-0.2		-0.1		-0.1
SD		0.3		0.4		0.4
Median		-0.2		-0.2		-0.2
Range	-0.8	0.7	-0.8	0.7	-0.8	0.7

**Table 2.2 (2 of 3): Clinical tests at study entry  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Intra Ocular Pressure (mmHg)						
Treated eye (mmHg)						
N		85		83		168
Mean		15.3		15.4		15.4
SD		1.9		1.8		1.9
Median		16.0		16.0		16.0
Range	10.0	19.0	10.0	20.0	10.0	20.0
Non-treated eye (mmHg)						
N		85		83		168
Mean		15.1		15.2		15.1
SD		2.0		1.7		1.8
Median		15.0		15.0		15.0
Range	10.0	20.0	10.0	19.0	10.0	20.0
Difference between Treated and Non-treated eye (mmHg)						
N		85		83		168
Mean		0.2		0.2		0.2
SD		1.4		1.4		1.4
Median		0.0		0.0		0.0
Range	-4.0	6.0	-5.0	4.0	-5.0	6.0

**Table 2.2 (3 of 3): Clinical tests at study entry  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Slit lamp examination performed - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
Grade of cellularity - (n %)						
0 grade	85	100.0	83	100.0	168	100.0
0.5 grade	0	0.0	0	0.0	0	0.0
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
Grade of flare - (n %)						
None	85	100.0	83	100.0	168	100.0
Faint	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0

SAS program: P03\_T02\_02.sas - SAS dataset(s): RAND,INTRA\_PRES,SLIT,SURGERY,AMSLER,OCT,VISUAL\_SCREEN

**Table 2.3 (1 of 1): Ophthalmoscopy test at study entry  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Test performed - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
Vitreous - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	85	100.0	83	100.0	168	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
Retina - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	83	97.6	81	97.6	164	97.6
Abnormal	2	2.4	2	2.4	4	2.4
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
Macula - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	85	100.0	83	100.0	168	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
Choroid - (n %)						
Not done	0	0.0	1	1.2	1	0.6
Normal	84	98.8	80	96.4	164	97.6
Abnormal	1	1.2	2	2.4	3	1.8
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0

SAS program: P03\_T02\_03.sas - SAS dataset(s): NameFile: RAND,OPHTHALMOSCOPY

**Table 2.4 (1 of 4): General medical history before surgery, by primary system organ class and preferred term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one event	59	69.4	61	73.5	120	71.4
Blood and lymphatic system disorders	.	.	1	1.2	1	0.6
Systemic mastocytosis	.	.	1	1.2	1	0.6
Cardiac disorders	9	10.6	8	9.6	17	10.1
Angina pectoris	1	1.2	.	.	1	0.6
Arrhythmia	2	2.4	.	.	2	1.2
Atrial fibrillation	2	2.4	1	1.2	3	1.8
Bradycardia	.	.	1	1.2	1	0.6
Cardiac disorder	1	1.2	3	3.6	4	2.4
Cardiac failure chronic	1	1.2	.	.	1	0.6
Cardiovascular disorder	.	.	1	1.2	1	0.6
Extrasystoles	1	1.2	.	.	1	0.6
Ischaemic cardiomyopathy	.	.	1	1.2	1	0.6
Myocardial ischaemia	1	1.2	1	1.2	2	1.2
Ear and labyrinth disorders	2	2.4	.	.	2	1.2
Hypoacusis	1	1.2	.	.	1	0.6
Vertigo labyrinthine	1	1.2	.	.	1	0.6
Endocrine disorders	5	5.9	9	10.8	14	8.3
Hypothyroidism	5	5.9	7	8.4	12	7.1
Thyroid mass	.	.	1	1.2	1	0.6
Thyroiditis	.	.	1	1.2	1	0.6
Gastrointestinal disorders	6	7.1	8	9.6	14	8.3
Abdominal pain upper	1	1.2	.	.	1	0.6
Constipation	1	1.2	.	.	1	0.6
Diverticulum	.	.	1	1.2	1	0.6
Diverticulum intestinal	1	1.2	.	.	1	0.6
Gastritis	.	.	1	1.2	1	0.6
Gastroesophageal reflux disease	2	2.4	5	6.0	7	4.2
Hiatus hernia	.	.	1	1.2	1	0.6
Inguinal hernia	1	1.2	.	.	1	0.6
General disorders and administration site conditions	2	2.4	.	.	2	1.2
Hyperplasia	1	1.2	.	.	1	0.6
Pain	1	1.2	.	.	1	0.6

**Table 2.4 (2 of 4): General medical history before surgery, by primary system organ class and preferred term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Hepatobiliary disorders	1	1.2	.	.	1	0.6
Cholelithiasis	1	1.2	.	.	1	0.6
Immune system disorders	1	1.2	5	6.0	6	3.6
Allergy to arthropod sting	.	.	1	1.2	1	0.6
Allergy to venom	.	.	1	1.2	1	0.6
Drug hypersensitivity	1	1.2	1	1.2	2	1.2
Food allergy	.	.	1	1.2	1	0.6
Seasonal allergy	.	.	1	1.2	1	0.6
Infections and infestations	1	1.2	.	.	1	0.6
Lyme disease	1	1.2	.	.	1	0.6
Investigations	1	1.2	1	1.2	2	1.2
Blood cholesterol increased	.	.	1	1.2	1	0.6
Blood uric acid increased	1	1.2	.	.	1	0.6
Metabolism and nutrition disorders	15	17.6	16	19.3	31	18.5
Diabetes mellitus	2	2.4	2	2.4	4	2.4
Dyslipidaemia	1	1.2	2	2.4	3	1.8
Fluid retention	.	.	1	1.2	1	0.6
Gout	2	2.4	.	.	2	1.2
Hypercholesterolaemia	11	12.9	11	13.3	22	13.1
Hyperlipidaemia	1	1.2	.	.	1	0.6
Hyperuricaemia	1	1.2	2	2.4	3	1.8
Type 2 diabetes mellitus	1	1.2	.	.	1	0.6
Vitamin B12 deficiency	.	.	1	1.2	1	0.6
Musculoskeletal and connective tissue disorders	8	9.4	5	6.0	13	7.7
Osteoarthritis	.	.	1	1.2	1	0.6
Osteopenia	1	1.2	.	.	1	0.6
Osteoporosis	6	7.1	4	4.8	10	6.0
Psoriatic arthropathy	.	.	1	1.2	1	0.6
Scleroderma	1	1.2	.	.	1	0.6



**Table 2.4 (3 of 4): General medical history before surgery, by primary system organ class and preferred term**  
**Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	1.2	5	6.0	6	3.6
Colon cancer	1	1.2	.	.	1	0.6
Lung neoplasm malignant	1	1.2	.	.	1	0.6
Malignant melanoma	.	.	1	1.2	1	0.6
Meningioma	.	.	1	1.2	1	0.6
Monoclonal gammopathy	.	.	1	1.2	1	0.6
Prostate cancer	.	.	1	1.2	1	0.6
Prostatic adenoma	.	.	1	1.2	1	0.6
Nervous system disorders	2	2.4	2	2.4	4	2.4
Ischaemic stroke	.	.	1	1.2	1	0.6
Neuropathy peripheral	.	.	1	1.2	1	0.6
Polyneuropathy	1	1.2	.	.	1	0.6
Transient ischaemic attack	1	1.2	.	.	1	0.6
Psychiatric disorders	9	10.6	4	4.8	13	7.7
Anxiety	5	5.9	1	1.2	6	3.6
Depression	2	2.4	1	1.2	3	1.8
Insomnia	2	2.4	2	2.4	4	2.4
Renal and urinary disorders	2	2.4	.	.	2	1.2
Bladder discomfort	1	1.2	.	.	1	0.6
Nephropathy	1	1.2	.	.	1	0.6
Reproductive system and breast disorders	1	1.2	3	3.6	4	2.4
Benign prostatic hyperplasia	1	1.2	2	2.4	3	1.8
Prostatomegaly	.	.	1	1.2	1	0.6
Respiratory, thoracic and mediastinal disorders	1	1.2	2	2.4	3	1.8
Asthma	.	.	1	1.2	1	0.6
Chronic obstructive pulmonary disease	.	.	1	1.2	1	0.6
Pulmonary hypertension	1	1.2	.	.	1	0.6
Social circumstances	1	1.2	.	.	1	0.6
Menopause	1	1.2	.	.	1	0.6

**Table 2.4 (4 of 4): General medical history before surgery, by primary system organ class and preferred term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Surgical and medical procedures	9	10.6	7	8.4	16	9.5
Adenoidectomy	1	1.2	.	.	1	0.6
Angioplasty	.	.	1	1.2	1	0.6
Appendicectomy	2	2.4	1	1.2	3	1.8
Breast conserving surgery	2	2.4	.	.	2	1.2
Carotid endarterectomy	1	1.2	.	.	1	0.6
Cholecystectomy	.	.	1	1.2	1	0.6
Hernia repair	.	.	1	1.2	1	0.6
Hysterectomy	.	.	1	1.2	1	0.6
Hysterosalpingo-oophorectomy	1	1.2	.	.	1	0.6
Nephrectomy	.	.	1	1.2	1	0.6
Prostatectomy	1	1.2	2	2.4	3	1.8
Renal tumour excision	1	1.2	.	.	1	0.6
Rotator cuff repair	.	.	1	1.2	1	0.6
Thyroidectomy	1	1.2	.	.	1	0.6
Tonsillectomy	1	1.2	.	.	1	0.6
Vascular disorders	44	51.8	40	48.2	84	50.0
Angiopathy	1	1.2	1	1.2	2	1.2
Hypertension	43	50.6	40	48.2	83	49.4
Thrombophlebitis	.	.	1	1.2	1	0.6
Thrombophlebitis superficial	1	1.2	.	.	1	0.6

SAS program: P03\_T02\_04.sas - SAS dataset(s): RAND,MEDHIS\_COD

A subject with multiple occurrences of an event is counted only once in the respective category.  
Arranged alphabetically by System Organ Class

**Table 2.5 (1 of 1): Ophthalmic medical history before surgery, by primary system organ class and preferred term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)		Difference between treatment	95% CI of difference	
	n	%	n	%	n	%			
Subjects with at least one event	18	21.2	17	20.5	35	20.8	6.9	-0.12	0.13
Eye disorders	10	11.8	11	13.3	21	12.5			
Amblyopia	1	1.2	.	.	1	0.6			
Cataract	9	10.6	10	12.0	19	11.3			
Dry eye	.	.	2	2.4	2	1.2			
Myopia	.	.	1	1.2	1	0.6			
Retinal detachment	1	1.2	.	.	1	0.6			
Retinal infarction	.	.	1	1.2	1	0.6			
Vitreomacular interface abnormal	.	.	1	1.2	1	0.6			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	1.2	.	.	1	0.6			
Eye naevus	1	1.2	.	.	1	0.6			
Surgical and medical procedures	9	10.6	11	13.3	20	11.9			
Cataract operation	9	10.6	9	10.8	18	10.7			
Lens capsulotomy	.	.	1	1.2	1	0.6			
Retinal laser coagulation	.	.	1	1.2	1	0.6			
Strabismus correction	.	.	1	1.2	1	0.6			

SAS program: P03\_T02\_05.sas - SAS dataset(s): RAND,OPHHIS\_COD

A subject with multiple occurrences of an event is counted only once in the respective category.  
Arranged alphabetically by System Organ Class

**Listing of patients with Ophthalmic medical history before surgery - Safety sample (1 of 3)**

Sbj Code	Study drug	Sex	Age (year)	Reported term	Date of diagnosis	Ongoing
100201 .	GEL .	Female .	80 .	LEFT EYE CATARACT SURGERY RIGHT EYE CATARACT	26JAN2017 2015	NO YES
100202 .	DROPS .	Female .	70 .	LEFT EYE CATARACT RIGHT EYE CATARACT	2016 2016	YES YES
100203 . .	DROPS . .	Female . .	76 . .	LEFT EYE CATARACT SURGERY LEFT EYE YAG LASER CAPSULOTOMY RIGHT EYE CATARACT	2013 2015 2015	NO NO YES
100204 .	GEL .	Male .	71 .	RIGHT EYE CATARACT	2016	YES
100205 .	GEL .	Male .	75 .	LEFT EYE CATARACT RIGHT EYE CATARACT	2016 2016	YES YES
100206 . .	DROPS . .	Female . .	81 . .	DRY EYE SYNDROME LEFT EYE CATARACT SURGERY RIGHT EYE CATARACT	2016 19OCT2017 2016	YES NO YES
100207 . .	DROPS . .	Female . .	65 . .	HIGH MYOPIA LEFT EYE CATARACT RIGHT EYE CATARACT	1967 2015 2015	YES YES YES
100208 .	GEL .	Female .	79 .	LEFT EYE CATARACT SURGERY	JAN2016	NO
100209 .	GEL .	Female .	77 .	LEFT EYE CATARACT RIGHT EYE CATARACT	2016 2016	YES YES
100210 .	DROPS .	Female .	70 .	LEFT EYE CATARACT SURGERY RIGHT EYE CATARACT	12OCT2017 2016	NO YES
100211 .	GEL .	Male .	67 .	LEFT EYE CATARACT RIGHT EYE CATARACT	2016 2016	YES YES
100212 .	DROPS .	Female .	82 .	LEFT EYE CATARACT SURGERY RIGHT EYE CATARACT SURGERY	2016 SEP2017	YES YES
100213 . .	DROPS . .	Female . .	81 . .	DRY EYE SYNDROME LEFT EYE CATARACT RIGHT EYE CATARACT SURGERY	2008 2016 9FEB2017	YES YES YES

**Listing of patients with Ophthalmic medical history before surgery - Safety sample (2 of 3)**

Sbj Code	Study drug	Sex	Age (year)	Reported term	Date of diagnosis	Ongoing
100214	DROPS	Female	77	LEFT EYE CATARACT	2016	YES
.	.	.	.	RIGHT EYE-VITREORETINAL INTERF ACE SYNDROME	2017	YES
100215	GEL	Female	83	LEFT EYE CATARACT	2007	YES
100216	GEL	Female	74	LEFT EYE CATARACT		YES
.	.	.	.	RIGHT EYE CATARACT SURGERY	APR2016	NO
100217	DROPS	Female	72	LEFT EYE CATARACT SURGERY	2NOV2017	NO
.	.	.	.	RIGHT EYE CATARACT	2016	YES
100218	DROPS	Male	72	LEFT EYE CATARACT SURGERY	23NOV2017	NO
100219	GEL	Female	83	CHOROIDEAL NEVUS LEFT EYE	JAN2018	YES
100220	GEL	Male	64	RIGHT EYE CATARACT SURGERY	14DEC2017	NO
100222	DROPS	Female	76	RIGHT EYE CATARACT SURGERY	2016	NO
100228	GEL	Female	68	LEFT EYE CATARACT SURGERY	2016	NO
100233	GEL	Female	72	RIGHT EYE CATARACT SURGERY	2017	NO
100234	GEL	Female	73	LEFT EYE CATARACT SURGERY	2017	NO
100235	DROPS	Male	64	LEFT EYE CATARACT SURGERY	2010	NO
100236	DROPS	Female	70	LEFT EYE RETINAL LASER BARRAGE	2016	NO
100237	DROPS	Male	73	STRABISMUS SURGERY	1990	NO
100238	GEL	Male	78	LEFT EYE CATARACT SURGERY	2014	NO
100240		Female	72	RIGHT EYE CATARACT SURGERY	2017	NO
100242	GEL	Female	67	CATARACT-BOTH EYES	2017	YES
100243	DROPS	Male	74	CATARACT-BOTH EYES	2017	YES

**Listing of patients with Ophthalmic medical history before surgery - Safety sample (3 of 3)**

```
=====
Sbj      Study      Age      Date of
Code  drug  Sex  (year)  Reported term      diagnosis  Ongoing
=====
100244 GEL    Female 66    LEFT EYE CATARACT SURGERY  JAN2018    NO
-----
100245 DROPS Female 69    CATARACT-BOTH EYES        2017       YES
-----
100305 DROPS Female 85    PREVIOUS INFARCTION OD    2016       NO
-----
100348 GEL    Female 38    MILD AMBLYOPIA            YES
-----
200203 GEL    Male   66    OD: CATARACT              10MAR2014  NO
.      .      .      OD: RHEGMATOGENOUS RETINAL DET 10MAR2014  NO
.      .      .      ACHMENT
.      .      .      OS: RHEGMATOGENOUS PERIPHERAL 25AUG2016  NO
.      .      .      RETINAL DETACHMENT
=====
SAS program: L03_List_05.sas - SAS dataset(s): RAND,DEMOGRAPHY,MEDHIS_COD,OPHHIS_COD
```

**Table 2.6 (1 of 1): Antibiotics before surgery, by primary system organ class and preferred term  
Safety sample**

Therapeutic area Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)		Difference between treatment	95% CI of difference	
	n	%	n	%	n	%			
Subjects with at least one medication	46	54.1	47	56.6	93	55.4	2.51	-12.52	17.54
SENSORY ORGANS	46	54.1	47	56.6	93	55.4			
LEVOFLOXACIN	20	23.5	20	24.1	40	23.8			
NETILDEX	2	2.4	3	3.6	5	3.0			
NETILMICIN	24	28.2	24	28.9	48	28.6			

SAS program: P03\_T02\_06.sas - SAS dataset(s): RAND,ANTI\_BEFORE\_COD

A subject with multiple occurrences of an event is counted only once in the respective category.  
Arranged alphabetically by Therapeutic Area

### **3. Evaluation at surgery day**



**Table 3.1 (1 of 1): Examinations at day of surgery  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Eye involved - (n %)						
Left eye	45	52.9	40	48.2	85	50.6
Right eye	40	47.1	43	51.8	83	49.4
Total	85	100.0	83	100.0	168	100.0
Bromfenac treatment before surgery - (n %)						
No	1	1.2	0	0.0	1	0.6
Yes	84	98.8	83	100.0	167	99.4
Total	85	100.0	83	100.0	168	100.0
3 days before surgery - (n %)						
No	2	2.4	0	0.0	2	1.2
Yes	83	97.6	83	100.0	166	98.8
Total	85	100.0	83	100.0	168	100.0
2 days before surgery - (n %)						
No	2	2.4	2	2.4	4	2.4
Yes	83	97.6	81	97.6	164	97.6
Total	85	100.0	83	100.0	168	100.0
1 day before surgery - (n %)						
No	1	1.2	2	2.4	3	1.8
Yes	84	98.8	81	97.6	165	98.2
Total	85	100.0	83	100.0	168	100.0
Ocular surface sterilization - (n %)						
No	1	1.2	1	1.2	2	1.2
Yes	84	98.8	82	98.8	166	98.8
Total	85	100.0	83	100.0	168	100.0

SAS program: P03\_T03\_01.sas - SAS dataset(s): RAND,SURGERY,BROM\_TRT

**Table 3.2 (1 of 1): Surgery problems  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Any procedural issue/problem (not AE) occurred during cataract surgery - (n %)						
No	85	100.0	83	100.0	168	100.0
Yes	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
Patient suffered from any surgical complication - (n %)						
No	85	100.0	83	100.0	168	100.0
Yes	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0

SAS program: P03\_T03\_02.sas - SAS dataset(s): RAND,SURGERY

**Table 3.3-1 (1 of 1): Mydriatic and Antibiotic drugs at surgery  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Mydriatic drugs during surgery - (n %)						
No	2	2.4	0	0.0	2	1.2
Yes	83	97.6	83	100.0	166	98.8
Total	85	100.0	83	100.0	168	100.0
Antibiotics after surgery - (n %)						
No	66	77.6	61	73.5	127	75.6
Yes	19	22.4	22	26.5	41	24.4
Total	85	100.0	83	100.0	168	100.0

SAS program: P03\_T03\_03\_01.sas - SAS dataset(s): RAND,MYDRIATIC\_YN,ANTI\_AFTER\_YN

**Table 3.3-2 (1 of 1): Study treatment administration during the study  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V2 (surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
No	0	0.0	3	3.6	3	1.8
Yes	83	100.0	80	96.4	163	98.2
Total	83	100.0	83	100.0	166	100.0
V4 (day 7 after surgery) - (n %)						
No	3	3.6	0	0.0	3	1.8
Yes	80	96.4	82	100.0	162	98.2
Total	83	100.0	82	100.0	165	100.0

SAS program: P03\_T03\_03\_02.sas - SAS dataset(s): RAND,TREATMENT

**Table 3.4 (1 of 2): Evaluation of ocular inflammation signs/symptoms at surgery  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Evaluation performed - (n %)						
No	7	8.2	7	8.4	14	8.3
Yes	78	91.8	76	91.6	154	91.7
Total	85	100.0	83	100.0	168	100.0
Anterior chamber flare - (n %)						
None	57	73.1	54	71.1	111	72.1
Faint	21	26.9	22	28.9	43	27.9
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
Anterior chamber cells - (n %)						
None	78	100.0	76	100.0	154	100.0
Mild	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
Conjunctival hyperemia - (n %)						
None	71	91.0	73	96.1	144	93.5
Mild	7	9.0	3	3.9	10	6.5
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
Lid edema - (n %)						
None	78	100.0	76	100.0	154	100.0
Mild	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
Corneal edema - (n %)						
None	78	100.0	76	100.0	154	100.0
Mild	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0

**Table 3.4 (2 of 2): Evaluation of ocular inflammation signs/symptoms at surgery  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Ocular discomfort: pain - (n %)						
None	77	98.7	76	100.0	153	99.4
Mild	1	1.3	0	0.0	1	0.6
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
Ocular discomfort: photophobia - (n %)						
None	69	88.5	67	88.2	136	88.3
Mild	9	11.5	9	11.8	18	11.7
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
Ocular discomfort: tearing - (n %)						
None	68	87.2	69	90.8	137	89.0
Mild	10	12.8	7	9.2	17	11.0
Moderate	0	0.0	0	0.0	0	0.0
Severe	0	0.0	0	0.0	0	0.0
Total	78	100.0	76	100.0	154	100.0
-----						
Total score						
N		78		76		154
Mean		0.6		0.5		0.6
SD		0.8		0.8		0.8
Median		0.0		0.0		0.0
Range		0.0 3.0		0.0 3.0		0.0 3.0

SAS program: P03\_T03\_04.sas - SAS dataset(s):

#### **4. Efficacy evaluation after surgery**

**Table 4.1-1 (1 of 1): Slit lamp evaluation during the study - Frequency of test execution  
ITT sample**

Visit	GEL (N=80)		EYE DROPS (N=80)		ALL (N=160)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	80	100.0	80	100.0	160	100.0
Total	80	100.0	80	100.0	160	100.0
V3 (day 1 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	80	100.0	80	100.0	160	100.0
Total	80	100.0	80	100.0	160	100.0
V4 (day 7 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	80	100.0	80	100.0	160	100.0
Total	80	100.0	80	100.0	160	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	80	100.0	80	100.0	160	100.0
Total	80	100.0	80	100.0	160	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	79	100.0	79	98.8	158	99.4
Total	79	100.0	80	100.0	159	100.0

SAS program: P03\_T04\_01\_01.sas - SAS dataset(s): RAND,SLIT

Note: patient 100152 with no measurement of SLIT lamp at Visit 6



**Table 4.1-2 (1 of 1): Slit lamp evaluation during the study - Frequency of test execution  
PP sample**

Visit	GEL (N=78)		EYE DROPS (N=80)		ALL (N=158)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	78	100.0	80	100.0	158	100.0
Total	78	100.0	80	100.0	158	100.0
V3 (day 1 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	78	100.0	80	100.0	158	100.0
Total	78	100.0	80	100.0	158	100.0
V4 (day 7 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	78	100.0	80	100.0	158	100.0
Total	78	100.0	80	100.0	158	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	78	100.0	80	100.0	158	100.0
Total	78	100.0	80	100.0	158	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	77	100.0	79	98.8	156	99.4
Total	77	100.0	80	100.0	157	100.0

SAS program: P03\_T04\_01\_02.sas - SAS dataset(s): RAND,SLIT

**Table 4.2-1 (1 of 1): Slit lamp evaluation during the study - Grade of CELLULARITY of the treated eye during the study and change from Day 1 ITT sample**

Visit	GEL (N=80)				EYE DROPS (N=80)				ALL (N=160)			
			Change from Day 1				Change from Day 1				Change from Day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)												
0 grade	70	87.5			71	88.8			141	88.1		
0.5 grade	6	7.5			4	5.0			10	6.3		
1 grade	4	5.0			5	6.3			9	5.6		
2 grade	0	0.0			0	0.0			0	0.0		
3 grade	0	0.0			0	0.0			0	0.0		
4 grade	0	0.0			0	0.0			0	0.0		
Total	80	100.0			80	100.0			160	100.0		
V4 (day 7 after surgery) - (n %)												
0 (<1 cell)	75	93.8	decreased	8 10.0	78	97.5	decreased	8 10.0	153	95.6	decreased	16 10.0
0.5 (1-5 cells)	5	6.3	unchanged	71 88.8	2	2.5	unchanged	72 90.0	7	4.4	unchanged	143 89.4
1 (6-15 cells)	0	0.0	increased	1 1.3	0	0.0	increased	0 0.0	0	0.0	increased	1 0.6
2 (16-25 cells)	0	0.0	total	80 100.0	0	0.0	total	80 100.0	0	0.0	total	160 100.0
3 (26-50 cells)	0	0.0			0	0.0			0	0.0		
4 (>50 cells)	0	0.0			0	0.0			0	0.0		
Total	80	100.0			80	100.0			160	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
0 (<1 cell)	80	100.0	decreased	10 12.5	79	98.8	decreased	9 11.3	159	99.4	decreased	19 11.9
0.5 (1-5 cells)	0	0.0	unchanged	70 87.5	1	1.3	unchanged	71 88.8	1	0.6	unchanged	141 88.1
1 (6-15 cells)	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
2 (16-25 cells)	0	0.0	total	80 100.0	0	0.0	total	80 100.0	0	0.0	total	160 100.0
3 (26-50 cells)	0	0.0			0	0.0			0	0.0		
4 (>50 cells)	0	0.0			0	0.0			0	0.0		
Total	80	100.0			80	100.0			160	100.0		
V6 (follow-up at day 60 after surgery) - (n %)												
0 (<1 cell)	77	97.5	decreased	10 12.5	79	100.0	decreased	8 10.0	156	98.7	decreased	18 11.3
0.5 (1-5 cells)	2	2.5	unchanged	67 83.8	0	0.0	unchanged	71 88.8	2	1.3	unchanged	138 86.3
1 (6-15 cells)	0	0.0	increased	2 2.5	0	0.0	increased	0 0.0	0	0.0	increased	2 1.3
2 (16-25 cells)	0	0.0	total	80 100.0	0	0.0	total	80 100.0	0	0.0	total	160 100.0
3 (26-50 cells)	0	0.0			0	0.0			0	0.0		
4 (>50 cells)	0	0.0			0	0.0			0	0.0		
Total	79	100.0			79	100.0			158	100.0		

SAS program: P03\_T04\_02\_01.sas - SAS dataset(s): RAND,SLIT

**Table 4.2-2 (1 of 1): Slit lamp evaluation during the study - Grade of CELLULARITY of the treated eye during the study and change from Day 1 PP sample**

Visit	GEL (N=78)				EYE DROPS (N=80)				ALL (N=158)			
			Change from Day 1				Change from Day 1				Change from Day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)												
0 grade	68	87.2			71	88.8			139	88.0		
0.5 grade	6	7.7			4	5.0			10	6.3		
1 grade	4	5.1			5	6.3			9	5.7		
2 grade	0	0.0			0	0.0			0	0.0		
3 grade	0	0.0			0	0.0			0	0.0		
4 grade	0	0.0			0	0.0			0	0.0		
Total	78	100.0			80	100.0			158	100.0		
V4 (day 7 after surgery) - (n %)												
0 (<1 cell)	73	93.6	decreased	8 10.3	78	97.5	decreased	8 10.0	151	95.6	decreased	16 10.1
0.5 (1-5 cells)	5	6.4	unchanged	69 88.5	2	2.5	unchanged	72 90.0	7	4.4	unchanged	141 89.2
1 (6-15 cells)	0	0.0	increased	1 1.3	0	0.0	increased	0 0.0	0	0.0	increased	1 0.6
2 (16-25 cells)	0	0.0	total	78 100.0	0	0.0	total	80 100.0	0	0.0	total	158 100.0
3 (26-50 cells)	0	0.0			0	0.0			0	0.0		
4 (>50 cells)	0	0.0			0	0.0			0	0.0		
Total	78	100.0			80	100.0			158	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
0 (<1 cell)	78	100.0	decreased	10 12.8	79	98.8	decreased	9 11.3	157	99.4	decreased	19 12.0
0.5 (1-5 cells)	0	0.0	unchanged	68 87.2	1	1.3	unchanged	71 88.8	1	0.6	unchanged	139 88.0
1 (6-15 cells)	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
2 (16-25 cells)	0	0.0	total	78 100.0	0	0.0	total	80 100.0	0	0.0	total	158 100.0
3 (26-50 cells)	0	0.0			0	0.0			0	0.0		
4 (>50 cells)	0	0.0			0	0.0			0	0.0		
Total	78	100.0			80	100.0			158	100.0		
V6 (follow-up at day 60 after surgery) - (n %)												
0 (<1 cell)	75	97.4	decreased	10 12.8	79	100.0	decreased	8 10.0	154	98.7	decreased	18 11.4
0.5 (1-5 cells)	2	2.6	unchanged	65 83.3	0	0.0	unchanged	71 88.8	2	1.3	unchanged	136 86.1
1 (6-15 cells)	0	0.0	increased	2 2.6	0	0.0	increased	0 0.0	0	0.0	increased	2 1.3
2 (16-25 cells)	0	0.0	total	78 100.0	0	0.0	total	80 100.0	0	0.0	total	158 100.0
3 (26-50 cells)	0	0.0			0	0.0			0	0.0		
4 (>50 cells)	0	0.0			0	0.0			0	0.0		
Total	77	100.0			79	100.0			156	100.0		

SAS program: P03\_T04\_02\_02.sas - SAS dataset(s): RAND,SLIT

**Table 4.3-1 (1 of 1): Slit lamp evaluation during the study - Grade of FLARE of the treated eye during the study and change from Day 1 ITT sample**

Visit	GEL (N=80)				EYE DROPS (N=80)				ALL (N=160)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%			n	%			n	%					
			n	%			n	%			n	%			
V3 (day 1 after surgery) - (n %)															
None	58	72.5			53	66.3			111	69.4					
Faint	22	27.5			27	33.8			49	30.6					
Moderate	0	0.0			0	0.0			0	0.0					
Marked	0	0.0			0	0.0			0	0.0					
Intense	0	0.0			0	0.0			0	0.0					
Total	80	100.0			80	100.0			160	100.0					
V4 (day 7 after surgery) - (n %)															
None	75	93.8	decreased	17	21.3	77	96.3	decreased	24	30.0	152	95.0	decreased	41	25.6
Faint	5	6.3	unchanged	63	78.8	3	3.8	unchanged	56	70.0	8	5.0	unchanged	119	74.4
Moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
Marked	0	0.0	total	80	100.0	0	0.0	total	80	100.0	0	0.0	total	160	100.0
Intense	0	0.0			0	0.0			0	0.0					
Total	80	100.0			80	100.0			160	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
None	80	100.0	decreased	22	27.5	80	100.0	decreased	27	33.8	160	100.0	decreased	49	30.6
Faint	0	0.0	unchanged	58	72.5	0	0.0	unchanged	53	66.3	0	0.0	unchanged	111	69.4
Moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
Marked	0	0.0	total	80	100.0	0	0.0	total	80	100.0	0	0.0	total	160	100.0
Intense	0	0.0			0	0.0			0	0.0					
Total	80	100.0			80	100.0			160	100.0					
V6 (follow-up at day 60 after surgery) - (n %)															
None	79	100.0	decreased	22	27.5	79	100.0	decreased	26	32.5	158	100.0	decreased	48	30.0
Faint	0	0.0	unchanged	57	71.3	0	0.0	unchanged	53	66.3	0	0.0	unchanged	110	68.8
Moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
Marked	0	0.0	total	80	100.0	0	0.0	total	80	100.0	0	0.0	total	160	100.0
Intense	0	0.0			0	0.0			0	0.0					
Total	79	100.0			79	100.0			158	100.0					

SAS program: P03\_T04\_03\_01.sas - SAS dataset(s): RAND,SLIT

**Table 4.3-2 (1 of 1): Slit lamp evaluation during the study - Grade of FLARE of the treated eye during the study and change from Day 1 PP sample**

Visit	GEL (N=78)				EYE DROPS (N=80)				ALL (N=158)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%			n	%			n	%					
			n	%			n	%			n	%			
V3 (day 1 after surgery) - (n %)															
None	56	71.8			53	66.3			109	69.0					
Faint	22	28.2			27	33.8			49	31.0					
Moderate	0	0.0			0	0.0			0	0.0					
Marked	0	0.0			0	0.0			0	0.0					
Intense	0	0.0			0	0.0			0	0.0					
Total	78	100.0			80	100.0			158	100.0					
V4 (day 7 after surgery) - (n %)															
None	73	93.6	decreased	17	21.8	77	96.3	decreased	24	30.0	150	94.9	decreased	41	25.9
Faint	5	6.4	unchanged	61	78.2	3	3.8	unchanged	56	70.0	8	5.1	unchanged	117	74.1
Moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
Marked	0	0.0	total	78	100.0	0	0.0	total	80	100.0	0	0.0	total	158	100.0
Intense	0	0.0			0	0.0			0	0.0					
Total	78	100.0			80	100.0			158	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
None	78	100.0	decreased	22	28.2	80	100.0	decreased	27	33.8	158	100.0	decreased	49	31.0
Faint	0	0.0	unchanged	56	71.8	0	0.0	unchanged	53	66.3	0	0.0	unchanged	109	69.0
Moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
Marked	0	0.0	total	78	100.0	0	0.0	total	80	100.0	0	0.0	total	158	100.0
Intense	0	0.0			0	0.0			0	0.0					
Total	78	100.0			80	100.0			158	100.0					
V6 (follow-up at day 60 after surgery) - (n %)															
None	77	100.0	decreased	22	28.2	79	100.0	decreased	26	32.5	156	100.0	decreased	48	30.4
Faint	0	0.0	unchanged	55	70.5	0	0.0	unchanged	53	66.3	0	0.0	unchanged	108	68.4
Moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
Marked	0	0.0	total	78	100.0	0	0.0	total	80	100.0	0	0.0	total	158	100.0
Intense	0	0.0			0	0.0			0	0.0					
Total	77	100.0			79	100.0			156	100.0					

SAS program: P03\_T04\_03\_02.sas - SAS dataset(s): RAND,SLIT

**Table 4.4-1 (1 of 2): Slit lamp evaluation during the study - Summary of study drug response at endpoint stratified by sex, age and centre  
ITT sample**

Variable	GEL (N=80)		EYE DROPS (N=80)		ALL (N=160)	
	n	%	n	%	n	%
<b>Whole sample - (n %)</b>						
full responder	72	90.0	76	95.0	148	92.5
partial responder	8	10.0	4	5.0	12	7.5
no responder	0	0.0	0	0.0	0	0.0
Total	80	100.0	80	100.0	160	100.0
<b>Sex - (n %)</b>						
Male						
full responder	35	94.6	23	95.8	58	95.1
partial responder	2	5.4	1	4.2	3	4.9
no responder	0	0.0	0	0.0	0	0.0
Total	37	100.0	24	100.0	61	100.0
Female						
full responder	37	86.0	53	94.6	90	90.9
partial responder	6	14.0	3	5.4	9	9.1
no responder	0	0.0	0	0.0	0	0.0
Total	43	100.0	56	100.0	99	100.0
<b>Age</b>						
<=65 yrs						
full responder	15	93.8	11	84.6	26	89.7
partial responder	1	6.3	2	15.4	3	10.3
no responder	0	0.0	0	0.0	0	0.0
Total	16	100.0	13	100.0	29	100.0
66-74 yrs						
full responder	32	88.9	28	100.0	60	93.8
partial responder	4	11.1	0	0.0	4	6.3
no responder	0	0.0	0	0.0	0	0.0
Total	36	100.0	28	100.0	64	100.0
>=75 yrs						
full responder	25	89.3	37	94.9	62	92.5
partial responder	3	10.7	2	5.1	5	7.5
no responder	0	0.0	0	0.0	0	0.0
Total	28	100.0	39	100.0	67	100.0

**Table 4.4-1 (2 of 2): Slit lamp evaluation during the study - Summary of study drug response at endpoint stratified by sex, age and centre  
ITT sample**

Variable	GEL (N=80)		EYE DROPS (N=80)		ALL (N=160)	
	n	%	n	%	n	%
<b>Centre</b>						
1001 (Rome)						
full responder	27	96.4	26	100.0	53	98.1
partial responder	1	3.6	0	0.0	1	1.9
no responder	0	0.0	0	0.0	0	0.0
Total	28	100.0	26	100.0	54	100.0
1002 (Florence)						
full responder	15	75.0	19	86.4	34	81.0
partial responder	5	25.0	3	13.6	8	19.0
no responder	0	0.0	0	0.0	0	0.0
Total	20	100.0	22	100.0	42	100.0
1003 (Milan)						
full responder	25	100.0	25	100.0	50	100.0
partial responder	0	0.0	0	0.0	0	0.0
no responder	0	0.0	0	0.0	0	0.0
Total	25	100.0	25	100.0	50	100.0
Germany						
full responder	5	71.4	6	85.7	11	78.6
partial responder	2	28.6	1	14.3	3	21.4
no responder	0	0.0	0	0.0	0	0.0
Total	7	100.0	7	100.0	14	100.0

SAS program: P03\_T04\_04\_01.sas - SAS dataset(s): RAND,SLIT

**NOTE:**

Responder is the patient who shows a decrease of the degree at endpoint respect to baseline or absence of degree in both the visits.

Based on this definition, the patients in analysis were classified as follows:

Full responder = both cellularity and flare measurements with degree zero at endpoint or absence of degree both at baseline and endpoint

Partial responder = only one response for the two measurements

No responder = no response for both measurements

**Table 4.4-2 (1 of 2): Slit lamp evaluation during the study - Summary of study drug response at endpoint stratified by sex, age and centre  
PP sample**

Variable	GEL (N=78)		EYE DROPS (N=80)		ALL (N=158)	
	n	%	n	%	n	%
<b>Whole sample - (n %)</b>						
full responder	70	89.7	76	95.0	146	92.4
partial responder	8	10.3	4	5.0	12	7.6
no responder	0	0.0	0	0.0	0	0.0
Total	78	100.0	80	100.0	158	100.0
<b>Sex - (n %)</b>						
Male						
full responder	34	94.4	23	95.8	57	95.0
partial responder	2	5.6	1	4.2	3	5.0
no responder	0	0.0	0	0.0	0	0.0
Total	36	100.0	24	100.0	60	100.0
Female						
full responder	36	85.7	53	94.6	89	90.8
partial responder	6	14.3	3	5.4	9	9.2
no responder	0	0.0	0	0.0	0	0.0
Total	42	100.0	56	100.0	98	100.0
<b>Age</b>						
<=65 yrs						
full responder	13	92.9	11	84.6	24	88.9
partial responder	1	7.1	2	15.4	3	11.1
no responder	0	0.0	0	0.0	0	0.0
Total	14	100.0	13	100.0	27	100.0
66-74 yrs						
full responder	32	88.9	28	100.0	60	93.8
partial responder	4	11.1	0	0.0	4	6.3
no responder	0	0.0	0	0.0	0	0.0
Total	36	100.0	28	100.0	64	100.0
>=75 yrs						
full responder	25	89.3	37	94.9	62	92.5
partial responder	3	10.7	2	5.1	5	7.5
no responder	0	0.0	0	0.0	0	0.0
Total	28	100.0	39	100.0	67	100.0



**Table 4.4-2 (2 of 2): Slit lamp evaluation during the study - Summary of study drug response at endpoint stratified by sex, age and centre PP sample**

Variable	GEL (N=78)		EYE DROPS (N=80)		ALL (N=158)	
	n	%	n	%	n	%
<b>Centre</b>						
1001 (Rome)						
full responder	27	96.4	26	100.0	53	98.1
partial responder	1	3.6	0	0.0	1	1.9
no responder	0	0.0	0	0.0	0	0.0
Total	28	100.0	26	100.0	54	100.0
1002 (Florence)						
full responder	15	75.0	19	86.4	34	81.0
partial responder	5	25.0	3	13.6	8	19.0
no responder	0	0.0	0	0.0	0	0.0
Total	20	100.0	22	100.0	42	100.0
1003 (Milan)						
full responder	23	100.0	25	100.0	48	100.0
partial responder	0	0.0	0	0.0	0	0.0
no responder	0	0.0	0	0.0	0	0.0
Total	23	100.0	25	100.0	48	100.0
Germany						
full responder	5	71.4	6	85.7	11	78.6
partial responder	2	28.6	1	14.3	3	21.4
no responder	0	0.0	0	0.0	0	0.0
Total	7	100.0	7	100.0	14	100.0

SAS program: P03\_T04\_04\_02.sas - SAS dataset(s): RAND,SLIT

**NOTE:**

Responder is the patient who shows a decrease of the degree at endpoint respect to baseline or absence of degree in both the visits.

Based on this definition, the patients in analysis were classified as follows:

Full responder = both cellularity and flare measurements with degree zero at endpoint or absence of degree both at baseline and endpoint

Partial responder = only one response for the two measurements

No responder = no response for both measurements

**Table 4.5-1 (1 of 1): Slit lamp evaluation during the study**  
**Analysis to test the noninferiority of GEL group (test) vs. EYE DROPS group (control) on occurrence of full-responder at endpoint ITT sample**

Study drug	Observed results		Non inferiority margin	Test	Estimated risk difference	97.5% Confidende interval	
	n/N	%				Lower	Upper
GEL	72/80	90.0	-0.10	Univariate test	-0.0500	-0.0580	0.1580
EYE DROPS	76/80	95.0		Multivariate test*	-0.0576	-0.0378	0.1530

SAS program: P03\_T04\_05\_01.sas - SAS dataset(s): RAND,SLIT

\* The co-factors Sex and Age were considered in the model  
The co-factor Site were not considered due the very small number of patients (N=14) for Germany

**Table 4.5-2 (1 of 1): Slit lamp evaluation during the study**  
**Analysis to test the noninferiority of GEL group (test) vs. EYE DROPS group (control) on occurrence of full-responder at endpoint PP sample**

Study drug	Observed results		Non inferiority margin	Test	Estimated risk difference	97.5% Confidende interval	
	n/N	%				Lower	Upper
GEL	70/78	89.7	-0.10	Univariate test	-0.0526	-0.0562	0.1613
EYE DROPS	76/80	95.0		Multivariate test*	-0.0599	-0.0366	0.1564

SAS program: P03\_T04\_05\_02.sas - SAS dataset(s): RAND,SLIT

\* The co-factors Sex and Age were considered in the model  
The co-factor Site were not considered due the very small number of patients (N=14) for Germany

**Table 4.6-1 (1 of 1): Slit lamp evaluation during the study**  
**Analysis to test the noninferiority of GEL group (test) vs. DRP group (control) on occurrence of full-responder at Visit 5 (Day 15)**  
**ITT sample**

Study drug	Observed results		Non inferiority margin	Test	Estimated risk difference	97.5% Confidende interval	
	n/N	%				Lower	Upper
GEL	80/80	100.0	-0.10	Univariate test	not evaluable		
EYE DROPS	80/80	100.0		Multivariate test*	not evaluable		

SAS program: P03\_T04\_06\_01.sas - SAS dataset(s): RAND,SLIT

\* The co-factors Sex and Age were considered in the model  
The co-factor Site were not considered due the very small number of patients (N=14) for Germany

**Table 4.6-2 (1 of 1): Slit lamp evaluation during the study**  
**Analysis to test the noninferiority of GEL group (test) vs. DRP group (control) on occurrence of full-responder at Visit 5 (Day 15)**  
**PP sample**

Study drug	Observed results		Non inferiority margin	Test	Estimated risk difference	97.5% Confidende interval	
	n/N	%				Lower	Upper
GEL	78/78	100.0	-0.10	Univariate test	not evaluable		
EYE DROPS	80/80	100.0		Multivariate test*	not evaluable		

SAS program: P03\_T04\_06\_02.sas - SAS dataset(s): RAND,SLIT

\* The co-factors Sex and Age were considered in the model  
The co-factor Site were not considered due the very small number of patients (N=14) for Germany

**Table 4.7-1 (1 of 1): Slit lamp evaluation during the study**  
**Grade of FLARE of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7)**  
**ITT sample**

Visit	GEL (N=22/80)		EYE DROPS (N=27/80)		ALL (N=49/160)	
	n	%	n	%	n	%
V4 (day 7 after surgery) - (n %)						
None	17	77.3	24	88.9	41	83.7
Faint	5	22.7	3	11.1	8	16.3
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	22	100.0	27	100.0	49	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
None	22	100.0	27	100.0	49	100.0
Faint	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	22	100.0	27	100.0	49	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
None	22	100.0	26	100.0	48	100.0
Faint	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	22	100.0	26	100.0	48	100.0

SAS program: P03\_T04\_07\_01.sas - SAS dataset(s): RAND,SLIT

**Table 4.7-2 (1 of 1): Slit lamp evaluation during the study**  
**Grade of FLARE of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7)**  
**PP sample**

Visit	GEL (N=22/78)		EYE DROPS (N=27/80)		ALL (N=49/158)	
	n	%	n	%	n	%
V4 (day 7 after surgery) - (n %)						
None	17	77.3	24	88.9	41	83.7
Faint	5	22.7	3	11.1	8	16.3
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	22	100.0	27	100.0	49	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
None	22	100.0	27	100.0	49	100.0
Faint	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	22	100.0	27	100.0	49	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
None	22	100.0	26	100.0	48	100.0
Faint	0	0.0	0	0.0	0	0.0
Moderate	0	0.0	0	0.0	0	0.0
Marked	0	0.0	0	0.0	0	0.0
Intense	0	0.0	0	0.0	0	0.0
Total	22	100.0	26	100.0	48	100.0

SAS program: P03\_T04\_07\_02.sas - SAS dataset(s): RAND,SLIT

**Table 4.8-1 (1 of 1): Slit lamp evaluation during the study**  
**Grade of CELLULARITY of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7)**  
**ITT sample**

Visit	GEL (N=10/80)		EYE DROPS (N=9/80)		ALL (N=19/160)	
	n	%	n	%	n	%
V4 (day 7 after surgery) - (n %)						
0 grade	6	60.0	7	77.8	13	68.4
0.5 grade	4	40.0	2	22.2	6	31.6
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	10	100.0	9	100.0	19	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
0 grade	10	100.0	8	88.9	18	94.7
0.5 grade	0	0.0	1	11.1	1	5.3
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	10	100.0	9	100.0	19	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
0 grade	10	100.0	8	100.0	18	100.0
0.5 grade	0	0.0	0	0.0	0	0.0
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	10	100.0	8	100.0	18	100.0

SAS program: P03\_T04\_08\_01.sas - SAS dataset(s): RAND,SLIT



**Table 4.8-2 (1 of 1): Slit lamp evaluation during the study**  
**Grade of CELLULARITY of the treated eye during the study only for patients showing degree greater than zero at Visit 3 (Day 7)**  
**PP sample**

Visit	GEL (N=10/78)		EYE DROPS (N=9/80)		ALL (N=19/158)	
	n	%	n	%	n	%
V4 (day 7 after surgery) - (n %)						
0 grade	6	60.0	7	77.8	13	68.4
0.5 grade	4	40.0	2	22.2	6	31.6
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	10	100.0	9	100.0	19	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
0 grade	10	100.0	8	88.9	18	94.7
0.5 grade	0	0.0	1	11.1	1	5.3
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	10	100.0	9	100.0	19	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
0 grade	10	100.0	8	100.0	18	100.0
0.5 grade	0	0.0	0	0.0	0	0.0
1 grade	0	0.0	0	0.0	0	0.0
2 grade	0	0.0	0	0.0	0	0.0
3 grade	0	0.0	0	0.0	0	0.0
4 grade	0	0.0	0	0.0	0	0.0
Total	10	100.0	8	100.0	18	100.0

SAS program: P03\_T04\_08\_02.sas - SAS dataset(s): RAND,SLIT

**Table 4.9 (1 of 1): Microbial load during the study - - Frequency of test execution  
ITT sample**

Visit	GEL (N=80)		EYE DROPS (N=80)		ALL (N=160)	
	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)						
No	80	100.0	80	100.0	160	100.0
Yes	0	0.0	0	0.0	0	0.0
Total	80	100.0	80	100.0	160	100.0
V4 (day 7 after surgery) - (n %)						
No	80	100.0	80	100.0	160	100.0
Yes	0	0.0	0	0.0	0	0.0
Total	80	100.0	80	100.0	160	100.0

SAS program: P03\_T04\_09.sas - SAS dataset(s): RAND,MICRO-LOAD

## **5. Medications**

**Table 5.1 (1 of 6): Number of patients with concomitant medications, by ATC therapeutic class and preferred term  
Safety sample**

ATC Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one concomitant medication	61	71.8	55	66.3	116	69.0
-----	-----	-----	-----	-----	-----	-----
ALIMENTARY TRACT AND METABOLISM	14	16.5	8	9.6	22	13.1
ALKALA N	1	1.2	.	.	1	0.6
CALCIUM	1	1.2	.	.	1	0.6
CALCIUM GLUCONATE	1	1.2	.	.	1	0.6
COLECALCIFEROL	4	4.7	1	1.2	5	3.0
ESOMEPRAZOLE	1	1.2	2	2.4	3	1.8
INSULIN HUMAN	.	.	1	1.2	1	0.6
LACTULOSE	.	.	1	1.2	1	0.6
LANSOPRAZOLE	.	.	2	2.4	2	1.2
LEKOVIT CA	1	1.2	.	.	1	0.6
LEVOCARNITINE	1	1.2	.	.	1	0.6
METFORMIN	1	1.2	1	1.2	2	1.2
METOCLOPRAMIDE	1	1.2	.	.	1	0.6
MOVICOL	1	1.2	.	.	1	0.6
OMEPRAZOLE	1	1.2	1	1.2	2	1.2
PANTOPRAZOLE	3	3.5	1	1.2	4	2.4
SITAGLIPTIN	.	.	1	1.2	1	0.6
THIOCTIC ACID	1	1.2	.	.	1	0.6
UBIDECARENONE	1	1.2	.	.	1	0.6
URSODEOXYCHOLIC ACID	1	1.2	.	.	1	0.6
ANTIINFECTIVES FOR SYSTEMIC USE	7	8.2	6	7.2	13	7.7
CEFUROXIME	7	8.2	6	7.2	13	7.7
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	1	1.2	1	1.2	2	1.2
IMATINIB	.	.	1	1.2	1	0.6
MYCOPHENOLIC ACID	1	1.2	.	.	1	0.6
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENT	.	.	1	1.2	1	0.6
HYDROXYCHLOROQUINE	.	.	1	1.2	1	0.6

**Table 5.1 (2 of 6): Number of patients with concomitant medications, by ATC therapeutic class and preferred term  
Safety sample**

ATC Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
BLOOD AND BLOOD FORMING ORGANS	16	18.8	17	20.5	33	19.6
ACETYLSALICYLIC ACID	12	14.1	12	14.5	24	14.3
CLOPIDOGREL	1	1.2	3	3.6	4	2.4
DABIGATRAN	2	2.4	.	.	2	1.2
EDOXABAN	.	.	2	2.4	2	1.2
FONDAPARINUX	1	1.2	.	.	1	0.6
HYDROXOCOBALAMIN	1	1.2	1	1.2	2	1.2
MESOGLYCAN	.	.	1	1.2	1	0.6
WARFARIN	.	.	1	1.2	1	0.6

**Table 5.1 (3 of 6): Number of patients with concomitant medications, by ATC therapeutic class and preferred term  
Safety sample**

ATC Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
CARDIOVASCULAR SYSTEM	49	57.6	46	55.4	95	56.5
AMIODARONE	1	1.2	.	.	1	0.6
AMLODIPINE	4	4.7	2	2.4	6	3.6
ATENOLOL	2	2.4	3	3.6	5	3.0
ATORVASTATIN	6	7.1	5	6.0	11	6.5
BENICAR HCT	.	.	1	1.2	1	0.6
BISOPROLOL	6	7.1	8	9.6	14	8.3
BOSENTAN	1	1.2	.	.	1	0.6
CANDESARTAN	4	4.7	2	2.4	6	3.6
CANDESARTAN W/HYDROCHLOROTHIAZIDE	.	.	1	1.2	1	0.6
CANRENOIC ACID	.	.	1	1.2	1	0.6
CARACE PLUS	.	.	1	1.2	1	0.6
CARVEDILOL	2	2.4	.	.	2	1.2
CHLORTALIDONE	1	1.2	1	1.2	2	1.2
CO-DIOVAN	1	1.2	2	2.4	3	1.8
DELAPRIDE	1	1.2	.	.	1	0.6
DILTIAZEM	.	.	1	1.2	1	0.6
ENALAPRIL	.	.	2	2.4	2	1.2
FENOFIBRATE	1	1.2	.	.	1	0.6
FISH OIL	.	.	1	1.2	1	0.6
FOSINOPRIL	.	.	1	1.2	1	0.6
FUROSEMIDE	.	.	3	3.6	3	1.8
GLYCERYL TRINITRATE	.	.	1	1.2	1	0.6
HYDROCHLOROTHIAZIDE	.	.	1	1.2	1	0.6
IRBESARTAN	1	1.2	1	1.2	2	1.2
ISOSORBIDE	.	.	1	1.2	1	0.6
KARVEA HCT	1	1.2	1	1.2	2	1.2
LACIDIPINE	1	1.2	.	.	1	0.6
LERCANIDIPINE	.	.	2	2.4	2	1.2
LISINOPRIL	5	5.9	.	.	5	3.0
LOSARTAN	2	2.4	.	.	2	1.2
METHYLDOPA	1	1.2	1	1.2	2	1.2
METOPROLOL	3	3.5	3	3.6	6	3.6
MODURETIC	2	2.4	2	2.4	4	2.4
NEBICARD-H	.	.	2	2.4	2	1.2
NEBIVOLOL	3	3.5	5	6.0	8	4.8
NIFEDIPINE	1	1.2	.	.	1	0.6
OLMESAFE AM	1	1.2	.	.	1	0.6
(cont'd)						

**Table 5.1 (4 of 6): Number of patients with concomitant medications, by ATC therapeutic class and preferred term  
Safety sample**

ATC Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
CARDIOVASCULAR SYSTEM						
OLMESARTAN	.	.	1	1.2	1	0.6
RAMIPRIL	9	10.6	5	6.0	14	8.3
ROSUVASTATIN	1	1.2	1	1.2	2	1.2
SILDENAFIL	1	1.2	.	.	1	0.6
SIMVASTATIN	7	8.2	6	7.2	13	7.7
SOTALOL	2	2.4	.	.	2	1.2
TELMISARTAN	.	.	1	1.2	1	0.6
VALSARTAN	1	1.2	3	3.6	4	2.4
VERAPAMIL	1	1.2	.	.	1	0.6
GENITO URINARY SYSTEM AND SEX HORMONES	2	2.4	3	3.6	5	3.0
ALFUZOSIN	1	1.2	.	.	1	0.6
DUTASTERIDE	1	1.2	1	1.2	2	1.2
FINASTERIDE	.	.	1	1.2	1	0.6
TAMSULOSIN	1	1.2	2	2.4	3	1.8
MUSCULO-SKELETAL SYSTEM	7	8.2	3	3.6	10	6.0
ALENDRONIC ACID	2	2.4	.	.	2	1.2
ALLOPURINOL	3	3.5	2	2.4	5	3.0
FOSAVANCE	.	.	1	1.2	1	0.6
IBANDRONIC ACID	1	1.2	.	.	1	0.6
RISEDRONIC ACID	1	1.2	.	.	1	0.6

**Table 5.1 (5 of 6): Number of patients with concomitant medications, by ATC therapeutic class and preferred term  
Safety sample**

ATC Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
NERVOUS SYSTEM	16	18.8	8	9.6	24	14.3
ADEMETIONINE	1	1.2	.	.	1	0.6
ALPRAZOLAM	2	2.4	.	.	2	1.2
BETAHISTINE	1	1.2	.	.	1	0.6
BROMAZEPAM	1	1.2	1	1.2	2	1.2
BROTIZOLAM	.	.	1	1.2	1	0.6
CITALOPRAM	1	1.2	.	.	1	0.6
ESCITALOPRAM	1	1.2	1	1.2	2	1.2
FENTANYL	.	.	1	1.2	1	0.6
LORAZEPAM	2	2.4	1	1.2	3	1.8
METAMIZOLE	1	1.2	.	.	1	0.6
NITRAZEPAM	7	8.2	5	6.0	12	7.1
OLANZAPINE	.	.	1	1.2	1	0.6
PAROXETINE	1	1.2	.	.	1	0.6
PRILOCAINE	7	8.2	4	4.8	11	6.5
VALPROIC ACID	1	1.2	.	.	1	0.6
RESPIRATORY SYSTEM	.	.	2	2.4	2	1.2
CETIRIZINE	.	.	1	1.2	1	0.6
DUOVENT	.	.	1	1.2	1	0.6
TIOTROPIUM	.	.	1	1.2	1	0.6
SENSORY ORGANS	8	9.4	8	9.6	16	9.5
BRIMONIDINE	1	1.2	.	.	1	0.6
BRINZOLAMIDE	.	.	1	1.2	1	0.6
COSOPT	2	2.4	.	.	2	1.2
DEXPANTHENOL	1	1.2	.	.	1	0.6
DICLOFENAC	.	.	1	1.2	1	0.6
EPINEPHRINE	5	5.9	.	.	5	3.0
HYALURONIC ACID	.	.	2	2.4	2	1.2
HYLO PARIN	.	.	1	1.2	1	0.6
HYPROMELLOSE	.	.	1	1.2	1	0.6
NEPAFENAC	.	.	1	1.2	1	0.6
OFLOXACIN	.	.	1	1.2	1	0.6
PHENYLEPHRINE W/TROPICAMIDE	4	4.7	4	4.8	8	4.8
PREDNISOLONE	1	1.2	1	1.2	2	1.2
SYSTANE LUBRICANT	.	.	1	1.2	1	0.6
TIMOLOL	1	1.2	.	.	1	0.6
TROPICAMIDE	2	2.4	1	1.2	3	1.8



**Table 5.1 (6 of 6): Number of patients with concomitant medications, by ATC therapeutic class and preferred term  
Safety sample**

ATC Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES	6	7.1	10	12.0	16	9.5
LEVOTHYROXINE	6	7.1	8	9.6	14	8.3
PREDNISOLONE	.	.	1	1.2	1	0.6
TERIPARATIDE	.	.	1	1.2	1	0.6
VARIOUS	1	1.2	1	1.2	2	1.2
CUCURBITA PEPO	1	1.2	.	.	1	0.6
GENERAL NUTRIENTS	1	1.2	.	.	1	0.6
SERENOA REPENS	.	.	1	1.2	1	0.6

SAS program: P02\_T05\_01.sas - SAS dataset(s):

**Note:**

- A subject with multiple occurrences is counted only once in the respective category.
- Arranged alphabetically

**Table 5.2 (1 of 1): Number of patients assuming study drugs during the study  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168 )	
	n	%	n	%	n	%
V2 (surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
No	0	0.0	3	3.6	3	1.8
Yes	83	100.0	80	96.4	163	98.2
Total	83	100.0	83	100.0	166	100.0
V4 (day 7 after surgery) - (n %)						
No	3	3.6	0	0.0	3	1.8
Yes	80	96.4	82	100.0	162	98.2
Total	83	100.0	82	100.0	165	100.0

SAS program: P03\_T05\_02.sas - SAS dataset(s): RAND,TREATMENT

## **6. Safety evaluation**

## **6.1 Intra Ocular Pressure**

**Table 6.1-1 (1 of 1): Intra ocular pressure on treated eye - Point estimate of IOP and change from Visit 1  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from Visit 1				Change from Visit 1				Change from Visit 1	
V1 (before surgery) - (n %)												
N	85				83				168			
Mean	15.3				15.4				15.4			
SD	1.9				1.8				1.9			
Median	16.0				16.0				16.0			
Range	10.0	19.0			10.0	20.0			10.0	20.0		
V3 (day 1 after surgery) - (n %)												
N	83		83		83		83		166		166	
Mean	16.0		0.7		15.6		0.2		15.8		0.4	
SD	2.7		2.5		2.2		2.2		2.4		2.4	
Median	16.0		0.0		16.0		0.0		16.0		0.0	
Range	12.0	34.0	-4.0	15.0	11.0	22.0	-4.0	8.0	11.0	34.0	-4.0	15.0
95 CI			0.1	1.2			-0.2	0.7			0.1	0.8
V4 (day 7 after surgery) - (n %)												
N	83		83		82		82		165		165	
Mean	15.0		-0.3		14.8		-0.6		14.9		-0.5	
SD	2.0		1.9		1.7		2.1		1.8		2.0	
Median	16.0		0.0		15.0		0.0		15.0		0.0	
Range	9.0	19.0	-7.0	4.0	10.0	19.0	-7.0	6.0	9.0	19.0	-7.0	6.0
95 CI			-0.8	0.1			-1.0	-0.1			-0.8	-0.2
V5 (day 15 after surgery - end of treatment) - (n %)												
N	81		81		81		81		162		162	
Mean	14.8		-0.6		14.9		-0.5		14.8		-0.5	
SD	2.0		2.1		1.9		2.2		2.0		2.2	
Median	15.0		0.0		15.0		0.0		15.0		0.0	
Range	8.0	18.0	-8.0	6.0	10.0	21.0	-7.0	6.0	8.0	21.0	-8.0	6.0
95 CI			-1.0	-0.1			-1.0	0.0			-0.8	-0.2
V6 (follow-up at day 60 after surgery) - (n %)												
N	80		80		80		80		160		160	
Mean	14.4		-0.9		14.6		-0.7		14.5		-0.8	
SD	1.7		1.9		1.7		2.1		1.7		2.0	
Median	15.0		-1.0		15.0		-1.0		15.0		-1.0	
Range	9.0	18.0	-6.0	5.0	10.0	20.0	-6.0	6.0	9.0	20.0	-6.0	6.0
95 CI			-1.3	-0.4			-1.1	-0.2			-1.1	-0.4

SAS program: P03\_T06\_01\_01.sas - SAS dataset(s): RAND,SURGERY,INTRA\_PRES

**Listing of patients with an increment of IOP between visits greater or equal to 6 mmHg during the study - Safety sample**

Subj. code	Study drug	Sex	Age	Change from Screening				Change between visits		
				Day 1 vs Screen.	Day 7 vs Screen.	Day 15 vs Screen.	Day 60 vs Screen.	Day 1 vs Day 7	Day 7 vs Day 15	Day 15 vs Day 60
100327	GEL	Female	74	7	-3	-2	-3	-10	1	-1
100345	GEL	Male	48	6	4	6	5	-2	2	-1
100347	GEL	Male	57	6	4	3	4	-2	-1	1
200101	GEL	Female	65	15	-3	-2	-3	-18	1	-1
100101	EYE DROPS	Female	84	-1	5	4	3	6	-1	-1
100312	EYE DROPS	Female	71	-1	-1	6	5	0	7	-1
100316	EYE DROPS	Male	76	0	-4	2	-1	-4	6	-3
100326	EYE DROPS	Male	81	2	-5	-5	1	-7	0	6
100328	EYE DROPS	Male	83	6	-1	-2	0	-7	-1	2
100344	EYE DROPS	Female	68	8	6	5	6	-2	-1	1
200112	EYE DROPS	Male	85	6	-2	2	-4	-8	4	-6
200202	EYE DROPS	Female	71	6	3	2	0	-3	-1	-2

Listing produced from SAS program P03\_T06\_01\_02 IOP change.sas - SAS dataset(s): RAND, INTRA\_PRES

**Table 6.1-2 (1 of 1): Intra ocular pressure on non-treated eye - Point estimate of IOP and change from Visit 1  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from Visit 1				Change from Visit 1				Change from Visit 1	
V1 (before surgery) - (n %)												
N	85				83				168			
Mean	15.1				15.2				15.1			
SD	2.0				1.7				1.8			
Median	15.0				15.0				15.0			
Range	10.0	20.0			10.0	19.0			10.0	20.0		
V3 (day 1 after surgery) - (n %)												
N	83		83		83		83		166		166	
Mean	15.6		0.4		15.3		0.2		15.5		0.3	
SD	2.0		2.2		1.8		2.0		1.9		2.1	
Median	16.0		0.0		15.0		0.0		16.0		0.0	
Range	11.0	20.0	-4.0	7.0	11.0	20.0	-6.0	8.0	11.0	20.0	-6.0	8.0
95 CI			-0.0	0.9			-0.3	0.6			-0.0	0.6
V4 (day 7 after surgery) - (n %)												
N	82		82		82		82		164		164	
Mean	15.1		0.0		14.9		-0.3		15.0		-0.2	
SD	1.8		1.8		1.7		1.8		1.7		1.8	
Median	15.0		0.0		15.0		0.0		15.0		0.0	
Range	10.0	19.0	-4.0	6.0	11.0	18.0	-5.0	6.0	10.0	19.0	-5.0	6.0
95 CI			-0.4	0.4			-0.7	0.1			-0.4	0.1
V5 (day 15 after surgery - end of treatment) - (n %)												
N	81		81		81		81		162		162	
Mean	15.0		-0.1		14.7		-0.5		14.8		-0.3	
SD	1.6		1.8		1.7		1.9		1.7		1.8	
Median	15.0		0.0		15.0		0.0		15.0		0.0	
Range	10.0	19.0	-4.0	6.0	10.0	19.0	-6.0	6.0	10.0	19.0	-6.0	6.0
95 CI			-0.5	0.3			-0.9	-0.0			-0.6	-0.0
V6 (follow-up at day 60 after surgery) - (n %)												
N	80		80		80		80		160		160	
Mean	14.6		-0.5		14.5		-0.6		14.6		-0.5	
SD	1.6		1.9		1.6		2.0		1.6		1.9	
Median	15.0		0.0		14.5		-1.0		15.0		-1.0	
Range	10.0	18.0	-6.0	5.0	10.0	19.0	-6.0	6.0	10.0	19.0	-6.0	6.0
95 CI			-0.9	-0.0			-1.0	-0.2			-0.8	-0.2

SAS program: P03\_T06\_01\_02.sas - SAS dataset(s): RAND,SURGERY,INTRA\_PRES

**Table 6.1-3 (1 of 1): Intra ocular pressure - Point estimate of the difference between Treated vs. Non-treated eye  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
V1 (before surgery) - (n %)						
N		85		83		168
Mean		0.2		0.2		0.2
SD		1.4		1.4		1.4
Median		0.0		0.0		0.0
Range	-4.0	6.0	-5.0	4.0	-5.0	6.0
V3 (day 1 after surgery) - (n %)						
N		83		83		166
Mean		0.4		0.3		0.4
SD		2.7		1.6		2.2
Median		0.0		0.0		0.0
Range	-6.0	18.0	-5.0	5.0	-6.0	18.0
V4 (day 7 after surgery) - (n %)						
N		82		82		164
Mean		-0.1		-0.1		-0.1
SD		1.5		1.5		1.5
Median		0.0		0.0		0.0
Range	-6.0	5.0	-6.0	5.0	-6.0	5.0
V5 (day 15 after surgery - end of treatment) - (n %)						
N		81		81		162
Mean		-0.2		0.2		-0.0
SD		1.7		1.2		1.5
Median		0.0		0.0		0.0
Range	-8.0	4.0	-2.0	4.0	-8.0	4.0
V6 (follow-up at day 60 after surgery) - (n %)						
N		80		80		160
Mean		-0.2		0.1		-0.0
SD		1.0		1.1		1.1
Median		0.0		0.0		0.0
Range	-5.0	3.0	-2.0	4.0	-5.0	4.0

SAS program: P03\_T06\_01\_03.sas - SAS dataset(s): RAND,SURGERY,INTRA\_PRES

Note: difference computed as treated eye-non-treated eye



## **6.2 Ophthalmoscopy test**

**Table 6.2-1 (1 of 1): Ophthalmoscopy test during the study - Frequency of test execution during the study  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	85	100.0	83	100.0	168	100.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
No	1	1.2	2	2.4	3	1.8
Yes	82	98.8	81	97.6	163	98.2
Total	83	100.0	83	100.0	166	100.0
V4 (day 7 after surgery) - (n %)						
No	2	2.4	3	3.7	5	3.0
Yes	81	97.6	79	96.3	160	97.0
Total	83	100.0	82	100.0	165	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
No	2	2.5	2	2.5	4	2.5
Yes	79	97.5	79	97.5	158	97.5
Total	81	100.0	81	100.0	162	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
(uncoded)	0	0.0	1	1.2	1	0.6
No	2	2.5	2	2.5	4	2.5
Yes	78	97.5	78	96.3	156	96.9
Total	80	100.0	81	100.0	161	100.0

SAS program: P03\_T06\_02\_01.sas - SAS dataset(s):

**Table 6.2-2-1 (1 of 1): Ophthalmoscopy test during the study - Frequency for Vitreous Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	85	100.0	83	100.0	168	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	82	100.0	81	100.0	163	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	82	100.0	81	100.0	163	100.0
V4 (day 7 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	81	100.0	79	100.0	160	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	81	100.0	79	100.0	160	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	79	100.0	79	100.0	158	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	79	100.0	79	100.0	158	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	78	100.0	78	100.0	156	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	78	100.0	78	100.0	156	100.0

SAS program: P03\_T06\_02\_02\_01.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

**Table 6.2-2-2 (1 of 1): Ophthalmoscopy test during the study - Shift table for Vitreous Safety sample**

Before surgery	Day 1	Day 7	Day 15	n	%	Cumulative frequency n	%	Missing (n)
<b>GEL (N=85)</b>								
Normal	Normal	Normal	Normal	79	100.00	79	100.00	6
<b>EYE DROPS (N=83)</b>								
Normal	Normal	Normal	Normal	78	100.00	78	100.00	5

SAS program: P03\_T06\_02\_02\_02.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

**Table 6.2-3-1 (1 of 1): Ophthalmoscopy test during the study - Frequency for Retina Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	83	97.6	81	97.6	164	97.6
Abnormal	2	2.4	2	2.4	4	2.4
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	80	97.6	79	97.5	159	97.5
Abnormal	2	2.4	2	2.5	4	2.5
Not assessable	0	0.0	0	0.0	0	0.0
Total	82	100.0	81	100.0	163	100.0
V4 (day 7 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	79	97.5	77	97.5	156	97.5
Abnormal	2	2.5	2	2.5	4	2.5
Not assessable	0	0.0	0	0.0	0	0.0
Total	81	100.0	79	100.0	160	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	77	97.5	77	97.5	154	97.5
Abnormal	2	2.5	2	2.5	4	2.5
Not assessable	0	0.0	0	0.0	0	0.0
Total	79	100.0	79	100.0	158	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
Not done	1	1.3	0	0.0	1	0.6
Normal	75	96.2	76	97.4	151	96.8
Abnormal	2	2.6	2	2.6	4	2.6
Not assessable	0	0.0	0	0.0	0	0.0
Total	78	100.0	78	100.0	156	100.0

SAS program: P03\_T06\_02\_03\_01.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

**Table 6.2-3-2 (1 of 2): Ophthalmoscopy test during the study - Shift table for Retina Safety sample**

Before surgery	Day 1	Day 7	Day 15	n	%	Cumulative frequency n	%	Missing (n)
<b>GEL (N=85)</b>								
Normal	Normal	Normal	Normal	77	97.47	77	97.47	6
Abnormal	Abnormal	Abnormal	Abnormal	2	2.53	79	100.00	
<b>EYE DROPS (N=83)</b>								
Normal	Normal	Normal	Normal	76	97.44	76	97.44	5
Abnormal	Abnormal	Abnormal	Abnormal	2	2.56	78	100.00	

SAS program: P03\_T06\_02\_02\_02.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

**Table 6.2-4-1 (1 of 1): Ophthalmoscopy test during the study - Frequency for Macula  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	85	100.0	83	100.0	168	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	82	100.0	81	100.0	163	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	82	100.0	81	100.0	163	100.0
V4 (day 7 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	81	100.0	79	100.0	160	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	81	100.0	79	100.0	160	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	79	100.0	79	100.0	158	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	79	100.0	79	100.0	158	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	78	100.0	78	100.0	156	100.0
Abnormal	0	0.0	0	0.0	0	0.0
Not assessable	0	0.0	0	0.0	0	0.0
Total	78	100.0	78	100.0	156	100.0

SAS program: P03\_T06\_02\_04\_01.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

**Table 6.2-4-2 (1 of 1): Ophthalmoscopy test during the study - Shift table for Macula  
Safety sample**

Before surgery	Day 1	Day 7	Day 15	n	%	Cumulative frequency n	%	Missing (n)
<b>GEL (N=85)</b>								
Normal	Normal	Normal	Normal	79	100.00	79	100.00	6
<b>EYE DROPS (N=83)</b>								
Normal	Normal	Normal	Normal	78	100.00	78	100.00	5

SAS program: P03\_T06\_02\_02\_02.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY



**Table 6.2-5-1 (1 of 1): Ophthalmoscopy test during the study - Frequency for Choroid Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V1 (before surgery) - (n %)						
Not done	0	0.0	1	1.2	1	0.6
Normal	84	98.8	80	96.4	164	97.6
Abnormal	1	1.2	2	2.4	3	1.8
Not assessable	0	0.0	0	0.0	0	0.0
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
Not done	1	1.2	1	1.2	2	1.2
Normal	81	98.8	78	96.3	159	97.5
Abnormal	0	0.0	2	2.5	2	1.2
Not assessable	0	0.0	0	0.0	0	0.0
Total	82	100.0	81	100.0	163	100.0
V4 (day 7 after surgery) - (n %)						
Not done	0	0.0	0	0.0	0	0.0
Normal	81	100.0	77	97.5	158	98.8
Abnormal	0	0.0	2	2.5	2	1.3
Not assessable	0	0.0	0	0.0	0	0.0
Total	81	100.0	79	100.0	160	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
Not done	0	0.0	1	1.3	1	0.6
Normal	79	100.0	76	96.2	155	98.1
Abnormal	0	0.0	2	2.5	2	1.3
Not assessable	0	0.0	0	0.0	0	0.0
Total	79	100.0	79	100.0	158	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
Not done	1	1.3	0	0.0	1	0.6
Normal	77	98.7	75	96.2	152	97.4
Abnormal	0	0.0	3	3.8	3	1.9
Not assessable	0	0.0	0	0.0	0	0.0
Total	78	100.0	78	100.0	156	100.0

SAS program: P03\_T06\_02\_05\_01.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

**Table 6.2-5-2 (1 of 1): Ophthalmoscopy test during the study - Shift table for Choroid Safety sample**

Before surgery	Day 1	Day 7	Day 15	n	%	Cumulative frequency n	%	Missing (n)
<b>GEL (N=85)</b>								
Normal	Normal	Normal	Normal	78	98.73	78	98.73	6
Abnormal	Normal	Normal	Normal	1	1.27	79	100.00	
<b>EYE DROPS (N=83)</b>								
Not done	Not done	Normal	Normal	1	1.28	1	1.28	5
Normal	Normal	Normal	Not done	1	1.28	2	2.56	
Normal	Normal	Normal	Normal	74	94.87	76	97.44	
Abnormal	Abnormal	Abnormal	Abnormal	2	2.56	78	100.00	

SAS program: P03\_T06\_02\_02\_02.sas - SAS dataset(s): RAND,OPHTHALMOSCOPY

### **6.3 Visual acuity**

**Table 6.3-1 (1 of 1): Visual acuity during the study for the treated eye  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
	Change from Day 1				Change from Day 1				Change from Day 1			
V1 (before surgery) - (n %)												
N	83				82				165			
Mean	0.5				0.5				0.5			
SD	0.2				0.2				0.2			
Median	0.5				0.5				0.5			
Range	0.0	1.0			0.0	1.0			0.0	1.0		
V3 (day 1 after surgery) - (n %)												
N	83				82				165			
Mean	0.6				0.6				0.6			
SD	0.4				0.4				0.4			
Median	0.8				0.8				0.8			
Range	0.0	1.0			0.0	1.3			0.0	1.3		
V4 (day 7 after surgery) - (n %)												
N	83		83		81		80		164		163	
Mean	0.7		0.0		0.7		0.1		0.7		0.1	
SD	0.4		0.1		0.5		0.3		0.4		0.2	
Median	1.0		0.0		1.0		0.0		1.0		0.0	
Range	0.0	1.2	-0.2	0.5	0.0	2.0	-0.5	1.8	0.0	2.0	-0.5	1.8
95 CI			0.0	0.1			0.0	0.1			0.0	0.1
V5 (day 15 after surgery - end of treatment) - (n %)												
N	80		80		81		80		161		160	
Mean	0.7		0.0		0.7		0.0		0.7		0.0	
SD	0.4		0.1		0.4		0.2		0.4		0.1	
Median	1.0		0.0		1.0		0.0		1.0		0.0	
Range	0.0	1.2	-0.2	0.5	0.0	1.3	-0.4	0.5	0.0	1.3	-0.4	0.5
95 CI			0.0	0.1			0.0	0.1			0.0	0.1

SAS program: P03\_T06\_03\_01.sas - SAS dataset(s): RAND,VISUAL\_SCREEN,VISUAL\_CONTROL

## **6.4 Ocular inflammation evaluation**

**Table 6.4-1 (1 of 1): Signs/Symptoms of ocular inflammation evaluation during the study - Frequency of test execution  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V2 (surgery) - (n %)						
No	7	8.2	7	8.4	14	8.3
Yes	78	91.8	76	91.6	154	91.7
Total	85	100.0	83	100.0	168	100.0
V3 (day 1 after surgery) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	83	100.0	83	100.0	166	100.0
Total	83	100.0	83	100.0	166	100.0
V4 (day 7 after surgery) - (n %)						
No	1	1.2	0	0.0	1	0.6
Yes	82	98.8	82	100.0	164	99.4
Total	83	100.0	82	100.0	165	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
No	0	0.0	0	0.0	0	0.0
Yes	81	100.0	81	100.0	162	100.0
Total	81	100.0	81	100.0	162	100.0
V6 (follow-up at day 60 after surgery) - (n %)						
No	2	2.5	1	1.2	3	1.9
Yes	78	97.5	79	97.5	157	97.5
Total	80	100.0	81	100.0	161	100.0

SAS program: P03\_T06\_04\_01.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-2 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Anterior chamber flare  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from day 1				Change from day 1				Change from day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V2 (surgery) - (n %)															
None	57	73.1			54	71.1			111	72.1					
Mild	21	26.9			22	28.9			43	27.9					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	78	100.0			76	100.0			154	100.0					
V3 (day 1 after surgery) - (n %)															
None	61	73.5			56	67.5			117	70.5					
Mild	22	26.5			27	32.5			49	29.5					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	83	100.0			83	100.0			166	100.0					
V4 (day 7 after surgery) - (n %)															
none	77	93.9	decreased	17	20.7	79	96.3	decreased	24	29.3	156	95.1	decreased	41	25.0
mild	5	6.1	unchanged	65	79.3	3	3.7	unchanged	58	70.7	8	4.9	unchanged	123	75.0
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
severe	0	0.0	total	82	100.0	0	0.0	total	82	100.0	0	0.0	total	164	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	81	100.0	decreased	21	25.9	81	100.0	decreased	27	33.3	162	100.0	decreased	48	29.6
mild	0	0.0	unchanged	60	74.1	0	0.0	unchanged	54	66.7	0	0.0	unchanged	114	70.4
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
severe	0	0.0	total	81	100.0	0	0.0	total	81	100.0	0	0.0	total	162	100.0
total	81	100.0			81	100.0			162	100.0					

SAS program: P03\_T06\_04\_02.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-3 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Anterior chamber cells  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V2 (surgery) - (n %)															
None	78	100.0			76	100.0			154	100.0					
Mild	0	0.0			0	0.0			0	0.0					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	78	100.0			76	100.0			154	100.0					
V3 (day 1 after surgery) - (n %)															
None	75	90.4			77	92.8			152	91.6					
Mild	8	9.6			6	7.2			14	8.4					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	83	100.0			83	100.0			166	100.0					
V4 (day 7 after surgery) - (n %)															
none	80	97.6	decreased	6	7.3	80	97.6	decreased	4	4.9	160	97.6	decreased	10	6.1
mild	2	2.4	unchanged	76	92.7	2	2.4	unchanged	77	93.9	4	2.4	unchanged	153	93.3
moderate	0	0.0	increased	0	0.0	0	0.0	increased	1	1.2	0	0.0	increased	1	0.6
severe	0	0.0	total	82	100.0	0	0.0	total	82	100.0	0	0.0	total	164	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	81	100.0	decreased	7	8.6	80	98.8	decreased	4	4.9	161	99.4	decreased	11	6.8
mild	0	0.0	unchanged	74	91.4	1	1.2	unchanged	77	95.1	1	0.6	unchanged	151	93.2
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
severe	0	0.0	total	81	100.0	0	0.0	total	81	100.0	0	0.0	total	162	100.0
total	81	100.0			81	100.0			162	100.0					

SAS program: P03\_T06\_04\_03.sas - SAS dataset(s): RAND,OCULAR\_INFLA



**Table 6.4-4 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Conjunctival hyperemia  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V2 (surgery) - (n %)															
None	71	91.0			73	96.1			144	93.5					
Mild	7	9.0			3	3.9			10	6.5					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	78	100.0			76	100.0			154	100.0					
V3 (day 1 after surgery) - (n %)															
None	75	90.4			74	89.2			149	89.8					
Mild	8	9.6			8	9.6			16	9.6					
Moderate	0	0.0			1	1.2			1	0.6					
Severe	0	0.0			0	0.0			0	0.0					
Total	83	100.0			83	100.0			166	100.0					
V4 (day 7 after surgery) - (n %)															
none	78	95.1	decreased	6	7.3	81	98.8	decreased	7	8.5	159	97.0	decreased	13	7.9
mild	4	4.9	unchanged	74	90.2	1	1.2	unchanged	75	91.5	5	3.0	unchanged	149	90.9
moderate	0	0.0	increased	2	2.4	0	0.0	increased	0	0.0	0	0.0	increased	2	1.2
severe	0	0.0	total	82	100.0	0	0.0	total	82	100.0	0	0.0	total	164	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	78	96.3	decreased	7	8.6	79	97.5	decreased	7	8.6	157	96.9	decreased	14	8.6
mild	3	3.7	unchanged	72	88.9	2	2.5	unchanged	73	90.1	5	3.1	unchanged	145	89.5
moderate	0	0.0	increased	2	2.5	0	0.0	increased	1	1.2	0	0.0	increased	3	1.9
severe	0	0.0	total	81	100.0	0	0.0	total	81	100.0	0	0.0	total	162	100.0
total	81	100.0			81	100.0			162	100.0					

SAS program: P03\_T06\_04\_04.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-5 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Lid edema  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V2 (surgery) - (n %)															
None	78	100.0			76	100.0			154	100.0					
Mild	0	0.0			0	0.0			0	0.0					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	78	100.0			76	100.0			154	100.0					
V3 (day 1 after surgery) - (n %)															
None	83	100.0			83	100.0			166	100.0					
Mild	0	0.0			0	0.0			0	0.0					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	83	100.0			83	100.0			166	100.0					
V4 (day 7 after surgery) - (n %)															
none	82	100.0	decreased	0	0.0	82	100.0	decreased	0	0.0	164	100.0	decreased	0	0.0
mild	0	0.0	unchanged	82	100.0	0	0.0	unchanged	82	100.0	0	0.0	unchanged	164	100.0
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
severe	0	0.0	total	82	100.0	0	0.0	total	82	100.0	0	0.0	total	164	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	81	100.0	decreased	0	0.0	81	100.0	decreased	0	0.0	162	100.0	decreased	0	0.0
mild	0	0.0	unchanged	81	100.0	0	0.0	unchanged	81	100.0	0	0.0	unchanged	162	100.0
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0
severe	0	0.0	total	81	100.0	0	0.0	total	81	100.0	0	0.0	total	162	100.0
total	81	100.0			81	100.0			162	100.0					

SAS program: P03\_T06\_04\_05.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-6 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Corneal edema  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from Day 1				Change from Day 1				Change from Day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V2 (surgery) - (n %)												
None	78	100.0			76	100.0			154	100.0		
Mild	0	0.0			0	0.0			0	0.0		
Moderate	0	0.0			0	0.0			0	0.0		
Severe	0	0.0			0	0.0			0	0.0		
Total	78	100.0			76	100.0			154	100.0		
V3 (day 1 after surgery) - (n %)												
None	80	96.4			81	97.6			161	97.0		
Mild	3	3.6			0	0.0			3	1.8		
Moderate	0	0.0			2	2.4			2	1.2		
Severe	0	0.0			0	0.0			0	0.0		
Total	83	100.0			83	100.0			166	100.0		
V4 (day 7 after surgery) - (n %)												
none	82	100.0	decreased	3 3.7	82	100.0	decreased	1 1.2	164	100.0	decreased	4 2.4
mild	0	0.0	unchanged	79 96.3	0	0.0	unchanged	81 98.8	0	0.0	unchanged	160 97.6
moderate	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
severe	0	0.0	total	82 100.0	0	0.0	total	82 100.0	0	0.0	total	164 100.0
total	82	100.0			82	100.0			164	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
none	81	100.0	decreased	2 2.5	81	100.0	decreased	1 1.2	162	100.0	decreased	3 1.9
mild	0	0.0	unchanged	79 97.5	0	0.0	unchanged	80 98.8	0	0.0	unchanged	159 98.1
moderate	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
severe	0	0.0	total	81 100.0	0	0.0	total	81 100.0	0	0.0	total	162 100.0
total	81	100.0			81	100.0			162	100.0		

SAS program: P03\_T06\_04\_06.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-7 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Ocular discomfort - Pain  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from Day 1				Change from Day 1				Change from Day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V2 (surgery) - (n %)												
None	77	98.7			76	100.0			153	99.4		
Mild	1	1.3			0	0.0			1	0.6		
Moderate	0	0.0			0	0.0			0	0.0		
Severe	0	0.0			0	0.0			0	0.0		
Total	78	100.0			76	100.0			154	100.0		
V3 (day 1 after surgery) - (n %)												
None	82	98.8			81	97.6			163	98.2		
Mild	1	1.2			1	1.2			2	1.2		
Moderate	0	0.0			1	1.2			1	0.6		
Severe	0	0.0			0	0.0			0	0.0		
Total	83	100.0			83	100.0			166	100.0		
V4 (day 7 after surgery) - (n %)												
none	82	100.0	decreased	1 1.2	82	100.0	decreased	1 1.2	164	100.0	decreased	2 1.2
mild	0	0.0	unchanged	81 98.8	0	0.0	unchanged	81 98.8	0	0.0	unchanged	162 98.8
moderate	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
severe	0	0.0	total	82 100.0	0	0.0	total	82 100.0	0	0.0	total	164 100.0
total	82	100.0			82	100.0			164	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
none	81	100.0	decreased	1 1.2	81	100.0	decreased	1 1.2	162	100.0	decreased	2 1.2
mild	0	0.0	unchanged	80 98.8	0	0.0	unchanged	80 98.8	0	0.0	unchanged	160 98.8
moderate	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
severe	0	0.0	total	81 100.0	0	0.0	total	81 100.0	0	0.0	total	162 100.0
total	81	100.0			81	100.0			162	100.0		
V6 (follow-up at day 60 after surgery) - (n %)												
none	78	100.0	decreased	1 1.3	79	100.0	decreased	1 1.3	157	100.0	decreased	2 1.3
mild	0	0.0	unchanged	77 98.7	0	0.0	unchanged	78 98.7	0	0.0	unchanged	155 98.7
moderate	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
severe	0	0.0	total	78 100.0	0	0.0	total	79 100.0	0	0.0	total	157 100.0
total	78	100.0			79	100.0			157	100.0		

SAS program: P03\_T06\_04\_07.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-8 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Ocular discomfort - Photophobia  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V2 (surgery) - (n %)															
None	69	88.5			67	88.2			136	88.3					
Mild	9	11.5			9	11.8			18	11.7					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	78	100.0			76	100.0			154	100.0					
V3 (day 1 after surgery) - (n %)															
None	74	89.2			78	94.0			152	91.6					
Mild	9	10.8			5	6.0			14	8.4					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	83	100.0			83	100.0			166	100.0					
V4 (day 7 after surgery) - (n %)															
none	79	96.3	decreased	7	8.5	81	98.8	decreased	4	4.9	160	97.6	decreased	11	6.7
mild	3	3.7	unchanged	74	90.2	1	1.2	unchanged	77	93.9	4	2.4	unchanged	151	92.1
moderate	0	0.0	increased	1	1.2	0	0.0	increased	1	1.2	0	0.0	increased	2	1.2
severe	0	0.0	total	82	100.0	0	0.0	total	82	100.0	0	0.0	total	164	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	79	97.5	decreased	8	9.9	79	97.5	decreased	3	3.7	158	97.5	decreased	11	6.8
mild	2	2.5	unchanged	72	88.9	2	2.5	unchanged	77	95.1	4	2.5	unchanged	149	92.0
moderate	0	0.0	increased	1	1.2	0	0.0	increased	1	1.2	0	0.0	increased	2	1.2
severe	0	0.0	total	81	100.0	0	0.0	total	81	100.0	0	0.0	total	162	100.0
total	81	100.0			81	100.0			162	100.0					

SAS program: P03\_T06\_04\_08.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-9 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Ocular discomfort - Tearing  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from Day 1				Change from Day 1				Change from Day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V2 (surgery) - (n %)															
None	68	87.2			69	90.8			137	89.0					
Mild	10	12.8			7	9.2			17	11.0					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	78	100.0			76	100.0			154	100.0					
V3 (day 1 after surgery) - (n %)															
None	73	88.0			76	91.6			149	89.8					
Mild	10	12.0			7	8.4			17	10.2					
Moderate	0	0.0			0	0.0			0	0.0					
Severe	0	0.0			0	0.0			0	0.0					
Total	83	100.0			83	100.0			166	100.0					
V4 (day 7 after surgery) - (n %)															
none	78	95.1	decreased	7	8.5	78	95.1	decreased	4	4.9	156	95.1	decreased	11	6.7
mild	4	4.9	unchanged	73	89.0	4	4.9	unchanged	76	92.7	8	4.9	unchanged	149	90.9
moderate	0	0.0	increased	2	2.4	0	0.0	increased	2	2.4	0	0.0	increased	4	2.4
severe	0	0.0	total	82	100.0	0	0.0	total	82	100.0	0	0.0	total	164	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	76	93.8	decreased	9	11.1	77	95.1	decreased	4	4.9	153	94.4	decreased	13	8.0
mild	5	6.2	unchanged	68	84.0	4	4.9	unchanged	75	92.6	9	5.6	unchanged	143	88.3
moderate	0	0.0	increased	4	4.9	0	0.0	increased	2	2.5	0	0.0	increased	6	3.7
severe	0	0.0	total	81	100.0	0	0.0	total	81	100.0	0	0.0	total	162	100.0
total	81	100.0			81	100.0			162	100.0					

SAS program: P03\_T06\_04\_09.sas - SAS dataset(s): RAND,OCULAR\_INFLA

**Table 6.4-10 (1 of 1): Evaluation of ocular inflammation signs/symptoms during the study - Total score**  
**Safety sample**

	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
Visit	Change from Day 1				Change from Day 1				Change from Day 1			
V3 (day 1 after surgery) - (n %)												
N	83				83				166			
Mean	0.7				0.7				0.7			
SD	1.0				1.3				1.1			
Median	0.0				0.0				0.0			
Range	0.0	4.0			0.0	8.0			0.0	8.0		
V4 (day 7 after surgery) - (n %)												
N	82		82		82		82		164		164	
Mean	0.2		-0.5		0.1		-0.5		0.2		-0.5	
SD	0.5		0.9		0.4		1.0		0.4		0.9	
Median	0.0		0.0		0.0		0.0		0.0		0.0	
Range	0.0	2.0	-4.0	1.0	0.0	2.0	-5.0	2.0	0.0	2.0	-5.0	2.0
95 CI			-0.7	-0.3			-0.7	-0.3			-0.7	-0.4
V5 (day 15 after surgery - end of treatment) - (n %)												
N	81		81		81		81		162		162	
Mean	0.1		-0.6		0.1		-0.6		0.1		-0.6	
SD	0.4		1.0		0.4		0.9		0.4		0.9	
Median	0.0		0.0		0.0		0.0		0.0		0.0	
Range	0.0	2.0	-4.0	2.0	0.0	2.0	-4.0	1.0	0.0	2.0	-4.0	2.0
95 CI			-0.8	-0.4			-0.8	-0.4			-0.7	-0.4

SAS program: P03\_T06\_04\_10.sas - SAS dataset(s): RAND,OCULAR\_INFLA

Total score calculated as the sum of the single signs/symptoms

## **6.5 Global tolerability**



**Table 6.5-1 (1 of 1): Evaluation of global tolerability by the investigator during the study - Frequency of test execution  
Safety sample**

Visit	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)						
No	0	0.0	1	1.2	1	0.6
Yes	83	100.0	82	98.8	165	99.4
Total	83	100.0	83	100.0	166	100.0
V4 (day 7 after surgery) - (n %)						
No	1	1.2	0	0.0	1	0.6
Yes	82	98.8	82	100.0	164	99.4
Total	83	100.0	82	100.0	165	100.0
V5 (day 15 after surgery - end of treatment) - (n %)						
No	1	1.2	0	0.0	1	0.6
Yes	80	98.8	81	100.0	161	99.4
Total	81	100.0	81	100.0	162	100.0

SAS program: P03\_T06\_05\_01.sas - SAS dataset(s): RAND,TOLERABILITY

**Table 6.5-2 (1 of 1): Evaluation of global tolerability by the investigator during the study - Burning  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from day 1				Change from day 1				Change from day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)												
None	79	95.2			79	96.3			158	95.8		
Mild	4	4.8			2	2.4			6	3.6		
Moderate	0	0.0			0	0.0			0	0.0		
Severe	0	0.0			1	1.2			1	0.6		
Total	83	100.0			82	100.0			165	100.0		
V4 (day 7 after surgery) - (n %)												
none	81	98.8	decreased	2	2.4	82	100.0	decreased	2	2.5	163	99.4
mild	1	1.2	unchanged	80	97.6	0	0.0	unchanged	79	97.5	1	0.6
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0
severe	0	0.0	total	82	100.0	0	0.0	total	81	100.0	0	0.0
total	82	100.0			82	100.0			164	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
none	80	100.0	decreased	3	3.8	81	100.0	decreased	2	2.5	161	100.0
mild	0	0.0	unchanged	77	96.3	0	0.0	unchanged	78	97.5	0	0.0
moderate	0	0.0	increased	0	0.0	0	0.0	increased	0	0.0	0	0.0
severe	0	0.0	total	80	100.0	0	0.0	total	80	100.0	0	0.0
total	80	100.0			81	100.0			161	100.0		

SAS program: P03\_T06\_05\_02.sas - SAS dataset(s): RAND,TOLERABILITY

**Table 6.5-3 (1 of 1): Evaluation of global tolerability by the investigator during the study - Stinging  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)						
			Change from day 1				Change from day 1				Change from day 1				
	n	%	n	%	n	%	n	%	n	%	n	%			
V3 (day 1 after surgery) - (n %)															
None	75	90.4			75	91.5			150	90.9					
Mild	7	8.4			6	7.3			13	7.9					
Moderate	1	1.2			0	0.0			1	0.6					
Severe	0	0.0			1	1.2			1	0.6					
Total	83	100.0			82	100.0			165	100.0					
V4 (day 7 after surgery) - (n %)															
none	77	93.9	decreased	4	4.9	77	93.9	decreased	3	3.7	154	93.9	decreased	7	4.3
mild	5	6.1	unchanged	77	93.9	5	6.1	unchanged	76	93.8	10	6.1	unchanged	153	93.9
moderate	0	0.0	increased	1	1.2	0	0.0	increased	2	2.5	0	0.0	increased	3	1.8
severe	0	0.0	total	82	100.0	0	0.0	total	81	100.0	0	0.0	total	163	100.0
total	82	100.0			82	100.0			164	100.0					
V5 (day 15 after surgery - end of treatment) - (n %)															
none	76	95.0	decreased	5	6.3	77	95.1	decreased	3	3.8	153	95.0	decreased	8	5.0
mild	4	5.0	unchanged	73	91.3	4	4.9	unchanged	76	95.0	8	5.0	unchanged	149	93.1
moderate	0	0.0	increased	2	2.5	0	0.0	increased	1	1.3	0	0.0	increased	3	1.9
severe	0	0.0	total	80	100.0	0	0.0	total	80	100.0	0	0.0	total	160	100.0
total	80	100.0			81	100.0			161	100.0					

SAS program: P03\_T06\_05\_03.sas - SAS dataset(s): RAND,TOLERABILITY

**Table 6.5-4 (1 of 1): Evaluation of global tolerability by the investigator during the study - Blurred vision  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from day 1				Change from day 1				Change from day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)												
None	80	96.4			81	98.8			161	97.6		
Mild	1	1.2			1	1.2			2	1.2		
Moderate	2	2.4			0	0.0			2	1.2		
Severe	0	0.0			0	0.0			0	0.0		
Total	83	100.0			82	100.0			165	100.0		
V4 (day 7 after surgery) - (n %)												
none	77	93.9	decreased	1 1.2	80	97.6	decreased	0 0.0	157	95.7	decreased	1 0.6
mild	4	4.9	unchanged	78 95.1	2	2.4	unchanged	79 97.5	6	3.7	unchanged	157 96.3
moderate	1	1.2	increased	3 3.7	0	0.0	increased	2 2.5	1	0.6	increased	5 3.1
severe	0	0.0	total	82 100.0	0	0.0	total	81 100.0	0	0.0	total	163 100.0
total	82	100.0			82	100.0			164	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
none	78	97.5	decreased	2 2.5	78	96.3	decreased	0 0.0	156	96.9	decreased	2 1.3
mild	1	1.3	unchanged	76 95.0	3	3.7	unchanged	77 96.3	4	2.5	unchanged	153 95.6
moderate	0	0.0	increased	2 2.5	0	0.0	increased	3 3.8	0	0.0	increased	5 3.1
severe	1	1.3	total	80 100.0	0	0.0	total	80 100.0	1	0.6	total	160 100.0
total	80	100.0			81	100.0			161	100.0		

SAS program: P03\_T06\_05\_04.sas - SAS dataset(s): RAND,TOLERABILITY

**Table 6.5-5 (1 of 1): Evaluation of global tolerability by the investigator during the study - Global subjective tolerability  
Safety sample**

Visit	GEL (N=85)				EYE DROPS (N=83)				ALL (N=168)			
			Change from day 1				Change from day 1				Change from day 1	
	n	%	n	%	n	%	n	%	n	%	n	%
V3 (day 1 after surgery) - (n %)												
None	81	97.6			81	98.8			162	98.2		
Mild	2	2.4			0	0.0			2	1.2		
Moderate	0	0.0			0	0.0			0	0.0		
Severe	0	0.0			1	1.2			1	0.6		
Total	83	100.0			82	100.0			165	100.0		
V4 (day 7 after surgery) - (n %)												
none	82	100.0	decreased	1 1.2	82	100.0	decreased	0 0.0	164	100.0	decreased	1 0.6
mild	0	0.0	unchanged	81 98.8	0	0.0	unchanged	81 100.0	0	0.0	unchanged	162 99.4
moderate	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0	0	0.0	increased	0 0.0
severe	0	0.0	total	0 0.0	0	0.0	total	0 0.0	0	0.0	total	0 0.0
total	82	100.0			82	100.0			164	100.0		
V5 (day 15 after surgery - end of treatment) - (n %)												
none	79	98.8	decreased	1 1.3	80	98.8	decreased	0 0.0	159	98.8	decreased	1 0.6
mild	0	0.0	unchanged	78 97.5	1	1.2	unchanged	79 98.8	1	0.6	unchanged	157 98.1
moderate	1	1.3	increased	1 1.3	0	0.0	increased	1 1.3	1	0.6	increased	2 1.3
severe	0	0.0	total	80 100.0	0	0.0	total	80 100.0	0	0.0	total	160 100.0
total	80	100.0			81	100.0			161	100.0		

SAS program: P03\_T06\_05\_05.sas - SAS dataset(s): RAND,TOLERABILITY

## **6.6 Adverse events**

**Table 6.6-1 (1 of 1): Overview of Adverse Events  
Safety sample**

Variable	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
All AEs	4	4.7	6	7.2	10	6.0
SAE	.	.	2	2.4	2	1.2
AE related to study drug	.	.	1	1.2	1	0.6
AE leading to discontinuation of study drug	1	1.2	1	1.2	2	1.2

Source: on-line editing

[1] Related=Relationship of Possibly, Probably or Definitely Related, as noted by investigator on the eCRF.

**Table 6.6-2 (1 of 1): Summary of all Adverse Events by MedDRA System Organ Class and Preferred Term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one event	4	4.7	6	7.2	10	6.0
Eye disorders	1	1.2	3	3.6	4	2.4
Conjunctival hyperaemia	.	.	1	1.2	1	0.6
Foreign body sensation in eyes	1	1.2	2	2.4	3	1.8
Macular oedema	.	.	1	1.2	1	0.6
Gastrointestinal disorders	1	1.2	.	.	1	0.6
Dyspepsia	1	1.2	.	.	1	0.6
Nausea	1	1.2	.	.	1	0.6
Immune system disorders	.	.	1	1.2	1	0.6
Drug hypersensitivity	.	.	1	1.2	1	0.6
Infections and infestations	.	.	1	1.2	1	0.6
Hordeolum	.	.	1	1.2	1	0.6
Injury, poisoning and procedural complications	1	1.2	.	.	1	0.6
Fibrin deposition on lens postoperative	1	1.2	.	.	1	0.6
Investigations	3	3.5	.	.	3	1.8
Blood pressure increased	1	1.2	.	.	1	0.6
Intraocular pressure increased	3	3.5	.	.	3	1.8
Vascular disorders	.	.	1	1.2	1	0.6
Vascular occlusion	.	.	1	1.2	1	0.6

SAS program: P03\_T06\_06\_02.sas - SAS dataset(s): RAND,AE\_COD

## Notes:

- A subject with multiple occurrences is counted only once in the respective category.
- Table is sorted alphabetically
- Within system organ class, AEs are sorted by descending frequency of preferred term



**Listing of patients with System Organ Class equal to *Investigations* - Safety sample**

Subj. code	Reported term	Start date	End date	SAE Severity	Study drug relat.	Action taken	Other action taken	Outcome
<b>GEL</b>								
200101	HIGH IOP ( LA 34MMHG)	17JAN2018	18JAN2018	NO MILD	UNRELATED	NONE	CONCOMITANT THERAPY	COMPLETELY RECOVERY
200111	INCREASED IOP	06NOV2018	07NOV2018	NO MODERATE	UNRELATED	NONE	CONCOMITANT THERAPY ADDITIONAL EYE DROPS TO LOWER DOWN THE IOP	COMPLETELY RECOVERY
200203	HIGH INTRAOCULAR PRESSURE (POSTOPERATIVE)	26JUN2018	27JUN2018	NO MILD	UNLIKELY	NONE	CONCOMITANT THERAPY TOPICAL ADMINISTRATTION OF COSOPT D GTT	COMPLETELY RECOVERY
	INCREASE OF BLOOD PRESSURE	23AUG2018	25AUG2018	NO MILD	UNLIKELY	NONE	CONCOMITANT THERAPY	COMPLETELY RECOVERY

Listing produced from SAS program P03\_T06\_06\_02.sas - SAS dataset(s): RAND,AE\_COD

**Table 6.6-3 (1 of 1): Summary of Serious Adverse Events, by MedDRA System Organ Class and Preferred Term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one event	.	.	1	1.2	1	0.6
Eye disorders	.	.	1	1.2	1	0.6
Macular oedema	.	.	1	1.2	1	0.6
Vascular disorders	.	.	1	1.2	1	0.6
Vascular occlusion	.	.	1	1.2	1	0.6

SAS program: P03\_T06\_06\_03.sas - SAS dataset(s): RAND,AE\_CODE

Notes:

- A subject with multiple occurrences is counted only once in the respective category.
- Table is sorted alphabetically
- Within system organ class, AEs are sorted by descending frequency of preferred term

**Table 6.6-4 (1 of 1): Summary of Related Adverse Events, by MedDRA System Organ Class and Preferred Term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one event	.	.	1	1.2	1	0.6
Immune system disorders	.	.	1	1.2	1	0.6
Drug hypersensitivity	.	.	1	1.2	1	0.6

SAS program: P03\_T06\_06\_04.sas - SAS dataset(s): RAND,AE\_CODE

Notes:

- A subject with multiple occurrences is counted only once in the respective category.
- Table is sorted alphabetically
- Within system organ class, AEs are sorted by descending frequency of preferred term
- AEs considered in this table are the event Possibly/Probably/Definitely related with study drug

**Table 6.6-5 (1 of 1): Summary of Adverse Events leading to discontinuation, by MedDRA System Organ Class and Preferred Term  
Safety sample**

System Organ Class Preferred term	GEL (N=85)		EYE DROPS (N=83)		ALL (N=168)	
	n	%	n	%	n	%
Subjects with at least one event	1	1.2	1	1.2	2	1.2
Immune system disorders	.	.	1	1.2	1	0.6
Drug hypersensitivity	.	.	1	1.2	1	0.6
Injury, poisoning and procedural complications	1	1.2	.	.	1	0.6
Fibrin deposition on lens postoperative	1	1.2	.	.	1	0.6

SAS program: P03\_T06\_06\_05.sas - SAS dataset(s): RAND,AE\_COD

Notes:

- A subject with multiple occurrences is counted only once in the respective category.
- Table is sorted alphabetically
- Within system organ class, AEs are sorted by descending frequency of preferred term

## Appendix 2: Individual patient listing

		Page
Listing 1	Patient information/ Registration	2
Listing 2	Eligibility criteria	11
Listing 3	Screening visit – Pregnancy test	20
Listing 4	Screening visit – Amsler and OCT tests at study entry	29
Listing 5	Screening visit – General and Ophthalmic medical history at study entry	38
Listing 6	Visual acuity, Intra-ocular pressure and Slit lamp examination during the study	48
Listing 7	Ophthalmoscopic test during the study	81
Listing 8	Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems	168
Listing 9	Mydriatic drugs and Antibiotic treatments before surgery	177
Listing 10	Antibiotic treatments after surgery	212
Listing 11	Study treatment after surgery	215
Listing 12	Signs/Symptoms of ocular inflammation during the study	232
Listing 13	Microbial load during the study	253
Listing 14	Evaluation of global tolerability by the investigator during the study	254
Listing 15	End of study	271
Listing 16	Concomitant treatments	280
Listing 17	Adverse event	345
Listing 18	Unscheduled visit	351

Note: all listings report under Study drug column:  
**GEL** for NETILDEX 3mg/mL / 1mg/mL ophthalmic gel  
**DROP** for NETILDEX 3mg/mL / 1mg/mL eye drops solutions

Listing 1 (1 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100101	03MAY1933	Female	84	White		10001	DROP
100102	14MAY1937	Male	80	White		10002	GEL
100103	07AUG1947	Female	70	White			
100104	06FEB1947	Male	70	White		10003	GEL
100105	19MAY1932	Female	85	White		10004	DROP
100106	14JAN1961	Male	56	White		10005	GEL
100107	24AUG1935	Female	82	White		10006	DROP
100108	23JAN1944	Female	73	White		10007	DROP
100109	29SEP1961	Female	56	White		10008	GEL
100110	01JUL1942	Female	75	White		10009	DROP
100111	04FEB1957	Female	60	White		10010	DROP
100112	23JUN1944	Male	73	White		10011	GEL
100113	01JUN1940	Female	77	White		10012	GEL
100114	03FEB1953	Male	64	White		10013	GEL
100115	05FEB1941	Male	76	White		10014	DROP
100116	14FEB1955	Male	62	White		10015	GEL
100117	31MAY1967	Female	51	White		10016	DROP
100118	28OCT1940	Female	78	White		10017	DROP
100119	21NOV1946	Female	72	White		10018	DROP
100120	14MAY1939	Male	79	White		10019	GEL
100121	21JAN1938	Male	80	White		10020	GEL
100122	19OCT1942	Female	76	White		10021	DROP

Listing 1 (2 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100123	19OCT1942	Female	76	White		10022	DROP
100124	29JUL1947	Female	71	White		10023	GEL
100125	05APR1956	Female	62	White		10024	GEL
100126	25JAN1933	Female	85	White		10025	GEL
100127	23NOV1950	Female	68	White		10026	GEL
100128	15SEP1938	Male	80	White		10027	DROP
100129	28FEB1940	Female	78	White		10028	DROP
100130	28MAR1952	Male	66	White		10029	GEL
100131	05JUN1941	Female	77	White		10030	DROP
100132	16NOV1949	Male	69	White		10031	DROP
100133	02JAN1944	Male	74	White		10032	GEL
100134	12JUN1952	Female	66	White		10033	DROP
100135	11JUL1949	Male	69	White		10034	GEL
100136	24NOV1928	Female	90	White		10035	GEL
100137	27JAN1956	Female	62	White		10036	DROP
100138	16MAY1955	Male	63	White		10037	GEL
100139	29OCT1947	Female	71	White		10038	DROP
100140	02APR1937	Male	81	White		10039	GEL
100141	08FEB1944	Female	74	White		10040	DROP
100142	15JAN1941	Female	77	White		10041	GEL
100143	25FEB1944	Male	74	White		10042	GEL
100144	08FEB1929	Female	89	White		10043	DROP

Listing 1 (3 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100145	29AUG1937	Male	81	White		10044	GEL
100146	17FEB1947	Male	71	White		10045	GEL
100147	25AUG1970	Male	48	White		10046	DROP
100148	13MAY1935	Female	83	White		10047	DROP
100149	07FEB1947	Female	71	White		10048	DROP
100150	09MAY1941	Female	77	White		100049	GEL
100151	15AUG1951	Female	67	White		100050	DROP
100152	26APR1940	Female	78	White		100051	GEL
100153	18JAN1937	Female	81	White		100052	DROP
100154	07NOV1950	Female	68	White		100053	GEL
100155	01FEB1939	Female	79	White		100054	DROP
100156	06JAN1949	Female	69	White		100055	GEL
100201	19MAY1937	Female	80	White		200-01	GEL
100202	19JUN1947	Female	70	White		200-02	DROP
100203	16MAR1941	Female	76	White		200-03	DROP
100204	13JUN1946	Male	71	White		200-04	GEL
100205	12AUG1942	Male	75	White		200-05	GEL
100206	13JUL1937	Female	81	White		200-06	DROP
100207	08APR1953	Female	65	White		200-07	DROP
100208	09FEB1939	Female	79	White		200-08	GEL
100209	14MAR1941	Female	77	White		200-09	GEL
100210	15MAR1948	Female	70	White		200-10	DROP



Listing 1 (4 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100211	04NOV1951	Male	67	White		200-11	GEL
100212	30APR1936	Female	82	White		200-12	DROP
100213	09APR1937	Female	81	White		200-13	DROP
100214	17NOV1941	Female	77	White		20014	DROP
100215	21JUL1935	Female	83	White		200-15	GEL
100216	04NOV1944	Female	74	White		20016	GEL
100217	16FEB1946	Female	72	White		20017	DROP
100218	02AUG1946	Male	72	White		20018	DROP
100219	12APR1935	Female	83	White		20019	GEL
100220	05DEC1954	Male	64	White		20020	GEL
100221	15NOV1942	Female	76	White		20021	GEL
100222	01JUN1942	Female	76	White		20022	DROP
100223	02SEP1957	Male	61	White		20023	DROP
100224	14MAY1943	Female	75	White		20024	GEL
100225	09JAN1939	Female	79	White		20025	DROP
100226	09SEP1944	Female	74	White		20026	GEL
100227	08SEP1950	Female	68	White		20027	DROP
100228	15APR1950	Female	68	White		20028	GEL
100229	06SEP1948	Female	70	White		20029	GEL
100230	21SEP1955	Female	63	White		20030	GEL
100231	06OCT1944	Female	74	White		20031	DROP
100232	06DEC1945	Female	73	White		20032	DROP

Listing 1 (5 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100233	16NOV1946	Female	72	White		20033	GEL
100234	17DEC1945	Female	73	White		20034	GEL
100235	13MAY1954	Male	64	White		20035	DROP
100236	20DEC1948	Female	70	White		20036	DROP
100237	22NOV1945	Male	73	White		20037	DROP
100238	14JAN1940	Male	78	White		20038	GEL
100239	21AUG1938	Female	80	White		20039	DROP
100240	26APR1946	Female	72	White		no treatmen	assigne
100241	15APR1944	Female	74	White		20040	GEL
100242	16FEB1951	Female	67	White		200-41	GEL
100243	04OCT1944	Male	74	White		20042	DROP
100244	12FEB1952	Female	66	White		20043	GEL
100245	23SEP1949	Female	69	Black		20044	DROP
100301	18JUL1949	Female	68	White		30001	GEL
100302	03APR1956	Male	61	White		3002	GEL
100303	06MAY1944	Female	73	White		30003	DROP
100304	22DEC1959	Male	58	Black		30004	DROP
100305	05JAN1932	Female	85	White		30005	DROP
100306	07JUL1933	Female	84	White		30006	DROP
100307	05DEC1944	Female	73	White		30007	GEL
100308	15MAR1932	Female	85	White		30008	GEL
100309	03SEP1956	Female	61	White		30009	DROP

Listing 1 (6 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100310	20MAR1944	Female	73	White		30010	GEL
100311	10OCT1934	Female	83	White		300011	GEL
100312	01DEC1946	Female	71	White		300012	DROP
100313	26APR1946	Male	71	White		30013	GEL
100314	19APR1950	Male	67	White		30014	DROP
100315	11JUL1952	Female	65	White		30015	GEL
100316	29SEP1941	Male	76	White		30016	DROP
100317	12JAN1932	Male	85	White		30017	GEL
100318	22MAR1937	Female	80	White		30018	GEL
100319	23MAR1947	Male	70	White		30019	DROP
100320	01APR1948	Male	69	White		30020	DROP
100321	13MAR1945	Male	72	White		30021	GEL
100322	15OCT1937	Male	80	White		30022	GEL
100323	29JUN1941	Female	76	White		30023	DROP
100324	11JUN1952	Male	65	White		30024	DROP
100325	20MAY1934	Female	83	White		30025	GEL
100326	16DEC1936	Male	81	White		30026	DROP
100327	11FEB1944	Female	73	White		30027	GEL
100328	04FEB1935	Male	82	White		30028	DROP
100329	11MAR1943	Male	74	White		30029	GEL
100330	07MAY1956	Male	61	White		30030	DROP
100331	30OCT1946	Female	71	White		30031	GEL

Listing 1 (7 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100332	19JUL1936	Male	82	White		30032	DROP
100333	11MAR1956	Male	62	White		30033	DROP
100334	01MAY1946	Male	72	White		30034	GEL
100335	06OCT1938	Female	80	White		30035	DROP
100336	19SEP1936	Female	82	White		30036	GEL
100337	02JAN1946	Male	72	White		30037	GEL
100338	26AUG1931	Female	87	White		30038	DROP
100339	27JAN1962	Male	56	White		30039	GEL
100340	05FEB1935	Male	83	White		30040	DROP
100341	19JUL1930	Male	88	White		30041	GEL
100342	20JUL1932	Female	86	White		30042	DROP
100343	18JUL1944	Male	74	White		30043	GEL
100344	16JAN1950	Female	68	White		30044	DROP
100345	02JAN1970	Male	48	Black		30045	GEL
100346	25SEP1941	Female	77	White		30046	DROP
100347	20OCT1960	Male	58	White		30047	GEL
100348	08APR1980	Female	38	White		30048	GEL
100349	07JUL1947	Male	71	White		30049	DROP
100350	25SEP1951	Female	67	White		30050	DROP
100351	29APR1939	Female	79	White		30051	GEL
100352	26JUL1955	Female	63	White		30052	DROP
100353	19MAR1946	Female	72	White		30053	GEL

Listing 1 (8 of 9): Patient Information/ Registration

Sbj Code	Date of birth	Sex	Age* (yrs)	Race	If Race=Other, specify	Randomiz. Number	Study Drug
100354	25JAN1938	Female	80	White		30054	GEL
100355	04APR1938	Female	80	White		30055	DROP
100356	16SEP1944	Male	74	White		30056	GEL
200101	18OCT1952	Female	66	White		40001	GEL
200102	06AUG1942	Female	76	White		40002	DROP
200103	18FEB1936	Male	82	White		40003	DROP
200104	21SEP1940	Female	78	White		40004	GEL
200105	11JUN1953	Female	65	White		40005	GEL
200106	04SEP1943	Female	75	White		40006	DROP
200107	31JUL1964	Female	54	White		40007	DROP
200108	17OCT1941	Male	77	White		40008	GEL
200109	14DEC1934	Female	84	White		40009	GEL
200110	15SEP1954	Male	64	White		40010	DROP
200111	26APR1945	Male	73	White		40011	GEL
200112	01JUN1933	Male	85	White		40012	DROP
200113	12JAN1941	Male	77	White		40013	DROP
200114	21FEB1954	Female	64	White		40014	DROP
200115	16JUN1948	Female	70	White		40015	GEL
200201	30SEP1947	Female	71	White			
200202	05APR1947	Female	71	White		50001	DROP

Listing 1 (9 of 9): Patient Information/ Registration

```
=====
Sbj      Date of      Age*      If Race=Other,  Randomiz.  Study
Code     birth        Sex      (yrs)      Race  specify      Number      Drug
=====
200203   29APR1952      Male      66      White                               50002      GEL
-----
200204   12JAN1960      Male      58      White                               50003      GEL
=====
SAS program: L03_List_01.sas  -  SAS dataset name(s): RAND,DEMOGRAPHY
```

\* Age was computed from date of birth and date of informed consent

Listing 2 (1 of 9): Eligibility criteria

[illegible]

[illegible]



Listing 2 (3 of 9): Eligibility criteria

[illegible]

Listing 2 (4 of 9): Eligibility criteria

[illegible]

Listing 2 (5 of 9): Eligibility criteria

[illegible]

Listing 2 (6 of 9): Eligibility criteria

[illegible]

Listing 2 (7 of 9): Eligibility criteria

[illegible]

[illegible]

Sbj Code	Study drug	Sex	Age (year)	Informed consent date	Inclusion criteria								Exclusion criteria																				
					1	2	3	4	5	6	7	8	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
200112	DROP	Male	85	18NOV2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
200113	DROP	Male	77	18NOV2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
200114	DROP	Female	64	12NOV2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
200115	GEL	Female	70	06DEC2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
200201		Female	71	24JAN2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	No	No	NA	No	No
200202	DROP	Female	71	13JUN2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No
200203	GEL	Male	66	21JUN2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	NA	NA	No	No
200204	GEL	Male	58	28JUN2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	NA	NA	No	No
SAS program: L03_List_02.sas    -    SAS dataset name(s): RAND,DEMOGRAPHY,INCLUSION,EXCLUSION																																	

Listing 3 (1 of 9): Screening visit - Pregnancy test

=====					
					Pregnancy test
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100101	DROP	Female 84	20OCT2017	NA (out of childbearing age)	.
100102	GEL	Male 80	27OCT2017	NA (male)	.
100103		Female 70	27OCT2017	NA (out of childbearing age)	.
100104	GEL	Male 70	03NOV2017	NA (male)	.
100105	DROP	Female 85	03NOV2017	NA (out of childbearing age)	.
100106	GEL	Male 56	09NOV2017	NA (male)	.
100107	DROP	Female 82	23NOV2017	NA (out of childbearing age)	.
100108	DROP	Female 73	01DEC2017	NA (out of childbearing age)	.
100109	GEL	Female 56	07DEC2017	NA (out of childbearing age)	.
100110	DROP	Female 75	07DEC2017	NA (out of childbearing age)	.
100111	DROP	Female 60	07DEC2017	NA (out of childbearing age)	.
100112	GEL	Male 73	28DEC2017	NA (male)	.
100113	GEL	Female 77	28DEC2017	NA (out of childbearing age)	.
100114	GEL	Male 64	29DEC2017	NA (male)	.
100115	DROP	Male 76	29DEC2017	NA (male)	.
100116	GEL	Male 62	29DEC2017	NA (male)	.
100117	DROP	Female 51	04JAN2018	NA (out of childbearing age)	.
100118	DROP	Female 78	11JAN2018	NA (out of childbearing age)	.
100119	DROP	Female 72	19JAN2018	NA (out of childbearing age)	.
100120	GEL	Male 79	19JAN2018	NA (male)	.
100121	GEL	Male 80	19JAN2018	NA (male)	.



Listing 3 (2 of 9): Screening visit - Pregnancy test

=====					
					Pregnancy test
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100122	DROP	Female 76	19JAN2018	NA (out of childbearing age)	.
100123	DROP	Female 76	19JAN2018	NA (out of childbearing age)	.
100124	GEL	Female 71	26JAN2018	NA (out of childbearing age)	.
100125	GEL	Female 62	26JAN2018	NA (out of childbearing age)	.
100126	GEL	Female 85	02FEB2018	NA (out of childbearing age)	.
100127	GEL	Female 68	02FEB2018	NA (out of childbearing age)	.
100128	DROP	Male 80	02FEB2018	NA (male)	.
100129	DROP	Female 78	02FEB2018	NA (out of childbearing age)	.
100130	GEL	Male 66	16FEB2018	NA (male)	.
100131	DROP	Female 77	16FEB2018	NA (out of childbearing age)	.
100132	DROP	Male 69	02MAR2018	NA (male)	.
100133	GEL	Male 74	02MAR2018	NA (male)	.
100134	DROP	Female 66	02MAR2018	NA (out of childbearing age)	.
100135	GEL	Male 69	09MAR2018	NA (male)	.
100136	GEL	Female 90	30MAR2018	NA (out of childbearing age)	.
100137	DROP	Female 62	13APR2018	NA (out of childbearing age)	.
100138	GEL	Male 63	13APR2018	NA (male)	.
100139	DROP	Female 71	20APR2018	NA (out of childbearing age)	.
100140	GEL	Male 81	27APR2018	NA (male)	.
100141	DROP	Female 74	27APR2018	NA (out of childbearing age)	.
100142	GEL	Female 77	11MAY2018	NA (out of childbearing age)	.

Listing 3 (3 of 9): Screening visit - Pregnancy test

=====					
Pregnancy test					
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100143	GEL	Male 74	15JUN2018	NA (male)	.
100144	DROP	Female 89	22JUN2018	NA (out of childbearing age)	.
100145	GEL	Male 81	29JUN2018	NA (male)	.
100146	GEL	Male 71	17AUG2018	NA (male)	.
100147	DROP	Male 48	24AUG2018	NA (male)	.
100148	DROP	Female 83	24AUG2018	NA (out of childbearing age)	.
100149	DROP	Female 71	24AUG2018	NA (out of childbearing age)	.
100150	GEL	Female 77	31AUG2018	NA (out of childbearing age)	.
100151	DROP	Female 67	28SEP2018	NA (out of childbearing age)	.
100152	GEL	Female 78	28SEP2018	NA (out of childbearing age)	.
100153	DROP	Female 81	12OCT2018	NA (out of childbearing age)	.
100154	GEL	Female 68	12OCT2018	NA (out of childbearing age)	.
100155	DROP	Female 79	12OCT2018	NA (out of childbearing age)	.
100156	GEL	Female 69	12OCT2018	NA (out of childbearing age)	.
100201	GEL	Female 80	01DEC2017	NA (out of childbearing age)	.
100202	DROP	Female 70	01DEC2017	NA (out of childbearing age)	.
100203	DROP	Female 76	07DEC2017	NA (out of childbearing age)	.
100204	GEL	Male 71	07DEC2017	NA (male)	.
100205	GEL	Male 75	14DEC2017	NA (male)	.
100206	DROP	Female 81	05JAN2018	NA (out of childbearing age)	.
100207	DROP	Female 65	05JAN2018	NA (out of childbearing age)	.

Listing 3 (4 of 9): Screening visit - Pregnancy test

=====					
Pregnancy test					
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100208	GEL	Female 79	05JAN2018	NA (out of childbearing age)	.
100209	GEL	Female 77	12JAN2018	NA (out of childbearing age)	.
100210	DROP	Female 70	12JAN2018	NA (out of childbearing age)	.
100211	GEL	Male 67	12JAN2018	NA (male)	.
100212	DROP	Female 82	12JAN2018	NA (out of childbearing age)	.
100213	DROP	Female 81	25JAN2018	NA (out of childbearing age)	.
100214	DROP	Female 77	05FEB2018	NA (out of childbearing age)	.
100215	GEL	Female 83	05FEB2018	NA (out of childbearing age)	.
100216	GEL	Female 74	09FEB2018	NA (out of childbearing age)	.
100217	DROP	Female 72	02MAR2018	NA (out of childbearing age)	.
100218	DROP	Male 72	02MAR2018	NA (male)	.
100219	GEL	Female 83	09MAR2018	NA (out of childbearing age)	.
100220	GEL	Male 64	09MAR2018	NA (male)	.
100221	GEL	Female 76	30MAR2018	NA (out of childbearing age)	.
100222	DROP	Female 76	05APR2018	NA (out of childbearing age)	.
100223	DROP	Male 61	05APR2018	NA (male)	.
100224	GEL	Female 75	20APR2018	NA (out of childbearing age)	.
100225	DROP	Female 79	20APR2018	NA (out of childbearing age)	.
100226	GEL	Female 74	20APR2018	NA (out of childbearing age)	.
100227	DROP	Female 68	27APR2018	NA (out of childbearing age)	.
100228	GEL	Female 68	27APR2018	NA (out of childbearing age)	.

Listing 3 (5 of 9): Screening visit - Pregnancy test

=====					
					Pregnancy test
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100229	GEL	Female 70	04MAY2018	NA (out of childbearing age)	.
100230	GEL	Female 63	04MAY2018	NA (out of childbearing age)	.
100231	DROP	Female 74	04MAY2018	NA (out of childbearing age)	.
100232	DROP	Female 73	04MAY2018	NA (out of childbearing age)	.
100233	GEL	Female 72	18MAY2018	NA (out of childbearing age)	.
100234	GEL	Female 73	18MAY2018	NA (out of childbearing age)	.
100235	DROP	Male 64	28MAY2018	NA (male)	.
100236	DROP	Female 70	28MAY2018	NA (out of childbearing age)	.
100237	DROP	Male 73	01JUN2018	NA (male)	.
100238	GEL	Male 78	01JUN2018	NA (male)	.
100239	DROP	Female 80	08JUN2018	NA (out of childbearing age)	.
100240		Female 72	06JUL2018	NA (out of childbearing age)	.
100241	GEL	Female 74	23OCT2018	NA (out of childbearing age)	.
100242	GEL	Female 67	31OCT2018	NA (out of childbearing age)	.
100243	DROP	Male 74	30NOV2018	NA (male)	.
100244	GEL	Female 66	07DEC2018	NA (out of childbearing age)	.
100245	DROP	Female 69	07DEC2018	NA (out of childbearing age)	.
100301	GEL	Female 68	13OCT2017	NA (out of childbearing age)	.
100302	GEL	Male 61	26OCT2017	NA (male)	.
100303	DROP	Female 73	26OCT2017	NA (out of childbearing age)	.
100304	DROP	Male 58	10NOV2017	NA (male)	.

Listing 3 (6 of 9): Screening visit - Pregnancy test

=====					
					Pregnancy test
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100305	DROP	Female 85	10NOV2017	NA (out of childbearing age)	.
100306	DROP	Female 84	16NOV2017	NA (out of childbearing age)	.
100307	GEL	Female 73	24NOV2017	NA (out of childbearing age)	.
100308	GEL	Female 85	24NOV2017	NA (out of childbearing age)	.
100309	DROP	Female 61	24NOV2017	NA (out of childbearing age)	.
100310	GEL	Female 73	24NOV2017	NA (out of childbearing age)	.
100311	GEL	Female 83	29NOV2017	NA (out of childbearing age)	.
100312	DROP	Female 71	29NOV2017	NA (out of childbearing age)	.
100313	GEL	Male 71	29NOV2017	NA (male)	.
100314	DROP	Male 67	30NOV2017	NA (male)	.
100315	GEL	Female 65	30NOV2017	NA (out of childbearing age)	.
100316	DROP	Male 76	30NOV2017	NA (male)	.
100317	GEL	Male 85	30NOV2017	NA (male)	.
100318	GEL	Female 80	30NOV2017	NA (out of childbearing age)	.
100319	DROP	Male 70	29NOV2017	NA (male)	.
100320	DROP	Male 69	30NOV2017	NA (male)	.
100321	GEL	Male 72	06DEC2017	NA (male)	.
100322	GEL	Male 80	06DEC2017	NA (male)	.
100323	DROP	Female 76	06DEC2017	NA (out of childbearing age)	.
100324	DROP	Male 65	13DEC2017	NA (male)	.
100325	GEL	Female 83	13DEC2017	NA (out of childbearing age)	.

Listing 3 (7 of 9): Screening visit - Pregnancy test

=====					
					Pregnancy test
Sbj	Study	Age	-----		
Code	drug	Sex (year)	Visit date	Performed?	Result
=====					
100326	DROP	Male 81	13DEC2017	NA (male)	.
100327	GEL	Female 73	13DEC2017	NA (out of childbearing age)	.
100328	DROP	Male 82	13DEC2017	NA (male)	.
100329	GEL	Male 74	13DEC2017	NA (male)	.
100330	DROP	Male 61	14DEC2017	NA (male)	.
100331	GEL	Female 71	14DEC2017	NA (out of childbearing age)	.
100332	DROP	Male 82	05JAN2018	NA (male)	.
100333	DROP	Male 62	19JAN2018	NA (male)	.
100334	GEL	Male 72	19JAN2018	NA (male)	.
100335	DROP	Female 80	31JAN2018	NA (out of childbearing age)	.
100336	GEL	Female 82	01MAR2018	NA (out of childbearing age)	.
100337	GEL	Male 72	10MAR2018	NA (male)	.
100338	DROP	Female 87	15MAR2018	NA (out of childbearing age)	.
100339	GEL	Male 56	22MAR2018	NA (out of childbearing age)	.
100340	DROP	Male 83	05APR2018	NA (male)	.
100341	GEL	Male 88	05APR2018	NA (male)	.
100342	DROP	Female 86	05APR2018	NA (out of childbearing age)	.
100343	GEL	Male 74	05APR2018	NA (male)	.
100344	DROP	Female 68	05APR2018	NA (out of childbearing age)	.
100345	GEL	Male 48	05APR2018	NA (male)	.
100346	DROP	Female 77	06APR2018	NA (out of childbearing age)	.

Listing 3 (8 of 9): Screening visit - Pregnancy test

=====					
					Pregnancy test
Sbj	Study	Age	-----		
Code	drug	Sex	(year)	Visit date	Performed? Result
=====					
100347	GEL	Male	58	12APR2018	NA (male) .
100348	GEL	Female	38	19APR2018	No .
100349	DROP	Male	71	18MAY2018	NA (male) .
100350	DROP	Female	67	18MAY2018	NA (out of childbearing age) .
100351	GEL	Female	79	18MAY2018	NA (out of childbearing age) .
100352	DROP	Female	63	23MAY2018	NA (out of childbearing age) .
100353	GEL	Female	72	31MAY2018	NA (out of childbearing age) .
100354	GEL	Female	80	01JUN2018	NA (out of childbearing age) .
100355	DROP	Female	80	08JUN2018	NA (out of childbearing age) .
100356	GEL	Male	74	12JUN2018	NA (male) .
200101	GEL	Female	66	11JAN2018	NA (out of childbearing age) .
200102	DROP	Female	76	25JAN2018	NA (out of childbearing age) .
200103	DROP	Male	82	12FEB2018	NA (male) .
200104	GEL	Female	78	03MAY2018	NA (out of childbearing age) .
200105	GEL	Female	65	24MAY2018	NA (out of childbearing age) .
200106	DROP	Female	75	18JUN2018	NA (out of childbearing age) .
200107	DROP	Female	54	25JUN2018	NA (out of childbearing age) .
200108	GEL	Male	77	29AUG2018	NA (male) .
200109	GEL	Female	84	29SEP2018	NA (out of childbearing age) .
200110	DROP	Male	64	05OCT2018	NA (male) .
200111	GEL	Male	73	01NOV2018	NA (male) .

Listing 3 (9 of 9): Screening visit - Pregnancy test

```
=====
                                Pregnancy test
Sbj      Study      Age      -----
Code drug Sex (year) Visit date  Performed?      Result
=====
200112 DROP  Male    85    09NOV2018    NA (male)      .
-----
200113 DROP  Male    77    09NOV2018    NA (male)      .
-----
200114 DROP  Female  64    23NOV2018    NA (out of childbearing age)  .
-----
200115 GEL   Female  70    14DEC2018    NA (out of childbearing age)  .
-----
200201      Female  71    24JAN2018    .              .
-----
200202 DROP  Female  71    13JUN2018    NA (out of childbearing age)  .
-----
200203 GEL   Male    66    21JUN2018    NA (male)      .
-----
200204 GEL   Male    58    28JUN2018    NA (male)      .
=====
SAS program: L03_List_03.sas - SAS dataset name(s): RAND,DEMOGRAPHY,PREGNANCY
```



Listing 4 (1 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100101	DROP	Female	84	Yes	Negative	Yes	Negative
100102	GEL	Male	80	Yes	Negative	Yes	Negative
100103		Female	70	Yes	Negative	Yes	Negative
100104	GEL	Male	70	Yes	Negative	Yes	Negative
100105	DROP	Female	85	Yes	Negative	Yes	Negative
100106	GEL	Male	56	Yes	Negative	Yes	Negative
100107	DROP	Female	82	Yes	Negative	Yes	Negative
100108	DROP	Female	73	Yes	Negative	Yes	Negative
100109	GEL	Female	56	Yes	Negative	Yes	Negative
100110	DROP	Female	75	Yes	Negative	Yes	Negative
100111	DROP	Female	60	Yes	Negative	Yes	Negative
100112	GEL	Male	73	Yes	Negative	Yes	Negative
100113	GEL	Female	77	Yes	Negative	Yes	Negative
100114	GEL	Male	64	Yes	Negative	Yes	Negative
100115	DROP	Male	76	Yes	Negative	Yes	Negative
100116	GEL	Male	62	Yes	Negative	Yes	Negative
100117	DROP	Female	51	Yes	Negative	Yes	Negative
100118	DROP	Female	78	Yes	Negative	Yes	Negative
100119	DROP	Female	72	Yes	Negative	Yes	Negative
100120	GEL	Male	79	Yes	Negative	Yes	Negative
100121	GEL	Male	80	Yes	Negative	Yes	Negative

Listing 4 (2 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100122	DROP	Female	76	Yes	Negative	Yes	Negative
-----							
100123	DROP	Female	76	Yes	Negative	Yes	Negative
-----							
100124	GEL	Female	71	Yes	Negative	Yes	Negative
-----							
100125	GEL	Female	62	Yes	Negative	Yes	Negative
-----							
100126	GEL	Female	85	Yes	Negative	Yes	Negative
-----							
100127	GEL	Female	68	Yes	Negative	Yes	Negative
-----							
100128	DROP	Male	80	Yes	Negative	Yes	Negative
-----							
100129	DROP	Female	78	Yes	Negative	Yes	Negative
-----							
100130	GEL	Male	66	Yes	Negative	Yes	Negative
-----							
100131	DROP	Female	77	Yes	Negative	Yes	Negative
-----							
100132	DROP	Male	69	Yes	Negative	Yes	Negative
-----							
100133	GEL	Male	74	Yes	Negative	Yes	Negative
-----							
100134	DROP	Female	66	Yes	Negative	Yes	Negative
-----							
100135	GEL	Male	69	Yes	Negative	Yes	Negative
-----							
100136	GEL	Female	90	Yes	Negative	Yes	Negative
-----							
100137	DROP	Female	62	Yes	Negative	Yes	Negative
-----							
100138	GEL	Male	63	Yes	Negative	Yes	Negative
-----							
100139	DROP	Female	71	Yes	Negative	Yes	Negative
-----							
100140	GEL	Male	81	Yes	Negative	Yes	Negative
-----							
100141	DROP	Female	74	Yes	Negative	Yes	Negative
-----							
100142	GEL	Female	77	Yes	Negative	Yes	Negative

Listing 4 (3 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100143	GEL	Male	74	Yes	Negative	Yes	Negative
-----							
100144	DROP	Female	89	Yes	Negative	Yes	Negative
-----							
100145	GEL	Male	81	Yes	Negative	Yes	Negative
-----							
100146	GEL	Male	71	Yes	Negative	Yes	Negative
-----							
100147	DROP	Male	48	Yes	Negative	Yes	Negative
-----							
100148	DROP	Female	83	Yes	Negative	Yes	Negative
-----							
100149	DROP	Female	71	Yes	Negative	Yes	Negative
-----							
100150	GEL	Female	77	Yes	Negative	Yes	Negative
-----							
100151	DROP	Female	67	Yes	Negative	Yes	Negative
-----							
100152	GEL	Female	78	Yes	Negative	Yes	Negative
-----							
100153	DROP	Female	81	Yes	Negative	Yes	Negative
-----							
100154	GEL	Female	68	Yes	Negative	Yes	Negative
-----							
100155	DROP	Female	79	Yes	Negative	Yes	Negative
-----							
100156	GEL	Female	69	Yes	Negative	Yes	Negative
-----							
100201	GEL	Female	80	Yes	Negative	Yes	Negative
-----							
100202	DROP	Female	70	Yes	Negative	Yes	Negative
-----							
100203	DROP	Female	76	Yes	Negative	Yes	Negative
-----							
100204	GEL	Male	71	Yes	Negative	Yes	Negative
-----							
100205	GEL	Male	75	Yes	Negative	Yes	Negative
-----							
100206	DROP	Female	81	Yes	Negative	Yes	Negative
-----							
100207	DROP	Female	65	Yes	Negative	Yes	Negative

Listing 4 (4 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100208	GEL	Female	79	Yes	Negative	Yes	Negative
-----							
100209	GEL	Female	77	Yes	Negative	Yes	Negative
-----							
100210	DROP	Female	70	Yes	Negative	Yes	Negative
-----							
100211	GEL	Male	67	Yes	Negative	Yes	Negative
-----							
100212	DROP	Female	82	Yes	Negative	Yes	Negative
-----							
100213	DROP	Female	81	Yes	Negative	Yes	Negative
-----							
100214	DROP	Female	77	Yes	Negative	Yes	Negative
-----							
100215	GEL	Female	83	Yes	Negative	Yes	Negative
-----							
100216	GEL	Female	74	Yes	Negative	Yes	Negative
-----							
100217	DROP	Female	72	Yes	Negative	Yes	Negative
-----							
100218	DROP	Male	72	Yes	Negative	Yes	Negative
-----							
100219	GEL	Female	83	Yes	Negative	Yes	Negative
-----							
100220	GEL	Male	64	Yes	Negative	Yes	Negative
-----							
100221	GEL	Female	76	Yes	Negative	Yes	Negative
-----							
100222	DROP	Female	76	Yes	Negative	Yes	Negative
-----							
100223	DROP	Male	61	Yes	Negative	Yes	Negative
-----							
100224	GEL	Female	75	Yes	Negative	Yes	Negative
-----							
100225	DROP	Female	79	Yes	Negative	Yes	Negative
-----							
100226	GEL	Female	74	Yes	Negative	Yes	Negative
-----							
100227	DROP	Female	68	Yes	Negative	Yes	Negative
-----							
100228	GEL	Female	68	Yes	Negative	Yes	Negative

Listing 4 (5 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100229	GEL	Female	70	Yes	Negative	Yes	Negative
100230	GEL	Female	63	Yes	Negative	Yes	Negative
100231	DROP	Female	74	Yes	Negative	Yes	Negative
100232	DROP	Female	73	Yes	Negative	Yes	Negative
100233	GEL	Female	72	Yes	Negative	Yes	Negative
100234	GEL	Female	73	Yes	Negative	Yes	Negative
100235	DROP	Male	64	Yes	Negative	Yes	Negative
100236	DROP	Female	70	Yes	Negative	Yes	Negative
100237	DROP	Male	73	Yes	Negative	Yes	Negative
100238	GEL	Male	78	Yes	Negative	Yes	Negative
100239	DROP	Female	80	Yes	Negative	Yes	Negative
100240		Female	72	Yes	Negative	Yes	Negative
100241	GEL	Female	74	Yes	Negative	Yes	Negative
100242	GEL	Female	67	Yes	Negative	Yes	Negative
100243	DROP	Male	74	Yes	Negative	Yes	Negative
100244	GEL	Female	66	Yes	Negative	Yes	Negative
100245	DROP	Female	69	Yes	Negative	Yes	Negative
100301	GEL	Female	68	Yes	Negative	Yes	Negative
100302	GEL	Male	61	Yes	Negative	Yes	Negative
100303	DROP	Female	73	Yes	Negative	Yes	Negative
100304	DROP	Male	58	Yes	Negative	Yes	Negative

Listing 4 (6 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100305	DROP	Female	85	Yes	Negative	Yes	Negative
100306	DROP	Female	84	Yes	Negative	Yes	Negative
100307	GEL	Female	73	Yes	Negative	Yes	Negative
100308	GEL	Female	85	Yes	Negative	Yes	Negative
100309	DROP	Female	61	Yes	Negative	Yes	Negative
100310	GEL	Female	73	Yes	Negative	Yes	Negative
100311	GEL	Female	83	Yes	Negative	Yes	Negative
100312	DROP	Female	71	Yes	Negative	Yes	Negative
100313	GEL	Male	71	Yes	Negative	Yes	Negative
100314	DROP	Male	67	Yes	Negative	Yes	Negative
100315	GEL	Female	65	Yes	Negative	Yes	Negative
100316	DROP	Male	76	Yes	Negative	Yes	Negative
100317	GEL	Male	85	Yes	Negative	Yes	Negative
100318	GEL	Female	80	Yes	Negative	Yes	Negative
100319	DROP	Male	70	Yes	Negative	Yes	Negative
100320	DROP	Male	69	Yes	Negative	Yes	Negative
100321	GEL	Male	72	Yes	Negative	Yes	Negative
100322	GEL	Male	80	Yes	Negative	Yes	Negative
100323	DROP	Female	76	Yes	Negative	Yes	Negative
100324	DROP	Male	65	Yes	Negative	Yes	Negative
100325	GEL	Female	83	Yes	Negative	Yes	Negative

Listing 4 (7 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100326	DROP	Male	81	Yes	Negative	Yes	Negative
-----							
100327	GEL	Female	73	Yes	Negative	Yes	Negative
-----							
100328	DROP	Male	82	Yes	Negative	Yes	Negative
-----							
100329	GEL	Male	74	Yes	Negative	Yes	Negative
-----							
100330	DROP	Male	61	Yes	Negative	Yes	Negative
-----							
100331	GEL	Female	71	Yes	Negative	Yes	Negative
-----							
100332	DROP	Male	82	Yes	Negative	Yes	Negative
-----							
100333	DROP	Male	62	Yes	Negative	Yes	Negative
-----							
100334	GEL	Male	72	Yes	Negative	Yes	Negative
-----							
100335	DROP	Female	80	Yes	Negative	Yes	Negative
-----							
100336	GEL	Female	82	Yes	Negative	Yes	Negative
-----							
100337	GEL	Male	72	Yes	Negative	Yes	Negative
-----							
100338	DROP	Female	87	Yes	Negative	Yes	Negative
-----							
100339	GEL	Male	56	Yes	Negative	Yes	Negative
-----							
100340	DROP	Male	83	Yes	Negative	Yes	Negative
-----							
100341	GEL	Male	88	Yes	Negative	Yes	Negative
-----							
100342	DROP	Female	86	Yes	Negative	Yes	Negative
-----							
100343	GEL	Male	74	Yes	Negative	Yes	Negative
-----							
100344	DROP	Female	68	Yes	Negative	Yes	Negative
-----							
100345	GEL	Male	48	Yes	Negative	Yes	Negative
-----							
100346	DROP	Female	77	Yes	Negative	Yes	Negative

Listing 4 (8 of 9): Screening visit - Amsler and OCT tests at study entry

=====							
Sbj Code	Study drug	Sex	Age (year)	Amsler test		OCT test	
				Performed?	Result	Performed?	Result
=====							
100347	GEL	Male	58	Yes	Negative	Yes	Negative
100348	GEL	Female	38	Yes	Negative	Yes	Negative
100349	DROP	Male	71	Yes	Negative	Yes	Negative
100350	DROP	Female	67	Yes	Negative	Yes	Negative
100351	GEL	Female	79	Yes	Negative	Yes	Negative
100352	DROP	Female	63	Yes	Negative	Yes	Negative
100353	GEL	Female	72	Yes	Negative	Yes	Negative
100354	GEL	Female	80	Yes	Negative	Yes	Negative
100355	DROP	Female	80	Yes	Negative	Yes	Negative
100356	GEL	Male	74	Yes	Negative	Yes	Negative
200101	GEL	Female	66	Yes	Negative	Yes	Negative
200102	DROP	Female	76	Yes	Negative	Yes	Negative
200103	DROP	Male	82	Yes	Negative	Yes	Negative
200104	GEL	Female	78	Yes	Negative	Yes	Negative
200105	GEL	Female	65	Yes	Negative	Yes	Negative
200106	DROP	Female	75	Yes	Negative	Yes	Negative
200107	DROP	Female	54	Yes	Negative	Yes	Negative
200108	GEL	Male	77	Yes	Negative	Yes	Negative
200109	GEL	Female	84	Yes	Negative	Yes	Negative
200110	DROP	Male	64	Yes	Negative	Yes	Negative
200111	GEL	Male	73	Yes	Negative	Yes	Negative



Listing 4 (9 of 9): Screening visit - Amsler and OCT tests at study entry

```
=====
                Amsler test                OCT test
Sbj   Study   Age   -----
Code  drug    Sex  (year) Performed? Result   Performed? Result
=====
200112 DROP   Male   85    Yes      Negative   Yes      Negative
-----
200113 DROP   Male   77    Yes      Negative   Yes      Negative
-----
200114 DROP   Female 64    Yes      Negative   Yes      Negative
-----
200115 GEL    Female 70    Yes      Negative   Yes      Negative
-----
200201        Female 71    .        .          .        .
-----
200202 DROP   Female 71    Yes      Negative   Yes      Negative
-----
200203 GEL    Male   66    Yes      Negative   Yes      Negative
-----
200204 GEL    Male   58    Yes      Negative   Yes      Negative
=====
SAS program: L03_List_04.sas - SAS dataset name(s): RAND,DEMOGRAPHY,AMSLER,OCT
```

Listing 5 (1 of 10): Screening visit - General and Ophthalmic medical history at study entry

General medical history							Ophthalmic medical history		
Sbj	Study	Age				Date of			
Code	drug	Sex	(year)	Reported term		diagnosis	Ongoing	Reported term	Date of
									diagnosis
									Ongoing
100101	DROP	Female	84	INTRACAVERNOUS MENINGIOMA	6MAR1976	NO			
.	.	.	.	IPERTENSION	4FEB2003	YES			
100105	DROP	Female	85	IPERTENSION	8FEB2002	YES			
100106	GEL	Male	56	ARTERIAL HYPERTENSION	2APR2012	YES			
.	.	.	.	THYROIDECTOMY	5MAY2004	NO			
100110	DROP	Female	75	ARTERIAL HYPERTENSION	FEB2007	YES			
100112	GEL	Male	73	APPENDICECTOMY	7FEB1999	NO			
.	.	.	.	ARTERIAL HYPERTENSION	20APR2005	YES			
100113	GEL	Female	77	ARTERIAL HYPERTENSION	7OCT2013	YES			
100114	GEL	Male	64	ARTERIAL HYPERTENSION	2MAY2012	YES			
100115	DROP	Male	76	PRIOR MIOCARDIAL ISCHEMIA	SEP2013	NO			
100118	DROP	Female	78	ARTERIAL HYPERTENSION	6OCT2007	YES			
.	.	.	.	HYPERCHOLESTEROLEMIA	23JAN2001	YES			
100119	DROP	Female	72	ARTERIAL HYPERTENSION	2002	YES			
100120	GEL	Male	79	ARTERIAL HYPERTENSION	6MAY2005	YES			
.	.	.	.	RENAL CARCINOMA ASPORTATION	2011	NO			
100121	GEL	Male	80	ARTERIAL HTPERTENSION	2000	YES			
100124	GEL	Female	71	ARTERIAL HYPERTENSION	FEB2001	YES			
100126	GEL	Female	85	ARTERIAL HYPERTENSION	2005	YES			
.	.	.	.	HYPERCHOLESTEROLEMIA	2008	YES			
100128	DROP	Male	80	ARTERIAL HYPERTENSION	APR2001	YES			
100130	GEL	Male	66	ARTERIAL HYPERTENSION	2000	YES			
.	.	.	.	MIOCARDIAL ISCHEMIA	2017	NO			
100131	DROP	Female	77	ARTERIAL HYPERTENSION	2010	YES			
100133	GEL	Male	74	ARTERIAL HYPERTENSION	MAR2005	YES			

General medical history										Ophthalmic medical history			
Sbj Code	Study drug	Sex	Age (year)	Reported term	Date of diagnosis	Ongoing	Reported term	Date of diagnosis	Ongoing				
100145	GEL	Male	81	ARTERIAL HYPERTENSION	2003	YES							
.	.	.	.	HYPERCOLESTEROLEMIA	2003	YES							
100149	DROP	Female	71	HYPOTHYROIDISM	1995	YES							
100153	DROP	Female	81	HYPERTENSION	2003	YES							
.	.	.	.	HYPOTHYROIDISM	2010	YES							
100154	GEL	Female	68	ARTERIAL HYPERTHENSION	FEB2007	YES							
100155	DROP	Female	79	ARTERIAL HYPERTHENSION	2002	YES							
100201	GEL	Female	80	APPENDICECTOMY	1957	NO	LEFT EYE CATARACT SURGERY	26JAN2017	NO				
.	.	.	.	HYSTEROANNESSIECTOMY	1990	NO	RIGHT EYE CATARACT	2015	YES				
.	.	.	.	MENOPAUSE	1990	YES							
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2007	YES							
100202	DROP	Female	70	LEFT ROTATOR SCUFF SURGERY	SEP2017	NO	LEFT EYE CATARACT	2016	YES				
.	.	.	.				RIGHT EYE CATARACT	2016	YES				
100203	DROP	Female	76	GASTROESOPHAGEAL REFLUX	2012	YES	LEFT EYE CATARACT SURGERY	2013	NO				
.	.	.	.	HYPERCOLESTEROLEMIA	2007	YES	LEFT EYE YAG LASER CAPSULOTOMY	2015	NO				
.	.	.	.	HYPERURICEMIA	2007	YES	RIGHT EYE CATARACT	2015	YES				
.	.	.	.	INSOMNIA	2007	YES							
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2007	YES							
100204	GEL	Male	71	ATRIAL FIBRILLATION	2012	YES	RIGHT EYE CATARACT	2016	YES				
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2012	YES							
100205	GEL	Male	75	GASTROESOPHAGEAL REFLUX	2007	YES	LEFT EYE CATARACT	2016	YES				
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2011	YES	RIGHT EYE CATARACT	2016	YES				
100206	DROP	Female	81	GASTROESOPHAGEAL REFLUX	2013	YES	DRY EYE SYNDROME	2016	YES				
.	.	.	.	HYPERCHOLESTEROLEMIA	2008	YES	LEFT EYE CATARACT SURGERY	19OCT2017	NO				
.	.	.	.				RIGHT EYE CATARACT	2016	YES				
100207	DROP	Female	65	HYPERCHOLESTEROLEMIA	2008	YES	HIGH MYOPIA	1967	YES				
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2013	YES	LEFT EYE CATARACT	2015	YES				
.	.	.	.				RIGHT EYE CATARACT	2015	YES				
100208	GEL	Female	79	DEPRESSION	2015	YES	LEFT EYE CATARACT SURGERY	JAN2016	NO				

Listing 5 (3 of 10): Screening visit - General and Ophthalmic medical history at study entry

=====									
General medical history							Ophthalmic medical history		
Sbj	Study	Age			Date of				Date of
Code	drug	Sex	(year)	Reported term	diagnosis	Ongoing	Reported term		diagnosis
=====									
100209	GEL	Female	77	CARDIAC ARRHYTHMIA	2008	YES	LEFT EYE CATARACT	2016	YES
.	.	.	.	INSOMNIA	2008	YES	RIGHT EYE CATARACT	2016	YES
-----									
100210	DROP	Female	70	HYPERCHOLESTEROLEMIA	2012	YES	LEFT EYE CATARACT SURGERY	12OCT2017	NO
.	.	.	.				RIGHT EYE CATARACT	2016	YES
-----									
100211	GEL	Male	67	HYPERCHOLESTEROLEMIA	2014	YES	LEFT EYE CATARACT	2016	YES
.	.	.	.				RIGHT EYE CATARACT	2016	YES
-----									
100212	DROP	Female	82	GASTROESOPHAGEAL REFLUX	2013	YES	LEFT EYE CATARACT SURGERY	2016	YES
.	.	.	.				RIGHT EYE CATARACT SURGERY	SEP2017	YES
-----									
100213	DROP	Female	81	HYPOTHYROIDISM	1988	YES	DRY EYE SYNDROME	2008	YES
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	1998	YES	LEFT EYE CATARACT	2016	YES
.	.	.	.				RIGHT EYE CATARACT SURGERY	9FEB2017	YES
-----									
100214	DROP	Female	77	HYPERCHOLESTEROLEMIA	2000	YES	LEFT EYE CATARACT	2016	YES
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	1996	YES	RIGHT EYE-VITREORETINAL INTERF	2017	YES
							ACE SYNDROME		
-----									
100215	GEL	Female	83				LEFT EYE CATARACT	2007	YES
-----									
100216	GEL	Female	74				LEFT EYE CATARACT		YES
.	.	.	.				RIGHT EYE CATARACT SURGERY	APR2016	NO
-----									
100217	DROP	Female	72	HYMENOPTERA VENOM ALLERGY	1978	YES	LEFT EYE CATARACT SURGERY	2NOV2017	NO
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2008	YES	RIGHT EYE CATARACT	2016	YES
-----									
100218	DROP	Male	72	PROSTATECTOMY	2014	NO	LEFT EYE CATARACT SURGERY	23NOV2017	NO
.	.	.	.	PROSTATIC CANCER	2014	NO			
-----									
100219	GEL	Female	83	SYSTEMIC ARTERIAL HYPERTENSION	2013	YES	CHOROIDEAL NEVUS LEFT EYE	JAN2018	YES
-----									
100220	GEL	Male	64	PULMONARY HYPERTENSION	2015	YES	RIGHT EYE CATARACT SURGERY	14DEC2017	NO
.	.	.	.	SCLERODERMA	2010	YES			
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2014	YES			
-----									
100221	GEL	Female	76	SYSTEMIC ARTERIAL HYPERTENSION	2008	YES			
-----									
100222	DROP	Female	76	SYSTEMIC ARTERIAL HYPERTENSION	2008	YES	RIGHT EYE CATARACT SURGERY	2016	NO
-----									
100223	DROP	Male	61	ISCHEMIC STROKE	2015	NO			

General medical history										Ophthalmic medical history		
Sbj Code	Study drug	Sex	Age (year)	Reported term	Date of diagnosis	Ongoing	Reported term	Date of diagnosis	Ongoing			
100224	GEL	Female	75	ANXIETY	2015	YES						
.	.	.	.	CAROTID ENDARTERECTOMY	2013	NO						
.	.	.	.	HYPERLIPIDEMIA	2013	YES						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2005	YES						
100225	DROP	Female	79	SYSTEMIC HYPERTENSION	2008	YES						
100226	GEL	Female	74	DEPRESSION	2010	YES						
.	.	.	.	SYSTEMIC HYPERTENSION	2008	YES						
100227	DROP	Female	68	HYPERCHOLESTEROLEMIA	2012	YES						
.	.	.	.	SYSTEMIC HYPERTENSION	2009	YES						
100228	GEL	Female	68	HYPERCHOLESTEROLEMIA	2012	YES	LEFT EYE CATARACT SURGERY	2016	NO			
.	.	.	.	OSTEOPOROSIS	2008	YES						
100229	GEL	Female	70	SYSTEMIC HYPERTENSION	2011	YES						
100231	DROP	Female	74	ANXIETY	2016	YES						
.	.	.	.	GASTRO ESOPHAGEAL REFLUX	2013	YES						
.	.	.	.	PARIETARIA ALLERGY	1964	YES						
.	.	.	.	SYSTEMIC HYPERTENSION	2011	YES						
100232	DROP	Female	73	MACROLIDES ALLERGY	1978	YES						
.	.	.	.	SYSTEMIC HYPERTENSION	2010	YES						
100233	GEL	Female	72	GALLSTONES	2010	YES	RIGHT EYE CATARACT SURGERY	2017	NO			
.	.	.	.	HYNOSOMNIA	2015	YES						
.	.	.	.	HYPOTHYROIDISM	2013	YES						
.	.	.	.	OSTHEOPOROSIS	2008	YES						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2010	YES						
100234	GEL	Female	73	ATRIAL FIBRILLATION	2013	YES	LEFT EYE CATARACT SURGERY	2017	NO			
.	.	.	.	HYPERCHOLESTEROLEMIA	2013	YES						
.	.	.	.	HYPOTHYROIDISM	2013	YES						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2010	YES						
100235	DROP	Male	64				LEFT EYE CATARACT SURGERY	2010	NO			
100236	DROP	Female	70	OSTEOPOROSIS	2017	YES	LEFT EYE RETINAL LASER BARRAGE	2016	NO			
100237	DROP	Male	73	PROSTATECTOMY	2014	NO	STRABISMUS SURGERY	1990	NO			

Listing 5 (5 of 10): Screening visit - General and Ophthalmic medical history at study entry

=====										
General medical history							Ophthalmic medical history			
Sbj	Study	Age	Date of			Date of				
Code	drug	Sex	(year)	Reported term	diagnosis	Ongoing	Reported term	diagnosis	Ongoing	
=====										
100238	GEL	Male	78	CHRONIC HEART FAILURE	2015	YES	LEFT EYE CATARACT SURGERY	2014	NO	
-----										
100239	DROP	Female	80	ATRIAL FIBRILLATION	2014	YES				
-----										
100240		Female	72	ASPIRIN,PENICILLIN,ROCEFEN,SUL PHAMIDIC ACIDALLERGY	1988	YES	RIGHT EYE CATARACT SURGERY	2017	NO	
.	.	.	.	ASTHMA	2013	YES				
.	.	.	.	HYPERCHOLESTEROLEMIA	2008	YES				
.	.	.	.	ISCHEMIC CARDIOMYOPATHY	2012	YES				
-----										
100241	GEL	Female	74	HYPERCOLESTEROLEMIA	1988	YES				
.	.	.	.	OSTEOPOROSIS	1988	YES				
-----										
100242	GEL	Female	67				CATARACT-BOTH EYES	2017	YES	
-----										
100243	DROP	Male	74	ALLERGY TO WASP STINGS	1998	YES	CATARACT-BOTH EYES	2017	YES	
.	.	.	.	HYPERCOLESTEROLEMIA	2015	YES				
.	.	.	.	ISCHEMIC CARDIOPATHY	2015	YES				
.	.	.	.	PSORIASIC ARTHRITIS	2013	YES				
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION	2008	YES				
-----										
100244	GEL	Female	66	ANXIOUS SYNDROME	2015	YES	LEFT EYE CATARACT SURGERY	JAN2018	NO	
.	.	.	.	EXTRASYSTOLIA	2016	YES				
.	.	.	.	PENICILLIN ALLERGY	1982	YES				
.	.	.	.	SUPERFICIAL THROMBOPHLEBITIS	SEP2018	YES				
-----										
100245	DROP	Female	69	HYDRIC RETENTION	2017	YES	CATARACT-BOTH EYES	2017	YES	
.	.	.	.	HYPERURICEMIA	2016	YES				
.	.	.	.	WHEAT ALLERGY	1988	YES				
-----										
100301	GEL	Female	68	ANXIOUS SYNDROME	2017	YES				
.	.	.	.	OSTEOPENIA	2015	YES				
-----										
100302	GEL	Male	61	CARDIOVASCULAR DISEASE	UNK	YES				
.	.	.	.	DIABETES MELLITUS	UNK	YES				
.	.	.	.	DYSLIPIDEMIA	UNK	YES				
.	.	.	.	HYPERTENSION	UNK	YES				
.	.	.	.	NEFROPHATHY	UNK	YES				
.	.	.	.	RENAL HYPERPALSA	UNK	YES				

Listing 5 (6 of 10): Screening visit - General and Ophthalmic medical history at study entry

General medical history							Ophthalmic medical history		
Sbj	Study	Age	Reported term	Date of diagnosis	Ongoing	Reported term	Date of diagnosis	Ongoing	
Code	drug	Sex (year)							
100303	DROP	Female 73	DIVERTICULOSIS	UNK	YES				
.	.	.	HYPERTENSION	UNK	YES				
.	.	.	OSTEOPOROSIS	UNK	YES				
.	.	.	POLYARTHROSIS	UNK	YES				
100305	DROP	Female 85	BRADICARDIA	UNK	YES	PREVIOUS INFARCTION OD	2016	NO	
.	.	.	HYPERTENSION	UNK	YES				
.	.	.	IPOTIROIDISMO	UNK	YES				
.	.	.	NEUROPATHY	UNK	NO				
100306	DROP	Female 84	DEPRESSIVE ANXIETY	UNK	NO				
.	.	.	DYSLIPIDEMIA	UNK	YES				
.	.	.	HYPERTENSION	UNK	YES				
100307	GEL	Female 73	HYPOTHYROIDIM	UNK	YES				
100308	GEL	Female 85	HYPERCOLESTEROLEMIA	UNK	YES				
.	.	.	HYPERTENSION	UNK	YES				
100309	DROP	Female 61	THYROID NODULE	UNK	YES				
100310	GEL	Female 73	QUADRANTECTOMY	2009	NO				
100311	GEL	Female 83	ANXIOUS SYNDROME	UNK	YES				
.	.	.	IPOACUSY	UNK	YES				
.	.	.	SYSTEMIC HIPERTENSION	UNK	YES				
100312	DROP	Female 71	HYPOTHYROIDIM	UNK	YES				
.	.	.	SYSTEMIC HIPERTENSION	UNK	YES				
100314	DROP	Male 67	APPENDICECTOMY	UNK	NO				
.	.	.	PROSTATIC HYPERTROPHY	UNK	YES				
100315	GEL	Female 65	ANXIOUS SYNDROME	UNK	YES				
100316	DROP	Male 76	ANGIOPLASTIC	2013	NO				
.	.	.	PROSTATIC HYPERTROPHY	UNK	YES				
100317	GEL	Male 85	PROSTATIC HYPERTROPHY	UNK	YES				
.	.	.	SYSTEMIC HYPERTENSION	UNK	YES				
100318	GEL	Female 80	SYSTEMIC HYPERTENSION	UNK	YES				

Listing 5 (7 of 10): Screening visit - General and Ophthalmic medical history at study entry

General medical history										Ophthalmic medical history		
Sbj	Study	Age	Sex (year)	General medical history		Date of diagnosis	Ongoing	Ophthalmic medical history		Date of diagnosis	Ongoing	
Code	drug			Reported term				Reported term				
100320	DROP	Male	69	CARDIOPATHY	UNK	YES						
.	.	.	.	DYSLIPIDEMIA	UNK	YES						
.	.	.	.	HYPERTENSION	UNK	YES						
100321	GEL	Male	72	ARTERIAL HYPERTENSION	UNK	YES						
.	.	.	.	DIVERTICULOSIS COLON	UNK	YES						
.	.	.	.	HYPOTHYROIDISM	UNK	YES						
.	.	.	.	PROSTECTOMY	UNK	NO						
100322	GEL	Male	80	ADENOIDECTOMIA	UNK	NO						
.	.	.	.	HYPERTENSION	UNK	YES						
.	.	.	.	TONSILLECTOMY	UNK	NO						
100323	DROP	Female	76	GASTROESOPHAGEAL REFLUX	UNK	YES						
.	.	.	.	HYPERCOLESTEROLEMIA	UNK	YES						
.	.	.	.	HYSTERECTOMY	UNK	NO						
.	.	.	.	MONOCLONAL GAMMAPATHY	UNK	YES						
.	.	.	.	NEPHRECTOMY	UNK	NO						
.	.	.	.	SYSTEMIC HIPERTENSION	UNK	YES						
100324	DROP	Male	65	HIATAL HERNIA	UNK	NO						
100325	GEL	Female	83	SISTEMIC HYPERTENSION	UNK	YES						
100326	DROP	Male	81	CARDIOPATHY	UNK	YES						
.	.	.	.	COLICISTECTOMY	UNK	NO						
.	.	.	.	ERNIOPLASTICA	UNK	NO						
.	.	.	.	HYPERTENSION	UNK	YES						
.	.	.	.	PROSTATIC ADENOMA	UNK	NO						
.	.	.	.	THROMBOPHLEBITIS	UNK	NO						
100327	GEL	Female	73	OSTEOPOROSIS	UNK	YES						
.	.	.	.	QUADRANTECTOMY	UNK	NO						
100328	DROP	Male	82	HYPERCHOLESTEROLEMIA	UNK	YES						
.	.	.	.	SYSTEMIC HIPERTENSION	UNK	YES						
100329	GEL	Male	74	SYSTEMIC HIPERTENSION	UNK	YES						
.	.	.	.	VASCULOPHATY	UNK	YES						
100330	DROP	Male	61	CARDIOPATHY	UNK	YES						



Listing 5 (8 of 10): Screening visit - General and Ophthalmic medical history at study entry

General medical history							Ophthalmic medical history		
Sbj	Study	Age	Date of		Date of		Date of		Date of
Code	drug	Sex	(year)	Reported term	diagnosis	Ongoing	Reported term	diagnosis	Ongoing
100331	GEL	Female	71	CARDIOPATHY	UNK	YES			
.	.	.	.	K COLON	1992	NO			
.	.	.	.	K LUNG	1994	NO			
100332	DROP	Male	82	GASTRITIS	UNK	YES			
.	.	.	.	HYPERTENSION	UNK	YES			
.	.	.	.	MELANOMA	UNK	YES			
.	.	.	.	VASCULOPATHY	UNK	YES			
100333	DROP	Male	62	INSOMNIA	UNK	YES			
100334	GEL	Male	72	SYSTEMIC HYPERTENSION	UNK	YES			
100335	DROP	Female	80	DYSLIPIDEMIA	UNK	YES			
.	.	.	.	OSTEOPOROSIS	UNK	YES			
.	.	.	.	SYSTEMIC HYPERTENSION	UNK	YES			
100336	GEL	Female	82	HYPERCOLESTEROLEMY	UNK	YES			
.	.	.	.	HYPERTENSION	UNK	YES			
100340	DROP	Male	83	HYPERTENSION	UNK	YES			
100341	GEL	Male	88	HYPERTENSION	UNK	YES			
100342	DROP	Female	86	HYPERTENSION	UNK	YES			
100343	GEL	Male	74	HYPERCOLESTEROLEMY	UNK	YES			
.	.	.	.	HYPERTENSION	UNK	YES			
100344	DROP	Female	68	HYPERTENSION	UNK	YES			
100346	DROP	Female	77	HYPERTENSION	UNK	YES			
.	.	.	.	HYPOTIROIDISM	UNK	YES			
100348	GEL	Female	38				MILD AMBLYOPIA		YES
100350	DROP	Female	67	HYPERTENSION	UNK	YES			
100351	GEL	Female	79	HYPERTENSION	UNK	YES			
100353	GEL	Female	72	HYPERCOLESTEROLEMY	UNK	YES			

Listing 5 (9 of 10): Screening visit - General and Ophthalmic medical history at study entry

General medical history										Ophthalmic medical history				
Sbj	Study	Age	Date of			Ongoing		Date of			Ongoing			
Code	drug	Sex	(year)	Reported term	diagnosis			Reported term	diagnosis					
100354	GEL	Female	80	HYPERTENSION	UNK	YES								
100355	DROP	Female	80	HYPERCOLESTEROLEMY	UNK	YES								
100356	GEL	Male	74	HYPERCOLESTEROLEMY	UNK	YES								
.	.	.	.	HYPERTENSION	UNK	YES								
200102	DROP	Female	76	HYPERTENSION	UNK	YES								
200103	DROP	Male	82	ENLARGED PROSTATE	UNK	YES								
.	.	.	.	HYPERTENSION	UNK	YES								
200104	GEL	Female	78	LABYRINTHINE VERTIGO	1992	YES								
.	.	.	.	OSTEOPOROSIS	2015	YES								
200105	GEL	Female	65	DIABETIS	2014	YES								
.	.	.	.	HYPERCHOLESTERIE	2010	YES								
.	.	.	.	HYPERTENSION	2010	YES								
200106	DROP	Female	75	DIABETIS	UNK	YES								
.	.	.	.	HYPERTENSION	UNK	YES								
.	.	.	.	HYPOTHYROIDISM	UNK	YES								
.	.	.	.	VITAMIN B12 DEFICIENCY	UNK	YES								
200107	DROP	Female	54	ASTHMA	UNK	YES								
.	.	.	.	DIABETIS	UNK	YES								
.	.	.	.	HYPERTENSION	UNK	YES								
.	.	.	.	OSTEOPOROSIS	UNK	YES								
.	.	.	.	SYSTEMIC MASTOCYTOSIS	UNK	YES								
200108	GEL	Male	77	ELEVATED URIC ACID LEVEL	UNK	YES								
.	.	.	.	HIGH BLOODPRESSURE	2008	YES								
.	.	.	.	HYPOTHYROIDISM	UNK	YES								
200109	GEL	Female	84	CONSTIPATION	UNK	YES								
.	.	.	.	HEART RHYTHM DISTURBANCES	1990	YES								
.	.	.	.	HIGH BLOODPRESSURE	2008	YES								
.	.	.	.	OSTEOPOROSIS	1998	YES								
200110	DROP	Male	64	COPD	UNK	YES								
.	.	.	.	HIGH BLODDPRESSURE	UNK	YES								

General medical history										Ophthalmic medical history			
Sbj Code	Study drug	Sex	Age (year)	Reported term	Date of diagnosis	Ongoing	Reported term	Date of diagnosis	Ongoing				
200111	GEL	Male	73	BLADDER DISCOMFORT	UNK	YES							
.	.	.	.	BORELLIOSIS	UNK	YES							
.	.	.	.	GOUT	UNK	YES							
.	.	.	.	HIGH BLOODPRESSURE	UNK	YES							
.	.	.	.	POLYNEUROPATHY	UNK	YES							
.	.	.	.	STOMACH PAIN	UNK	YES							
200112	DROP	Male	85	HIGH BLOODPRESSURE	2006	YES							
200113	DROP	Male	77	CIRCULATORY DISORDER	2013	YES							
.	.	.	.	DEPRESSION	2017	YES							
.	.	.	.	HIGH CHOLESTEROL	UNK	YES							
200114	DROP	Female	64	ARTERIAL HYPERTENSION	UNK	YES							
.	.	.	.	DIABETIS MELLITUS	UNK	YES							
.	.	.	.	GOUT	UNK	YES							
.	.	.	.	HIGH BLOOD PRESSURE	UNK	YES							
200115	GEL	Female	70	CRONIC PAIN SYNDROME	2017	YES							
.	.	.	.	REFLUX ESOPHAGITIS	2012	YES							
200202	DROP	Female	71	THYROIDITIS	2004	YES							
200203	GEL	Male	66	ARTERIAL HYPERTENSION	JUN2013	YES	OD: CATARACT	10MAR2014	NO				
.	.	.	.				OD: RHEGMATOGENOUS RETINAL DET	10MAR2014	NO				
.	.	.	.				ACHMENT						
							OS: RHEGMATOGENOUS PERIPHERAL	25AUG2016	NO				
							RETINAL DETACHMENT						
200204	GEL	Male	58	ARTERIAL HYPERTENSION	2008	YES							
.	.	.	.	GOUT	2008	YES							
.	.	.	.	HYPERURICEMIA	2008	YES							
.	.	.	.	INGUINAL HERNIA	1999	NO							
.	.	.	.	TRANSIENT ISCHEMIC ATTACK	2003	NO							
SAS program: L03 List 05.sas - SAS dataset(s): RAND,DEMOGRAPHY,MEDHIS COD,OPHHIS COD													

Listing 6 (1 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				-----		-----				-----		-----		
Sbj	Study	Age						Operated eye						
Code	drug	Sex	(year)	No.	Date	Left eye	Right eye	Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100101	DROP	Female	84	1	20OCT2017	0.8	0.4	.	.	13	18	Yes	0 grade	None
.	.	.	.	2	25OCT2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	26OCT2017	.	.	Left	1	12	12	Yes	0 grade	None
.	.	.	.	4	02NOV2017	.	.	Left	.	18	15	Yes	0 grade	None
.	.	.	.	5	08NOV2017	.	.	Left	1	17	15	Yes	0 grade	None
.	.	.	.	6	27DEC2017	.	.	Left	1	16	14	Yes	0 grade	None
-----														
100102	GEL	Male	80	1	27OCT2017	0.6	0.6	.	.	12	16	Yes	0 grade	None
.	.	.	.	2	31OCT2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	01NOV2017	.	.	Right	1	18	12	Yes	0 grade	None
.	.	.	.	4	07NOV2017	.	.	Right	1	15	12	Yes	0 grade	None
.	.	.	.	5	15NOV2017	.	.	Right	1	14	12	Yes	0 grade	None
.	.	.	.	6	29DEC2017	.	.	Right	1	14	13	Yes	0 grade	None
-----														
100103		Female	70	1	27OCT2017	0.1	0.9	.	.	15	15	Yes	0 grade	None
-----														
100104	GEL	Male	70	1	03NOV2017	1	0.6	.	.	12	15	Yes	0 grade	None
.	.	.	.	2	07NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08NOV2017	.	.	Right	0.8	12	17	Yes	0 grade	None
.	.	.	.	4	14NOV2017	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	5	22NOV2017	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	6	05JAN2018	.	.	Right	1	16	15	Yes	0 grade	None
-----														
100105	DROP	Female	85	1	03NOV2017	0.5	1	.	.	13	14	Yes	0 grade	None
.	.	.	.	2	08NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09NOV2017	.	.	Left	1	11	11	Yes	0 grade	None
.	.	.	.	4	15NOV2017	.	.	Left	1	12	12	Yes	0 grade	None
.	.	.	.	5	23NOV2017	.	.	Left	1	11	12	Yes	0 grade	None
.	.	.	.	6	08JAN2018	.	.	Left	1	11	12	Yes	0 grade	None
-----														
100106	GEL	Male	56	1	09NOV2017	0.8	1	.	.	17	19	Yes	0 grade	None
.	.	.	.	2	15NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	16NOV2017	.	.	Left	1	17	18	Yes	0 grade	None
.	.	.	.	4	22NOV2017	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	30NOV2017	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	6	15JAN2018	.	.	Left	1	15	15	Yes	0 grade	None

Listing 6 (2 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
												anterior ocular chamber		
Sbj	Study	Age												
Code	drug	Sex	(year)	No.	Date	Left eye	Right eye	Operated eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
-----														
100107	DROP	Female	82	1	23NOV2017	0.2	0.5	.	.	18	18	Yes	0 grade	None
.	.	.	.	2	28NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	29NOV2017	.	.	Left	0.8	15	15	Yes	0 grade	None
.	.	.	.	4	05DEC2017	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	13DEC2017	.	.	Left	1	14	15	Yes	0 grade	None
.	.	.	.	6	26JAN2018	.	.	Left	1	14	15	Yes	0 grade	None
-----														
100108	DROP	Female	73	1	01DEC2017	0.9	0.6	.	.	13	13	Yes	0 grade	None
.	.	.	.	2	06DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	07DEC2017	.	.	Right	1.2	13	12	Yes	0 grade	None
.	.	.	.	4	13DEC2017	.	.	Right	1.2	13	12	Yes	0 grade	None
.	.	.	.	5	21DEC2017	.	.	Right	1.2	12	12	Yes	0 grade	None
.	.	.	.	6	06FEB2018	.	.	Right	1.2	12	13	Yes	0 grade	None
-----														
100109	GEL	Female	56	1	07DEC2017	1	0.9	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	12DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13DEC2017	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	4	19DEC2017	.	.	Right	1.2	17	18	Yes	0 grade	None
.	.	.	.	5	27DEC2017	.	.	Right	1.2	17	18	Yes	0 grade	None
.	.	.	.	6	12FEB2018	.	.	Right	1.2	18	17	Yes	0 grade	None
-----														
100110	DROP	Female	75	1	07DEC2017	0.6	0.6	.	.	14	15	Yes	0 grade	None
.	.	.	.	2	13DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14DEC2017	.	.	Right	1.2	15	18	Yes	0 grade	None
.	.	.	.	4	20DEC2017	.	.	Right	1.2	15	16	Yes	0 grade	None
.	.	.	.	5	28DEC2017	.	.	Right	1.2	15	15	Yes	0 grade	None
.	.	.	.	6	12FEB2018	.	.	Right	1.2	15	15	Yes	0 grade	None
-----														
100111	DROP	Female	60	1	07DEC2017	0.5	1	.	.	16	15	Yes	0 grade	None
.	.	.	.	2	13DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14DEC2017	.	.	Left	0.9	12	15	Yes	0 grade	None
.	.	.	.	4	20DEC2017	.	.	Left	1	13	15	Yes	0 grade	None
.	.	.	.	5	28DEC2017	.	.	Left	1	13	14	Yes	0 grade	None
.	.	.	.	6	12FEB2018	.	.	Left	1	13	14	Yes	0 grade	None

Listing 6 (3 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100112	GEL	Male	73	1	28DEC2017	0.6	0.2	.	.	14	15	Yes	0 grade	None
.	.	.	.	2	03JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04JAN2018	.	.	Right	0.8	15	15	Yes	0 grade	None
.	.	.	.	4	10JAN2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	5	17JAN2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	6	05MAR2018	.	.	Right	1	15	15	Yes	0 grade	None
-----														
100113	GEL	Female	77	1	28DEC2017	0.9	0.4	.	.	15	17	Yes	0 grade	None
.	.	.	.	2	03JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04JAN2018	.	.	Right	0.9	15	17	Yes	0 grade	None
.	.	.	.	4	10JAN2018	.	.	Right	1	15	17	Yes	0 grade	None
.	.	.	.	5	17JAN2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	05MAR2018	.	.	Left	1	16	16	Yes	0 grade	None
-----														
100114	GEL	Male	64	1	29DEC2017	0.8	1	.	.	13	12	Yes	0 grade	None
.	.	.	.	2	03JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04JAN2018	.	.	Left	1	13	13	Yes	0 grade	None
.	.	.	.	4	10JAN2018	.	.	Left	1	13	13	Yes	0 grade	None
.	.	.	.	5	17JAN2018	.	.	Left	1	12	12	Yes	0 grade	None
.	.	.	.	6	05MAR2018	.	.	Left	1	12	12	Yes	0 grade	None
-----														
100115	DROP	Male	76	1	29DEC2017	0.7	0.6	.	.	15	16	Yes	0 grade	None
.	.	.	.	2	04JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	05JAN2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	4	11JAN2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	5	18JAN2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	6	06MAR2018	.	.	Right	1	15	15	Yes	0 grade	None
-----														
100116	GEL	Male	62	1	29DEC2017	0.8	1	.	.	14	13	Yes	0 grade	None
.	.	.	.	2	04JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	05JAN2018	.	.	Left	1	14	13	Yes	0 grade	None
.	.	.	.	4	11JAN2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	19JAN2018	.	.	Left	1	13	13	Yes	0 grade	None
.	.	.	.	6	06MAR2018	.	.	Left	1	13	13	Yes	0 grade	None

Listing 6 (4 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				-----		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100117	DROP	Female	51	1	04JAN2018	0.7	1	.	.	16	15	Yes	0 grade	None
.	.	.	.	2	10JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11JAN2018	.	.	Left	1	18	15	Yes	0 grade	None
.	.	.	.	4	17JAN2018	.	.	Left	1	16	15	Yes	0 grade	None
.	.	.	.	5	23JAN2018	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	6	12MAR2018	.	.	Left	1	15	15	Yes	0 grade	None
-----														
100118	DROP	Female	78	1	11JAN2018	0.7	0.6	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	17JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	18JAN2018	.	.	Right	1	15	16	Yes	0 grade	None
.	.	.	.	4	24JAN2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	31JAN2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	19MAR2018	.	.	Right	1	16	16	Yes	0 grade	None
-----														
100119	DROP	Female	72	1	19JAN2018	0.5	0.2	.	.	19	19	Yes	0 grade	None
.	.	.	.	2	24JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25JAN2018	.	.	Right	1	19	19	Yes	0 grade	None
.	.	.	.	4	31JAN2018	.	.	Right	1	18	19	Yes	0 grade	None
.	.	.	.	5	08FEB2018	.	.	Right	0.6	18	19	Yes	0 grade	None
.	.	.	.	6	26MAR2018	.	.	Right	0.6	18	18	Yes	0 grade	None
-----														
100120	GEL	Male	79	1	19JAN2018	0.3	1	.	.	18	15	Yes	0 grade	None
.	.	.	.	2	24JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25JAN2018	.	.	Left	0.8	16	15	Yes	0 grade	None
.	.	.	.	4	31JAN2018	.	.	Left	0.8	16	15	Yes	0 grade	None
.	.	.	.	5	07FEB2018	.	.	Left	0.8	16	15	Yes	0 grade	None
.	.	.	.	6	26MAR2018	.	.	Left	0.8	15	15	Yes	0 grade	None
-----														
100121	GEL	Male	80	1	19JAN2018	0.6	0.9	.	.	16	14	Yes	0 grade	None
.	.	.	.	2	24JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25JAN2018	.	.	Left	1	15	14	Yes	0 grade	None
.	.	.	.	4	31JAN2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	07FEB2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	6	26MAR2018	.	.	Left	1	14	14	Yes	0 grade	None

Listing 6 (5 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination anterior ocular chamber		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100122	DROP	Female	76	1	19JAN2018	0.7	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	25JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	26JAN2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	4	01FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	08FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	27MAR2018	.	.	Left	1	16	16	Yes	0 grade	None
-----														
100123	DROP	Female	76	1	19JAN2018	0.6	1	.	.	18	18	Yes	0 grade	None
.	.	.	.	2	25JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	26JAN2018	.	.	Left	1	18	18	Yes	0 grade	None
.	.	.	.	4	01FEB2018	.	.	Left	1	18	18	Yes	0 grade	None
.	.	.	.	5	08FEB2018	.	.	Left	1	18	18	Yes	0 grade	None
.	.	.	.	6	27MAR2018	.	.	Left	1	18	18	Yes	0 grade	None
-----														
100124	GEL	Female	71	1	26JAN2018	0.8	1	.	.	16	10	Yes	0 grade	None
.	.	.	.	2	01FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	02FEB2018	.	.	Left	1	16	11	Yes	0 grade	None
.	.	.	.	4	08FEB2018	.	.	Left	1	16	11	Yes	0 grade	None
.	.	.	.	5	16FEB2018	.	.	Left	1	16	12	Yes	0 grade	None
.	.	.	.	6	03APR2018	.	.	Left	1	15	12	Yes	0 grade	None
-----														
100125	GEL	Female	62	1	26JAN2018	0.3	1	.	.	19	18	Yes	0 grade	None
.	.	.	.	2	01FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	02FEB2018	.	.	Left	1	18	18	Yes	0 grade	None
.	.	.	.	4	08FEB2018	.	.	Left	1	18	18	Yes	0 grade	None
.	.	.	.	5	16FEB2018	.	.	Left	1	17	17	Yes	0 grade	None
.	.	.	.	6	03APR2018	.	.	Left	1	17	17	Yes	0 grade	None
-----														
100126	GEL	Female	85	1	02FEB2018	0.6	0.9	.	.	14	12	Yes	0 grade	None
.	.	.	.	2	07FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08FEB2018	.	.	Left	0.9	14	19	Yes	0 grade	None
.	.	.	.	4	14FEB2018	.	.	Left	0.9	14	18	Yes	0 grade	None
.	.	.	.	5	21FEB2018	.	.	Left	0.9	17	17	Yes	0 grade	None
.	.	.	.	6	09APR2018	.	.	Left	0.9	16	17	Yes	0 grade	None



Listing 6 (6 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination anterior ocular chamber		
Sbj Code	Study drug	Sex	Age (year)	-----		-----		-----		-----		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100127	GEL	Female	68	1	02FEB2018	1	0.6	.	.	15	18	Yes	0 grade	None
.	.	.	.	2	08FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09FEB2018	.	.	Right	1	16	18	Yes	0 grade	None
.	.	.	.	4	15FEB2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	24FEB2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	10APR2018	.	.	Right	1	16	16	Yes	0 grade	None
-----														
100128	DROP	Male	80	1	02FEB2018	0.5	1	.	.	15	11	Yes	0 grade	None
.	.	.	.	2	08FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09FEB2018	.	.	Left	1	16	11	Yes	0 grade	None
.	.	.	.	4	15FEB2018	.	.	Left	1	16	11	Yes	0 grade	None
.	.	.	.	5	24FEB2018	.	.	Left	1	16	12	Yes	0 grade	None
.	.	.	.	6	10APR2018	.	.	Left	1	16	12	Yes	0 grade	None
-----														
100129	DROP	Female	78	1	02FEB2018	0.5	0.5	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	08FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	4	15FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	23FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	10APR2018	.	.	Left	1	16	16	Yes	0 grade	None
-----														
100130	GEL	Male	66	1	16FEB2018	0.5	0.5	.	.	15	18	Yes	0 grade	None
.	.	.	.	2	21FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	22FEB2018	.	.	Left	1	15	16	Yes	0 grade	None
.	.	.	.	4	28FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	07MAR2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	23APR2018	.	.	Left	1	15	15	Yes	0 grade	None
-----														
100131	DROP	Female	77	1	16FEB2018	0.7	0.9	.	.	14	13	Yes	0 grade	None
.	.	.	.	2	21FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	22FEB2018	.	.	Left	0.9	14	14	Yes	0 grade	None
.	.	.	.	4	28FEB2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	07MAR2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	6	23APR2018	.	.	Left	1	12	12	Yes	0 grade	None

Listing 6 (7 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100132	DROP	Male	69	1	02MAR2018	1	0.6	.	.	17	16	Yes	0 grade	None
.	.	.	.	2	07MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08MAR2018	.	.	Right	1	18	16	Yes	0 grade	None
.	.	.	.	4	14MAR2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	21MAR2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	08MAY2018	.	.	Right	1	14	15	Yes	0 grade	None
-----														
100133	GEL	Male	74	1	02MAR2018	0.5	0.7	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	07MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08MAR2018	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	4	14MAR2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	21MAR2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	08MAY2018	.	.	Left	1	15	14	Yes	0 grade	None
-----														
100134	DROP	Female	66	1	02MAR2018	1	0.3	.	.	13	12	Yes	0 grade	None
.	.	.	.	2	07MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08MAR2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	4	14MAR2018	.	.	Left	1	13	13	Yes	0 grade	None
.	.	.	.	5	21MAR2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	6	08MAY2018	.	.	Left	1	15	14	Yes	0 grade	None
-----														
100135	GEL	Male	69	1	09MAR2018	1	0.4	.	.	19	19	Yes	0 grade	None
.	.	.	.	2	15MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	16MAR2018	.	.	Right	1	19	18	Yes	0 grade	None
.	.	.	.	4	22MAR2018	.	.	Right	1	19	18	Yes	0 grade	None
.	.	.	.	5	29MAR2018	.	.	Right	1	18	18	Yes	0 grade	None
.	.	.	.	6	15MAY2018	.	.	Right	1	17	17	Yes	0 grade	None
-----														
100136	GEL	Female	90	1	30MAR2018	0.3	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	05APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06APR2018	.	.	Left	0.8	16	16	Yes	0 grade	None
.	.	.	.	4	12APR2018	.	.	Left	0.8	16	16	Yes	0 grade	None
.	.	.	.	5	20APR2018	.	.	Left	0.8	16	16	Yes	0 grade	None
.	.	.	.	6	06JUN2018	.	.	Left	0.8	16	16	Yes	0 grade	None

Listing 6 (8 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100137	DROP	Female	62	1	13APR2018	1	0.8	.	.	18	16	Yes	0 grade	None
.	.	.	.	2	19APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	20APR2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	4	26APR2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	04MAY2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	19JUN2018	.	.	Right	1	16	16	Yes	0 grade	None
-----														
100138	GEL	Male	63	1	13APR2018	0.9	0.8	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	19APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	20APR2018	.	.	Right	1	14	15	Yes	0 grade	None
.	.	.	.	4	26APR2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	5	04MAY2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	6	19JUN2018	.	.	Right	1	15	15	Yes	0 grade	None
-----														
100139	DROP	Female	71	1	20APR2018	0.7	0.6	.	.	12	11	Yes	0 grade	None
.	.	.	.	2	26APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	27APR2018	.	.	Right	1	12	13	Yes	0 grade	None
.	.	.	.	4	03MAY2018	.	.	Right	1	13	13	Yes	0 grade	None
.	.	.	.	5	11MAY2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	6	26JUN2018	.	.	Right	1	15	14	Yes	0 grade	None
-----														
100140	GEL	Male	81	1	27APR2018	0.7	0.6	.	.	15	12	Yes	0 grade	None
.	.	.	.	2	02MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	03MAY2018	.	.	Right	1	15	13	Yes	0 grade	None
.	.	.	.	4	09MAY2018	.	.	Right	1	15	12	Yes	0 grade	None
.	.	.	.	5	17MAY2018	.	.	Right	1	14	12	Yes	0 grade	None
.	.	.	.	6	02JUL2018	.	.	Right	1	14	12	Yes	0 grade	None
-----														
100141	DROP	Female	74	1	27APR2018	0.9	0.6	.	.	15	17	Yes	0 grade	None
.	.	.	.	2	02MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	03MAY2018	.	.	Right	1	14	15	Yes	0 grade	None
.	.	.	.	4	10MAY2018	.	.	Right	1	14	12	Yes	0 grade	None
.	.	.	.	5	16MAY2018	.	.	Right	1	13	12	Yes	0 grade	None
.	.	.	.	6	02JUL2018	.	.	Right	1	12	12	Yes	0 grade	None

Listing 6 (9 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity						Slit lamp examination		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				Intra-ocular pressure		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100142	GEL	Female	77	1	11MAY2018	0.7	0.9	.	.	16	17	Yes	0 grade	None
.	.	.	.	2	16MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	17MAY2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	4	23MAY2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	31MAY2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	16JUL2018	.	.	Left	1	16	16	Yes	0 grade	None
-----														
100143	GEL	Male	74	1	15JUN2018	0.4	0.7	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	20JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	21JUN2018	.	.	Left	1	16	15	Yes	0 grade	None
.	.	.	.	4	27JUN2018	.	.	Left	1	16	15	Yes	0 grade	None
.	.	.	.	5	04JUL2018	.	.	Left	1	17	15	Yes	0 grade	None
.	.	.	.	6	20AUG2018	.	.	Left	1	16	15	Yes	0 grade	None
-----														
100144	DROP	Female	89	1	22JUN2018	0.3	0.2	.	.	14	13	Yes	0 grade	None
.	.	.	.	2	27JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	28JUN2018	.	.	Right	0.8	14	12	Yes	0 grade	None
.	.	.	.	4	04JUL2018	.	.	Right	0.8	13	12	Yes	0 grade	None
.	.	.	.	5	12JUL2018	.	.	Right	0.8	13	12	Yes	0 grade	None
.	.	.	.	6	27AUG2018	.	.	Right	0.8	13	12	Yes	0 grade	None
-----														
100145	GEL	Male	81	1	29JUN2018	0.9	0.6	.	.	12	12	Yes	0 grade	None
.	.	.	.	2	04JUL2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	05JUL2018	.	.	Right	1	12	12	Yes	0 grade	None
.	.	.	.	4	11JUL2018	.	.	Right	1	12	13	Yes	0 grade	None
.	.	.	.	5	18JUL2018	.	.	Right	1	12	12	Yes	0 grade	None
.	.	.	.	6	04SEP2018	.	.	Right	1	13	12	Yes	0 grade	None
-----														
100146	GEL	Male	71	1	17AUG2018	1	0.6	.	.	18	18	Yes	0 grade	None
.	.	.	.	2	21AUG2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	22AUG2018	.	.	Right	1	18	17	Yes	0 grade	None
.	.	.	.	4	29AUG2018	.	.	Right	1	18	17	Yes	0 grade	None
.	.	.	.	5	06SEP2018	.	.	Right	1	18	17	Yes	0 grade	None
.	.	.	.	6	22OCT2018	.	.	Right	1	17	17	Yes	0 grade	None
-----														
100147	DROP	Male	48	1	24AUG2018	1	0.4	.	.	17	16	Yes	0 grade	None
.	.	.	.	2	28AUG2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	29AUG2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	4	20SEP2018	.	.	Right	1	16	16	Yes	0 grade	None

Listing 6 (10 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
-----														
100148	DROP	Female	83	1	24AUG2018	0.7	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	30AUG2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	31AUG2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	4	06SEP2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	13SEP2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	29OCT2018	.	.	Left	1	15	15	Yes	0 grade	None
-----														
100149	DROP	Female	71	1	24AUG2018	1	0.7	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	30AUG2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	31AUG2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	4	06SEP2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	15SEP2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	29OCT2018	.	.	Right	1	16	16	Yes	0 grade	None
-----														
100150	GEL	Female	77	1	31AUG2018	1	0.4	.	.	16	15	Yes	0 grade	None
.	.	.	.	2	05SEP2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06SEP2018	.	.	Right	1	16	14	Yes	0 grade	None
.	.	.	.	4	12SEP2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	21SEP2018	.	.	Right	1	15	16	Yes	0 grade	None
.	.	.	.	6	05NOV2018	.	.	Right	1	16	16	Yes	0 grade	None
-----														
100151	DROP	Female	67	1	28SEP2018	0.6	0.7	.	.	18	18	Yes	0 grade	None
.	.	.	.	2	04OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	05OCT2018	.	.	Left	1	18	17	Yes	0 grade	None
.	.	.	.	4	12OCT2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	20OCT2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	04DEC2018	.	.	Left	1	15	15	Yes	0 grade	None
-----														
100152	GEL	Female	78	1	28SEP2018	0.7	0.6	.	.	18	18	Yes	0 grade	None
.	.	.	.	2	04OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	05OCT2018	.	.	Left	0.7	17	18	Yes	0 grade	None
.	.	.	.	4	12OCT2018	.	.	Left	0.7	17	17	Yes	0 grade	None
.	.	.	.	5	20OCT2018	.	.	Left	0.7	16	17	Yes	0 grade	None
-----														
100153	DROP	Female	81	1	12OCT2018	0.4	0.5	.	.	12	17	Yes	0 grade	None
.	.	.	.	2	17OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	18OCT2018	.	.	Left	0.8	16	13	Yes	0 grade	None
.	.	.	.	4	24OCT2018	.	.	Left	0.8	16	13	Yes	0 grade	None
.	.	.	.	5	29OCT2018	.	.	Left	0.8	16	13	Yes	0 grade	None
.	.	.	.	6	18DEC2018	.	.	Left	0.8	15	13	Yes	0 grade	None

Listing 6 (11 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity						Slit lamp examination anterior ocular chamber		
Sbj Code	Study drug	Sex	Age (year)	-----		-----		-----		Intra-ocular pressure		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100154	GEL	Female	68	1	12OCT2018	1	0.6	.	.	18	18	Yes	0 grade	None
.	.	.	.	2	18OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19OCT2018	.	.	Right	1	18	18	Yes	0 grade	None
.	.	.	.	4	26OCT2018	.	.	Right	1	18	18	Yes	0.5 grade	None
.	.	.	.	5	02NOV2018	.	.	Right	1	18	18	Yes	0 grade	None
.	.	.	.	6	18DEC2018	.	.	Right	1	17	17	Yes	0 grade	None
-----														
100155	DROP	Female	79	1	12OCT2018	0.4	0.5	.	.	19	19	Yes	0 grade	None
.	.	.	.	2	18OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19OCT2018	.	.	Left	0.8	19	19	Yes	0 grade	None
.	.	.	.	4	26OCT2018	.	.	Left	0.8	18	18	Yes	0 grade	None
.	.	.	.	5	02NOV2018	.	.	Left	0.8	17	17	Yes	0 grade	None
.	.	.	.	6	18DEC2018	.	.	Left	0.8	17	17	Yes	0 grade	None
-----														
100156	GEL	Female	69	1	12OCT2018	0.9	0.8	.	.	19	19	Yes	0 grade	None
.	.	.	.	2	18OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19OCT2018	.	.	Right	0.9	19	19	Yes	0 grade	None
.	.	.	.	4	26OCT2018	.	.	Right	0.9	19	19	Yes	0 grade	None
.	.	.	.	5	02NOV2018	.	.	Right	1	18	18	Yes	0 grade	None
.	.	.	.	6	18DEC2018	.	.	Right	1	18	18	Yes	0 grade	None
-----														
100201	GEL	Female	80	1	01DEC2017	0.8	0.3	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	07DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09DEC2017	.	.	Right	0.5	14	15	Yes	0 grade	Faint
.	.	.	.	4	13DEC2017	.	.	Right	1	16	16	Yes	0 grade	Faint
.	.	.	.	5	22DEC2017	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	08FEB2018	.	.	Right	1	15	15	Yes	0 grade	None
-----														
100202	DROP	Female	70	1	01DEC2017	0.7	0.5	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	07DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09DEC2017	.	.	Right	0.7	16	16	Yes	0 grade	Faint
.	.	.	.	4	14DEC2017	.	.	Right	1	12	12	Yes	0 grade	None
.	.	.	.	5	20DEC2017	.	.	Right	1	12	12	Yes	0 grade	None
.	.	.	.	6	08FEB2018	.	.	Right	1	12	12	Yes	0 grade	None

Listing 6 (12 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100203	DROP	Female	76	1	07DEC2017	0.9	0.3	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	14DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	15DEC2017	.	.	Right	0.7	14	14	Yes	0 grade	Faint
.	.	.	.	4	20DEC2017	.	.	Right	0.95	12	12	Yes	0 grade	None
.	.	.	.	5	28DEC2017	.	.	Right	0.95	12	12	Yes	0 grade	None
.	.	.	.	6	15FEB2018	.	.	Right	0.95	12	12	Yes	0 grade	None
-----														
100204	GEL	Male	71	1	07DEC2017	0.6	0.2	.	.	19	19	Yes	0 grade	None
.	.	.	.	2	14DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	15DEC2017	.	.	Right	1	16	16	Yes	0 grade	Faint
.	.	.	.	4	20DEC2017	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	28DEC2017	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	6	15FEB2018	.	.	Right	1	15	15	Yes	0 grade	None
-----														
100205	GEL	Male	75	1	14DEC2017	0.5	0.8	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	08FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09FEB2018	.	.	Left	1	16	16	Yes	0 grade	Faint
.	.	.	.	4	14FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	21FEB2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	09APR2018	.	.	Left	1	15	15	Yes	0 grade	None
-----														
100206	DROP	Female	81	1	05JAN2018	0.8	0.4	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	11JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	12JAN2018	.	.	Right	0.8	14	14	Yes	0 grade	Faint
.	.	.	.	4	18JAN2018	.	.	Right	0.9	14	14	Yes	0 grade	Faint
.	.	.	.	5	24JAN2018	.	.	Right	0.95	13	13	Yes	0 grade	None
.	.	.	.	6	14MAR2018	.	.	Right	0.95	14	14	Yes	0 grade	None
-----														
100207	DROP	Female	65	1	05JAN2018	0.6	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	11JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	12JAN2018	.	.	Right	0.8	14	14	Yes	0 grade	Faint
.	.	.	.	4	18JAN2018	.	.	Right	1	14	14	Yes	0 grade	Faint
.	.	.	.	5	24JAN2018	.	.	Right	1	13	13	Yes	0 grade	None
.	.	.	.	6	14MAR2018	.	.	Right	1	14	14	Yes	0 grade	None

Listing 6 (13 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	anterior ocular chamber	
														Cellul. grade*
-----														
100208	GEL	Female	79	1	05JAN2018	0.8	0.6	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	11JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	12JAN2018	.	.	Right	0.8	14	14	Yes	0 grade	Faint
.	.	.	.	4	18JAN2018	.	.	Right	1	14	14	Yes	0 grade	Faint
.	.	.	.	5	31JAN2018	.	.	Right	0.95	14	14	Yes	0 grade	None
.	.	.	.	6	14MAR2018	.	.	Right	0.95	14	14	Yes	0 grade	None
-----														
100209	GEL	Female	77	1	12JAN2018	0.6	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	18JAN2018	.	.	.	.	.	.	.	.	.
-----														
100210	DROP	Female	70	1	12JAN2018	1	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	18JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19JAN2018	.	.	Right	0.8	14	14	Yes	0 grade	Faint
.	.	.	.	4	24JAN2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	5	31JAN2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	6	22MAR2018	.	.	Right	1	14	14	Yes	0 grade	None
-----														
100211	GEL	Male	67	1	12JAN2018	0.4	0.8	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	18JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19JAN2018	.	.	Left	0.6	16	16	Yes	0 grade	Faint
.	.	.	.	4	24JAN2018	.	.	Left	0.9	16	16	Yes	0 grade	Faint
.	.	.	.	5	31JAN2018	.	.	Left	0.9	16	16	Yes	0 grade	None
.	.	.	.	6	22MAR2018	.	.	Left	0.9	15	15	Yes	0 grade	None
-----														
100212	DROP	Female	82	1	12JAN2018	0.4	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	18JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19JAN2018	.	.	Left	0.8	16	16	Yes	0 grade	Faint
.	.	.	.	4	24JAN2018	.	.	Left	1	16	16	Yes	0 grade	Faint
.	.	.	.	5	31JAN2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	22MAR2018	.	.	Left	1	14	14	Yes	0 grade	None
-----														
100213	DROP	Female	81	1	25JAN2018	0.4	1	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	01FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	02FEB2018	.	.	Left	0.8	15	15	Yes	0 grade	Faint
.	.	.	.	4	07FEB2018	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	5	16FEB2018	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	6	04APR2018	.	.	Left	1	14	14	Yes	0 grade	None



Listing 6 (14 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

														Slit lamp examination	
				Visit		Visual acuity				Intra-ocular pressure		anterior ocular chamber			
Sbj Code	Study drug	Sex	Age (year)			Left eye	Right eye	Operated eye		Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**	
				No.	Date			Eye	Value						
100214	DROP	Female	77	1	05FEB2018	0.5	1	.	.	16	16	Yes	0 grade	None	
.	.	.	.	2	08FEB2018	.	.	.	.	.	.	.	.	.	
.	.	.	.	3	09FEB2018	.	.	Left	0.8	16	16	Yes	0 grade	Faint	
.	.	.	.	4	14FEB2018	.	.	Left	1	15	15	Yes	0 grade	None	
.	.	.	.	5	21FEB2018	.	.	Left	1	15	15	Yes	0 grade	None	
.	.	.	.	6	09APR2018	.	.	Left	1	14	14	Yes	0 grade	None	
100215	GEL	Female	83	1	05FEB2018	0.5	0.6	.	.	15	15	Yes	0 grade	None	
.	.	.	.	2	08FEB2018	.	.	.	.	.	.	.	.	.	
.	.	.	.	3	09FEB2018	.	.	Left	0.8	15	15	Yes	0 grade	Faint	
.	.	.	.	4	14FEB2018	.	.	Left	0.9	12	15	Yes	0 grade	None	
.	.	.	.	5	21FEB2018	.	.	Left	0.9	14	14	Yes	0 grade	None	
.	.	.	.	6	09APR2018	.	.	Left	0.9	14	14	Yes	0 grade	None	
100216	GEL	Female	74	1	09FEB2018	0.5	1	.	.	16	16	Yes	0 grade	None	
.	.	.	.	2	15FEB2018	.	.	.	.	.	.	.	.	.	
.	.	.	.	3	16FEB2018	.	.	Left	0.9	15	15	Yes	0 grade	Faint	
.	.	.	.	4	21FEB2018	.	.	Left	1	16	16	Yes	0 grade	None	
.	.	.	.	5	28FEB2018	.	.	Left	1	14	14	Yes	0 grade	None	
.	.	.	.	6	16APR2018	.	.	Left	1	14	14	Yes	0 grade	None	
100217	DROP	Female	72	1	02MAR2018	1	0.5	.	.	13	13	Yes	0 grade	None	
.	.	.	.	2	08MAR2018	.	.	.	.	.	.	.	.	.	
.	.	.	.	3	09MAR2018	.	.	Right	0.8	13	13	Yes	0 grade	Faint	
.	.	.	.	4	14MAR2018	.	.	Right	1	14	14	Yes	0 grade	None	
.	.	.	.	5	21MAR2018	.	.	Right	1	14	14	Yes	0 grade	None	
.	.	.	.	6	08MAY2018	.	.	Right	1	14	14	Yes	0 grade	None	
100218	DROP	Male	72	1	02MAR2018	1	0.5	.	.	13	13	Yes	0 grade	None	
.	.	.	.	2	08MAR2018	.	.	.	.	.	.	.	.	.	
.	.	.	.	3	09MAR2018	.	.	Right	0.7	13	13	Yes	0 grade	Faint	
.	.	.	.	4	14MAR2018	.	.	Right	1	15	15	Yes	0 grade	None	
.	.	.	.	5	21MAR2018	.	.	Right	1	14	14	Yes	0 grade	None	
.	.	.	.	6	08MAY2018	.	.	Right	1	17	17	Yes	0 grade	None	

Listing 6 (15 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye		Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
								Eye	Value					
-----														
100219	GEL	Female	83	1	09MAR2018	0.5	0.5	.	.	13	13	Yes	0 grade	None
.	.	.	.	2	15MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	16MAR2018	.	.	Right	0.7	13	13	Yes	0 grade	Faint
.	.	.	.	4	21MAR2018	.	.	Right	0.8	14	14	Yes	0 grade	Faint
.	.	.	.	5	28MAR2018	.	.	Right	0.8	13	13	Yes	0 grade	None
.	.	.	.	6	16MAY2018	.	.	Right	0.8	14	14	Yes	0 grade	None
-----														
100220	GEL	Male	64	1	09MAR2018	0.4	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	15MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	16MAR2018	.	.	Left	0.8	14	14	Yes	0 grade	Faint
.	.	.	.	4	21MAR2018	.	.	Left	0.9	13	13	Yes	0 grade	Faint
.	.	.	.	5	28MAR2018	.	.	Left	0.9	13	13	Yes	0 grade	None
.	.	.	.	6	16MAY2018	.	.	Left	0.9	14	14	Yes	0 grade	None
-----														
100221	GEL	Female	76	1	30MAR2018	0.6	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	05APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06APR2018	.	.	Right	0.7	13	18	Yes	0 grade	Faint
.	.	.	.	4	11APR2018	.	.	Right	1	14	18	Yes	0 grade	None
.	.	.	.	5	20APR2018	.	.	Right	1	14	16	Yes	0 grade	None
.	.	.	.	6	01JUN2018	.	.	Right	1	14	14	Yes	0 grade	None
-----														
100222	DROP	Female	76	1	05APR2018	0.3	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	12APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13APR2018	.	.	Left	0.7	16	16	Yes	0 grade	Faint
.	.	.	.	4	18APR2018	.	.	Left	0.9	16	16	Yes	0 grade	None
.	.	.	.	5	26APR2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	14JUN2018	.	.	Left	1	16	16	Yes	0 grade	None
-----														
100223	DROP	Male	61	1	05APR2018	0.6	0.65	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	12APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13APR2018	.	.	Left	0.8	16	16	Yes	0 grade	Faint
.	.	.	.	4	18APR2018	.	.	Left	0.95	16	16	Yes	0 grade	None
.	.	.	.	5	26APR2018	.	.	Left	0.95	16	16	Yes	0 grade	None
.	.	.	.	6	14JUN2018	.	.	Left	0.95	15	15	Yes	0 grade	None

Listing 6 (16 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity						Slit lamp examination		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				Intra-ocular pressure		-----		
				No.	Date	Left eye	Right eye	Operated eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100224	GEL	Female	75	1	20APR2018	0.5	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	26APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	27APR2018	.	.	Right	0.8	16	16	Yes	0 grade	Faint
.	.	.	.	4	02MAY2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	09MAY2018	.	.	Right	1	16	14	Yes	0 grade	None
.	.	.	.	6	27JUN2018	.	.	Right	1	14	14	Yes	0 grade	None
-----														
100225	DROP	Female	79	1	20APR2018	0.1	0.6	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	26APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	27APR2018	.	.	Right	0.9	13	13	Yes	0 grade	Faint
.	.	.	.	4	02MAY2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	5	09MAY2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	6	27JUN2018	.	.	Right	1	14	14	Yes	0 grade	None
-----														
100226	GEL	Female	74	1	20APR2018	1	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	26APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	27APR2018	.	.	Right	0.8	16	16	Yes	0 grade	Faint
.	.	.	.	4	02MAY2018	.	.	Right	0.9	16	16	Yes	0 grade	None
.	.	.	.	5	09MAY2018	.	.	Right	0.9	15	15	Yes	0 grade	None
.	.	.	.	6	27JUN2018	.	.	Right	0.9	15	15	Yes	0 grade	None
-----														
100227	DROP	Female	68	1	27APR2018	0.4	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	03MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04MAY2018	.	.	Left	1	16	16	Yes	0 grade	Faint
.	.	.	.	4	09MAY2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	5	16MAY2018	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	6	04JUL2018	.	.	Left	1	15	15	Yes	0 grade	None
-----														
100228	GEL	Female	68	1	27APR2018	1	0.7	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	03MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04MAY2018	.	.	Right	0.8	16	16	Yes	0 grade	Faint
.	.	.	.	4	09MAY2018	.	.	Right	0.95	16	16	Yes	0 grade	None
-----														
100229	GEL	Female	70	1	04MAY2018	0.5	0.7	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	10MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11MAY2018	.	.	Left	0.8	16	15	Yes	0 grade	Faint
.	.	.	.	4	16MAY2018	.	.	Left	1	15	15	Yes	0 grade	None
.	.	.	.	5	23MAY2018	.	.	Left	1	14	15	Yes	0 grade	None
.	.	.	.	6	10JUL2018	.	.	Left	1	14	14	Yes	0 grade	None

Listing 6 (17 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity						Slit lamp examination		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				Intra-ocular pressure		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100230	GEL	Female	63	1	04MAY2018	0.6	0.9	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	10MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11MAY2018	.	.	Left	0.9	15	15	Yes	0 grade	Faint
.	.	.	.	4	16MAY2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	23MAY2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	11JUL2018	.	.	Left	1	16	16	Yes	0 grade	None
-----														
100231	DROP	Female	74	1	04MAY2018	0.8	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	10MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11MAY2018	.	.	Right	0.8	15	15	Yes	0 grade	Faint
.	.	.	.	4	16MAY2018	.	.	Right	0.95	14	14	Yes	0 grade	None
.	.	.	.	5	23MAY2018	.	.	Right	1	16	15	Yes	0 grade	None
.	.	.	.	6	06JUL2018	.	.	Right	1	15	15	Yes	0 grade	None
-----														
100232	DROP	Female	73	1	04MAY2018	0.5	0.9	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	10MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11MAY2018	.	.	Left	0.8	15	15	Yes	0 grade	Faint
.	.	.	.	4	16MAY2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	23MAY2018	.	.	Left	1	14	15	Yes	0 grade	None
.	.	.	.	6	06JUL2018	.	.	Left	1	15	14	Yes	0 grade	None
.	.	.	.	7	.	.	.	.	.	.	.	.	.	.
-----														
100233	GEL	Female	72	1	18MAY2018	0.3	1	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	24MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25MAY2018	.	.	Left	0.8	15	15	Yes	0 grade	Faint
.	.	.	.	4	30MAY2018	.	.	Left	0.8	16	16	Yes	0 grade	None
.	.	.	.	5	06JUN2018	.	.	Left	0.9	16	16	Yes	0 grade	None
.	.	.	.	6	20JUL2018	.	.	Left	0.9	16	16	Yes	0 grade	None
-----														
100234	GEL	Female	73	1	18MAY2018	1	0.5	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	24MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25MAY2018	.	.	Right	0.8	15	13	Yes	0 grade	Faint
.	.	.	.	4	30MAY2018	.	.	Right	1	13	13	Yes	0 grade	None
.	.	.	.	5	06JUN2018	.	.	Right	1	13	13	Yes	0 grade	None
.	.	.	.	6	20JUL2018	.	.	Right	1	13	13	Yes	0 grade	None

Listing 6 (18 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye		Left eye	Right eye	Performed?	anterior ocular chamber	
								Eye	Value				Cellul. grade*	Flare grade**
-----														
100235	DROP	Male	64	1	28MAY2018	1	0.2	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	31MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	01JUN2018	.	.	Right	0.6	15	14	Yes	0 grade	Faint
.	.	.	.	4	06JUN2018	.	.	Right	0.7	14	14	Yes	0 grade	None
.	.	.	.	5	13JUN2018	.	.	Right	0.8	13	13	Yes	0 grade	None
.	.	.	.	6	01AUG2018	.	.	Right	0.85	13	13	Yes	0 grade	None
-----														
100236	DROP	Female	70	1	28MAY2018	0.6	0.3	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	31MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	01JUN2018	.	.	Right	0.7	14	15	Yes	0 grade	Faint
.	.	.	.	4	06JUN2018	.	.	Right	1	15	15	Yes	0 grade	None
.	.	.	.	5	13JUN2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	6	01AUG2018	.	.	Right	1	14	14	Yes	0 grade	None
-----														
100237	DROP	Male	73	1	01JUN2018	0.4	0.6	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	07JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08JUN2018	.	.	Left	0.6	14	14	Yes	0 grade	Faint
.	.	.	.	4	13JUN2018	.	.	Left	0.8	14	14	Yes	0 grade	None
.	.	.	.	5	20JUN2018	.	.	Left	0.8	14	14	Yes	0 grade	None
.	.	.	.	6	06AUG2018	.	.	Left	0.85	14	14	Yes	0 grade	None
-----														
100238	GEL	Male	78	1	01JUN2018	1	0.3	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	07JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08JUN2018	.	.	Right	0.6	14	16	Yes	0 grade	Faint
.	.	.	.	4	13JUN2018	.	.	Right	0.8	16	16	Yes	0 grade	None
.	.	.	.	5	20JUN2018	.	.	Right	0.8	14	14	Yes	0 grade	None
.	.	.	.	6	06AUG2018	.	.	Right	0.9	14	14	Yes	0 grade	None
-----														
100239	DROP	Female	80	1	08JUN2018	0.8	0.3	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	14JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	15JUN2018	.	.	Right	0.7	14	15	Yes	0 grade	Faint
.	.	.	.	4	20JUN2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	5	27JUN2018	.	.	Right	1	14	14	Yes	0 grade	None
.	.	.	.	6	14AUG2018	.	.	Right	1	14	14	Yes	0 grade	None
-----														
100240		Female	72	1	06JUL2018	0.5	1	.	.	16	16	Yes	0 grade	None

Listing 6 (19 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100241	GEL	Female	74	1	23OCT2018	0.6	0.7	.	.	13	13	Yes	0 grade	None
.	.	.	.	2	25OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	26OCT2018	.	.	Left	0.7	14	14	Yes	0 grade	Faint
.	.	.	.	4	31OCT2018	.	.	Left	1	14	14	Yes	0 grade	None
.	.	.	.	5	07NOV2018	.	.	Left	1	13	14	Yes	0 grade	None
.	.	.	.	6	24DEC2018	.	.	Left	1	14	14	Yes	0 grade	None
-----														
100242	GEL	Female	67	1	31OCT2018	0.8	0.6	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	08NOV2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09NOV2018	.	.	Right	0.8	14	15	Yes	0 grade	Faint
.	.	.	.	4	14NOV2018	.	.	Right	0.95	14	14	Yes	0 grade	None
.	.	.	.	5	22NOV2018	.	.	Right	0.95	14	14	Yes	0 grade	None
.	.	.	.	6	12JAN2019	.	.	Right	0.95	14	14	Yes	0 grade	None
-----														
100243	DROP	Male	74	1	30NOV2018	0.8	0.5	.	.	16	18	Yes	0 grade	None
.	.	.	.	2	06DEC2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	07DEC2018	.	.	Right	0.6	15	16	Yes	0 grade	Faint
.	.	.	.	4	12DEC2018	.	.	Right	0.8	17	17	Yes	0 grade	None
.	.	.	.	5	19DEC2018	.	.	Right	0.85	17	17	Yes	0 grade	None
.	.	.	.	6	04FEB2019	.	.	Right	0.85	17	17	Yes	0 grade	None
-----														
100244	GEL	Female	66	1	07DEC2018	0.3	1	.	.	10	10	Yes	0 grade	None
.	.	.	.	2	13DEC2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14DEC2018	.	.	Left	0.8	12	12	Yes	0 grade	None
.	.	.	.	4	19DEC2018	.	.	Left	1	12	12	Yes	0 grade	None
.	.	.	.	5	27DEC2018	.	.	Left	1	12	12	Yes	0 grade	None
.	.	.	.	6	08FEB2019	.	.	Left	1	12	12	Yes	0 grade	None
-----														
100245	DROP	Female	69	1	07DEC2018	0.5	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	13DEC2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14DEC2018	.	.	Right	0.8	16	17	Yes	0 grade	Faint
.	.	.	.	4	19DEC2018	.	.	Right	1	16	16	Yes	0 grade	None
.	.	.	.	5	27DEC2018	.	.	Right	1	14	16	Yes	0 grade	None
.	.	.	.	6	08FEB2019	.	.	Right	1	16	16	Yes	0 grade	None



Listing 6 (21 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
										Slit lamp examination				
				Visit		Visual acuity				Intra-ocular pressure		anterior ocular chamber		
Sbj Code	Study drug	Age Sex	(year)	-----		-----				-----		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100307	GEL	Female	73	1	24NOV2017	0.4	0.1	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	29NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	30NOV2017	.	.	Left	0	14	15	Yes	0 grade	None
.	.	.	.	4	06DEC2017	.	.	Left	0	14	14	Yes	0 grade	None
.	.	.	.	5	14DEC2017	.	.	Left	0	14	14	Yes	0 grade	None
.	.	.	.	6	29JAN2018	.	.	Left	0	15	15	Yes	0 grade	None
-----														
100308	GEL	Female	85	1	24NOV2017	0.1	0.5	.	.	15	16	Yes	0 grade	None
.	.	.	.	2	29NOV2017	.	.	.	.	.	.	.	.	.
-----														
100309	DROP	Female	61	1	24NOV2017	0.5	0.2	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	29NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	30NOV2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	4	06DEC2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	5	14DEC2017	.	.	Left	0	12	10	Yes	0 grade	None
.	.	.	.	6	29JAN2018	.	.	Left	0	10	10	Yes	0 grade	None
-----														
100310	GEL	Female	73	1	24NOV2017	0.5	0.1	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	30NOV2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	01DEC2017	.	.	Left	0.2	17	15	Yes	0 grade	None
.	.	.	.	4	06DEC2017	.	.	Left	0.1	16	16	Yes	0 grade	None
.	.	.	.	5	14DEC2017	.	.	Left	0.2	17	16	Yes	0 grade	None
.	.	.	.	6	29JAN2018	.	.	Left	0.2	17	16	Yes	0.5 grade	None
-----														
100311	GEL	Female	83	1	29NOV2017	0.4	0.5	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Right	0.2	20	18	Yes	0.5 grade	None
.	.	.	.	4	13DEC2017	.	.	Right	0.1	14	13	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Right	0.1	14	14	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Right	0.1	13	14	Yes	0 grade	None
-----														
100312	DROP	Female	71	1	29NOV2017	0.5	0.5	.	.	15	14	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Left	0	14	18	Yes	0.5 grade	None
.	.	.	.	4	13DEC2017	.	.	Left	0	14	18	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Left	0	21	19	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Left	0	20	16	Yes	0 grade	None
-----														
100313	GEL	Male	71	1	29NOV2017	0.1	0.7	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	04DEC2017	.	.	.	.	.	.	.	.	.



Listing 6 (22 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100314	DROP	Male	67	1	30NOV2017	0	0.4	.	.	15	16	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Right	0.2	16	20	Yes	0 grade	None
.	.	.	.	4	13DEC2017	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Right	0	16	17	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Right	0	16	15	Yes	0 grade	None
-----														
100315	GEL	Female	65	1	30NOV2017	0.5	0.6	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Right	0.1	20	16	Yes	0.5 grade	None
.	.	.	.	4	13DEC2017	.	.	Right	0	16	18	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Right	0	16	17	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Right	0	16	15	Yes	0 grade	None
-----														
100316	DROP	Male	76	1	30NOV2017	0.4	0	.	.	16	15	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	4	13DEC2017	.	.	Left	0	12	12	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Left	0	18	15	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Left	0	15	13	Yes	0 grade	None
-----														
100317	GEL	Male	85	1	30NOV2017	0.5	0.1	.	.	15	16	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Right	0	20	16	Yes	0 grade	None
.	.	.	.	4	14DEC2017	.	.	Right	0.1	16	13	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Right	0	15	15	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Right	0	16	14	Yes	0 grade	None
-----														
100318	GEL	Female	80	1	30NOV2017	0.1	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Right	0.3	16	18	Yes	0 grade	None
.	.	.	.	4	13DEC2017	.	.	Right	0.3	16	16	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Right	0.3	16	17	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Right	0.3	16	16	Yes	0 grade	None

Listing 6 (23 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination anterior ocular chamber		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				-----		-----		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100319	DROP	Male	70	1	29NOV2017	0.5	0	.	.	17	15	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Left	0.1	15	20	Yes	0 grade	None
.	.	.	.	4	13DEC2017	.	.	Left	0.1	17	16	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Left	0	13	15	Yes	0 grade	None
.	.	.	.	6	01FEB2018	.	.	Left	0	16	15	Yes	0 grade	None
-----														
100320	DROP	Male	69	1	30NOV2017	0.4	0	.	.	18	15	Yes	0 grade	None
.	.	.	.	2	05DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	06DEC2017	.	.	Left	0	18	16	Yes	0.5 grade	None
.	.	.	.	4	13DEC2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	5	19DEC2017	.	.	Left	0	18	16	Yes	0 grade	None
.	.	.	.	6	01JAN2018	.	.	Left	0	16	16	Yes	0 grade	None
-----														
100321	GEL	Male	72	1	06DEC2017	0.5	0.1	.	.	16	20	Yes	0 grade	None
.	.	.	.	2	11DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	12DEC2017	.	.	Left	0	16	16	Yes	0.5 grade	None
.	.	.	.	4	27DEC2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	5	27DEC2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	6	05FEB2018	.	.	Left	0	16	16	Yes	0 grade	None
-----														
100322	GEL	Male	80	1	06DEC2017	0.6	0.1	.	.	17	17	Yes	0 grade	None
.	.	.	.	2	13DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14DEC2017	.	.	Right	0.2	16	18	Yes	0.5 grade	None
.	.	.	.	4	19DEC2017	.	.	Right	0.1	15	12	Yes	0 grade	None
.	.	.	.	5	27DEC2017	.	.	Right	0	15	15	Yes	0 grade	None
.	.	.	.	6	12FEB2018	.	.	Right	0	15	14	Yes	0 grade	None
-----														
100323	DROP	Female	76	1	06DEC2017	0.5	0.3	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	13DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14DEC2017	.	.	Left	0.1	15	14	Yes	0 grade	None
.	.	.	.	4	19DEC2017	.	.	Left	0.1	15	14	Yes	0 grade	None
.	.	.	.	5	27DEC2017	.	.	Left	0	17	14	Yes	0 grade	None
.	.	.	.	6	12FEB2018	.	.	Left	0	13	13	Yes	0 grade	None

Listing 6 (24 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity						Slit lamp examination		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				Intra-ocular pressure		-----		
				No.	Date	Left eye	Right eye	Operated eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
100324	DROP	Male	65	1	13DEC2017	0.2	0.7	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	18DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19DEC2017	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	5	02JAN2018	.	.	Right	0	17	16	Yes	0 grade	None
.	.	.	.	6	16FEB2018	.	.	Right	0	16	16	Yes	0 grade	None
-----														
100325	GEL	Female	83	1	13DEC2017	0.5	0.5	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	18DEC2017	.	.	.	.	.	.	.	.	.
-----														
100326	DROP	Male	81	1	13DEC2017	0.5	0	.	.	16	13	Yes	0 grade	None
.	.	.	.	2	18DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19DEC2017	.	.	Left	0	18	17	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Left	0	11	11	Yes	0 grade	None
.	.	.	.	5	03JAN2018	.	.	Left	0	11	12	Yes	0 grade	None
.	.	.	.	6	26FEB2018	.	.	Left	0	17	19	Yes	0 grade	None
-----														
100327	GEL	Female	73	1	13DEC2017	0.4	0.8	.	.	13	14	Yes	0 grade	None
.	.	.	.	2	18DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19DEC2017	.	.	Left	0	20	20	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Left	0	10	10	Yes	0 grade	None
.	.	.	.	5	02JAN2018	.	.	Left	0	11	10	Yes	0 grade	None
.	.	.	.	6	16FEB2018	.	.	Left	0	10	11	Yes	0 grade	None
-----														
100328	DROP	Male	82	1	13DEC2017	0.3	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	18DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19DEC2017	.	.	Right	0.2	19	22	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Right	0.1	16	15	Yes	0 grade	None
.	.	.	.	5	02JAN2018	.	.	Right	0.1	15	14	Yes	0 grade	None
.	.	.	.	6	16FEB2018	.	.	Right	0.1	14	16	Yes	0 grade	None
-----														
100329	GEL	Male	74	1	13DEC2017	0.3	0.2	.	.	17	15	Yes	0 grade	None
.	.	.	.	2	18DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19DEC2017	.	.	Left	0.1	16	16	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	5	02JAN2018	.	.	Left	0	16	15	Yes	0 grade	None
.	.	.	.	6	16FEB2018	.	.	Left	0	13	13	Yes	0 grade	None

Listing 6 (25 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
-----														
100330	DROP	Male	61	1	14DEC2017	0.5	0	.	.	17	14	Yes	0 grade	None
.	.	.	.	2	19DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	20DEC2017	.	.	Left	0	15	15	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Left	0	16	12	Yes	0 grade	None
.	.	.	.	5	03JAN2018	.	.	Left	0	15	12	Yes	0 grade	None
.	.	.	.	6	19FEB2018	.	.	Left	0	14	14	Yes	0 grade	None
-----														
100331	GEL	Female	71	1	14DEC2017	0.1	0.8	.	.	14	16	Yes	0 grade	None
.	.	.	.	2	19DEC2017	.	.	.	.	.	.	.	.	.
.	.	.	.	3	20DEC2017	.	.	Right	0.2	16	18	Yes	0 grade	None
.	.	.	.	4	27DEC2017	.	.	Right	0.2	11	13	Yes	0 grade	None
.	.	.	.	5	03JAN2018	.	.	Right	0.1	13	12	Yes	0 grade	None
.	.	.	.	6	19FEB2018	.	.	Right	0	14	14	Yes	0 grade	None
-----														
100332	DROP	Male	82	1	05JAN2018	0.4	0.7	.	.	14	13	Yes	0 grade	None
.	.	.	.	2	12JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13JAN2018	.	.	Right	0.2	15	15	Yes	0 grade	None
.	.	.	.	4	19JAN2018	.	.	Right	0	16	13	Yes	0 grade	None
.	.	.	.	5	25JAN2018	.	.	Right	0	15	14	Yes	0 grade	None
.	.	.	.	6	12MAR2018	.	.	Right	0	14	14	Yes	0 grade	None
-----														
100333	DROP	Male	62	1	19JAN2018	0	0.5	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	25JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	26JAN2018	.	.	Right	0.1	18	18	Yes	0 grade	None
.	.	.	.	4	01FEB2018	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	5	09FEB2018	.	.	Right	0	14	15	Yes	0 grade	None
.	.	.	.	6	26MAR2018	.	.	Right	0	15	16	Yes	0 grade	None
-----														
100334	GEL	Male	72	1	19JAN2018	0.4	0	.	.	12	12	Yes	0 grade	None
.	.	.	.	2	24JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25JAN2018	.	.	Left	0.2	12	12	Yes	0 grade	None
.	.	.	.	4	01FEB2018	.	.	Left	0	10	10	Yes	0 grade	None
.	.	.	.	5	08FEB2018	.	.	Left	0	12	12	Yes	0 grade	None
.	.	.	.	6	26MAR2018	.	.	Left	0	12	12	Yes	0 grade	None

Listing 6 (26 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity						Slit lamp examination		
Sbj Code	Study drug	Sex	Age (year)	-----		-----				Intra-ocular pressure		-----		
				No.	Date	Left eye	Right eye	Operated eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
-----														
100335	DROP	Female	80	1	31JAN2018	0.3	0.5	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	06FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	07FEB2018	.	.	Right	0.2	18	18	Yes	0 grade	None
.	.	.	.	4	12FEB2018	.	.	Right	0.1	16	16	Yes	0 grade	None
.	.	.	.	5	20FEB2018	.	.	Right	0.1	14	16	Yes	0 grade	None
.	.	.	.	6	05APR2018	.	.	Right	0.1	14	14	Yes	0 grade	None
.	.	.	.	7	19MAR2018	.	.	.	.	.	.	Yes	0 grade	None
-----														
100336	GEL	Female	82	1	01MAR2018	0.7	0.6	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	06MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	07MAR2018	.	.	Left	0.3	17	17	Yes	0 grade	None
.	.	.	.	4	12MAR2018	.	.	Left	0.2	16	16	Yes	0 grade	None
.	.	.	.	5	20MAR2018	.	.	Left	0.2	16	15	Yes	0 grade	None
.	.	.	.	6	02MAY2018	.	.	Left	0.2	16	16	Yes	0 grade	None
-----														
100337	GEL	Male	72	1	10MAR2018	0	0.5	.	.	15	14	Yes	0 grade	None
.	.	.	.	2	16MAR2018	.	.	.	.	.	.	.	.	.
-----														
100338	DROP	Female	87	1	15MAR2018	0.2	0.6	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	21MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	22MAR2018	.	.	Right	0.2	17	17	Yes	0 grade	None
.	.	.	.	4	27MAR2018	.	.	Right	2	16	14	Yes	0 grade	None
.	.	.	.	5	05APR2018	.	.	Right	0.2	15	15	Yes	0 grade	None
.	.	.	.	6	21MAY2018	.	.	Right	0.1	14	14	Yes	0 grade	None
-----														
100339	GEL	Male	56	1	22MAR2018	0	0.6	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	28MAR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	29MAR2018	.	.	Left	0.1	16	16	Yes	0 grade	None
.	.	.	.	4	05APR2018	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	5	11APR2018	.	.	Left	0	15	15	Yes	0 grade	None
.	.	.	.	6	28MAY2018	.	.	Left	0	14	14	Yes	0 grade	None
-----														
100340	DROP	Male	83	1	05APR2018	0.2	0.4	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	12APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13APR2018	.	.	Right	0.1	17	17	Yes	0 grade	None
.	.	.	.	4	19APR2018	.	.	Right	0.1	16	16	Yes	0 grade	None
.	.	.	.	5	26APR2018	.	.	Right	0	15	15	Yes	0 grade	None
.	.	.	.	6	12JUN2018	.	.	Right	0	16	16	Yes	0 grade	None

Listing 6 (27 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior ocular chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100341	GEL	Male	88	1	05APR2018	0.7	0.7	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	12APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13APR2018	.	.	Left	0.2	14	14	Yes	0 grade	None
.	.	.	.	4	19APR2018	.	.	Left	0.1	14	14	Yes	0 grade	None
.	.	.	.	5	26APR2018	.	.	Left	0.1	16	16	Yes	0 grade	None
.	.	.	.	6	12JUL2018	.	.	Left	0.1	16	16	Yes	0 grade	None
-----														
100342	DROP	Female	86	1	05APR2018	0.5	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	12APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13APR2018	.	.	Left	0.2	17	17	Yes	0 grade	None
.	.	.	.	4	19APR2018	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	5	26APR2018	.	.	Left	0	15	15	Yes	0 grade	None
.	.	.	.	6	12JUN2018	.	.	Left	0	15	15	Yes	0 grade	None
-----														
100343	GEL	Male	74	1	05APR2018	0	0.7	.	.	12	12	Yes	0 grade	None
.	.	.	.	2	10APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11APR2018	.	.	Right	0.1	16	16	Yes	0 grade	None
.	.	.	.	4	17APR2018	.	.	Right	0.1	15	15	Yes	0 grade	None
.	.	.	.	5	24APR2018	.	.	Right	0	15	15	Yes	0 grade	None
.	.	.	.	6	12JUN2018	.	.	Right	0	14	14	Yes	0 grade	None
-----														
100344	DROP	Female	68	1	05APR2018	0.7	0.5	.	.	10	10	Yes	0 grade	None
.	.	.	.	2	10APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11APR2018	.	.	Left	0.3	18	18	Yes	0 grade	None
.	.	.	.	4	17APR2018	.	.	Left	0.2	16	16	Yes	0 grade	None
.	.	.	.	5	23APR2018	.	.	Left	0.2	15	15	Yes	0 grade	None
.	.	.	.	6	11JUN2018	.	.	Left	0.2	16	16	Yes	0 grade	None
-----														
100345	GEL	Male	48	1	05APR2018	0.4	0	.	.	10	10	Yes	0 grade	None
.	.	.	.	2	10APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	11APR2018	.	.	Left	0.2	16	16	Yes	0 grade	None
.	.	.	.	4	17APR2018	.	.	Left	0.1	14	14	Yes	0 grade	None
.	.	.	.	5	23APR2018	.	.	Left	0.1	16	16	Yes	0 grade	None
.	.	.	.	6	11JUN2018	.	.	Left	0.1	15	15	Yes	0 grade	None

Listing 6 (28 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	anterior chamber		
												Performed?	Cellul. grade*	Flare grade**
=====														
100346	DROP	Female	77	1	06APR2018	0.4	0.6	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	12APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	13APR2018	.	.	Right	0.1	14	14	Yes	0 grade	None
.	.	.	.	4	19APR2018	.	.	Right	0	15	15	Yes	0 grade	None
.	.	.	.	5	26APR2018	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	6	12JUN2018	.	.	Right	0	15	15	Yes	0 grade	None
-----														
100347	GEL	Male	58	1	12APR2018	0.1	0.5	.	.	14	12	Yes	0 grade	None
.	.	.	.	2	18APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19APR2018	.	.	Right	0	14	18	Yes	0 grade	None
.	.	.	.	4	24APR2018	.	.	Right	0	14	16	Yes	0 grade	None
.	.	.	.	5	02MAY2018	.	.	Right	0	14	15	Yes	0 grade	None
.	.	.	.	6	18JUN2018	.	.	Right	0	16	16	Yes	0 grade	None
-----														
100348	GEL	Female	38	1	19APR2018	0.4	0.4	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	24APR2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25APR2018	.	.	Right	0.1	18	18	Yes	0 grade	None
.	.	.	.	4	30APR2018	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	5	08MAY2018	.	.	Right	0	14	14	Yes	0 grade	None
.	.	.	.	6	25JUN2018	.	.	Right	0	15	15	Yes	0 grade	None
-----														
100349	DROP	Male	71	1	18MAY2018	0.4	0.4	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	24MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	25MAY2018	.	.	Right	0.2	14	14	Yes	0 grade	None
.	.	.	.	4	30MAY2018	.	.	Right	0.1	14	16	Yes	0 grade	None
.	.	.	.	5	06JUN2018	.	.	Right	0.1	16	16	Yes	0 grade	None
.	.	.	.	6	25JUL2018	.	.	Right	0.1	16	16	Yes	0 grade	None
-----														
100350	DROP	Female	67	1	18MAY2018	0.4	0.7	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	22MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	23MAY2018	.	.	Left	0.2	15	16	Yes	0 grade	None
.	.	.	.	4	30MAY2018	.	.	Left	0.1	15	15	Yes	0 grade	None
.	.	.	.	5	05JUN2018	.	.	Left	0	16	16	Yes	0 grade	None
.	.	.	.	6	23JUL2018	.	.	Left	0	15	15	Yes	0 grade	None

Listing 6 (29 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
												anterior ocular chamber		
Sbj	Study	Age						Operated eye						
Code	drug	Sex	(year)	No.	Date	Left eye	Right eye	Eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
-----														
100351	GEL	Female	79	1	18MAY2018	0.5	0	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	25MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	26MAY2018	.	.	Left	0	18	18	Yes	0 grade	None
.	.	.	.	4	01JUN2018	.	.	Left	0	16	18	Yes	0 grade	None
.	.	.	.	5	08JUN2018	.	.	Left	0	15	15	Yes	0 grade	None
.	.	.	.	6	25JUL2018	.	.	Left	0	15	15	Yes	0 grade	None
-----														
100352	DROP	Female	63	1	23MAY2018	0.2	0.8	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	29MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	30MAY2018	.	.	Right	0.2	15	15	Yes	0 grade	None
.	.	.	.	4	06JUN2018	.	.	Right	0.2	16	16	Yes	0 grade	None
.	.	.	.	5	13JUN2018	.	.	Right	0.1	15	15	Yes	0 grade	None
.	.	.	.	6	30JUL2018	.	.	Right	0	15	15	Yes	0 grade	None
-----														
100353	GEL	Female	72	1	31MAY2018	0.5	0.2	.	.	14	15	Yes	0 grade	None
.	.	.	.	2	07JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08JUN2018	.	.	Left	0.1	16	16	Yes	0 grade	None
.	.	.	.	4	14JUN2018	.	.	Left	0	14	14	Yes	0 grade	None
.	.	.	.	5	21JUN2018	.	.	Left	0	14	14	Yes	0 grade	None
.	.	.	.	6	31JUL2018	.	.	Left	0	14	14	Yes	0 grade	None
-----														
100354	GEL	Female	80	1	01JUN2018	0.5	0.5	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	07JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	08JUN2018	.	.	Left	0.2	17	17	Yes	0 grade	None
.	.	.	.	4	14JUN2018	.	.	Left	0.2	16	16	Yes	0 grade	None
.	.	.	.	5	21JUN2018	.	.	Left	0.1	15	15	Yes	0 grade	None
.	.	.	.	6	07AUG2018	.	.	Left	0.1	15	15	Yes	0.5 grade	None
.	.	.	.	7	25JUN2018	.	.	.	.	.	.	Yes	0 grade	None
-----														
100355	DROP	Female	80	1	08JUN2018	0.8	0.5	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	13JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14JUN2018	.	.	Left	0	15	15	Yes	0 grade	None
.	.	.	.	4	21JUN2018	.	.	Left	0	14	14	Yes	0 grade	None
.	.	.	.	5	27JUN2018	.	.	Left	0	14	14	Yes	0 grade	None
.	.	.	.	6	13AUG2018	.	.	Left	0	15	15	Yes	0 grade	None



Listing 6 (30 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye		Left eye	Right eye	Performed?	anterior ocular chamber	
								Eye	Value				Cellul. grade*	Flare grade**
-----														
100356	GEL	Male	74	1	12JUN2018	0.2	0.6	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	18JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19JUN2018	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	4	26JUN2018	.	.	Right	0	16	16	Yes	0 grade	None
.	.	.	.	5	04JUL2018	.	.	Right	0	14	14	Yes	0 grade	None
.	.	.	.	6	20AUG2018	.	.	Right	0	14	14	Yes	0 grade	None
-----														
200101	GEL	Female	66	1	11JAN2018	1	0.9	.	.	19	17	Yes	0 grade	None
.	.	.	.	2	16JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	17JAN2018	.	.	Left	1	34	16	Yes	0.5 grade	None
.	.	.	.	4	24JAN2018	.	.	Left	1.1	16	17	Yes	0.5 grade	None
.	.	.	.	5	31JAN2018	.	.	Left	1	17	18	Yes	0 grade	None
.	.	.	.	6	19MAR2018	.	.	Left	1.1	16	16	Yes	0 grade	None
.	.	.	.	7	17JAN2018	.	.	.	.	.	.	Yes	0.5 grade	None
-----														
200102	DROP	Female	76	1	25JAN2018	1	0.8	.	.	14	14	Yes	0 grade	None
.	.	.	.	2	30JAN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	31JAN2018	.	.	Right	0.6	12	14	Yes	1 grade	Faint
.	.	.	.	4	05FEB2018	.	.	Right	0.63	11	13	Yes	0 grade	None
.	.	.	.	5	13FEB2018	.	.	Right	0.9	13	16	Yes	0 grade	None
.	.	.	.	6	28MAR2018	.	.	Right	1	11	15	Yes	0 grade	None
-----														
200103	DROP	Male	82	1	12FEB2018	1	0.5	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	13FEB2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	14FEB2018	.	.	Right	1	16	12	Yes	1 grade	Faint
.	.	.	.	4	19FEB2018	.	.	Right	1	15	14	Yes	0.5 grade	None
.	.	.	.	5	26FEB2018	.	.	Right	0.8	16	16	Yes	0 grade	None
.	.	.	.	6	16APR2018	.	.	Left	1	14	12	Yes	0 grade	None
.	.	.	.	7	14MAR2018	.	.	.	.	.	.	Yes	0 grade	None
-----														
200104	GEL	Female	78	1	03MAY2018	0.5	0.4	.	.	13	12	Yes	0 grade	None
.	.	.	.	2	08MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	09MAY2018	.	.	Right	0.6	15	14	Yes	0.5 grade	None
.	.	.	.	4	16MAY2018	.	.	Right	1	16	15	Yes	0 grade	None
.	.	.	.	5	23MAY2018	.	.	Right	1	17	15	Yes	0 grade	None
.	.	.	.	6	06JUN2018	.	.	Right	0.9	12	10	Yes	0 grade	None

Listing 6 (31 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
				Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
Sbj Code	Study drug	Age Sex	(year)	-----		-----				-----		-----		
				No.	Date	Left eye	Right eye	Operated eye	Value	Left eye	Right eye	Performed?	Cellul. grade*	Flare grade**
=====														
200105	GEL	Female	65	1	24MAY2018	1	1	.	.	16	15	Yes	0 grade	None
.	.	.	.	2	29MAY2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	30MAY2018	.	.	Right	1	13	15	Yes	0 grade	Faint
.	.	.	.	4	06JUN2018	.	.	Right	1.1	15	12	Yes	0 grade	None
.	.	.	.	5	13JUN2018	.	.	Right	1.1	19	11	Yes	0 grade	None
.	.	.	.	6	23JUN2018	.	.	Right	1	13	12	Yes	0 grade	None
-----														
200106	DROP	Female	75	1	18JUN2018	0.4	0.7	.	.	20	18	Yes	0 grade	None
.	.	.	.	2	26JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	27JUN2018	.	.	Left	0.5	17	15	Yes	1 grade	Faint
.	.	.	.	4	04JUL2018	.	.	Left	1	15	16	Yes	0 grade	None
.	.	.	.	5	11JUL2018	.	.	Left	1	16	16	Yes	0 grade	None
.	.	.	.	6	22AUG2018	.	.	(uncode.)	.	.	.	(uncoded).	.	.
-----														
200107	DROP	Female	54	1	25JUN2018	0.32	0.4	.	.	19	16	Yes	0 grade	None
.	.	.	.	2	03JUL2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04JUL2018	.	.	Left	0.6	17	16	Yes	1 grade	None
-----														
200108	GEL	Male	77	1	29AUG2018	0.63	0.9	.	.	17	16	Yes	0 grade	None
.	.	.	.	2	04SEP2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	05SEP2018	.	.	Left	1	19	14	Yes	1 grade	Faint
.	.	.	.	4	12SEP2018	.	.	Left	1	16	14	Yes	0 grade	None
.	.	.	.	5	20SEP2018	.	.	Left	1.1	9	16	Yes	0 grade	None
.	.	.	.	6	05NOV2018	.	.	Left	1	11	10	Yes	0 grade	None
-----														
200109	GEL	Female	84	1	29SEP2018	0.63	0.63	.	.	16	16	Yes	0 grade	None
.	.	.	.	2	02OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	03OCT2018	.	.	Right	0.2	16	17	Yes	0.5 grade	None
.	.	.	.	4	10OCT2018	.	.	Right	0.7	15	9	Yes	0 grade	None
-----														
200110	DROP	Male	64	1	05OCT2018	0.63	0.25	.	.	16	19	Yes	0 grade	None
.	.	.	.	2	09OCT2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	10OCT2018	.	.	Right	0.7	16	21	Yes	0.5 grade	None
.	.	.	.	4	17OCT2018	.	.	Right	0.2	17	12	Yes	0.5 grade	None
.	.	.	.	5	23OCT2018	.	.	Right	0.4	12	12	Yes	0 grade	None
.	.	.	.	6	05DEC2018	.	.	Right	1.1	15	15	Yes	0 grade	None



Listing 6 (33 of 33): Visual acuity, Intra-ocular pressure and Slit lamp examination during the study

=====														
Sbj Code	Study drug	Sex	Age (year)	Visit		Visual acuity				Intra-ocular pressure		Slit lamp examination		
				No.	Date	Left eye	Right eye	Operated eye Eye	Value	Left eye	Right eye	Performed?	anterior ocular chamber	
													Cellul. grade*	Flare grade**
-----														
200202	DROP	Female	71	1	13JUN2018	1	1	.	.	14	12	Yes	0 grade	None
.	.	.	.	2	18JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	19JUN2018	.	.	Right	1.25	18	18	Yes	0.5 grade	None
.	.	.	.	4	25JUN2018	.	.	Right	0.8	15	15	Yes	0 grade	None
.	.	.	.	5	03JUL2018	.	.	Right	1.25	14	14	Yes	0 grade	None
.	.	.	.	6	17AUG2018	.	.	Right	1.25	12	12	Yes	0 grade	None
.	.	.	.	7	06JUL2018	.	.	.	.	.	.	Yes	0 grade	None
-----														
200203	GEL	Male	66	1	21JUN2018	0.6	0.8	.	.	18	14	Yes	0 grade	None
.	.	.	.	2	26JUN2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	27JUN2018	.	.	Left	0.8	15	15	Yes	1 grade	None
.	.	.	.	4	02JUL2018	.	.	Left	0.63	15	.	Yes	0.5 grade	None
.	.	.	.	5	12JUL2018	.	.	Left	0.8	13	13	Yes	0 grade	None
.	.	.	.	6	04SEP2018	.	.	Left	1.25	14	12	Yes	0 grade	None
-----														
200204	GEL	Male	58	1	28JUN2018	0.5	1.25	.	.	15	15	Yes	0 grade	None
.	.	.	.	2	03JUL2018	.	.	.	.	.	.	.	.	.
.	.	.	.	3	04JUL2018	.	.	Left	1	14	14	Yes	1 grade	None
.	.	.	.	4	10JUL2018	.	.	Left	1	13	13	Yes	0 grade	None
.	.	.	.	5	18JUL2018	.	.	Left	.	12	13	Yes	0 grade	None
.	.	.	.	6	04SEP2018	.	.	Left	1.25	12	12	Yes	0 grade	None

SAS program: L03\_List\_06.sas - SAS dataset name(s): RAND,DEMOGRAPHY,VISUAL\_SCREEN,VISUAL\_CONTROL,INTRA\_PRES,SLIT

\* Cellularity grade: 0= <1 cell/field,  
0.5= 1-5 cells/field,  
1= 6-15 cells/field,  
2= 16-25 cells/field,  
3= 26-50 cells/field,  
4= >50 cells/field

\*\* Flare grade: 0= none  
1= faint  
2= moderate  
3= marked  
4= intense

Listing 7 (1 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100101	DROP	Female	84	1	20OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	26OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	02NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100102	GEL	Male	80	1	27OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	01NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	07NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	15NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	29DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (2 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100103		Female	70	1	27OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100104	GEL	Male	70	1	03NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	22NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
=====									

Listing 7 (3 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100105	DROP	Female	85	1	03NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	15NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100106	GEL	Male	56	1	09NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	16NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	22NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	15JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (4 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100107	DROP	Female	82	1	23NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	29NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	05DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100108	DROP	Female	73	1	01DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	07DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	06FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (5 of 87): Ophthalmoscopy test during the study

=====										
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment	
				No.	Date					
=====										
100109	GEL	Female	56	1	07DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	3	13DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	4	19DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	5	27DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	6	12FEB2018	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
-----										
100110	DROP	Female	75	1	07DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	3	14DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	4	20DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	5	28DEC2017	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.
.	.	.	.	6	12FEB2018	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.		Retina	Normal	.
.	.	.	.	.	.	.		Macula	Normal	.
.	.	.	.	.	.	.		Choroid	Normal	.

Listing 7 (6 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100111	DROP	Female	60	1	07DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	28DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100112	GEL	Male	73	1	28DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	10JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	17JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (7 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100113	GEL	Female	77	1	28DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	10JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	17JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100114	GEL	Male	64	1	29DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	10JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	17JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (8 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100115	DROP	Male	76	1	29DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	3	05JAN2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	4	11JAN2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	5	18JAN2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	6	06MAR2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100116	GEL	Male	62	1	29DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	3	05JAN2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	4	11JAN2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	5	19JAN2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	6	06MAR2018	Yes	Vitreous	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (9 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100117	DROP	Female	51	1	04JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	17JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100118	DROP	Female	78	1	11JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	18JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	24JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	19MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (10 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100119	DROP	Female	72	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100120	GEL	Male	79	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	07FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (11 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100121	GEL	Male	80	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	07FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100122	DROP	Female	76	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	26JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (12 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100123	DROP	Female	76	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	26JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100124	GEL	Female	71	1	26JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	02FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	03APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (13 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100125	GEL	Female	62	1	26JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	3	02FEB2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	4	08FEB2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	5	16FEB2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	6	03APR2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100126	GEL	Female	85	1	02FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	3	08FEB2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	4	14FEB2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	5	21FEB2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	6	09APR2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (14 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100127	GEL	Female	68	1	02FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	15FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	24FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	10APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100128	DROP	Male	80	1	02FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	15FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	24FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	10APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (15 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100129	DROP	Female	78	1	02FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	15FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	10APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100130	GEL	Male	66	1	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	22FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	28FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	07MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	23APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (16 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100131	DROP	Female	77	1	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	22FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	28FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	07MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	23APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
-----									
100132	DROP	Male	69	1	02MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (17 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100133	GEL	Male	74	1	02MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100134	DROP	Female	66	1	02MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (18 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100135	GEL	Male	69	1	09MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	16MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	22MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	29MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	15MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100136	GEL	Female	90	1	30MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (19 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100137	DROP	Female	62	1	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	19JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100138	GEL	Male	63	1	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	19JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (20 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100139	DROP	Female	71	1	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	03MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	11MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100140	GEL	Male	81	1	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	03MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	17MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	02JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
=====									



Listing 7 (21 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100141	DROP	Female	74	1	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	03MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	10MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	02JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100142	GEL	Female	77	1	11MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	17MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	31MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (22 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100143	GEL	Male	74	1	15JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	21JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	04JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	20AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100144	DROP	Female	89	1	22JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	28JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	04JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	12JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (23 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100145	GEL	Male	81	1	29JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	05JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	11JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	18JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	04SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100146	GEL	Male	71	1	17AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	22AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	29AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	06SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	22OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (24 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100147	DROP	Male	48	1	24AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	29AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	20SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100148	DROP	Female	83	1	24AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	31AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	13SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	29OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (25 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100149	DROP	Female	71	1	24AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	31AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	15SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	29OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100150	GEL	Female	77	1	31AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (26 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100151	DROP	Female	67	1	28SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	05OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	04DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100152	GEL	Female	78	1	28SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	05OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (27 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100153	DROP	Female	81	1	12OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	18OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	24OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	29OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	18DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100154	GEL	Female	68	1	12OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	26OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	18DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (28 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100155	DROP	Female	79	1	12OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	26OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	18DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100156	GEL	Female	69	1	12OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	26OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	18DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (29 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100201	GEL	Female	80	1	01DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	22DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100202	DROP	Female	70	1	01DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (30 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100203	DROP	Female	76	1	07DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	15DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	28DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	15FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100204	GEL	Male	71	1	07DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	15DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	28DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	15FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (31 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100205	GEL	Male	75	1	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	09APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100206	DROP	Female	81	1	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	18JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	24JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (32 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100207	DROP	Female	65	1	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	3	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	4	18JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	5	24JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	6	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100208	GEL	Female	79	1	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	18JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (33 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100209	GEL	Female	77	1	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100210	DROP	Female	70	1	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	24JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	22MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (34 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100211	GEL	Male	67	1	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	3	19JAN2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	4	24JAN2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	5	31JAN2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	6	22MAR2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100212	DROP	Female	82	1	12JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	3	19JAN2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	4	24JAN2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	5	31JAN2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	6	22MAR2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (35 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100213	DROP	Female	81	1	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	3	02FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	4	07FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	5	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	6	04APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
-----									
100214	DROP	Female	77	1	05FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	09APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (36 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100215	GEL	Female	83	1	05FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	09APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100216	GEL	Female	74	1	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	21FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	28FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (37 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100217	DROP	Female	72	1	02MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100218	DROP	Male	72	1	02MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (38 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100219	GEL	Female	83	1	09MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
.	.	.	.	3	16MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	28MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100220	GEL	Male	64	1	09MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	16MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	21MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	28MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (39 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100221	GEL	Female	76	1	30MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	11APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100222	DROP	Female	76	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	18APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	14JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (40 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100223	DROP	Male	61	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	18APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	14JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100224	GEL	Female	75	1	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	02MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (41 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100225	DROP	Female	79	1	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	02MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100226	GEL	Female	74	1	20APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	02MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (42 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100227	DROP	Female	68	1	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	04JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100228	GEL	Female	68	1	27APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (43 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100229	GEL	Female	70	1	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	10JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100230	GEL	Female	63	1	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	11JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (44 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100231	DROP	Female	74	1	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	06JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100232	DROP	Female	73	1	04MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	16MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	06JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	.	.	.	.	.



Listing 7 (45 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100233	GEL	Female	72	1	18MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	30MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	20JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100234	GEL	Female	73	1	18MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	30MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	20JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (46 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100235	DROP	Male	64	1	28MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	13JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100236	DROP	Female	70	1	28MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	13JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (47 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100237	DROP	Male	73	1	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	06AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100238	GEL	Male	78	1	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	06AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (48 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100239	DROP	Female	80	1	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	15JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	20JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	14AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100240		Female	72	1	06JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (49 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100241	GEL	Female	74	1	23OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	26OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	31OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	07NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	24DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100242	GEL	Female	67	1	31OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	22NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12JAN2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (50 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100243	DROP	Male	74	1	30NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	07DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	04FEB2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100244	GEL	Female	66	1	07DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08FEB2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (51 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100245	DROP	Female	69	1	07DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	08FEB2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100301	GEL	Female	68	1	13OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	20OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	25OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	03NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	13DEC2017	.	.	.	.

Listing 7 (52 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100302	GEL	Male	61	1	26OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	03NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	09NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	17NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	29NOV2017	.	.	.	.
-----									
100303	DROP	Female	73	1	26OCT2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	03NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	09NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	17NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (53 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100304	DROP	Male	58	1	10NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	17NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	23NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100305	DROP	Female	85	1	10NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	17NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	23NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (54 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
-----									
100306	DROP	Female	84	1	16NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100307	GEL	Female	73	1	24NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	29JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100308	GEL	Female	85	1	24NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (55 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100309	DROP	Female	61	1	24NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	29JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Abnormal	.
-----									
100310	GEL	Female	73	1	24NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	01DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	29JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
=====									

Listing 7 (56 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100311	GEL	Female	83	1	29NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100312	DROP	Female	71	1	29NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (57 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100313	GEL	Male	71	1	29NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100314	DROP	Male	67	1	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (58 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100315	GEL	Female	65	1	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100316	DROP	Male	76	1	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (59 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100317	GEL	Male	85	1	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100318	GEL	Female	80	1	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (60 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100319	DROP	Male	70	1	29NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100320	DROP	Male	69	1	30NOV2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	01JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (61 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100321	GEL	Male	72	1	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	12DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100322	GEL	Male	80	1	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (62 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100323	DROP	Female	76	1	06DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100324	DROP	Male	65	1	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (63 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100325	GEL	Female	83	1	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100326	DROP	Male	81	1	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	03JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (64 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100327	GEL	Female	73	1	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100328	DROP	Male	82	1	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (65 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100329	GEL	Male	74	1	13DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100330	DROP	Male	61	1	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	03JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	19FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (66 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100331	GEL	Female	71	1	14DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	20DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2017	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	03JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	19FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100332	DROP	Male	82	1	05JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (67 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100333	DROP	Male	62	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	26JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	09FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100334	GEL	Male	72	1	19JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	01FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	26MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (68 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100335	DROP	Female	80	1	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	07FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	19MAR2018	.	.	.	.
-----									
100336	GEL	Female	82	1	01MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	07MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	02MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (69 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100337	GEL	Male	72	1	10MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100338	DROP	Female	87	1	15MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	22MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	21MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
=====									

Listing 7 (70 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100339	GEL	Male	56	1	22MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	29MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	11APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	28MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100340	DROP	Male	83	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (71 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100341	GEL	Male	88	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100342	DROP	Female	86	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (72 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100343	GEL	Male	74	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	17APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	24APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100344	DROP	Female	68	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	17APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	11JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (73 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100345	GEL	Male	48	1	05APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	11APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	17APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	11JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100346	DROP	Female	77	1	06APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	13APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	19APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	12JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (74 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100347	GEL	Male	58	1	12APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	24APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	02MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	18JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100348	GEL	Female	38	1	19APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	30APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	25JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
=====									

Listing 7 (75 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100349	DROP	Male	71	1	18MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	25MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	30MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	25JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100350	DROP	Female	67	1	18MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	30MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	05JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	23JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (76 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
100351	GEL	Female	79	1	18MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	26MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	25JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100352	DROP	Female	63	1	23MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	30MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	13JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	30JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (77 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100353	GEL	Female	72	1	31MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	31JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100354	GEL	Female	80	1	01JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	07AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	25JUN2018	.	.	.	.

Listing 7 (78 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
100355	DROP	Female	80	1	08JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	21JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	13AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
100356	GEL	Male	74	1	12JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	26JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	04JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	20AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (79 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
200101	GEL	Female	66	1	11JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	17JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	24JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	19MAR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Not done	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Not done	.
.	.	.	.	7	17JAN2018	.	.	.	.
-----									
200102	DROP	Female	76	1	25JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	31JAN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	05FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	13FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Not done	.
.	.	.	.	6	28MAR2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.

Listing 7 (80 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
200103	DROP	Male	82	1	12FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Not done	.
.	.	.	.	3	14FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Not done	.
.	.	.	.	4	19FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	26FEB2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	16APR2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	14MAR2018	.	.	.	.
-----									
200104	GEL	Female	78	1	03MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	09MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Not done	.
.	.	.	.	4	16MAY2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	5	23MAY2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	6	06JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (81 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?	Result	Comment	
				No.	Date				
=====									
200105	GEL	Female	65	1	24MAY2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	30MAY2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	4	06JUN2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	5	13JUN2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	6	23JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
200106	DROP	Female	75	1	18JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	04JUL2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	5	11JUL2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	6	22AUG2018	(uncoded)	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.

Listing 7 (82 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
200107	DROP	Female	54	1	25JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04JUL2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
-----									
200108	GEL	Male	77	1	29AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	05SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	12SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	20SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05NOV2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
-----									
200109	GEL	Female	84	1	29SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	03OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	10OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

Listing 7 (83 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
200110	DROP	Male	64	1	05OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	10OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	17OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	23OCT2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	05DEC2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
-----									
200111	GEL	Male	73	1	01NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	07NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	14NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	21NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	02JAN2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	06NOV2018	.	.	.	.

Listing 7 (84 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
200112	DROP	Male	85	1	09NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	21NOV2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	5	28NOV2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	6	09JAN2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	30NOV2018	.	.	.	.
-----									
200113	DROP	Male	77	1	09NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	14NOV2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	4	21NOV2018	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
.	.	.	.	5	29NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	11JAN2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.



Listing 7 (85 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
200114	DROP	Female	64	1	23NOV2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
-----									
200115	GEL	Female	70	1	14DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	27DEC2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	03JAN2019	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	13FEB2019	No	Vitreous	.	.
.	.	.	.	.	.	.	Retina	.	.
.	.	.	.	.	.	.	Macula	.	.
.	.	.	.	.	.	.	Choroid	.	.
=====									
200201		Female	71	1	24JAN2018	.		.	.

Listing 7 (86 of 87): Ophthalmoscopy test during the study

=====									
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment
				No.	Date				
=====									
200202	DROP	Female	71	1	13JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	19JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	25JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	03JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	17AUG2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	7	06JUL2018	.	.	.	.
-----									
200203	GEL	Male	66	1	21JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	27JUN2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	02JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	12JUL2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	04SEP2018	Yes	Vitreous	Normal	.
.	.	.	.	.	.	.	Retina	Abnormal	.
.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	Choroid	Normal	.

=====										
Sbj Code	Study Drug	Sex	Age (year)	Visit		Performed?		Result	Comment	
				No.	Date					
=====										
200204	GEL	Male	58	1	28JUN2018	Yes		Vitreous	Normal	.
.	.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	3	04JUL2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	4	10JUL2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	5	18JUL2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	.	Choroid	Normal	.
.	.	.	.	6	04SEP2018	Yes	.	Vitreous	Normal	.
.	.	.	.	.	.	.	.	Retina	Normal	.
.	.	.	.	.	.	.	.	Macula	Normal	.
.	.	.	.	.	.	.	.	Choroid	Normal	.
=====										
SAS program: L03_List_06.sas - SAS dataset name(s): RAND,DEMOGRAPHY,OPHTHALMOSCOPY										

Listing 8 (1 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Complication
100101	DROP	Female	84	2	25OCT2017	Left eye	Yes	Yes	Yes	Yes	No	
100102	GEL	Male	80	2	31OCT2017	Right eye	Yes	Yes	Yes	Yes	No	
100103		Female	70	1	.	.	.	.	.	.	.	
100104	GEL	Male	70	2	07NOV2017	Right eye	Yes	Yes	Yes	Yes	No	
100105	DROP	Female	85	2	08NOV2017	Left eye	Yes	Yes	Yes	Yes	No	
100106	GEL	Male	56	2	15NOV2017	Left eye	Yes	Yes	Yes	Yes	No	
100107	DROP	Female	82	2	28NOV2017	Left eye	Yes	Yes	Yes	Yes	No	
100108	DROP	Female	73	2	06DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100109	GEL	Female	56	2	12DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100110	DROP	Female	75	2	13DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100111	DROP	Female	60	2	13DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100112	GEL	Male	73	2	03JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100113	GEL	Female	77	2	03JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100114	GEL	Male	64	2	03JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100115	DROP	Male	76	2	04JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100116	GEL	Male	62	2	04JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100117	DROP	Female	51	2	10JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100118	DROP	Female	78	2	17JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100119	DROP	Female	72	2	24JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100120	GEL	Male	79	2	24JAN2018	Left eye	Yes	Yes	Yes	Yes	No	

Listing 8 (2 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Complication
100121	GEL	Male	80	2	24JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100122	DROP	Female	76	2	25JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100123	DROP	Female	76	2	25JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100124	GEL	Female	71	2	01FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100125	GEL	Female	62	2	01FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100126	GEL	Female	85	2	07FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100127	GEL	Female	68	2	08FEB2018	Right eye	Yes	Yes	Yes	Yes	No	
100128	DROP	Male	80	2	08FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100129	DROP	Female	78	2	08FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100130	GEL	Male	66	2	21FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100131	DROP	Female	77	2	21FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100132	DROP	Male	69	2	07MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
100133	GEL	Male	74	2	07MAR2018	Left eye	Yes	Yes	Yes	Yes	No	
100134	DROP	Female	66	2	07MAR2018	Left eye	Yes	Yes	Yes	Yes	No	
100135	GEL	Male	69	2	15MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
100136	GEL	Female	90	2	05APR2018	Left eye	Yes	Yes	Yes	Yes	No	
100137	DROP	Female	62	2	19APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100138	GEL	Male	63	2	19APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100139	DROP	Female	71	2	26APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100140	GEL	Male	81	2	02MAY2018	Right eye	Yes	Yes	Yes	Yes	No	

Listing 8 (3 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Complication
100141	DROP	Female	74	2	02MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100142	GEL	Female	77	2	16MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100143	GEL	Male	74	2	20JUN2018	Left eye	Yes	Yes	Yes	Yes	No	
100144	DROP	Female	89	2	27JUN2018	Right eye	Yes	Yes	Yes	Yes	No	
100145	GEL	Male	81	2	04JUL2018	Right eye	Yes	Yes	Yes	Yes	No	
100146	GEL	Male	71	2	21AUG2018	Right eye	Yes	Yes	Yes	Yes	No	
100147	DROP	Male	48	2	28AUG2018	Right eye	Yes	Yes	Yes	Yes	No	
100148	DROP	Female	83	2	30AUG2018	Left eye	Yes	Yes	Yes	Yes	No	
100149	DROP	Female	71	2	30AUG2018	Right eye	Yes	Yes	Yes	Yes	No	
100150	GEL	Female	77	2	05SEP2018	Right eye	Yes	Yes	Yes	Yes	No	
100151	DROP	Female	67	2	04OCT2018	Left eye	Yes	Yes	Yes	Yes	No	
100152	GEL	Female	78	2	04OCT2018	Left eye	Yes	Yes	Yes	Yes	No	
100153	DROP	Female	81	2	17OCT2018	Left eye	Yes	Yes	Yes	Yes	No	
100154	GEL	Female	68	2	18OCT2018	Right eye	Yes	Yes	Yes	Yes	No	
100155	DROP	Female	79	2	18OCT2018	Left eye	Yes	Yes	Yes	Yes	No	
100156	GEL	Female	69	2	18OCT2018	Left eye	Yes	Yes	Yes	Yes	No	
100201	GEL	Female	80	2	07DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100202	DROP	Female	70	2	07DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100203	DROP	Female	76	2	14DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100204	GEL	Male	71	2	14DEC2017	Right eye	Yes	Yes	Yes	Yes	No	

Listing 8 (4 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Complication
100205	GEL	Male	75	2	08FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100206	DROP	Female	81	2	11JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100207	DROP	Female	65	2	11JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100208	GEL	Female	79	2	11JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100209	GEL	Female	77	2	18JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100210	DROP	Female	70	2	18JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100211	GEL	Male	67	2	18JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100212	DROP	Female	82	2	18JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100213	DROP	Female	81	2	01FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100214	DROP	Female	77	2	08FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100215	GEL	Female	83	2	08FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100216	GEL	Female	74	2	15FEB2018	Left eye	Yes	Yes	Yes	Yes	No	
100217	DROP	Female	72	2	08MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
100218	DROP	Male	72	2	08MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
100219	GEL	Female	83	2	15MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
100220	GEL	Male	64	2	15MAR2018	Left eye	Yes	Yes	Yes	Yes	No	
100221	GEL	Female	76	2	05APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100222	DROP	Female	76	2	12APR2018	Left eye	Yes	Yes	Yes	Yes	No	
100223	DROP	Male	61	2	12APR2018	Left eye	Yes	Yes	Yes	Yes	No	
100224	GEL	Female	75	2	26APR2018	Right eye	Yes	Yes	Yes	Yes	No	

Listing 8 (5 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Complication
100225	DROP	Female	79	2	26APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100226	GEL	Female	74	2	26APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100227	DROP	Female	68	2	03MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100228	GEL	Female	68	2	03MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100229	GEL	Female	70	2	10MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100230	GEL	Female	63	2	10MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100231	DROP	Female	74	2	10MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100232	DROP	Female	73	2	10MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100233	GEL	Female	72	2	24MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100234	GEL	Female	73	2	24MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100235	DROP	Male	64	2	31MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100236	DROP	Female	70	2	31MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100237	DROP	Male	73	2	07JUN2018	Left eye	Yes	Yes	Yes	Yes	No	
100238	GEL	Male	78	2	07JUN2018	Right eye	Yes	Yes	Yes	Yes	No	
100239	DROP	Female	80	2	14JUN2018	Right eye	Yes	Yes	Yes	Yes	No	
100240		Female	72	1	.	.	.	.	.	.	.	
100241	GEL	Female	74	2	25OCT2018	Left eye	Yes	Yes	Yes	Yes	No	
100242	GEL	Female	67	2	08NOV2018	Right eye	Yes	Yes	Yes	Yes	No	
100243	DROP	Male	74	2	06DEC2018	Right eye	Yes	Yes	Yes	Yes	No	
100244	GEL	Female	66	2	13DEC2018	Left eye	Yes	Yes	Yes	Yes	No	



Listing 8 (6 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====													
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication		
				No.	Date		3 days before	2 days before	1 day before		N/Y	Proc.problem	Complication
100245	DROP	Female	69	2	13DEC2018	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100301	GEL	Female	68	2	19OCT2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100302	GEL	Male	61	2	02NOV2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100303	DROP	Female	73	2	02NOV2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100304	DROP	Male	58	2	16NOV2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100305	DROP	Female	85	2	16NOV2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100306	DROP	Female	84	2	22NOV2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100307	GEL	Female	73	2	29NOV2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100308	GEL	Female	85	2	29NOV2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100309	DROP	Female	61	2	29NOV2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100310	GEL	Female	73	2	30NOV2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100311	GEL	Female	83	2	05DEC2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100312	DROP	Female	71	2	05DEC2017	Left eye	Yes	Yes	Yes	Yes	No		
-----													
100313	GEL	Male	71	2	04DEC2017	Right eye	Yes	Yes	Yes	Yes	No	BREAKAGE POSTERIOR CAPSULE	
-----													
100314	DROP	Male	67	2	05DEC2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100315	GEL	Female	65	2	05DEC2017	Right eye	Yes	Yes	Yes	No	No		
-----													
100316	DROP	Male	76	2	05DEC2017	Left eye	Yes	Yes	Yes	No	No		
-----													
100317	GEL	Male	85	2	05DEC2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100318	GEL	Female	80	2	05DEC2017	Right eye	Yes	Yes	Yes	Yes	No		
-----													
100319	DROP	Male	70	2	05DEC2017	Left eye	Yes	Yes	Yes	Yes	No		

Listing 8 (7 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Complication
100320	DROP	Male	69	2	05DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100321	GEL	Male	72	2	11DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100322	GEL	Male	80	2	13DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100323	DROP	Female	76	2	13DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100324	DROP	Male	65	2	18DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100325	GEL	Female	83	2	18DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100326	DROP	Male	81	2	18DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100327	GEL	Female	73	2	18DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100328	DROP	Male	82	2	18DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100329	GEL	Male	74	2	18DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100330	DROP	Male	61	2	19DEC2017	Left eye	Yes	Yes	Yes	Yes	No	
100331	GEL	Female	71	2	19DEC2017	Right eye	Yes	Yes	Yes	Yes	No	
100332	DROP	Male	82	2	12JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100333	DROP	Male	62	2	25JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
100334	GEL	Male	72	2	24JAN2018	Left eye	Yes	Yes	Yes	Yes	No	
100335	DROP	Female	80	2	06FEB2018	Right eye	Yes	Yes	Yes	Yes	No	
100336	GEL	Female	82	2	06MAR2018	Left eye	Yes	Yes	Yes	Yes	No	
100337	GEL	Male	72	2	16MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
BREAKAGE OF THE POSTERIOR CAPSULE												
100338	DROP	Female	87	2	21MAR2018	Right eye	Yes	Yes	Yes	Yes	No	
100339	GEL	Male	56	2	28MAR2018	Left eye	Yes	Yes	Yes	Yes	No	

Bromfenac treatment administration												
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	-----			Ocular surface sterilization	Procedural problem and complication	
				No.	Date		3 days before	2 days before	1 day before		N/Y	Proc.problem
100340	DROP	Male	83	2	12APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100341	GEL	Male	88	2	12APR2018	Left eye	No	No	No	Yes	No	
100342	DROP	Female	86	2	12APR2018	Left eye	Yes	Yes	Yes	Yes	No	
100343	GEL	Male	74	2	10APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100344	DROP	Female	68	2	10APR2018	Left eye	Yes	Yes	Yes	Yes	No	
100345	GEL	Male	48	2	10APR2018	Left eye	Yes	Yes	Yes	Yes	No	
100346	DROP	Female	77	2	12APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100347	GEL	Male	58	2	18APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100348	GEL	Female	38	2	24APR2018	Right eye	Yes	Yes	Yes	Yes	No	
100349	DROP	Male	71	2	24MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100350	DROP	Female	67	2	22MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100351	GEL	Female	79	2	25MAY2018	Left eye	Yes	Yes	Yes	Yes	No	
100352	DROP	Female	63	2	29MAY2018	Right eye	Yes	Yes	Yes	Yes	No	
100353	GEL	Female	72	2	07JUN2018	Left eye	Yes	Yes	Yes	Yes	No	
100354	GEL	Female	80	2	07JUN2018	Left eye	Yes	Yes	Yes	Yes	No	
100355	DROP	Female	80	2	13JUN2018	Left eye	Yes	Yes	Yes	Yes	No	
100356	GEL	Male	74	2	18JUN2018	Right eye	Yes	Yes	Yes	Yes	No	
200101	GEL	Female	66	2	16JAN2018	Left eye	No	No	Yes	Yes	No	
200102	DROP	Female	76	2	30JAN2018	Right eye	Yes	Yes	Yes	Yes	No	
200103	DROP	Male	82	2	13FEB2018	Right eye	Yes	No	No	Yes	No	

Listing 8 (9 of 9): Bromfenac treatment before surgery, Ocular surface sterilization and Surgery problems

=====													
Sbj Code	Study drug	Sex	Age (year)	Visit		Which eye involved	Bromfenac treatment administration			Ocular surface sterilization	Procedural problem and complication		
				No.	Date		3 days before	2 days before	1 day before		N/Y	Proc.problem	Complication
200104	GEL	Female	78	2	08MAY2018	Right eye	Yes	Yes	Yes	Yes	No		
200105	GEL	Female	65	2	29MAY2018	Right eye	Yes	Yes	Yes	Yes	No		
200106	DROP	Female	75	2	26JUN2018	Left eye	Yes	Yes	Yes	Yes	No		
200107	DROP	Female	54	2	03JUL2018	Left eye	Yes	No	No	Yes	No		
200108	GEL	Male	77	2	04SEP2018	Left eye	Yes	Yes	Yes	Yes	No		
200109	GEL	Female	84	2	02OCT2018	Right eye	Yes	Yes	Yes	Yes	No		
200110	DROP	Male	64	2	09OCT2018	Right eye	Yes	Yes	Yes	Yes	No		
200111	GEL	Male	73	2	06NOV2018	Left eye	Yes	Yes	Yes	Yes	No		
200112	DROP	Male	85	2	13NOV2018	Left eye	Yes	Yes	Yes	Yes	No		
200113	DROP	Male	77	2	13NOV2018	Left eye	Yes	Yes	Yes	Yes	No		
200114	DROP	Female	64	2	27NOV2018	Right eye	Yes	Yes	Yes	Yes	No		
200115	GEL	Female	70	2	18DEC2018	Left eye	Yes	Yes	Yes	Yes	No		
200201		Female	71	1	.	.	.	.	.	.	.		
200202	DROP	Female	71	2	18JUN2018	Right eye	Yes	Yes	Yes	Yes	No		
200203	GEL	Male	66	2	26JUN2018	Left eye	Yes	Yes	Yes	Yes	No		
200204	GEL	Male	58	2	03JUL2018	Left eye	Yes	Yes	Yes	Yes	No		
=====													
SAS program: L03_List_08.sas - SAS dataset name(s): RAND,DEMOGRAPHY,SURGERY,BROM_TRT													

SAS program: L03\_List\_08.sas - SAS dataset name(s): RAND,DEMOGRAPHY,SURGERY,BROM\_TRT

Listing 9 (1 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug	Antibiotic before surgery	
				No.	Date				
100101	DROP	Female	84	1	20OCT2017	Name		NETILMICIN COLL	
.	.	.	.	.	.	Dosage		0.3%	
.	.	.	.	.	.	Unit		1	
.	.	.	.	.	.	Frequency		3 TIMES PER DAY	
.	.	.	.	2	25OCT2017	Name	MYDRIASERT		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100102	GEL	Male	80	1	27OCT2017	Name		NETILMICIN	
.	.	.	.	.	.	Dosage		0.3 %	
.	.	.	.	.	.	Unit		5 ml	
.	.	.	.	.	.	Frequency		3 TIMES PER DAY	
.	.	.	.	2	31OCT2017	Name	TROPICAMIDE		
.	.	.	.	.	.	Dosage	1 %		
.	.	.	.	.	.	Unit	3		
.	.	.	.	.	.	Frequency	AS NEEDED		
-----									
100104	GEL	Male	70	1	03NOV2017	Name		NETILMICIN	
.	.	.	.	.	.	Dosage		0.3 %	
.	.	.	.	.	.	Unit		5 ml	
.	.	.	.	.	.	Frequency		3 TIMES PER DAY	
.	.	.	.	2	07NOV2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	5.4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100105	DROP	Female	85	1	03NOV2017	Name		NETILMICIN COLL	
.	.	.	.	.	.	Dosage		0.3%	
.	.	.	.	.	.	Unit		1	
.	.	.	.	.	.	Frequency		3 TIMES PER DAY	
.	.	.	.	2	08NOV2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (2 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug			Antibiotic before surgery
				No.	Date				
100106	GEL	Male	56	1	09NOV2017	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3 %
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	15NOV2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	5.4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100107	DROP	Female	82	1	23NOV2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3 %
.	.	.	.	.	.	Unit			5 ml
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	28NOV2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100108	DROP	Female	73	1	01DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3 %
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	06DEC2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	5.4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100109	GEL	Female	56	1	07DEC2017	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	12DEC2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5.4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (3 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug			Antibiotic before surgery
				No.	Date				
100110	DROP	Female	75	1	07DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	13DEC2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5.4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100111	DROP	Female	60	1	07DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	13DEC2017	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5.4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100112	GEL	Male	73	1	28DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	03JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100113	GEL	Female	77	1	28DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	03JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (4 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug			Antibiotic before surgery
				No.	Date				
100114	GEL	Male	64	1	29DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	03JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100115	DROP	Male	76	1	29DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	04JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100116	GEL	Male	62	1	29DEC2017	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	04JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100117	DROP	Female	51	1	04JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			1
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	10JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4 MG		
.	.	.	.	.	.	Unit	1		
.	.	.	.	.	.	Frequency	ONCE		



Listing 9 (5 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100118	DROP	Female	78	1	11JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			ml
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	17JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100119	DROP	Female	72	1	19JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			ml
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	24JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100120	GEL	Male	79	1	19JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3 %
.	.	.	.	.	.	Unit			5 ml
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	24JAN2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/ 5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100121	GEL	Male	80	1	19JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3%
.	.	.	.	.	.	Unit			ml
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	24JAN2018	Name	MYDRIASERT		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (6 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100122	DROP	Female	76	1	19JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	25JAN2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28+5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100123	DROP	Female	76	1	19JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	25JAN2018	Name	MYDIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28+4.5		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100124	GEL	Female	71	1	26JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	01FEB2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.25 + 4.8		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100125	GEL	Female	62	1	26JAN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	01FEB2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (7 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug			Antibiotic before surgery
				No.	Date				
100126	GEL	Female	85	1	02FEB2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	07FEB2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100127	GEL	Female	68	1	02FEB2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	08FEB2018	Name	MYDRIASERT		
.	.	.	.	.	.	Dosage	0.28 + 5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100128	DROP	Male	80	1	02FEB2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	08FEB2018	Name	MYDRIASERT		
.	.	.	.	.	.	Dosage	0.28 + 5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100129	DROP	Female	78	1	02FEB2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	08FEB2018	Name	MYDRIASERT		
.	.	.	.	.	.	Dosage	0.28 + 5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (8 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100130	GEL	Male	66	1	16FEB2018	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	21FEB2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28 + 5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100131	DROP	Female	77	1	16FEB2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	21FEB2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100132	DROP	Male	69	1	02MAR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	07MAR2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100133	GEL	Male	74	1	02MAR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	07MAR2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (9 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100134	DROP	Female	66	1	02MAR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	07MAR2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100135	GEL	Male	69	1	09MAR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	15MAR2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5,4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100136	GEL	Female	90	1	30MAR2018	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	05APR2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100137	DROP	Female	62	1	13APR2018	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	19APR2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (10 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date				
=====									
100138	GEL	Male	63	1	13APR2018	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	19APR2018	Name	MYDRAISERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	MG		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100139	DROP	Female	71	1	20APR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	26APR2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100140	GEL	Male	81	1	27APR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	02MAY2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100141	DROP	Female	74	1	27APR2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			ONCE
.	.	.	.	2	02MAY2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (11 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug			Antibiotic before surgery
				No.	Date				
100142	GEL	Female	77	1	11MAY2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	16MAY2018	Name	MYDRIASERT (PHENYLEPHRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	5.4 + 0.28		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100143	GEL	Male	74	1	15JUN2018	Name			NETILMICIN
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			ml
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	20JUN2018	Name	MYDRIASERT(TROPICAMIDE/PHENYLEFRINE)		
.	.	.	.	.	.	Dosage	0.28/4.5		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100144	DROP	Female	89	1	22JUN2018	Name			NETILMICIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	27JUN2018	Name	MYDRIASERT(TROPICAMIDE/PHENYLEFRINE)		
.	.	.	.	.	.	Dosage	0.28/4.5		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100145	GEL	Male	81	1	29JUN2018	Name			NETTACIN COLL
.	.	.	.	.	.	Dosage			0.3
.	.	.	.	.	.	Unit			%
.	.	.	.	.	.	Frequency			3 TIMES PER DAY
.	.	.	.	2	04JUL2018	Name	MYDRIASERT (TROPICAMIDE/PHENYLEPHRINE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (12 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug	Antibiotic before surgery		
				No.	Date				
100146	GEL	Male	71	1	17AUG2018	Name	NETILMICIN		
.	.	.	.	.	.	Dosage	0.3		
.	.	.	.	.	.	Unit	%		
.	.	.	.	.	.	Frequency	3 TIMES PER DAY		
.	.	.	.	2	21AUG2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100147	DROP	Male	48	1	24AUG2018	Name	NETILMICIN		
.	.	.	.	.	.	Dosage	0.3		
.	.	.	.	.	.	Unit	%		
.	.	.	.	.	.	Frequency	3 TIMES PER DAY		
.	.	.	.	2	28AUG2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100148	DROP	Female	83	1	24AUG2018	Name	NETILMICIN COLL		
.	.	.	.	.	.	Dosage	0.3		
.	.	.	.	.	.	Unit	%		
.	.	.	.	.	.	Frequency	3 TIMES PER DAY		
.	.	.	.	2	30AUG2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100149	DROP	Female	71	1	24AUG2018	Name	NETILMICIN COLL		
.	.	.	.	.	.	Dosage	0.3		
.	.	.	.	.	.	Unit	%		
.	.	.	.	.	.	Frequency	3 TIMES PER DAY		
.	.	.	.	2	30AUG2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100150	GEL	Female	77	2	05SEP2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		



Listing 9 (13 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100151	DROP	Female	67	1	28SEP2018	Name			NETIDEX
.	.	.	.	.	.	Dosage			3
.	.	.	.	.	.	Unit			mg
.	.	.	.	.	.	Frequency			ONCE
.	.	.	.	2	04OCT2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100152	GEL	Female	78	2	04OCT2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100153	DROP	Female	81	1	12OCT2018	Name			NETILDEX
.	.	.	.	.	.	Dosage			3
.	.	.	.	.	.	Unit			mg
.	.	.	.	.	.	Frequency			ONCE
.	.	.	.	2	17OCT2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100154	GEL	Female	68	1	12OCT2018	Name			NETILDEX
.	.	.	.	.	.	Dosage			3
.	.	.	.	.	.	Unit			mg
.	.	.	.	.	.	Frequency			ONCE
.	.	.	.	2	18OCT2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100155	DROP	Female	79	1	12OCT2018	Name			NETILDEX
.	.	.	.	.	.	Dosage			3
.	.	.	.	.	.	Unit			mg
.	.	.	.	.	.	Frequency			ONCE
.	.	.	.	2	18OCT2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (14 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug			Antibiotic before surgery
				No.	Date				
100156	GEL	Female	69	1	12OCT2018	Name			NETILDEX
.	.	.	.	.	.	Dosage			3
.	.	.	.	.	.	Unit			mg
.	.	.	.	.	.	Frequency			ONCE
.	.	.	.	2	18OCT2018	Name	MYDRIASERT (PHENYLEFRINE/TROPICAMIDE)		
.	.	.	.	.	.	Dosage	0.28/5.4		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100201	GEL	Female	80	1	01DEC2017	Name			LEVOFLOXACINA EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	07DEC2017	Name	TROPICAMIDE + PHENYLEPHRINE		
.	.	.	.	.	.	Dosage	100+5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100202	DROP	Female	70	2	07DEC2017	Name	VISUMDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100203	DROP	Female	76	1	07DEC2017	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	14DEC2017	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100204	GEL	Male	71	1	07DEC2017	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	14DEC2017	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (15 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100205	GEL	Male	75	1	14DEC2017	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	08FEB2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100206	DROP	Female	81	1	05JAN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	11JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100207	DROP	Female	65	2	11JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100208	GEL	Female	79	1	05JAN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	11JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100209	GEL	Female	77	2	18JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (16 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100210	DROP	Female	70	1	12JAN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	18JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100211	GEL	Male	67	1	12JAN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	18JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100212	DROP	Female	82	1	12JAN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			MG/ML
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	18JAN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100213	DROP	Female	81	1	25JAN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	01FEB2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (17 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100214	DROP	Female	77	1	05FEB2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	08FEB2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100215	GEL	Female	83	2	08FEB2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100216	GEL	Female	74	1	09FEB2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	15FEB2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100217	DROP	Female	72	1	02MAR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	08MAR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100218	DROP	Male	72	1	02MAR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	08MAR2018	Name	TROPICAMIDE 100 MG/ML+ FENILEFRINA 5 MG/ L		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (18 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date				
=====									
100219	GEL	Female	83	1	09MAR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			MG/ML
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	15MAR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	DROP		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100220	GEL	Male	64	1	09MAR2018	Name			LEVOFLOXACIN EYEDROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			MG/ML
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	15MAR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	DROP		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100221	GEL	Female	76	1	30MAR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			MG/ML
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	05APR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	DROP		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100222	DROP	Female	76	1	05APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			MG/ML
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	12APR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	DROP		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (19 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100223	DROP	Male	61	1	05APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			MG/ML
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	12APR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	DROP		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100224	GEL	Female	75	1	20APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	26APR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100225	DROP	Female	79	1	20APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	26APR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100226	GEL	Female	74	1	20APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	26APR2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (20 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100227	DROP	Female	68	1	27APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	03MAY2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100228	GEL	Female	68	1	27APR2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	03MAY2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100229	GEL	Female	70	1	04MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	10MAY2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100230	GEL	Female	63	1	04MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	10MAY2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		



Listing 9 (21 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit				Mydriatic drug	Antibiotic before surgery
				No.	Date				
100231	DROP	Female	74	1	04MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	10MAY2018	Name		VISUMIDRIATIC FENILEFRINA	
.	.	.	.	.	.	Dosage		1	
.	.	.	.	.	.	Unit		drop	
.	.	.	.	.	.	Frequency		ONCE	
-----									
100232	DROP	Female	73	1	04MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	10MAY2018	Name		VISUMIDRIATIC FENILEFRINA	
.	.	.	.	.	.	Dosage		1	
.	.	.	.	.	.	Unit		drop	
.	.	.	.	.	.	Frequency		ONCE	
-----									
100233	GEL	Female	72	1	18MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	24MAY2018	Name		VISUMIDRIATIC FENILEFRINA	
.	.	.	.	.	.	Dosage		1	
.	.	.	.	.	.	Unit		DROP	
.	.	.	.	.	.	Frequency		ONCE	
-----									
100234	GEL	Female	73	1	18MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	24MAY2018	Name		VISUMIDRIATIC FENILEFRINA	
.	.	.	.	.	.	Dosage		1	
.	.	.	.	.	.	Unit		drop	
.	.	.	.	.	.	Frequency		ONCE	

Listing 9 (22 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit			Mydriatic drug		Antibiotic before surgery
				No.	Date				
100235	DROP	Male	64	1	28MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	31MAY2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100236	DROP	Female	70	1	28MAY2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	31MAY2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100237	DROP	Male	73	1	01JUN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	07JUN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100238	GEL	Male	78	1	01JUN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			mg/ml
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	07JUN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (23 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date				
=====									
100239	DROP	Female	80	1	08JUN2018	Name			LEVOFLOXACIN EYE DROPS
.	.	.	.	.	.	Dosage			5
.	.	.	.	.	.	Unit			m
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	14JUN2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100241	GEL	Female	74	1	23OCT2018	Name			LEVOFLOXACINA
.	.	.	.	.	.	Dosage			4 DROPTS
.	.	.	.	.	.	Unit			500mg
.	.	.	.	.	.	Frequency			DAILY
.	.	.	.	2	25OCT2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	5		
.	.	.	.	.	.	Unit	mg		
.	.	.	.	.	.	Frequency	DAILY		
-----									
100242	GEL	Female	67	1	31OCT2018	Name			LEVOFLOXACIN 0.5% EYE DROP
.	.	.	.	.	.	Dosage			1
.	.	.	.	.	.	Unit			drop
.	.	.	.	.	.	Frequency			EVERY 4 HOURS
.	.	.	.	2	08NOV2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100243	DROP	Male	74	1	30NOV2018	Name			LEVOFLOXACIN 0.5% EYE DROP
.	.	.	.	.	.	Dosage			1
.	.	.	.	.	.	Unit			drop
.	.	.	.	.	.	Frequency			EVERY 4 HOURS
.	.	.	.	2	06DEC2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (24 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date				
-----									
100244	GEL	Female	66	1	07DEC2018	Name			LEVOFLOXACIN 0.5% EYE DROP
.	.	.	.	.	.	Dosage			1
.	.	.	.	.	.	Unit			drop
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	13DEC2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100245	DROP	Female	69	1	07DEC2018	Name			LEVOFLOXACIN 5MG/ML
.	.	.	.	.	.	Dosage			1
.	.	.	.	.	.	Unit			DROP
.	.	.	.	.	.	Frequency			4 TIMES PER DAY
.	.	.	.	2	13DEC2018	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	DROP		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100303	DROP	Female	73	2	02NOV2017	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	100+5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100304	DROP	Male	58	2	16NOV2017	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	100+5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100305	DROP	Female	85	2	16NOV2017	Name	VISUMIDRIATC FENILEFRINA		
.	.	.	.	.	.	Dosage	100+5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100306	DROP	Female	84	2	22NOV2017	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	100/50		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100307	GEL	Female	73	2	29NOV2017	Name	VISUMIDRIATIC FENILEFRINA		
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		

Listing 9 (25 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date	Mydriatic drug		Antibiotic before surgery	
=====									
100308	GEL	Female	85	2	29NOV2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100309	DROP	Female	61	2	29NOV2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100310	GEL	Female	73	2	30NOV2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100311	GEL	Female	83	2	05DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100312	DROP	Female	71	2	05DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100313	GEL	Male	71	2	04DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100314	DROP	Male	67	2	05DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100315	GEL	Female	65	2	05DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		



Listing 9 (27 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date	Mydriatic drug		Antibiotic before surgery	
=====									
100324	DROP	Male	65	2	18DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100325	GEL	Female	83	2	18DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100326	DROP	Male	81	2	18DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100327	GEL	Female	73	2	18DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100328	DROP	Male	82	2	18DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100329	GEL	Male	74	2	18DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100330	DROP	Male	61	2	19DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
-----									
100331	GEL	Female	71	2	19DEC2017	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		

[illegible]



Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date				
100340	DROP	Male	83	2	12APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		
100341	GEL	Male	88	2	12APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		
100342	DROP	Female	86	2	12APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		
100343	GEL	Male	74	2	10APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	ml/mg		
.	.	.	.	.	.	Frequency	ONCE		
100344	DROP	Female	68	2	10APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
100345	GEL	Male	48	2	10APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
100346	DROP	Female	77	2	12APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		
100347	GEL	Male	58	2	18APR2018	Name	VISUMIDRIATIC	FENILEFRINA	
.	.	.	.	.	.	Dosage	100/5		
.	.	.	.	.	.	Unit	mg/ml		
.	.	.	.	.	.	Frequency	ONCE		

Sbj Code	Study drug	Sex	Age (year)	Visit		Name	Dosage	Unit	Frequency	Mydriatic drug	Antibiotic before surgery
				No.	Date						
100348	GEL	Female	38	2	24APR2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				
100349	DROP	Male	71	2	24MAY2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				
100350	DROP	Female	67	2	22MAY2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				
100351	GEL	Female	79	2	25MAY2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				
100352	DROP	Female	63	2	29MAY2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/mg				
.	.	.	.	.	.	Frequency	ONCE				
100353	GEL	Female	72	2	07JUN2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				
100354	GEL	Female	80	2	07JUN2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				
100355	DROP	Female	80	2	13JUN2018	Name	VISUMIDRIATIC	FENILEFRINA			
.	.	.	.	.	.	Dosage	100/5				
.	.	.	.	.	.	Unit	mg/ml				
.	.	.	.	.	.	Frequency	ONCE				





=====									
Sbj Code	Study drug	Sex	Age (year)	Visit					
				No.	Date				
=====									
200109	GEL	Female	84	2	02OCT2018	Name	ADRENALIN	0,05%	
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	ml		
.	.	.	.	.	.	Frequency	ONCE		
.	.	.	.	2	02OCT2018	Name	PHENYLEPHRIN-TROPICAMID		
.	.	.	.	.	.	Dosage	2		
.	.	.	.	.	.	Unit	Drops		
.	.	.	.	.	.	Frequency	ONCE		
-----									
200110	DROP	Male	64	2	09OCT2018	Name	ADRENALIN	0,05%	
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	ml		
.	.	.	.	.	.	Frequency	ONCE		
.	.	.	.	2	09OCT2018	Name	PHENYLEPHRIN-TROPICAMID		
.	.	.	.	.	.	Dosage	2		
.	.	.	.	.	.	Unit	Dropa		
.	.	.	.	.	.	Frequency	ONCE		
-----									
200111	GEL	Male	73	2	06NOV2018	Name	ADRENALIN		
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	ml		
.	.	.	.	.	.	Frequency	ONCE		
.	.	.	.	2	06NOV2018	Name	PHENYLEPHRIN-TROPICAMID		
.	.	.	.	.	.	Dosage	2		
.	.	.	.	.	.	Unit	Drop		
.	.	.	.	.	.	Frequency	ONCE		
-----									
200112	DROP	Male	85	2	13NOV2018	Name	ADRENALIN	0,05%	
.	.	.	.	.	.	Dosage	1		
.	.	.	.	.	.	Unit	ml		
.	.	.	.	.	.	Frequency	ONCE		
.	.	.	.	2	13NOV2018	Name	PHENYLEPHRIN-TROPICAMID		
.	.	.	.	.	.	Dosage	2		
.	.	.	.	.	.	Unit	Drops		
.	.	.	.	.	.	Frequency	ONCE		
=====									

Listing 9 (34 of 35): Mydriatic drugs and Antibiotic treatments before surgery

=====							
Sbj Code	Study drug	Sex	Age (year)	Visit		Mydriatic drug	Antibiotic before surgery
				No.	Date		
200113	DROP	Male	77	2	13NOV2018	Name	ADRENALIN 0,05%
.	.	.	.	.	.	Dosage	1
.	.	.	.	.	.	Unit	ml
.	.	.	.	.	.	Frequency	ONCE
.	.	.	.	2	13NOV2018	Name	PHENYLEPHRIN-TROPICAMID
.	.	.	.	.	.	Dosage	2
.	.	.	.	.	.	Unit	Drops
.	.	.	.	.	.	Frequency	ONCE
-----							
200114	DROP	Female	64	2	27NOV2018	Name	ADRENALIN 0,05%
.	.	.	.	.	.	Dosage	1
.	.	.	.	.	.	Unit	ml
.	.	.	.	.	.	Frequency	ONCE
.	.	.	.	2	27NOV2018	Name	PHENYLEPHRIN-TROPICAMID
.	.	.	.	.	.	Dosage	2
.	.	.	.	.	.	Unit	drops
.	.	.	.	.	.	Frequency	ONCE
-----							
200115	GEL	Female	70	2	18DEC2018	Name	ADRENALIN
.	.	.	.	.	.	Dosage	1
.	.	.	.	.	.	Unit	ml
.	.	.	.	.	.	Frequency	ONCE
.	.	.	.	2	18DEC2018	Name	PHENYLEPHRIN-TROPICAMID
.	.	.	.	.	.	Dosage	2
.	.	.	.	.	.	Unit	drops
.	.	.	.	.	.	Frequency	ONCE
-----							
200202	DROP	Female	71	2	18JUN2018	Name	MYDRUM (TROPICAMIDE)
.	.	.	.	.	.	Dosage	5MG TROPICAMIDE/1ML
.	.	.	.	.	.	Unit	drop
.	.	.	.	.	.	Frequency	UNKNOWN
-----							
200203	GEL	Male	66	2	26JUN2018	Name	MYDRUM (TROPICAMIDE)
.	.	.	.	.	.	Dosage	5MG TROPICAMIDE/1ML
.	.	.	.	.	.	Unit	drop
.	.	.	.	.	.	Frequency	UNKNOWN

Listing 9 (35 of 35): Mydriatic drugs and Antibiotic treatments before surgery

```
=====
                        Visit
Sbj      Study      Age  -----
Code     drug  Sex  (year)  No.  Date
=====
200204 GEL    Male   58      2   03JUL2018  Name      MYDRUM (TROPICAMIDE)
.          .      .      .      .      Dosage    5MG TROPICAMIDE/1ML
.          .      .      .      .      Unit      drop
.          .      .      .      .      Frequency UNKNOWN
=====
SAS program: L03_List_09.sas  -  SAS dataset name(s): RAND,DEMOGRAPHY,MYDRIATIC_COD,ANTI_BEFORE_COD
```

Listing 10 (1 of 3): Antibiotic treatments after surgery

=====									
Sbj Code	Study drug	Sex	Age (year)	Visit		Antibiotic after surgery			
				No.	Date	Name	Dosage	Unit	Frequency
=====									
100201	GEL	Female	80	1	01DEC2017	CEFUROXIME	1 MG/100mg/microl		ONCE
100202	DROP	Female	70	1	01DEC2017	APROKAM 1 MG/0.1ML	0.1	mL	ONCE
100203	DROP	Female	76	1	07DEC2017	APROKAM 1 MG/0.1ML	0.1	mL	ONCE
100204	GEL	Male	71	1	07DEC2017	APROKAM 1 MG /0.1 ML	0.1	ml	ONCE
100205	GEL	Male	75	1	14DEC2017	APROKAM 1MG/0.1ML	0.1	ML	ONCE
100206	DROP	Female	81	1	05JAN2018	APROKAM 1 MG /0.1 ML	0.1	ml	ONCE
100207	DROP	Female	65	1	05JAN2018	APROKAM 1 MG/0.1 ML	0.1	ml	ONCE
100208	GEL	Female	79	1	05JAN2018	APROKAM 1 MG/ML	0.1	ml	ONCE
100213	DROP	Female	81	1	25JAN2018	APROKAM 1 MG/100 MICROL	100	microl	ONCE
100214	DROP	Female	77	1	05FEB2018	APROKAM 1 MG /0.1 ML	0.1	ml	ONCE
100215	GEL	Female	83	1	05FEB2018	APROKAM 1 MG /0.1 ML	0.1	ml	ONCE
100216	GEL	Female	74	1	09FEB2018	APROKAM 1MG /0.1 ML	0.1	ml	ONCE
100217	DROP	Female	72	1	02MAR2018	APROKAM 1 MG /0.1 ML	0.1	ml	ONCE
100218	DROP	Male	72	1	02MAR2018	APROKAM 1 MG/0.1 ML	0.1	ml	ONCE
100219	GEL	Female	83	1	09MAR2018	APROKAM 1MG/0.1 ML	0.1	ML	ONCE
100220	GEL	Male	64	1	09MAR2018	APROKAM 1 MG/0.1 ML	0.1	ML	ONCE
100221	GEL	Female	76	1	30MAR2018	APROKAM 1 MG/0.1 ML	0.1	ML	ONCE
100222	DROP	Female	76	1	05APR2018	APROKAM 1 MG/0.1 ML	0.1	ML	ONCE
100223	DROP	Male	61	1	05APR2018	APROKAM 1 MG/0.1 ML	0.1	ML	ONCE
100224	GEL	Female	75	1	20APR2018	APROKAM 1 MG/0.1ML	0.1	ml	ONCE



Listing 10 (2 of 3): Antibiotic treatments after surgery

=====											
Sbj Code	Study drug	Sex	Age (year)	Visit		Antibiotic after surgery					
				No.	Date	Name	Dosage	Unit	Frequency		
=====											
100225	DROP	Female	79	1	20APR2018	APROKAM	1MG/0.1	ML	0.1	ml	ONCE
100226	GEL	Female	74	1	20APR2018	APROKAM	1MG/0.1	ML	0.1	0.1 ml	ONCE
100227	DROP	Female	68	1	27APR2018	APROKAM	1MG/0.1	ML	0.1	ml	ONCE
100228	GEL	Female	68	1	27APR2018	APROKAM	1MG/0.1	ML	0.1	ml	ONCE
100229	GEL	Female	70	1	04MAY2018	APROKAM	1MG/0.1	ML	0.1	ml	ONCE
100230	GEL	Female	63	1	04MAY2018	APROKAM	1MG/0.1	ML	0.1	ml	ONCE
100231	DROP	Female	74	1	04MAY2018	APROKAM	1MG/0.1	ML	0.1	ml	ONCE
100232	DROP	Female	73	1	04MAY2018	APROKAM	1MG/0.1	ML	0.1	0.1 ml	ONCE
100233	GEL	Female	72	1	18MAY2018	APROKAM	1 MG/0.1	ML	0.1	ML	ONCE
100234	GEL	Female	73	1	18MAY2018	APROKAM	1 MG /0.1	ML	0.1	ml	ONCE
100235	DROP	Male	64	1	28MAY2018	APROKAM	1 MG /0.1	ML	0.1	ml	ONCE
100236	DROP	Female	70	1	28MAY2018	APROKAM	1 MG /0.1	ML	0.1	ml	ONCE
100237	DROP	Male	73	1	01JUN2018	APROKAM	1 MG /0.1	ML	0.1	ml	ONCE
100238	GEL	Male	78	1	01JUN2018	APROKAM	1 MG /0.1	ML	0.1	ml	ONCE
100239	DROP	Female	80	1	08JUN2018	APROKAM	1 MG /0.1	ML	0.1	ml	ONCE
100242	GEL	Female	67	1	31OCT2018	APROKAM	1MG/100	MICROL	100	microl	ONCE
100243	DROP	Male	74	1	30NOV2018	APROKAM	1MG/100	MICROL	100	microl	ONCE
100244	GEL	Female	66	1	07DEC2018	APROKAM	1MG/100	MICROL	100	microl	ONCE
100245	DROP	Female	69	1	07DEC2018	APROKAM	1 MG/0,1	ML	0,1	ML	ONCE
100304	DROP	Male	58	1	10NOV2017	APROKAM			#	#	ONCE

Listing 10 (3 of 3): Antibiotic treatments after surgery

```
=====
                        Visit                        Antibiotic after surgery
Sbj      Study      Age  -----
Code     drug  Sex  (year)  No.  Date      Name      Dosage  Unit      Frequency
=====
200103 DROP  Male   82      1   12FEB2018  CEFUROXIM      1      ml      ONCE
=====
SAS program: L03_List_10.sas - SAS dataset name(s): RAND,DEMOGRAPHY,ANTI_AFTER_COD
```

Listing 11 (1 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100101	DROP	Female	84	2	25OCT2017	Yes
.	.	.	.	3	26OCT2017	Yes
.	.	.	.	4	02NOV2017	Yes
100102	GEL	Male	80	2	31OCT2017	Yes
.	.	.	.	3	01NOV2017	Yes
.	.	.	.	4	07NOV2017	Yes
100104	GEL	Male	70	2	07NOV2017	Yes
.	.	.	.	3	08NOV2017	Yes
.	.	.	.	4	14NOV2017	Yes
100105	DROP	Female	85	2	08NOV2017	Yes
.	.	.	.	3	09NOV2017	Yes
.	.	.	.	4	15NOV2017	Yes
100106	GEL	Male	56	2	15NOV2017	Yes
.	.	.	.	3	16NOV2017	Yes
.	.	.	.	4	22NOV2017	Yes
100107	DROP	Female	82	2	28NOV2017	Yes
.	.	.	.	3	29NOV2017	Yes
.	.	.	.	4	05DEC2017	Yes
100108	DROP	Female	73	2	06DEC2017	Yes
.	.	.	.	3	07DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100109	GEL	Female	56	2	12DEC2017	Yes
.	.	.	.	3	13DEC2017	Yes
.	.	.	.	4	19DEC2017	Yes
100110	DROP	Female	75	2	13DEC2017	Yes
.	.	.	.	3	14DEC2017	Yes
.	.	.	.	4	20DEC2017	Yes
100111	DROP	Female	60	2	13DEC2017	Yes
.	.	.	.	3	14DEC2017	Yes
.	.	.	.	4	20DEC2017	Yes

Listing 11 (2 of 17): Study treatment administration during the study

=====						
Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
=====						
100112	GEL	Male	73	2	03JAN2018	Yes
.	.	.	.	3	04JAN2018	Yes
.	.	.	.	4	10JAN2018	Yes
-----						
100113	GEL	Female	77	2	03JAN2018	Yes
.	.	.	.	3	04JAN2018	Yes
.	.	.	.	4	10JAN2018	Yes
-----						
100114	GEL	Male	64	2	03JAN2018	Yes
.	.	.	.	3	04JAN2018	Yes
.	.	.	.	4	10JAN2018	Yes
-----						
100115	DROP	Male	76	2	04JAN2018	Yes
.	.	.	.	3	05JAN2018	Yes
.	.	.	.	4	11JAN2018	Yes
-----						
100116	GEL	Male	62	2	04JAN2018	Yes
.	.	.	.	3	05JAN2018	Yes
.	.	.	.	4	11JAN2018	Yes
-----						
100117	DROP	Female	51	2	10JAN2018	Yes
.	.	.	.	3	11JAN2018	Yes
.	.	.	.	4	17JAN2018	Yes
-----						
100118	DROP	Female	78	2	17JAN2018	Yes
.	.	.	.	3	18JAN2018	Yes
.	.	.	.	4	24JAN2018	Yes
-----						
100119	DROP	Female	72	2	24JAN2018	Yes
.	.	.	.	3	25JAN2018	Yes
.	.	.	.	4	31JAN2018	Yes
-----						
100120	GEL	Male	79	2	24JAN2018	Yes
.	.	.	.	3	25JAN2018	Yes
.	.	.	.	4	31JAN2018	Yes
-----						
100121	GEL	Male	80	2	24JAN2018	Yes
.	.	.	.	3	25JAN2018	Yes
.	.	.	.	4	31JAN2018	Yes

Listing 11 (3 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100122	DROP	Female	76	2	25JAN2018	Yes
.	.	.	.	3	26JAN2018	Yes
.	.	.	.	4	01FEB2018	Yes
100123	DROP	Female	76	2	25JAN2018	Yes
.	.	.	.	3	26JAN2018	Yes
.	.	.	.	4	01FEB2018	Yes
100124	GEL	Female	71	2	01FEB2018	Yes
.	.	.	.	3	02FEB2018	Yes
.	.	.	.	4	08FEB2018	Yes
100125	GEL	Female	62	2	01FEB2018	Yes
.	.	.	.	3	02FEB2018	Yes
.	.	.	.	4	08FEB2018	Yes
100126	GEL	Female	85	2	07FEB2018	Yes
.	.	.	.	3	08FEB2018	Yes
.	.	.	.	4	14FEB2018	Yes
100127	GEL	Female	68	2	08FEB2018	Yes
.	.	.	.	3	09FEB2018	Yes
.	.	.	.	4	15FEB2018	Yes
100128	DROP	Male	80	2	08FEB2018	Yes
.	.	.	.	3	09FEB2018	Yes
.	.	.	.	4	15FEB2018	Yes
100129	DROP	Female	78	2	08FEB2018	Yes
.	.	.	.	3	09FEB2018	Yes
.	.	.	.	4	15FEB2018	Yes
100130	GEL	Male	66	2	21FEB2018	Yes
.	.	.	.	3	22FEB2018	Yes
.	.	.	.	4	28FEB2018	Yes
100131	DROP	Female	77	2	21FEB2018	Yes
.	.	.	.	3	22FEB2018	Yes
.	.	.	.	4	28FEB2018	Yes

Listing 11 (4 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100132	DROP	Male	69	2	07MAR2018	Yes
.	.	.	.	3	08MAR2018	Yes
.	.	.	.	4	14MAR2018	Yes
100133	GEL	Male	74	2	07MAR2018	Yes
.	.	.	.	3	08MAR2018	Yes
.	.	.	.	4	14MAR2018	Yes
100134	DROP	Female	66	2	07MAR2018	Yes
.	.	.	.	3	08MAR2018	Yes
.	.	.	.	4	14MAR2018	Yes
100135	GEL	Male	69	2	15MAR2018	Yes
.	.	.	.	3	16MAR2018	Yes
.	.	.	.	4	22MAR2018	Yes
100136	GEL	Female	90	2	05APR2018	Yes
.	.	.	.	3	06APR2018	Yes
.	.	.	.	4	12APR2018	Yes
100137	DROP	Female	62	2	19APR2018	Yes
.	.	.	.	3	20APR2018	Yes
.	.	.	.	4	26APR2018	Yes
100138	GEL	Male	63	2	19APR2018	Yes
.	.	.	.	3	20APR2018	Yes
.	.	.	.	4	26APR2018	Yes
100139	DROP	Female	71	2	26APR2018	Yes
.	.	.	.	3	27APR2018	Yes
.	.	.	.	4	03MAY2018	Yes
100140	GEL	Male	81	2	02MAY2018	Yes
.	.	.	.	3	03MAY2018	Yes
.	.	.	.	4	09MAY2018	Yes
100141	DROP	Female	74	2	02MAY2018	Yes
.	.	.	.	3	03MAY2018	Yes
.	.	.	.	4	10MAY2018	Yes

Listing 11 (5 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100142	GEL	Female	77	2	16MAY2018	Yes
.	.	.	.	3	17MAY2018	Yes
.	.	.	.	4	23MAY2018	Yes
100143	GEL	Male	74	2	20JUN2018	Yes
.	.	.	.	3	21JUN2018	Yes
.	.	.	.	4	27JUN2018	Yes
100144	DROP	Female	89	2	27JUN2018	Yes
.	.	.	.	3	28JUN2018	Yes
.	.	.	.	4	04JUL2018	Yes
100145	GEL	Male	81	2	04JUL2018	Yes
.	.	.	.	3	05JUL2018	Yes
.	.	.	.	4	11JUL2018	Yes
100146	GEL	Male	71	2	21AUG2018	Yes
.	.	.	.	3	22AUG2018	Yes
.	.	.	.	4	29AUG2018	Yes
100147	DROP	Male	48	2	28AUG2018	Yes
.	.	.	.	3	29AUG2018	No
.	.	.	.	4	20SEP2018	Yes
100148	DROP	Female	83	2	30AUG2018	Yes
.	.	.	.	3	31AUG2018	Yes
.	.	.	.	4	06SEP2018	Yes
100149	DROP	Female	71	2	30AUG2018	Yes
.	.	.	.	3	31AUG2018	Yes
.	.	.	.	4	06SEP2018	Yes
100150	GEL	Female	77	2	05SEP2018	Yes
.	.	.	.	3	06SEP2018	Yes
.	.	.	.	4	12SEP2018	Yes
100151	DROP	Female	67	2	04OCT2018	Yes
.	.	.	.	3	05OCT2018	Yes
.	.	.	.	4	12OCT2018	Yes

Listing 11 (6 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100152	GEL	Female	78	2	04OCT2018	Yes
.	.	.	.	3	05OCT2018	Yes
.	.	.	.	4	12OCT2018	Yes
100153	DROP	Female	81	2	17OCT2018	Yes
.	.	.	.	3	18OCT2018	Yes
.	.	.	.	4	24OCT2018	Yes
100154	GEL	Female	68	2	18OCT2018	Yes
.	.	.	.	3	19OCT2018	Yes
.	.	.	.	4	26OCT2018	Yes
100155	DROP	Female	79	2	18OCT2018	Yes
.	.	.	.	3	19OCT2018	Yes
.	.	.	.	4	26OCT2018	Yes
100156	GEL	Female	69	2	18OCT2018	Yes
.	.	.	.	3	19OCT2018	Yes
.	.	.	.	4	26OCT2018	Yes
100201	GEL	Female	80	2	07DEC2017	Yes
.	.	.	.	3	09DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100202	DROP	Female	70	2	07DEC2017	Yes
.	.	.	.	3	09DEC2017	Yes
.	.	.	.	4	14DEC2017	Yes
100203	DROP	Female	76	2	14DEC2017	Yes
.	.	.	.	3	15DEC2017	Yes
.	.	.	.	4	20DEC2017	Yes
100204	GEL	Male	71	2	14DEC2017	Yes
.	.	.	.	3	15DEC2017	Yes
.	.	.	.	4	20DEC2017	Yes
100205	GEL	Male	75	2	08FEB2018	Yes
.	.	.	.	3	09FEB2018	Yes
.	.	.	.	4	14FEB2018	Yes



Listing 11 (7 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100206	DROP	Female	81	2	11JAN2018	Yes
.	.	.	.	3	12JAN2018	Yes
.	.	.	.	4	18JAN2018	Yes
100207	DROP	Female	65	2	11JAN2018	Yes
.	.	.	.	3	12JAN2018	Yes
.	.	.	.	4	18JAN2018	Yes
100208	GEL	Female	79	2	11JAN2018	Yes
.	.	.	.	3	12JAN2018	Yes
.	.	.	.	4	18JAN2018	Yes
100209	GEL	Female	77	2	18JAN2018	Yes
100210	DROP	Female	70	2	18JAN2018	Yes
.	.	.	.	3	19JAN2018	Yes
.	.	.	.	4	24JAN2018	Yes
100211	GEL	Male	67	2	18JAN2018	Yes
.	.	.	.	3	19JAN2018	Yes
.	.	.	.	4	24JAN2018	Yes
100212	DROP	Female	82	2	18JAN2018	Yes
.	.	.	.	3	19JAN2018	Yes
.	.	.	.	4	24JAN2018	Yes
100213	DROP	Female	81	2	01FEB2018	Yes
.	.	.	.	3	02FEB2018	Yes
.	.	.	.	4	07FEB2018	Yes
100214	DROP	Female	77	2	08FEB2018	Yes
.	.	.	.	3	09FEB2018	Yes
.	.	.	.	4	14FEB2018	Yes
100215	GEL	Female	83	2	08FEB2018	Yes
.	.	.	.	3	09FEB2018	Yes
.	.	.	.	4	14FEB2018	Yes
100216	GEL	Female	74	2	15FEB2018	Yes
.	.	.	.	3	16FEB2018	Yes
.	.	.	.	4	21FEB2018	Yes

Listing 11 (8 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100217	DROP	Female	72	2	08MAR2018	Yes
.	.	.	.	3	09MAR2018	Yes
.	.	.	.	4	14MAR2018	Yes
100218	DROP	Male	72	2	08MAR2018	Yes
.	.	.	.	3	09MAR2018	Yes
.	.	.	.	4	14MAR2018	Yes
100219	GEL	Female	83	2	15MAR2018	Yes
.	.	.	.	3	16MAR2018	Yes
.	.	.	.	4	21MAR2018	Yes
100220	GEL	Male	64	2	15MAR2018	Yes
.	.	.	.	3	16MAR2018	Yes
.	.	.	.	4	21MAR2018	Yes
100221	GEL	Female	76	2	05APR2018	Yes
.	.	.	.	3	06APR2018	Yes
.	.	.	.	4	11APR2018	Yes
100222	DROP	Female	76	2	12APR2018	Yes
.	.	.	.	3	13APR2018	Yes
.	.	.	.	4	18APR2018	Yes
100223	DROP	Male	61	2	12APR2018	Yes
.	.	.	.	3	13APR2018	Yes
.	.	.	.	4	18APR2018	Yes
100224	GEL	Female	75	2	26APR2018	Yes
.	.	.	.	3	27APR2018	Yes
.	.	.	.	4	02MAY2018	Yes
100225	DROP	Female	79	2	26APR2018	Yes
.	.	.	.	3	27APR2018	Yes
.	.	.	.	4	02MAY2018	Yes
100226	GEL	Female	74	2	26APR2018	Yes
.	.	.	.	3	27APR2018	Yes
.	.	.	.	4	02MAY2018	Yes

Listing 11 (9 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100227	DROP	Female	68	2	03MAY2018	Yes
.	.	.	.	3	04MAY2018	Yes
.	.	.	.	4	09MAY2018	Yes
100228	GEL	Female	68	2	03MAY2018	Yes
.	.	.	.	3	04MAY2018	Yes
.	.	.	.	4	09MAY2018	No
100229	GEL	Female	70	2	10MAY2018	Yes
.	.	.	.	3	11MAY2018	Yes
.	.	.	.	4	16MAY2018	Yes
100230	GEL	Female	63	2	10MAY2018	Yes
.	.	.	.	3	11MAY2018	Yes
.	.	.	.	4	16MAY2018	Yes
100231	DROP	Female	74	2	10MAY2018	Yes
.	.	.	.	3	11MAY2018	Yes
.	.	.	.	4	16MAY2018	Yes
100232	DROP	Female	73	2	10MAY2018	Yes
.	.	.	.	3	11MAY2018	Yes
.	.	.	.	4	16MAY2018	Yes
100233	GEL	Female	72	2	24MAY2018	Yes
.	.	.	.	3	25MAY2018	Yes
.	.	.	.	4	30MAY2018	Yes
100234	GEL	Female	73	2	24MAY2018	Yes
.	.	.	.	3	25MAY2018	Yes
.	.	.	.	4	30MAY2018	Yes
100235	DROP	Male	64	2	31MAY2018	Yes
.	.	.	.	3	01JUN2018	Yes
.	.	.	.	4	06JUN2018	Yes
100236	DROP	Female	70	2	31MAY2018	Yes
.	.	.	.	3	01JUN2018	Yes
.	.	.	.	4	06JUN2018	Yes

Listing 11 (10 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100237	DROP	Male	73	2	07JUN2018	Yes
.	.	.	.	3	08JUN2018	Yes
.	.	.	.	4	13JUN2018	Yes
100238	GEL	Male	78	2	07JUN2018	Yes
.	.	.	.	3	08JUN2018	Yes
.	.	.	.	4	13JUN2018	Yes
100239	DROP	Female	80	2	14JUN2018	Yes
.	.	.	.	3	15JUN2018	Yes
.	.	.	.	4	20JUN2018	Yes
100241	GEL	Female	74	2	25OCT2018	Yes
.	.	.	.	3	26OCT2018	Yes
.	.	.	.	4	31OCT2018	Yes
100242	GEL	Female	67	2	08NOV2018	Yes
.	.	.	.	3	09NOV2018	Yes
.	.	.	.	4	14NOV2018	Yes
100243	DROP	Male	74	2	06DEC2018	Yes
.	.	.	.	3	07DEC2018	Yes
.	.	.	.	4	12DEC2018	Yes
100244	GEL	Female	66	2	13DEC2018	Yes
.	.	.	.	3	14DEC2018	Yes
.	.	.	.	4	19DEC2018	Yes
100245	DROP	Female	69	2	13DEC2018	Yes
.	.	.	.	3	14DEC2018	Yes
.	.	.	.	4	19DEC2018	Yes
100301	GEL	Female	68	2	19OCT2017	Yes
.	.	.	.	3	20OCT2017	Yes
.	.	.	.	4	25OCT2017	Yes
100302	GEL	Male	61	2	02NOV2017	Yes
.	.	.	.	3	03NOV2017	Yes
.	.	.	.	4	09NOV2017	Yes

Listing 11 (11 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100303	DROP	Female	73	2	02NOV2017	Yes
.	.	.	.	3	03NOV2017	Yes
.	.	.	.	4	09NOV2017	Yes
100304	DROP	Male	58	2	16NOV2017	Yes
.	.	.	.	3	17NOV2017	Yes
.	.	.	.	4	23NOV2017	Yes
100305	DROP	Female	85	2	16NOV2017	Yes
.	.	.	.	3	17NOV2017	Yes
.	.	.	.	4	23NOV2017	Yes
100306	DROP	Female	84	2	22NOV2017	No
100307	GEL	Female	73	2	29NOV2017	Yes
.	.	.	.	3	30NOV2017	Yes
.	.	.	.	4	06DEC2017	Yes
100308	GEL	Female	85	2	29NOV2017	No
100309	DROP	Female	61	2	29NOV2017	Yes
.	.	.	.	3	30NOV2017	Yes
.	.	.	.	4	06DEC2017	Yes
100310	GEL	Female	73	2	30NOV2017	Yes
.	.	.	.	3	01DEC2017	Yes
.	.	.	.	4	06DEC2017	Yes
100311	GEL	Female	83	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100312	DROP	Female	71	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100313	GEL	Male	71	2	04DEC2017	No
100314	DROP	Male	67	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes

Listing 11 (12 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100315	GEL	Female	65	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100316	DROP	Male	76	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100317	GEL	Male	85	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	14DEC2017	Yes
100318	GEL	Female	80	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100319	DROP	Male	70	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100320	DROP	Male	69	2	05DEC2017	Yes
.	.	.	.	3	06DEC2017	Yes
.	.	.	.	4	13DEC2017	Yes
100321	GEL	Male	72	2	11DEC2017	Yes
.	.	.	.	3	12DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100322	GEL	Male	80	2	13DEC2017	Yes
.	.	.	.	3	14DEC2017	Yes
.	.	.	.	4	19DEC2017	Yes
100323	DROP	Female	76	2	13DEC2017	Yes
.	.	.	.	3	14DEC2017	Yes
.	.	.	.	4	19DEC2017	Yes
100324	DROP	Male	65	2	18DEC2017	Yes
.	.	.	.	3	19DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100325	GEL	Female	83	2	18DEC2017	Yes

Listing 11 (13 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100326	DROP	Male	81	2	18DEC2017	Yes
.	.	.	.	3	19DEC2017	No
.	.	.	.	4	27DEC2017	Yes
100327	GEL	Female	73	2	18DEC2017	Yes
.	.	.	.	3	19DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100328	DROP	Male	82	2	18DEC2017	Yes
.	.	.	.	3	19DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100329	GEL	Male	74	2	18DEC2017	Yes
.	.	.	.	3	19DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100330	DROP	Male	61	2	19DEC2017	Yes
.	.	.	.	3	20DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100331	GEL	Female	71	2	19DEC2017	Yes
.	.	.	.	3	20DEC2017	Yes
.	.	.	.	4	27DEC2017	Yes
100332	DROP	Male	82	2	12JAN2018	Yes
.	.	.	.	3	13JAN2018	Yes
.	.	.	.	4	19JAN2018	Yes
100333	DROP	Male	62	2	25JAN2018	Yes
.	.	.	.	3	26JAN2018	Yes
.	.	.	.	4	01FEB2018	Yes
100334	GEL	Male	72	2	24JAN2018	Yes
.	.	.	.	3	25JAN2018	Yes
.	.	.	.	4	01FEB2018	Yes
100335	DROP	Female	80	2	06FEB2018	Yes
.	.	.	.	3	07FEB2018	Yes
.	.	.	.	4	12FEB2018	Yes

Listing 11 (14 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100336	GEL	Female	82	2	06MAR2018	Yes
.	.	.	.	3	07MAR2018	Yes
.	.	.	.	4	12MAR2018	Yes
100337	GEL	Male	72	2	16MAR2018	No
100338	DROP	Female	87	2	21MAR2018	Yes
.	.	.	.	3	22MAR2018	Yes
.	.	.	.	4	27MAR2018	Yes
100339	GEL	Male	56	2	28MAR2018	Yes
.	.	.	.	3	29MAR2018	Yes
.	.	.	.	4	05APR2018	Yes
100340	DROP	Male	83	2	12APR2018	Yes
.	.	.	.	3	13APR2018	Yes
.	.	.	.	4	19APR2018	Yes
100341	GEL	Male	88	2	12APR2018	Yes
.	.	.	.	3	13APR2018	Yes
.	.	.	.	4	19APR2018	Yes
100342	DROP	Female	86	2	12APR2018	Yes
.	.	.	.	3	13APR2018	Yes
.	.	.	.	4	19APR2018	Yes
100343	GEL	Male	74	2	10APR2018	Yes
.	.	.	.	3	11APR2018	Yes
.	.	.	.	4	17APR2018	Yes
100344	DROP	Female	68	2	10APR2018	Yes
.	.	.	.	3	11APR2018	Yes
.	.	.	.	4	17APR2018	Yes
100345	GEL	Male	48	2	10APR2018	Yes
.	.	.	.	3	11APR2018	Yes
.	.	.	.	4	17APR2018	Yes
100346	DROP	Female	77	2	12APR2018	Yes
.	.	.	.	3	13APR2018	Yes
.	.	.	.	4	19APR2018	Yes



Listing 11 (15 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
100347	GEL	Male	58	2	18APR2018	Yes
.	.	.	.	3	19APR2018	Yes
.	.	.	.	4	24APR2018	Yes
100348	GEL	Female	38	2	24APR2018	Yes
.	.	.	.	3	25APR2018	Yes
.	.	.	.	4	30APR2018	Yes
100349	DROP	Male	71	2	24MAY2018	Yes
.	.	.	.	3	25MAY2018	Yes
.	.	.	.	4	30MAY2018	Yes
100350	DROP	Female	67	2	22MAY2018	Yes
.	.	.	.	3	23MAY2018	Yes
.	.	.	.	4	30MAY2018	Yes
100351	GEL	Female	79	2	25MAY2018	Yes
.	.	.	.	3	26MAY2018	Yes
.	.	.	.	4	01JUN2018	Yes
100352	DROP	Female	63	2	29MAY2018	Yes
.	.	.	.	3	30MAY2018	Yes
.	.	.	.	4	06JUN2018	Yes
100353	GEL	Female	72	2	07JUN2018	Yes
.	.	.	.	3	08JUN2018	Yes
.	.	.	.	4	14JUN2018	Yes
100354	GEL	Female	80	2	07JUN2018	Yes
.	.	.	.	3	08JUN2018	Yes
.	.	.	.	4	14JUN2018	Yes
100355	DROP	Female	80	2	13JUN2018	Yes
.	.	.	.	3	14JUN2018	Yes
.	.	.	.	4	21JUN2018	Yes
100356	GEL	Male	74	2	18JUN2018	Yes
.	.	.	.	3	19JUN2018	Yes
.	.	.	.	4	26JUN2018	Yes

Listing 11 (16 of 17): Study treatment administration during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Study Treatment administered after surgery
				No.	Date	
200101	GEL	Female	66	2	16JAN2018	Yes
.	.	.	.	3	17JAN2018	Yes
.	.	.	.	4	24JAN2018	Yes
200102	DROP	Female	76	2	30JAN2018	Yes
.	.	.	.	3	31JAN2018	Yes
.	.	.	.	4	05FEB2018	Yes
200103	DROP	Male	82	2	13FEB2018	Yes
.	.	.	.	3	14FEB2018	Yes
.	.	.	.	4	19FEB2018	Yes
200104	GEL	Female	78	2	08MAY2018	Yes
.	.	.	.	3	09MAY2018	Yes
.	.	.	.	4	16MAY2018	No
200105	GEL	Female	65	2	29MAY2018	Yes
.	.	.	.	3	30MAY2018	Yes
.	.	.	.	4	06JUN2018	Yes
200106	DROP	Female	75	2	26JUN2018	Yes
.	.	.	.	3	27JUN2018	Yes
.	.	.	.	4	04JUL2018	Yes
200107	DROP	Female	54	2	03JUL2018	Yes
.	.	.	.	3	04JUL2018	No
200108	GEL	Male	77	2	04SEP2018	Yes
.	.	.	.	3	05SEP2018	Yes
.	.	.	.	4	12SEP2018	Yes
200109	GEL	Female	84	2	02OCT2018	Yes
.	.	.	.	3	03OCT2018	Yes
.	.	.	.	4	10OCT2018	No
200110	DROP	Male	64	2	09OCT2018	Yes
.	.	.	.	3	10OCT2018	Yes
.	.	.	.	4	17OCT2018	Yes
200111	GEL	Male	73	2	06NOV2018	Yes
.	.	.	.	3	07NOV2018	Yes
.	.	.	.	4	14NOV2018	Yes

Listing 11 (17 of 17): Study treatment administration during the study

```
=====
Sbj      Study      Age      Visit      Study Treatment
Code     drug    Sex (year)  No.      Date      administered
-----
200112 DROP    Male    85        2      13NOV2018      Yes
.          .        .          3      14NOV2018      Yes
.          .        .          4      21NOV2018      Yes
-----
200113 DROP    Male    77        2      13NOV2018      Yes
.          .        .          3      14NOV2018      Yes
.          .        .          4      21NOV2018      Yes
-----
200114 DROP    Female  64        2      27NOV2018      No
-----
200115 GEL     Female  70        2      18DEC2018      Yes
.          .        .          3      19DEC2018      Yes
.          .        .          4      27DEC2018      Yes
-----
200202 DROP    Female  71        2      18JUN2018      Yes
.          .        .          3      19JUN2018      Yes
.          .        .          4      25JUN2018      Yes
-----
200203 GEL     Male    66        2      26JUN2018      Yes
.          .        .          3      27JUN2018      Yes
.          .        .          4      02JUL2018      Yes
-----
200204 GEL     Male    58        2      03JUL2018      Yes
.          .        .          3      04JUL2018      Yes
.          .        .          4      10JUL2018      Yes
=====
SAS program: L03_List_11.sas - SAS dataset name(s): RAND,DEMOGRAPHY,TREATMENT
```

[illegible]

Listing 12 (2 of 21): Signs/Symptoms of ocular inflammation during the study

[illegible]

[illegible]

[illegible]

[illegible]



[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]



[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Listing 12 (21 of 21): Signs/Symptoms of ocular inflammation during the study

Sbj Code	Study drug	Sex	Age (year)	Visit		Anterior chamber flare	Anterior chamber cells	Conjunctival hyperemia	Lid edema	Corneal edema	Ocular discomfort pain	Ocular discomfort photophobia	Ocular discomfort tearing
				No.	Date								
200202	DROP	Female	71	3	19JUN2018	None	None	None	None	None	None	None	None
.	.	.	.	4	25JUN2018	None	None	None	None	None	None	None	None
.	.	.	.	5	03JUL2018	None	None	None	None	None	None	None	None
.	.	.	.	6	17AUG2018	None	None	None	None	None	None	None	None
.	.	.	.	7	06JUL2018	.	.	.	.	.	.	.	.
200203	GEL	Male	66	3	27JUN2018	None	Mild	Mild	None	None	None	None	None
.	.	.	.	4	02JUL2018	None	None	Mild	None	None	None	None	None
.	.	.	.	5	12JUL2018	None	None	None	None	None	None	Mild	None
.	.	.	.	6	04SEP2018	None	None	None	None	None	None	None	None
200204	GEL	Male	58	3	04JUL2018	None	Mild	Mild	None	None	None	None	None
.	.	.	.	4	10JUL2018	None	None	None	None	None	None	Mild	None
.	.	.	.	5	18JUL2018	None	None	None	None	None	None	None	None
.	.	.	.	6	04SEP2018	None	None	None	None	None	None	None	None

SAS program: L03\_List\_12.sas - SAS dataset name(s): RAND,DEMOGRAPHY,OCULAR\_INFLA



NO data in the database !!! (dataset ANTIBIOGRAM)

Sbj Code	Study drug	Sex	Age (year)	Visit		Microbial species found	Antibiotic tested	
				No.	Date		Name	Antibiogram result
##-###	####	#####	###	3	##/##/####	#####	Netilmicin	#####
							Cephuroxime	#####
							Other 1: #####	#####
							Other 2: #####	#####
							Other 3: #####	#####
						#####	Netilmicin	#####
							Cephuroxime	#####
							Other 1: #####	#####
							Other 2: #####	#####
							Other 3: #####	#####
						#####	Netilmicin	#####
							Cephuroxime	#####
							Other 1: #####	#####
							Other 2: #####	#####
							Other 3: #####	#####
				4	##/##/####	#####	Netilmicin	#####
							Cephuroxime	#####
							Other 1: #####	#####
							Other 2: #####	#####
							Other 3: #####	#####
						#####	Netilmicin	#####
							Cephuroxime	#####
							Other 1: #####	#####
							Other 2: #####	#####
							Other 3: #####	#####
						#####	Netilmicin	#####
							Cephuroxime	#####
							Other 1: #####	#####
							Other 2: #####	#####
							Other 3: #####	#####

=====

SAS program: L03\_List\_l3.sas - SAS dataset(s):

Listing 14 (1 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100101	DROP	Female	84	3	26OCT2017	Yes	None	None	None	None
.	.	.	.	4	02NOV2017	Yes	None	None	None	None
.	.	.	.	5	08NOV2017	Yes	None	None	None	None
-----										
100102	GEL	Male	80	3	01NOV2017	Yes	None	None	None	None
.	.	.	.	4	07NOV2017	Yes	None	None	None	None
.	.	.	.	5	15NOV2017	Yes	None	None	None	None
-----										
100104	GEL	Male	70	3	08NOV2017	Yes	None	None	None	None
.	.	.	.	4	14NOV2017	Yes	None	None	None	None
.	.	.	.	5	22NOV2017	Yes	None	None	None	None
-----										
100105	DROP	Female	85	3	09NOV2017	Yes	None	None	None	None
.	.	.	.	4	15NOV2017	Yes	None	None	None	None
.	.	.	.	5	23NOV2017	Yes	None	None	None	None
-----										
100106	GEL	Male	56	3	16NOV2017	Yes	None	None	None	None
.	.	.	.	4	22NOV2017	Yes	None	None	None	None
.	.	.	.	5	30NOV2017	Yes	None	None	None	None
-----										
100107	DROP	Female	82	3	29NOV2017	Yes	None	None	None	None
.	.	.	.	4	05DEC2017	Yes	None	None	None	None
.	.	.	.	5	13DEC2017	Yes	None	None	None	None
-----										
100108	DROP	Female	73	3	07DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	21DEC2017	Yes	None	None	None	None
-----										
100109	GEL	Female	56	3	13DEC2017	Yes	None	None	None	None
.	.	.	.	4	19DEC2017	Yes	None	None	None	None
.	.	.	.	5	27DEC2017	Yes	None	None	None	None
-----										
100110	DROP	Female	75	3	14DEC2017	Yes	None	None	None	None
.	.	.	.	4	20DEC2017	Yes	None	None	None	None
.	.	.	.	5	28DEC2017	Yes	None	None	None	None
-----										
100111	DROP	Female	60	3	14DEC2017	Yes	None	None	None	None
.	.	.	.	4	20DEC2017	Yes	None	None	None	None
.	.	.	.	5	28DEC2017	Yes	None	None	None	None

Listing 14 (2 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100112	GEL	Male	73	3	04JAN2018	Yes	None	None	None	None
.	.	.	.	4	10JAN2018	Yes	None	None	None	None
.	.	.	.	5	17JAN2018	Yes	None	None	None	None
-----										
100113	GEL	Female	77	3	04JAN2018	Yes	None	None	None	None
.	.	.	.	4	10JAN2018	Yes	None	None	None	None
.	.	.	.	5	17JAN2018	Yes	None	None	None	None
-----										
100114	GEL	Male	64	3	04JAN2018	Yes	None	None	None	None
.	.	.	.	4	10JAN2018	Yes	None	None	None	None
.	.	.	.	5	17JAN2018	Yes	None	None	None	None
-----										
100115	DROP	Male	76	3	05JAN2018	Yes	None	None	None	None
.	.	.	.	4	11JAN2018	Yes	None	None	None	None
.	.	.	.	5	18JAN2018	Yes	None	None	None	None
-----										
100116	GEL	Male	62	3	05JAN2018	Yes	None	None	None	None
.	.	.	.	4	11JAN2018	Yes	None	None	None	None
.	.	.	.	5	19JAN2018	Yes	None	None	None	None
-----										
100117	DROP	Female	51	3	11JAN2018	Yes	None	None	None	None
.	.	.	.	4	17JAN2018	Yes	None	None	None	None
.	.	.	.	5	23JAN2018	Yes	None	None	None	None
-----										
100118	DROP	Female	78	3	18JAN2018	Yes	None	None	None	None
.	.	.	.	4	24JAN2018	Yes	None	None	None	None
.	.	.	.	5	31JAN2018	Yes	None	None	None	None
-----										
100119	DROP	Female	72	3	25JAN2018	Yes	None	None	None	None
.	.	.	.	4	31JAN2018	Yes	None	None	None	None
.	.	.	.	5	08FEB2018	Yes	None	None	None	None
-----										
100120	GEL	Male	79	3	25JAN2018	Yes	None	None	None	None
.	.	.	.	4	31JAN2018	Yes	None	None	None	None
.	.	.	.	5	07FEB2018	Yes	None	None	None	None
-----										
100121	GEL	Male	80	3	25JAN2018	Yes	None	None	None	None
.	.	.	.	4	31JAN2018	Yes	None	None	None	None
.	.	.	.	5	07FEB2018	Yes	None	None	None	None

Listing 14 (3 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100122	DROP	Female	76	3	26JAN2018	Yes	None	None	None	None
.	.	.	.	4	01FEB2018	Yes	None	None	None	None
.	.	.	.	5	08FEB2018	Yes	None	None	None	None
-----										
100123	DROP	Female	76	3	26JAN2018	Yes	None	None	None	None
.	.	.	.	4	01FEB2018	Yes	None	None	None	None
.	.	.	.	5	08FEB2018	Yes	None	None	None	None
-----										
100124	GEL	Female	71	3	02FEB2018	Yes	None	None	None	None
.	.	.	.	4	08FEB2018	Yes	None	None	None	None
.	.	.	.	5	16FEB2018	Yes	None	None	None	None
-----										
100125	GEL	Female	62	3	02FEB2018	Yes	None	None	None	None
.	.	.	.	4	08FEB2018	Yes	None	None	None	None
.	.	.	.	5	16FEB2018	Yes	None	None	None	None
-----										
100126	GEL	Female	85	3	08FEB2018	Yes	None	None	None	None
.	.	.	.	4	14FEB2018	Yes	None	None	None	None
.	.	.	.	5	21FEB2018	Yes	None	None	None	None
-----										
100127	GEL	Female	68	3	09FEB2018	Yes	None	None	None	None
.	.	.	.	4	15FEB2018	Yes	None	None	None	None
.	.	.	.	5	24FEB2018	Yes	None	None	None	None
-----										
100128	DROP	Male	80	3	09FEB2018	Yes	None	None	None	None
.	.	.	.	4	15FEB2018	Yes	None	None	None	None
.	.	.	.	5	24FEB2018	Yes	None	None	None	None
-----										
100129	DROP	Female	78	3	09FEB2018	Yes	None	None	None	None
.	.	.	.	4	15FEB2018	Yes	None	None	None	None
.	.	.	.	5	23FEB2018	Yes	None	None	None	None
-----										
100130	GEL	Male	66	3	22FEB2018	Yes	None	None	None	None
.	.	.	.	4	28FEB2018	Yes	None	None	None	None
.	.	.	.	5	07MAR2018	Yes	None	None	None	None
-----										
100131	DROP	Female	77	3	22FEB2018	Yes	None	None	None	None
.	.	.	.	4	28FEB2018	Yes	None	None	None	None
.	.	.	.	5	07MAR2018	Yes	None	None	None	None

Listing 14 (4 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100132	DROP	Male	69	3	08MAR2018	Yes	None	None	None	None
.	.	.	.	4	14MAR2018	Yes	None	None	None	None
.	.	.	.	5	21MAR2018	Yes	None	None	None	None
-----										
100133	GEL	Male	74	3	08MAR2018	Yes	None	None	None	None
.	.	.	.	4	14MAR2018	Yes	None	None	None	None
.	.	.	.	5	21MAR2018	Yes	None	None	None	None
-----										
100134	DROP	Female	66	3	08MAR2018	Yes	None	None	None	None
.	.	.	.	4	14MAR2018	Yes	None	None	None	None
.	.	.	.	5	21MAR2018	Yes	None	None	None	None
-----										
100135	GEL	Male	69	3	16MAR2018	Yes	None	None	None	None
.	.	.	.	4	22MAR2018	Yes	None	None	None	None
.	.	.	.	5	29MAR2018	Yes	None	None	None	None
-----										
100136	GEL	Female	90	3	06APR2018	Yes	None	None	None	None
.	.	.	.	4	12APR2018	Yes	None	None	None	None
.	.	.	.	5	20APR2018	Yes	None	None	None	None
-----										
100137	DROP	Female	62	3	20APR2018	Yes	None	None	None	None
.	.	.	.	4	26APR2018	Yes	None	None	None	None
.	.	.	.	5	04MAY2018	Yes	None	None	None	None
-----										
100138	GEL	Male	63	3	20APR2018	Yes	None	None	None	None
.	.	.	.	4	26APR2018	Yes	None	None	None	None
.	.	.	.	5	04MAY2018	Yes	None	None	None	None
-----										
100139	DROP	Female	71	3	27APR2018	Yes	None	None	None	None
.	.	.	.	4	03MAY2018	Yes	None	None	None	None
.	.	.	.	5	11MAY2018	Yes	None	None	None	None
-----										
100140	GEL	Male	81	3	03MAY2018	Yes	None	None	None	None
.	.	.	.	4	09MAY2018	Yes	None	None	None	None
.	.	.	.	5	17MAY2018	Yes	None	None	None	None
-----										
100141	DROP	Female	74	3	03MAY2018	Yes	None	None	None	None
.	.	.	.	4	10MAY2018	Yes	None	None	None	None
.	.	.	.	5	16MAY2018	Yes	None	None	None	None

Listing 14 (5 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100142	GEL	Female	77	3	17MAY2018	Yes	None	None	None	None
.	.	.	.	4	23MAY2018	Yes	None	None	None	None
.	.	.	.	5	31MAY2018	Yes	None	None	None	None
-----										
100143	GEL	Male	74	3	21JUN2018	Yes	None	None	None	None
.	.	.	.	4	27JUN2018	Yes	None	None	None	None
.	.	.	.	5	04JUL2018	Yes	None	None	None	None
-----										
100144	DROP	Female	89	3	28JUN2018	Yes	None	None	None	None
.	.	.	.	4	04JUL2018	Yes	None	None	None	None
.	.	.	.	5	12JUL2018	Yes	None	None	None	None
-----										
100145	GEL	Male	81	3	05JUL2018	Yes	None	None	None	None
.	.	.	.	4	11JUL2018	Yes	None	None	None	None
.	.	.	.	5	18JUL2018	Yes	None	None	None	None
-----										
100146	GEL	Male	71	3	22AUG2018	Yes	None	None	None	None
.	.	.	.	4	29AUG2018	Yes	None	None	None	None
.	.	.	.	5	06SEP2018	Yes	None	None	None	None
-----										
100147	DROP	Male	48	3	29AUG2018	Yes	None	None	None	None
.	.	.	.	4	20SEP2018	Yes	None	None	None	None
-----										
100148	DROP	Female	83	3	31AUG2018	Yes	None	None	None	None
.	.	.	.	4	06SEP2018	Yes	None	None	None	None
.	.	.	.	5	13SEP2018	Yes	None	None	None	None
-----										
100149	DROP	Female	71	3	31AUG2018	Yes	None	None	None	None
.	.	.	.	4	06SEP2018	Yes	None	None	None	None
.	.	.	.	5	15SEP2018	Yes	None	None	None	None
-----										
100150	GEL	Female	77	3	06SEP2018	Yes	None	None	None	None
.	.	.	.	4	12SEP2018	Yes	None	None	None	None
.	.	.	.	5	21SEP2018	Yes	None	None	None	None
-----										
100151	DROP	Female	67	3	05OCT2018	Yes	None	None	None	None
.	.	.	.	4	12OCT2018	Yes	None	None	None	None
.	.	.	.	5	20OCT2018	Yes	None	None	None	None
-----										
100152	GEL	Female	78	3	05OCT2018	Yes	None	None	None	Mild
.	.	.	.	4	12OCT2018	Yes	None	None	None	None
.	.	.	.	5	20OCT2018	Yes	None	None	None	None

Listing 14 (6 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100153	DROP	Female	81	3	18OCT2018	Yes	None	None	None	None
.	.	.	.	4	24OCT2018	Yes	None	None	None	None
.	.	.	.	5	29OCT2018	Yes	None	None	None	None
-----										
100154	GEL	Female	68	3	19OCT2018	Yes	None	None	None	None
.	.	.	.	4	26OCT2018	Yes	None	None	None	None
.	.	.	.	5	02NOV2018	Yes	None	None	None	None
-----										
100155	DROP	Female	79	3	19OCT2018	Yes	None	None	None	None
.	.	.	.	4	26OCT2018	Yes	None	None	None	None
.	.	.	.	5	02NOV2018	Yes	None	None	None	None
-----										
100156	GEL	Female	69	3	19OCT2018	Yes	None	None	None	None
.	.	.	.	4	26OCT2018	Yes	None	None	None	None
.	.	.	.	5	02NOV2018	Yes	None	None	None	None
-----										
100201	GEL	Female	80	3	09DEC2017	Yes	None	Mild	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	22DEC2017	Yes	None	None	None	None
-----										
100202	DROP	Female	70	3	09DEC2017	Yes	None	None	None	None
.	.	.	.	4	14DEC2017	Yes	None	None	None	None
.	.	.	.	5	20DEC2017	Yes	None	None	None	None
-----										
100203	DROP	Female	76	3	15DEC2017	Yes	None	None	None	None
.	.	.	.	4	20DEC2017	Yes	None	None	None	None
.	.	.	.	5	28DEC2017	Yes	None	None	None	None
-----										
100204	GEL	Male	71	3	15DEC2017	Yes	None	None	None	None
.	.	.	.	4	20DEC2017	Yes	None	None	None	None
.	.	.	.	5	28DEC2017	Yes	None	None	None	None
-----										
100205	GEL	Male	75	3	09FEB2018	Yes	None	None	None	None
.	.	.	.	4	14FEB2018	Yes	None	None	None	None
.	.	.	.	5	21FEB2018	Yes	None	None	None	None
-----										
100206	DROP	Female	81	3	12JAN2018	Yes	None	Mild	None	None
.	.	.	.	4	18JAN2018	Yes	None	Mild	None	None
.	.	.	.	5	24JAN2018	Yes	None	Mild	None	None

Listing 14 (7 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100207	DROP	Female	65	3	12JAN2018	Yes	None	None	None	None
.	.	.	.	4	18JAN2018	Yes	None	None	None	None
.	.	.	.	5	24JAN2018	Yes	None	None	None	None
-----										
100208	GEL	Female	79	3	12JAN2018	Yes	None	Mild	None	None
.	.	.	.	4	18JAN2018	Yes	None	Mild	None	None
.	.	.	.	5	31JAN2018	Yes	None	Mild	None	None
-----										
100210	DROP	Female	70	3	19JAN2018	Yes	None	None	None	None
.	.	.	.	4	24JAN2018	Yes	None	None	None	None
.	.	.	.	5	31JAN2018	Yes	None	None	None	None
-----										
100211	GEL	Male	67	3	19JAN2018	Yes	None	Mild	None	None
.	.	.	.	4	24JAN2018	Yes	None	Mild	None	None
.	.	.	.	5	31JAN2018	Yes	None	None	None	None
-----										
100212	DROP	Female	82	3	19JAN2018	Yes	None	None	None	None
.	.	.	.	4	24JAN2018	Yes	None	None	None	None
.	.	.	.	5	31JAN2018	Yes	None	Mild	None	None
-----										
100213	DROP	Female	81	3	02FEB2018	Yes	None	None	None	None
.	.	.	.	4	07FEB2018	Yes	None	None	None	None
.	.	.	.	5	16FEB2018	Yes	None	None	None	None
-----										
100214	DROP	Female	77	3	09FEB2018	Yes	None	None	None	None
.	.	.	.	4	14FEB2018	Yes	None	None	None	None
.	.	.	.	5	21FEB2018	Yes	None	None	None	None
-----										
100215	GEL	Female	83	3	09FEB2018	Yes	None	None	None	None
.	.	.	.	4	14FEB2018	Yes	None	None	None	None
.	.	.	.	5	21FEB2018	Yes	None	None	None	None
-----										
100216	GEL	Female	74	3	16FEB2018	Yes	None	None	None	None
.	.	.	.	4	21FEB2018	Yes	None	None	None	None
.	.	.	.	5	28FEB2018	Yes	None	None	None	None
-----										
100217	DROP	Female	72	3	09MAR2018	Yes	None	None	None	None
.	.	.	.	4	14MAR2018	Yes	None	None	None	None
.	.	.	.	5	21MAR2018	Yes	None	None	None	None



Listing 14 (8 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100218	DROP	Male	72	3	09MAR2018	Yes	None	Mild	None	None
.	.	.	.	4	14MAR2018	Yes	None	Mild	None	None
.	.	.	.	5	21MAR2018	Yes	None	Mild	None	None
-----										
100219	GEL	Female	83	3	16MAR2018	Yes	Mild	None	None	None
.	.	.	.	4	21MAR2018	Yes	None	None	None	None
.	.	.	.	5	28MAR2018	Yes	None	Mild	None	None
-----										
100220	GEL	Male	64	3	16MAR2018	Yes	None	None	None	None
.	.	.	.	4	21MAR2018	Yes	None	None	None	None
.	.	.	.	5	28MAR2018	Yes	None	None	None	None
-----										
100221	GEL	Female	76	3	06APR2018	Yes	None	None	None	None
.	.	.	.	4	11APR2018	Yes	None	None	None	None
.	.	.	.	5	20APR2018	Yes	None	None	None	None
-----										
100222	DROP	Female	76	3	13APR2018	Yes	None	None	None	None
.	.	.	.	4	18APR2018	Yes	None	None	None	None
.	.	.	.	5	26APR2018	Yes	None	None	None	None
-----										
100223	DROP	Male	61	3	13APR2018	Yes	None	None	None	None
.	.	.	.	4	18APR2018	Yes	None	None	None	None
.	.	.	.	5	26APR2018	Yes	None	None	None	None
-----										
100224	GEL	Female	75	3	27APR2018	Yes	None	None	None	None
.	.	.	.	4	02MAY2018	Yes	None	None	None	None
.	.	.	.	5	09MAY2018	Yes	None	None	None	None
-----										
100225	DROP	Female	79	3	27APR2018	Yes	None	None	None	None
.	.	.	.	4	02MAY2018	Yes	None	None	None	None
.	.	.	.	5	09MAY2018	Yes	None	None	None	None
-----										
100226	GEL	Female	74	3	27APR2018	Yes	None	None	None	None
.	.	.	.	4	02MAY2018	Yes	None	None	None	None
.	.	.	.	5	09MAY2018	Yes	None	None	None	None
-----										
100227	DROP	Female	68	3	04MAY2018	Yes	None	None	None	None
.	.	.	.	4	09MAY2018	Yes	None	None	None	None
.	.	.	.	5	16MAY2018	Yes	None	None	None	None
-----										
100228	GEL	Female	68	3	04MAY2018	Yes	None	None	None	None
.	.	.	.	4	09MAY2018	Yes	None	None	None	None

Listing 14 (9 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100229	GEL	Female	70	3	11MAY2018	Yes	None	None	None	None
.	.	.	.	4	16MAY2018	Yes	None	None	None	None
.	.	.	.	5	23MAY2018	Yes	None	None	None	None
-----										
100230	GEL	Female	63	3	11MAY2018	Yes	None	None	None	None
.	.	.	.	4	16MAY2018	Yes	None	None	None	None
.	.	.	.	5	23MAY2018	Yes	None	None	None	None
-----										
100231	DROP	Female	74	3	11MAY2018	Yes	None	None	None	None
.	.	.	.	4	16MAY2018	Yes	None	None	None	None
.	.	.	.	5	23MAY2018	Yes	None	None	None	None
-----										
100232	DROP	Female	73	3	11MAY2018	Yes	None	None	None	None
.	.	.	.	4	16MAY2018	Yes	None	None	None	None
.	.	.	.	5	23MAY2018	Yes	None	None	None	None
-----										
100233	GEL	Female	72	3	25MAY2018	Yes	None	None	None	None
.	.	.	.	4	30MAY2018	Yes	None	None	None	None
.	.	.	.	5	06JUN2018	Yes	None	None	None	None
-----										
100234	GEL	Female	73	3	25MAY2018	Yes	None	None	None	None
.	.	.	.	4	30MAY2018	Yes	None	None	None	None
.	.	.	.	5	06JUN2018	Yes	None	None	None	None
-----										
100235	DROP	Male	64	3	01JUN2018	Yes	None	None	None	None
.	.	.	.	4	06JUN2018	Yes	None	None	None	None
.	.	.	.	5	13JUN2018	Yes	None	None	None	None
-----										
100236	DROP	Female	70	3	01JUN2018	Yes	None	None	None	None
.	.	.	.	4	06JUN2018	Yes	None	None	None	None
.	.	.	.	5	13JUN2018	Yes	None	None	None	None
-----										
100237	DROP	Male	73	3	08JUN2018	Yes	None	None	None	None
.	.	.	.	4	13JUN2018	Yes	None	None	None	None
.	.	.	.	5	20JUN2018	Yes	None	None	None	None
-----										
100238	GEL	Male	78	3	08JUN2018	Yes	None	None	None	None
.	.	.	.	4	13JUN2018	Yes	None	None	None	None
.	.	.	.	5	20JUN2018	Yes	None	None	None	None

Listing 14 (10 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100239	DROP	Female	80	3	15JUN2018	Yes	None	None	None	None
.	.	.	.	4	20JUN2018	Yes	None	None	None	None
.	.	.	.	5	27JUN2018	Yes	None	None	None	None
-----										
100241	GEL	Female	74	3	26OCT2018	Yes	None	None	None	None
.	.	.	.	4	31OCT2018	Yes	None	None	None	None
.	.	.	.	5	07NOV2018	Yes	None	None	None	None
-----										
100242	GEL	Female	67	3	09NOV2018	Yes	None	None	None	None
.	.	.	.	4	14NOV2018	Yes	None	None	None	None
.	.	.	.	5	22NOV2018	Yes	None	None	None	None
-----										
100243	DROP	Male	74	3	07DEC2018	Yes	None	None	None	None
.	.	.	.	4	12DEC2018	Yes	None	None	None	None
.	.	.	.	5	19DEC2018	Yes	None	None	None	None
-----										
100244	GEL	Female	66	3	14DEC2018	Yes	None	None	None	None
.	.	.	.	4	19DEC2018	Yes	None	None	None	None
.	.	.	.	5	27DEC2018	Yes	None	None	None	None
-----										
100245	DROP	Female	69	3	14DEC2018	Yes	None	None	None	None
.	.	.	.	4	19DEC2018	Yes	None	None	None	None
.	.	.	.	5	27DEC2018	Yes	None	None	None	None
-----										
100301	GEL	Female	68	3	20OCT2017	Yes	None	None	None	None
.	.	.	.	4	25OCT2017	Yes	None	None	None	None
.	.	.	.	5	03NOV2017	Yes	None	None	None	None
-----										
100302	GEL	Male	61	3	03NOV2017	Yes	None	None	None	None
.	.	.	.	4	09NOV2017	Yes	None	None	None	None
.	.	.	.	5	17NOV2017	Yes	None	None	None	None
-----										
100303	DROP	Female	73	3	03NOV2017	Yes	None	None	None	None
.	.	.	.	4	09NOV2017	Yes	None	None	None	None
.	.	.	.	5	17NOV2017	Yes	None	None	None	None
-----										
100304	DROP	Male	58	3	17NOV2017	Yes	None	None	None	None
.	.	.	.	4	23NOV2017	Yes	None	None	None	None
.	.	.	.	5	30NOV2017	Yes	None	None	None	None

Listing 14 (11 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100305	DROP	Female	85	3	17NOV2017	Yes	None	None	None	None
.	.	.	.	4	23NOV2017	Yes	None	None	None	None
.	.	.	.	5	30NOV2017	Yes	None	None	None	None
-----										
100307	GEL	Female	73	3	30NOV2017	Yes	None	None	None	None
.	.	.	.	4	06DEC2017	Yes	None	None	None	None
.	.	.	.	5	14DEC2017	Yes	None	None	None	None
-----										
100309	DROP	Female	61	3	30NOV2017	Yes	None	None	None	None
.	.	.	.	4	06DEC2017	Yes	None	None	None	None
.	.	.	.	5	14DEC2017	Yes	None	None	None	None
-----										
100310	GEL	Female	73	3	01DEC2017	Yes	None	None	None	None
.	.	.	.	4	06DEC2017	Yes	None	None	None	None
.	.	.	.	5	14DEC2017	Yes	None	None	None	None
-----										
100311	GEL	Female	83	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100312	DROP	Female	71	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100314	DROP	Male	67	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100315	GEL	Female	65	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100316	DROP	Male	76	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100317	GEL	Male	85	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	14DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None

Listing 14 (12 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100318	GEL	Female	80	3	06DEC2017	Yes	None	None	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100319	DROP	Male	70	3	06DEC2017	Yes	None	Mild	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	None	None	None
-----										
100320	DROP	Male	69	3	06DEC2017	Yes	None	Mild	None	None
.	.	.	.	4	13DEC2017	Yes	None	None	None	None
.	.	.	.	5	19DEC2017	Yes	None	Mild	None	None
-----										
100321	GEL	Male	72	3	12DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	27DEC2017	Yes	None	None	None	None
-----										
100322	GEL	Male	80	3	14DEC2017	Yes	None	Mild	None	None
.	.	.	.	4	19DEC2017	Yes	None	None	None	None
.	.	.	.	5	27DEC2017	Yes	None	None	None	None
-----										
100323	DROP	Female	76	3	14DEC2017	Yes	None	None	None	None
.	.	.	.	4	19DEC2017	Yes	None	None	None	None
.	.	.	.	5	27DEC2017	Yes	None	None	None	None
-----										
100324	DROP	Male	65	3	19DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	02JAN2018	Yes	None	None	None	None
-----										
100326	DROP	Male	81	3	19DEC2017	Yes	None	Mild	None	None
.	.	.	.	4	27DEC2017	Yes	None	Mild	None	None
.	.	.	.	5	03JAN2018	Yes	None	None	None	None
-----										
100327	GEL	Female	73	3	19DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	02JAN2018	Yes	None	None	None	None
-----										
100328	DROP	Male	82	3	19DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	02JAN2018	Yes	None	None	None	None

Listing 14 (13 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100329	GEL	Male	74	3	19DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	02JAN2018	Yes	None	None	None	None
-----										
100330	DROP	Male	61	3	20DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	03JAN2018	Yes	None	None	None	None
-----										
100331	GEL	Female	71	3	20DEC2017	Yes	None	None	None	None
.	.	.	.	4	27DEC2017	Yes	None	None	None	None
.	.	.	.	5	03JAN2018	Yes	None	None	None	None
-----										
100332	DROP	Male	82	3	13JAN2018	Yes	None	None	None	None
.	.	.	.	4	19JAN2018	Yes	None	None	None	None
.	.	.	.	5	25JAN2018	Yes	None	None	None	None
-----										
100333	DROP	Male	62	3	26JAN2018	Yes	None	None	None	None
.	.	.	.	4	01FEB2018	Yes	None	None	None	None
.	.	.	.	5	09FEB2018	Yes	None	None	None	None
-----										
100334	GEL	Male	72	3	25JAN2018	Yes	None	None	None	None
.	.	.	.	4	01FEB2018	Yes	None	None	None	None
.	.	.	.	5	08FEB2018	Yes	None	None	None	None
-----										
100335	DROP	Female	80	3	07FEB2018	Yes	None	None	None	None
.	.	.	.	4	12FEB2018	Yes	None	None	None	None
.	.	.	.	5	20FEB2018	Yes	None	None	None	None
-----										
100336	GEL	Female	82	3	07MAR2018	Yes	None	None	None	None
.	.	.	.	4	12MAR2018	Yes	None	None	None	None
.	.	.	.	5	20MAR2018	Yes	None	None	None	None
-----										
100338	DROP	Female	87	3	22MAR2018	Yes	None	None	None	None
.	.	.	.	4	27MAR2018	Yes	None	None	None	None
.	.	.	.	5	05APR2018	Yes	None	None	None	None
-----										
100339	GEL	Male	56	3	29MAR2018	Yes	None	Mild	None	None
.	.	.	.	4	05APR2018	Yes	None	None	None	None
.	.	.	.	5	11APR2018	Yes	None	None	None	None

Listing 14 (14 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100340	DROP	Male	83	3	13APR2018	Yes	None	None	None	None
.	.	.	.	4	19APR2018	Yes	None	None	None	None
.	.	.	.	5	26APR2018	Yes	None	None	None	None
-----										
100341	GEL	Male	88	3	13APR2018	Yes	None	None	None	None
.	.	.	.	4	19APR2018	Yes	None	None	None	None
.	.	.	.	5	26APR2018	Yes	None	None	None	None
-----										
100342	DROP	Female	86	3	13APR2018	Yes	None	None	None	None
.	.	.	.	4	19APR2018	Yes	None	None	None	None
.	.	.	.	5	26APR2018	Yes	None	None	None	None
-----										
100343	GEL	Male	74	3	11APR2018	Yes	None	None	None	None
.	.	.	.	4	17APR2018	Yes	None	None	None	None
.	.	.	.	5	24APR2018	Yes	None	None	None	None
-----										
100344	DROP	Female	68	3	11APR2018	Yes	None	None	None	None
.	.	.	.	4	17APR2018	Yes	None	None	None	None
.	.	.	.	5	23APR2018	Yes	None	None	None	None
-----										
100345	GEL	Male	48	3	11APR2018	Yes	None	None	None	None
.	.	.	.	4	17APR2018	Yes	None	None	None	None
.	.	.	.	5	23APR2018	Yes	None	None	None	None
-----										
100346	DROP	Female	77	3	13APR2018	Yes	None	None	None	None
.	.	.	.	4	19APR2018	Yes	None	None	None	None
.	.	.	.	5	26APR2018	Yes	None	None	None	None
-----										
100347	GEL	Male	58	3	19APR2018	Yes	None	None	None	None
.	.	.	.	4	24APR2018	Yes	None	None	None	None
.	.	.	.	5	02MAY2018	No	.	.	.	.
-----										
100348	GEL	Female	38	3	25APR2018	Yes	None	None	None	None
.	.	.	.	4	30APR2018	Yes	None	None	None	None
.	.	.	.	5	08MAY2018	Yes	None	None	None	None
-----										
100349	DROP	Male	71	3	25MAY2018	Yes	None	None	None	None
.	.	.	.	4	30MAY2018	Yes	None	None	None	None
.	.	.	.	5	06JUN2018	Yes	None	None	None	None

Listing 14 (15 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
100350	DROP	Female	67	3	23MAY2018	No	.	.	.	.
.	.	.	.	4	30MAY2018	Yes	None	None	None	None
.	.	.	.	5	05JUN2018	Yes	None	None	None	None
-----										
100351	GEL	Female	79	3	26MAY2018	Yes	None	None	None	None
.	.	.	.	4	01JUN2018	Yes	None	None	None	None
.	.	.	.	5	08JUN2018	Yes	None	None	None	None
-----										
100352	DROP	Female	63	3	30MAY2018	Yes	None	None	None	None
.	.	.	.	4	06JUN2018	Yes	None	None	None	None
.	.	.	.	5	13JUN2018	Yes	None	None	None	None
-----										
100353	GEL	Female	72	3	08JUN2018	Yes	None	None	None	None
.	.	.	.	4	14JUN2018	Yes	None	None	None	None
.	.	.	.	5	21JUN2018	Yes	None	None	None	None
-----										
100354	GEL	Female	80	3	08JUN2018	Yes	None	None	None	None
.	.	.	.	4	14JUN2018	Yes	None	None	None	None
.	.	.	.	5	21JUN2018	Yes	None	None	None	None
-----										
100355	DROP	Female	80	3	14JUN2018	Yes	None	None	None	None
.	.	.	.	4	21JUN2018	Yes	None	None	None	None
.	.	.	.	5	27JUN2018	Yes	None	None	None	None
-----										
100356	GEL	Male	74	3	19JUN2018	Yes	None	None	None	None
.	.	.	.	4	26JUN2018	Yes	None	None	None	None
.	.	.	.	5	04JUL2018	Yes	None	None	None	None
-----										
200101	GEL	Female	66	3	17JAN2018	Yes	None	Mild	Moderate	None
.	.	.	.	4	24JAN2018	Yes	None	Mild	Mild	None
.	.	.	.	5	31JAN2018	Yes	None	Mild	None	None
-----										
200102	DROP	Female	76	3	31JAN2018	Yes	Mild	Mild	None	None
.	.	.	.	4	05FEB2018	Yes	None	None	None	None
.	.	.	.	5	13FEB2018	Yes	None	None	Mild	Mild
-----										
200103	DROP	Male	82	3	14FEB2018	Yes	None	None	None	None
.	.	.	.	4	19FEB2018	Yes	None	Mild	None	None
.	.	.	.	5	26FEB2018	Yes	None	None	None	None



Listing 14 (16 of 17): Evaluation of global tolerability by the investigator during the study

=====										
Sbj Code	Study drug	Sex	Age (year)	Visit		Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date					
=====										
200104	GEL	Female	78	3	09MAY2018	Yes	None	None	None	None
.	.	.	.	4	16MAY2018	Yes	None	None	None	None
.	.	.	.	5	23MAY2018	Yes	None	Mild	None	None
-----										
200105	GEL	Female	65	3	30MAY2018	Yes	Mild	Moderate	Mild	None
.	.	.	.	4	06JUN2018	Yes	None	Mild	Mild	None
.	.	.	.	5	13JUN2018	Yes	None	None	None	None
-----										
200106	DROP	Female	75	3	27JUN2018	Yes	None	None	None	None
.	.	.	.	4	04JUL2018	Yes	None	None	None	None
.	.	.	.	5	11JUL2018	Yes	None	None	None	None
-----										
200107	DROP	Female	54	3	04JUL2018	Yes	Severe	Severe	Mild	Severe
-----										
200108	GEL	Male	77	3	05SEP2018	Yes	Mild	None	None	None
.	.	.	.	4	12SEP2018	Yes	Mild	None	Mild	None
.	.	.	.	5	20SEP2018	Yes	None	None	Severe	Moderate
-----										
200109	GEL	Female	84	3	03OCT2018	Yes	Mild	Mild	Moderate	Mild
.	.	.	.	4	10OCT2018	No	.	.	.	.
-----										
200110	DROP	Male	64	3	10OCT2018	Yes	None	None	None	None
.	.	.	.	4	17OCT2018	Yes	None	Mild	Mild	None
.	.	.	.	5	23OCT2018	Yes	None	None	Mild	None
-----										
200111	GEL	Male	73	3	07NOV2018	Yes	None	None	None	None
.	.	.	.	4	14NOV2018	Yes	None	Mild	Moderate	None
.	.	.	.	5	21NOV2018	Yes	None	None	Mild	None
-----										
200112	DROP	Male	85	3	14NOV2018	Yes	Mild	None	None	None
.	.	.	.	4	21NOV2018	Yes	None	None	Mild	None
.	.	.	.	5	28NOV2018	Yes	None	None	Mild	None
-----										
200113	DROP	Male	77	3	14NOV2018	Yes	None	None	None	None
.	.	.	.	4	21NOV2018	Yes	None	None	None	None
.	.	.	.	5	29NOV2018	Yes	None	None	None	None
-----										
200115	GEL	Female	70	3	19DEC2018	Yes	None	None	None	None
.	.	.	.	4	27DEC2018	Yes	None	None	None	None
.	.	.	.	5	03JAN2019	Yes	None	None	None	None

Sbj Code	Study drug	Sex	Age (year)	Visit			Performed?	Burning	Stinging	Blurred vision	Global subjective tolerability
				No.	Date						
200202	DROP	Female	71	3	19JUN2018	Yes	None	None	None	None	None
.	.	.	.	4	25JUN2018	Yes	None	None	None	None	None
.	.	.	.	5	03JUL2018	Yes	None	None	None	None	None
200203	GEL	Male	66	3	27JUN2018	Yes	None	None	None	None	None
.	.	.	.	4	02JUL2018	Yes	None	None	Mild	None	None
.	.	.	.	5	12JUL2018	Yes	None	None	None	None	None
200204	GEL	Male	58	3	04JUL2018	Yes	None	None	None	None	None
.	.	.	.	4	10JUL2018	Yes	None	None	None	None	None
.	.	.	.	5	18JUL2018	Yes	None	None	None	None	None
SAS program: L03_List_14.sas - SAS dataset name(s): RAND,DEMOGRAPHY,TOLERABILITY											

Listing 15 (1 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100101	DROP	Female	84	27DEC2017	Yes	.	NO	.	
100102	GEL	Male	80	29DEC2017	Yes	.	NO	.	
100103		Female	70	27OCT2017	No	Adverse event	NO	.	
100104	GEL	Male	70	05JAN2018	Yes	.	NO	.	
100105	DROP	Female	85	08JAN2018	Yes	.	NO	.	
100106	GEL	Male	56	15JAN2018	Yes	.	NO	.	
100107	DROP	Female	82	26JAN2018	Yes	.	NO	.	
100108	DROP	Female	73	06FEB2018	Yes	.	NO	.	
100109	GEL	Female	56	12FEB2018	Yes	.	NO	.	
100110	DROP	Female	75	12FEB2018	Yes	.	NO	.	
100111	DROP	Female	60	12FEB2018	Yes	.	NO	.	
100112	GEL	Male	73	05MAR2018	Yes	.	NO	.	
100113	GEL	Female	77	05MAR2018	Yes	.	NO	.	
100114	GEL	Male	64	05MAR2018	Yes	.	NO	.	
100115	DROP	Male	76	06MAR2018	Yes	.	NO	.	
100116	GEL	Male	62	06MAR2018	Yes	.	NO	.	
100117	DROP	Female	51	12MAR2018	Yes	.	NO	.	
100118	DROP	Female	78	19MAR2018	Yes	.	NO	.	
100119	DROP	Female	72	26MAR2018	Yes	.	NO	.	
100120	GEL	Male	79	26MAR2018	Yes	.	NO	.	
100121	GEL	Male	80	26MAR2018	Yes	.	NO	.	

Listing 15 (2 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100122	DROP	Female	76	27MAR2018	Yes	.	NO	.	
100123	DROP	Female	76	27MAR2018	Yes	.	NO	.	
100124	GEL	Female	71	03APR2018	Yes	.	NO	.	
100125	GEL	Female	62	03APR2018	Yes	.	NO	.	
100126	GEL	Female	85	09APR2018	Yes	.	NO	.	
100127	GEL	Female	68	10APR2018	Yes	.	NO	.	
100128	DROP	Male	80	10APR2018	Yes	.	NO	.	
100129	DROP	Female	78	10APR2018	Yes	.	NO	.	
100130	GEL	Male	66	23APR2018	Yes	.	NO	.	
100131	DROP	Female	77	23APR2018	Yes	.	NO	.	
100132	DROP	Male	69	08MAY2018	Yes	.	NO	.	
100133	GEL	Male	74	08MAY2018	Yes	.	NO	.	
100134	DROP	Female	66	08MAY2018	Yes	.	NO	.	
100135	GEL	Male	69	15MAY2018	Yes	.	NO	.	
100136	GEL	Female	90	06JUN2018	Yes	.	NO	.	
100137	DROP	Female	62	19JUN2018	Yes	.	NO	.	
100138	GEL	Male	63	19JUN2018	Yes	.	NO	.	
100139	DROP	Female	71	26JUN2018	Yes	.	NO	.	
100140	GEL	Male	81	02JUL2018	Yes	.	NO	.	
100141	DROP	Female	74	02JUL2018	Yes	.	NO	.	
100142	GEL	Female	77	16JUL2018	Yes	.	NO	.	

Listing 15 (3 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100143	GEL	Male	74	20AUG2018	Yes	.	NO	.	
100144	DROP	Female	89	27AUG2018	Yes	.	NO	.	
100145	GEL	Male	81	04SEP2018	Yes	.	NO	.	
100146	GEL	Male	71	22OCT2018	Yes	.	NO	.	
100147	DROP	Male	48	04SEP2018	No	Withdrawal of consent/Patient choice	NO	.	
100148	DROP	Female	83	29OCT2018	Yes	.	NO	.	
100149	DROP	Female	71	29OCT2018	Yes	.	NO	.	
100150	GEL	Female	77	05NOV2018	Yes	.	NO	.	
100151	DROP	Female	67	04DEC2018	Yes	.	NO	.	
100152	GEL	Female	78	20OCT2018	No	Withdrawal of consent/Patient choice	NO	.	
100153	DROP	Female	81	18DEC2018	Yes	.	NO	.	
100154	GEL	Female	68	18DEC2018	Yes	.	NO	.	
100155	DROP	Female	79	18DEC2018	Yes	.	NO	.	
100156	GEL	Female	69	18DEC2018	Yes	.	NO	.	
100201	GEL	Female	80	08FEB2018	Yes	.	NO	.	
100202	DROP	Female	70	08FEB2018	Yes	.	NO	.	
100203	DROP	Female	76	15FEB2018	Yes	.	NO	.	
100204	GEL	Male	71	15FEB2018	Yes	.	NO	.	
100205	GEL	Male	75	09APR2018	Yes	.	NO	.	
100206	DROP	Female	81	14MAR2018	Yes	.	NO	.	
100207	DROP	Female	65	14MAR2018	Yes	.	NO	.	

Listing 15 (4 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100208	GEL	Female	79	14MAR2018	Yes	.	NO	.	
100209	GEL	Female	77	18JAN2018	No	Withdrawal of consent/Patient choice	NO	.	
100210	DROP	Female	70	22MAR2018	Yes	.	NO	.	
100211	GEL	Male	67	22MAR2018	Yes	.	NO	.	
100212	DROP	Female	82	22MAR2018	Yes	.	NO	.	
100213	DROP	Female	81	04APR2018	Yes	.	NO	.	
100214	DROP	Female	77	09APR2018	Yes	.	NO	.	
100215	GEL	Female	83	09APR2018	Yes	.	NO	.	
100216	GEL	Female	74	16APR2018	Yes	.	NO	.	
100217	DROP	Female	72	08MAY2018	Yes	.	NO	.	
100218	DROP	Male	72	08MAY2018	Yes	.	NO	.	
100219	GEL	Female	83	16MAY2018	Yes	.	NO	.	
100220	GEL	Male	64	16MAY2018	Yes	.	NO	.	
100221	GEL	Female	76	01JUN2018	Yes	.	NO	.	
100222	DROP	Female	76	14JUN2018	Yes	.	NO	.	
100223	DROP	Male	61	14JUN2018	Yes	.	NO	.	
100224	GEL	Female	75	27JUN2018	Yes	.	NO	.	
100225	DROP	Female	79	27JUN2018	Yes	.	NO	.	
100226	GEL	Female	74	27JUN2018	Yes	.	NO	.	
100227	DROP	Female	68	04JUL2018	Yes	.	NO	.	
100228	GEL	Female	68	09MAY2018	No	Withdrawal of consent/Patient choice	NO	.	

Listing 15 (5 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100229	GEL	Female	70	10JUL2018	Yes	.	NO	.	
100230	GEL	Female	63	11JUL2018	Yes	.	NO	.	
100231	DROP	Female	74	06JUL2018	Yes	.	NO	.	
100232	DROP	Female	73	06JUL2018	Yes	.	NO	.	
100233	GEL	Female	72	20JUL2018	Yes	.	NO	.	
100234	GEL	Female	73	20JUL2018	Yes	.	NO	.	
100235	DROP	Male	64	01AUG2018	Yes	.	NO	.	
100236	DROP	Female	70	01AUG2018	Yes	.	NO	.	
100237	DROP	Male	73	06AUG2018	Yes	.	NO	.	
100238	GEL	Male	78	06AUG2018	Yes	.	NO	.	
100239	DROP	Female	80	14AUG2018	Yes	.	NO	.	
100240		Female	72	07JUL2018	No	Withdrawal of consent/Patient choice	NO	.	
100241	GEL	Female	74	24DEC2018	Yes	.	NO	.	
100242	GEL	Female	67	12JAN2019	Yes	.	NO	.	
100243	DROP	Male	74	04FEB2019	Yes	.	NO	.	
100244	GEL	Female	66	08FEB2019	Yes	.	NO	.	
100245	DROP	Female	69	08FEB2019	Yes	.	NO	.	
100301	GEL	Female	68	20DEC2017	Yes	.	NO	.	
100302	GEL	Male	61	05JAN2017	Yes	.	NO	.	
100303	DROP	Female	73	05JAN2018	Yes	.	NO	.	
100304	DROP	Male	58	16JAN2018	Yes	.	NO	.	

Listing 15 (6 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100305	DROP	Female	85	16JAN2017	Yes	.	NO	.	
100306	DROP	Female	84	22NOV2017	No	Withdrawal of consent/Patient choice	NO	.	
100307	GEL	Female	73	29JAN2018	Yes	.	NO	.	
100308	GEL	Female	85	29NOV2017	No	Withdrawal of consent/Patient choice	NO	.	
100309	DROP	Female	61	29JAN2018	Yes	.	NO	.	
100310	GEL	Female	73	29JAN2018	Yes	.	NO	.	
100311	GEL	Female	83	01FEB2018	Yes	.	NO	.	
100312	DROP	Female	71	01FEB2018	Yes	.	NO	.	
100313	GEL	Male	71	04DEC2017	No	Major complications during cataract surgery	NO	.	
100314	DROP	Male	67	01FEB2017	Yes	.	NO	.	
100315	GEL	Female	65	01FEB2018	Yes	.	NO	.	
100316	DROP	Male	76	01FEB2018	Yes	.	NO	.	
100317	GEL	Male	85	01FEB2018	Yes	.	NO	.	
100318	GEL	Female	80	01FEB2018	Yes	.	NO	.	
100319	DROP	Male	70	01FEB2018	Yes	.	NO	.	
100320	DROP	Male	69	01FEB2018	Yes	.	NO	.	
100321	GEL	Male	72	05FEB2018	Yes	.	NO	.	
100322	GEL	Male	80	12FEB2018	Yes	.	NO	.	
100323	DROP	Female	76	12FEB2018	Yes	.	NO	.	
100324	DROP	Male	65	20FEB2018	Yes	.	NO	.	
100325	GEL	Female	83	18DEC2017	No	Withdrawal of consent/Patient choice	NO	.	



Listing 15 (7 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100326	DROP	Male	81	16FEB2018	Yes	.	NO	.	
100327	GEL	Female	73	16FEB2018	Yes	.	NO	.	
100328	DROP	Male	82	16FEB2018	Yes	.	NO	.	
100329	GEL	Male	74	16FEB2018	Yes	.	NO	.	
100330	DROP	Male	61	19FEB2018	Yes	.	NO	.	
100331	GEL	Female	71	19FEB2018	Yes	.	NO	.	
100332	DROP	Male	82	12MAR2018	Yes	.	NO	.	
100333	DROP	Male	62	26MAR2018	Yes	.	NO	.	
100334	GEL	Male	72	26MAR2018	Yes	.	NO	.	
100335	DROP	Female	80	05APR2018	Yes	.	NO	.	
100336	GEL	Female	82	02MAY2018	Yes	.	NO	.	
100337	GEL	Male	72	10MAR2018	No	Withdrawal of consent/Patient choice	NO	.	
100338	DROP	Female	87	21MAY2018	Yes	.	NO	.	
100339	GEL	Male	56	28MAY2018	Yes	.	NO	.	
100340	DROP	Male	83	12JUN2018	Yes	.	NO	.	
100341	GEL	Male	88	12JUN2018	Yes	.	NO	.	
100342	DROP	Female	86	12JUN2018	Yes	.	NO	.	
100343	GEL	Male	74	11JUN2018	Yes	.	NO	.	
100344	DROP	Female	68	11JUN2018	Yes	.	NO	.	
100345	GEL	Male	48	11JUN2018	Yes	.	NO	.	
100346	DROP	Female	77	12JUN2018	Yes	.	NO	.	

Listing 15 (8 of 9): End of study

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
100347	GEL	Male	58	18JUN2018	Yes	.	NO	.	
100348	GEL	Female	38	25JUN2018	Yes	.	NO	.	
100349	DROP	Male	71	25JUL2018	Yes	.	NO	.	
100350	DROP	Female	67	23JUL2018	Yes	.	NO	.	
100351	GEL	Female	79	25JUL2018	Yes	.	NO	.	
100352	DROP	Female	63	30JUL2018	Yes	.	NO	.	
100353	GEL	Female	72	31JUL2018	Yes	.	NO	.	
100354	GEL	Female	80	07AUG2018	Yes	.	NO	.	
100355	DROP	Female	80	13AUG2018	Yes	.	NO	.	
100356	GEL	Male	74	20AUG2018	Yes	.	NO	.	
200101	GEL	Female	66	19MAR2018	Yes	.	NO	.	
200102	DROP	Female	76	28MAR2018	Yes	.	NO	.	
200103	DROP	Male	82	16APR2018	Yes	.	NO	.	
200104	GEL	Female	78	06JUL2018	Yes	.	NO	.	
200105	GEL	Female	65	23JUN2018	Yes	.	NO	.	
200106	DROP	Female	75	22AUG2018	Yes	.	NO	.	
200107	DROP	Female	54	05JUL2018	No	Adverse event	NO	.	
200108	GEL	Male	77	05NOV2018	Yes	.	NO	.	
200109	GEL	Female	84	10OCT2018	No	Adverse event	NO	.	
200110	DROP	Male	64	05DEC2018	Yes	.	NO	.	
200111	GEL	Male	73	02JAN2019	Yes	.	NO	.	

Sbj Code	Study drug	Sex	Age (year)	Last visit date	Study completed N/Y	Reason for withdrawal	Random code broken		
							N/Y	Date	Reason
200112	DROP	Male	85	09JAN2019	Yes	.	NO	.	
200113	DROP	Male	77	11JAN2019	Yes	.	NO	.	
200114	DROP	Female	64	28NOV2018	No	Protocol violation, including disallowed concomitant therapy	NO	.	
200115	GEL	Female	70	13FEB2019	Yes	.	NO	.	
200201		Female	71	24JAN2018	No	Protocol violation, including disallowed concomitant therapy	#	.	
200202	DROP	Female	71	17AUG2018	Yes	.	NO	.	
200203	GEL	Male	66	04SEP2018	Yes	.	NO	.	
200204	GEL	Male	58	04SEP2018	Yes	.	NO	.	
SAS program: L03_List_15.sas    -    SAS dataset name(s): RAND,DEMOGRAPHY,EOS									

Listing 16 (1 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100101	DROP	Female	84	RAMIPRIL CPS	4FEB2003	YES	2.5 mg	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
100105	DROP	Female	85	LOBIVON	8FEB2002	YES	5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	ARTERIAL HYPERTENSION						
100106	GEL	Male	56	CANDESARTAN	2APR2012	YES	4	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CANDESARTAN						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	LEVOTIROXIN	6MAY2004	YES	25	mg	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	POST- THYROIDECTOMY ADMINISTRATION						
100110	DROP	Female	75	LOBIDIUR (NEBIVOLOLO+IDROCLOROTIAZIDE)	FEB2007	YES	5 + 12	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBICARD-H						
.	.	.	.	ARTERIAL HYPERTENSION						
100112	GEL	Male	73	RAMIPRIL	20APR2005	YES	5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
100113	GEL	Female	77	LISINOPRIL	7OCT2013	YES	5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LISINOPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						

Listing 16 (2 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100114	GEL	Male	64	LISINOPRIL	2MAY2012	YES	5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LISINOPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
100118	DROP	Female	78	RATACAND	6OCT2007	YES	16	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CANDESARTAN						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	MEDIPO	23JAN2001	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
100119	DROP	Female	72	BLOPRESS	2002	YES	16	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CANDESARTAN						
.	.	.	.	ARTERIAL HYPERTENSION						
100120	GEL	Male	79	LISINOPRIL	6MAY2005	YES	mg	5	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LISINOPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
100121	GEL	Male	80	LISINOPRIL	2000	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LISINOPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
100124	GEL	Female	71	NEBILOX	FEB2001	YES	5	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	ARTERIAL HYPERTENSION						

Listing 16 (3 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100126	GEL	Female	85	NEOLOTAN	2005	YES	50	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LOSARTAN						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	CRESTOR	2008	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ROSUVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
100128	DROP	Male	80	CONGESCOR	APR2001	YES	1.25	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	ARTERIAL HYPERTENSION						
100130	GEL	Male	66	NORVASC	2000	YES	5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMLODIPINE						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	DILATREND	2000	YES	12.5	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CARVEDILOL						
.	.	.	.	ARTERIAL HYPERTENSION						
100131	DROP	Female	77	LOBIDIUR (NEBIVOLOLO+IDROCLOROTIAZIDE)	FEB2010	YES	5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBICARD-H						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	VALSARTAN	FEB2010	YES	40	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	VALSARTAN						
.	.	.	.	ARTERIAL HYPERTENSION						

Listing 16 (4 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100133	GEL	Male	74	ADALAT CRONO	MAR2005	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NIFEDIPINE						
.	.	.	.	ARTERIAL HYPERTENSION						
100145	GEL	Male	81	TOTALIP	2003	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
.	.	.	.	TRIATEC	2003	YES	2.5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
100149	DROP	Female	71	EUTIROX	1995	YES	50	mcg	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTHYROIDISM						
100153	DROP	Female	81	CONGESCOR	2003	YES	1.25	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	NORVASC	2003	YES	5	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMLODIPINE						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	EUTIROX	2010	YES	100	mg	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPERTHYROIDISM						

Listing 16 (5 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100154	GEL	Female	68	TRIATEC	FEB2007	YES	5	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	ARTERIAL HYPERTENSION						
-----										
100155	DROP	Female	79	MILARDIS	2002	YES	40	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	TELMISARTAN						
.	.	.	.	ARTERIAL HYPERTENSION						
-----										
100201	GEL	Female	80	DELAPRIL 30 MG + INDAPAMIDE 2.5 MG	2007	YES	15+1.25	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	DELAPRIDE						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						



Listing 16 (6 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100203	DROP	Female	76	PLAUNAZIDE 40+25 MG CARDIOVASCULAR SYSTEM	2007	YES	1	cp	DAILY	ORAL
.	.	.	.	BENICAR HCT SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	ALLOPURINOLO 10 MG MUSCULO-SKELETAL SYSTEM	2007	YES	1	cp	DAILY	ORAL
.	.	.	.	ALLOPURINOL HYPERURICEMIA						
.	.	.	.	OMISTAT 10 MG CARDIOVASCULAR SYSTEM	2007	YES	1	cp	DAILY	ORAL
.	.	.	.	SIMVASTATIN HYPERCHOLESTEROLEMIA						
.	.	.	.	LANSOPRAZOLO 30 MG ALIMENTARY TRACT AND METABOLISM	2012	YES	1	cp	DAILY	ORAL
.	.	.	.	LANSOPRAZOLE GASTROESOPHAGEAL REFLUX						
.	.	.	.	TAVOR NERVOUS SYSTEM	2007	YES	1	cp	DAILY	ORAL
.	.	.	.	LORAZEPAM INSOMNIA						
100204	GEL	Male	71	LOSARTAN 100 MG CARDIOVASCULAR SYSTEM	2012	YES	1	cp	DAILY	ORAL
.	.	.	.	LOSARTAN SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	PRADAXA 75 MG BLOOD AND BLOOD FORMING ORGANS	2012	YES	1	cp	DAILY	ORAL
.	.	.	.	DABIGATRAN ATRIAL FIBRILLATION						
.	.	.	.	NORMOPRESS 100+2.5 MG CARDIOVASCULAR SYSTEM	2012	YES	1	cp	DAILY	ORAL
.	.	.	.	METHYLDOPA SYSTEMIC ARTERIAL HYPERTENSION						

Listing 16 (7 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100205	GEL	Male	75	LACIREX 4 MG	2011	YES	1	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LACIDIPINE						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	LOBIVON 5 MG	2011	YES	1/4	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	LUCEN 20 MG	2007	YES	1	cp	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	ESOMEPRAZOLE						
.	.	.	.	GASTROESOPHAGEAL REFLUX						
-----										
100206	DROP	Female	81	SIMVASTATINA 20 MG	2008	YES	1	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
.	.	.	.	LUCEN 20 MG	2013	YES	1	cp	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	ESOMEPRAZOLE						
.	.	.	.	GASTROESOPHAGEAL REFLUX						
.	.	.	.	SYSTANE IDRA	2016	YES	1	drop	TWICE PER DAY	OCULAR
.	.	.	.	SENSORY ORGANS						
.	.	.	.	SYSTANE LUBRICANT						
.	.	.	.	DRY EYE SYNDROME						

Listing 16 (8 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100207	DROP	Female	65	TAREG 40 MG	2013	YES	1	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	VALSARTAN						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	EZIMEGA PLUS	2008	YES	1	cp	DAILY	ORAL
.	.	.	.							
.	.	.	.	HYPERCHOLESTEROLEMIA						
100208	GEL	Female	79	PAROXETINA 20 MG	2015	YES	1	drop	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	PAROXETINE						
.	.	.	.	DEPRESSION						
100209	GEL	Female	77	TAVOR 1 MG	2008	YES	1	cp	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	LORAZEPAM						
.	.	.	.	INSOMNIA						
.	.	.	.	SEQUACOR 2.5 MG	2008	YES	1	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	ARRHYTHMIA						
100210	DROP	Female	70	SIMVASTATINA 20 MG	2012	YES	1	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
100211	GEL	Male	67	OMISTAT 20 MG	2014	YES	1	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						

Listing 16 (9 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100212	DROP	Female	82	OMEPRAZOLO DIGERENT 150 MG	2016	YES	1	cp	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	OMEPRAZOLE						
.	.	.	.	GASTROEPHAGEAL REFLUX						
100213	DROP	Female	81	EUTIROX 100 MCG	1988	YES	1	cp	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTHYROIDISM						
.	.	.	.	NEBIVOLOLO 5 MG	1998	YES	1/2	cp	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	ASPIRINETTA	2008	YES	1	cp	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	CARDIOVASCULAR PROPHYLAXIS						
.	.	.	.	HYALISTIL	2008	YES	1	drop	3 TIMES PER DAY	ORAL
.	.	.	.	SENSORY ORGANS						
.	.	.	.	HYALURONIC ACID						
.	.	.	.	DRY EYE SYNDROME						
100214	DROP	Female	77	TORVAST	2010	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
.	.	.	.	COTAREG	1996	YES	160+12,5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CO-DIOVAN						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						

Listing 16 (10 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100217	DROP	Female	72	NORMOPRESS 100+12.5 MG	2008	YES	1	tab	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	METHYLDOPA						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
100219	GEL	Female	83	RAMIPRIL	2013	YES	5	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
100220	GEL	Male	64	CELLCEPT	2010	YES	500	MG	3 TIMES PER DAY	ORAL
.	.	.	.	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS						
.	.	.	.	MYCOPHENOLIC ACID						
.	.	.	.	SCLERODERMA						
.	.	.	.	REVATIO	2015	YES	20	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SILDENAFIL						
.	.	.	.	PULMONARY HYPERTENSION						
.	.	.	.	TRACLEER	2015	YES	125	MG	TWICE PER DAY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BOSENTAN						
.	.	.	.	PULMONARY HYPERTENSION						
.	.	.	.	BISOPROLOLO	2014	YES	1,2	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
100221	GEL	Female	76	ALAPRIL	2008	YES	20	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LISINOPRIL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						

Listing 16 (11 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100222	DROP	Female	76	VALSARTAN	2008	YES	160	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	VALSARTAN						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	BISOPROLOLO	2008	YES	1.25	MG	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	LASIX	2008	YES	25	MG	AS NEEDED	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	FUROSEMIDE						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
-----										
100223	DROP	Male	61	CARDIOASPIRIN	2015	YES	100	MG	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	ISCHEMIC STROKE						

Listing 16 (12 of 64): Concomitant treatments

Sbj	Study	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
100224	GEL	Female	75	KARVEZIDE 300+25 MG CARDIOVASCULAR SYSTEM	2005	YES	1	tablet	DAILY	ORAL
.	.	.	.	KARVEA HCT SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	FULCROSUPRA CARDIOVASCULAR SYSTEM	2013	YES	145	mg	DAILY	ORAL
.	.	.	.	FENOFIBRATE HYPERLIPIDEMIA						
.	.	.	.	XANAX NERVOUS SYSTEM	2015	YES	0,5	mg	DAILY	ORAL
.	.	.	.	ALPRAZOLAM ANXIETY						
.	.	.	.	CARDIOASPIRINA BLOOD AND BLOOD FORMING ORGANS	2013	YES	100	mg	DAILY	ORAL
.	.	.	.	ACETYLSALICYLIC ACID CARDIOVASCULAR PROPHYLAXIS						
.	.	.	.	OMEPRAZEN ALIMENTARY TRACT AND METABOLISM	2013	YES	10	mg	DAILY	ORAL
.	.	.	.	OMEPRAZOLE GASTRIC PROTECTION						
100225	DROP	Female	79	TRIATEC 2.5 MG CARDIOVASCULAR SYSTEM	2008	YES	1	tablet	DAILY	ORAL
.	.	.	.	RAMIPRIL SYSTEMIC HYPERTENSION						
.	.	.	.	CARDIOASPIRIN 100 MG BLOOD AND BLOOD FORMING ORGANS	2013	YES	1	tablet	DAILY	ORAL
.	.	.	.	ACETYLSALICYLIC ACID CARDIOVASCULAR PREVENTION						

Listing 16 (13 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100226	GEL	Female	74	COMBISARTAN 160+12.5	2008	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CO-DIOVAN						
.	.	.	.	SYSTEMIC HYPERTENSION						
.	.	.	.	LOBIVON 5 MG	2008	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	SYSTEMIC HYPERTENSION						
.	.	.	.	SAMYR 400 MG	2010	YES	1	tablet	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	ADEMETIONINE						
.	.	.	.	DEPRESSION						
-----										
100227	DROP	Female	68	OLPRESS 20 MG	2009	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	OLMESARTAN						
.	.	.	.	SYSTEMIC HYPERTENSION						
.	.	.	.	SIMVASTATINA 20 MG	2012	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
.	.	.	.	PLAVIX 75 MG	2016	YES	1	tablet	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	CLOPIDOGREL						
.	.	.	.	CARDIOVASCULAR PREVENTION						



Listing 16 (14 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100228	GEL	Female	68	VITAMIN D3	2008	YES	50000	ui	AS NEEDED	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	COLECALCIFEROL						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	OPTIMATE	2008	YES	75	mg	DAILY	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	RISEDRONIC ACID						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	ALFEUS	2012	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
-----										
100229	GEL	Female	70	TRIATEC 25 MG	2011	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	SYSTEMIC HYPERTENSION						
.	.	.	.	NORVASC 10 MG	2011	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMLODIPINE						
.	.	.	.	SYSTEMIC HYPERTENSION						

Listing 16 (15 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100231	DROP	Female	74	SELES BETA 100 MG	2011	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATENOLOL						
.	.	.	.	SYSTEMIC HYPERTENSION						
.	.	.	.	LEXOTAN 2.5 MG/ML	2016	YES	15	gtt	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	BROMAZEPAM						
.	.	.	.	ANXIETY						
.	.	.	.	PEPTAZOL 20 MG	2013	YES	1	tablet	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	LANSOPRAZOLE						
.	.	.	.	MRGE						
-----										
100232	DROP	Female	73	LOBIVON 5 MG	2010	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	SYSTEMIC HYPERTENSION						

Listing 16 (16 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100233	GEL	Female	72	SEQUACOR	2010	YES	2.5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	EUTIROX	2013	YES	100	mcg	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTHYROIDISM						
.	.	.	.	DIBASE	2008	YES	5000	ui	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	COLECALCIFEROL						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	TAVOR	2015	YES	1	mg	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	LORAZEPAM						
.	.	.	.	HYNOSOMNIA						
.	.	.	.	DEURSIL	2010	YES	450	mg	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	URSODEOXYCHOLIC ACID						
.	.	.	.	GALLSTONES						

Listing 16 (17 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100234	GEL	Female	73	PRADAXA	2013	YES	150	mg	TWICE PER DAY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	DABIGATRAN						
.	.	.	.	ATRIAL FIBRILLATION						
.	.	.	.	CORDARONE	2013	YES	50	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMIODARONE						
.	.	.	.	ATRIAL FIBRILLATION						
.	.	.	.	GIANT 20MG +5MG	2010	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	OLMESAFE AM						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	EUTIROX	2013	YES	75	mcg	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTHYROIDISM						
.	.	.	.	ATORVASTATINA	2013	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
100236	DROP	Female	70	TERIPARATIDE	2017	YES	20	mg	DAILY	
SUBCUTANEOUS										
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	TERIPARATIDE						
.	.	.	.	OSTEOPOROSIS						

Listing 16 (18 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100237	DROP	Male	73	CARDIOASPIRIN	2015	YES	100	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	PRIMARY CARDIOVASCULAR PROPHYLAXIS						
.	.	.	.	PRISMA	2015	YES	50	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	MESOGLYCAN						
.	.	.	.	PRIMARY CARDIOVASCULAR PROPHYLAXIS						
100238	GEL	Male	78	DROMOS	2015	YES	500	mg	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	LEVOCARNITINE						
.	.	.	.	CHRONIC HEART FAILURE						
100239	DROP	Female	80	LIXIANA	2014	YES	60	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	EDOXABAN						
.	.	.	.	ATRIAL FIBRILLATION						
.	.	.	.	ATENOLOLO	2014	YES	50	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATENOLOL						
.	.	.	.	ATRIAL FIBRILLATION						

Listing 16 (19 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100240		Female	72	CRESTOR 5 MG	2008	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ROSUVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
.	.	.	.	ZYLLT 75 MG	2012	YES	1	tablet	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	CLOPIDOGREL						
.	.	.	.	ISCHEMIC CARDIOMYOPATHY						
.	.	.	.	CONGESCOR 3.75 MG	2012	YES	1	tablet	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	ISCHEMIC CARDIOMYOPATHY						
.	.	.	.	FOSTER 100 MCG + 6 MCG	2013	YES	1	puff	DAILY	INHALATION
.	.	.	.	RESPIRATORY SYSTEM						
.	.	.	.	BEKFORM						
.	.	.	.	ASTHMA						
100241	GEL	Female	74	ALENDROS	1998	YES	70	mg	DAILY	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	ALENDRONIC ACID						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	NATECAL D3 600 MG +400UI	1998	YES	1	tablet	TWICE PER DAY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	CALCIUM						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	TOTALIP	1998	YES	10	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						

Listing 16 (20 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100243	DROP	Male	74	PLAVIX	2015	YES	75	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	CLOPIDOGREL						
.	.	.	.	ISCHEMIC CARDIOPATHY						
.	.	.	.	ALTIAZEM	2015	YES	60	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	DILTIAZEM						
.	.	.	.	ISCHEMIC CARDIOPATHY						
.	.	.	.	MONOCINQUE	2015	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ISOSORBIDE						
.	.	.	.	ISCHEMIC CARDIOPATHY						
.	.	.	.	TRIATEC	2008	YES	2.5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	SYSTEMIC ARTERIAL HYPERTENSION						
.	.	.	.	TOTALIP	2015	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCHOLESTEROLEMIA						
.	.	.	.	PLAQUENIL	2013	YES	200	mg	DAILY	ORAL
.	.	.	.	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLEN						
.	.	.	.	HYDROXYCHLOROQUINE						
.	.	.	.	PSORIATIC ARTHRITIS						

Listing 16 (21 of 64): Concomitant treatments

Sbj	Study	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)						
100244	GEL	Female	66	ARIXTRA	OCT2018	YES	2.5	mg	ONCE
	SUBCUTANEOUS								
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS					
.	.	.	.	FONDAPARINUX					
.	.	.	.	SUPERFICIAL THROMBOPHLEBITIS					
.	.	.	.	SOTALOL	2016	YES	80	mg	ONCE
.	.	.	.	CARDIOVASCULAR SYSTEM					ORAL
.	.	.	.	SOTALOL					
.	.	.	.	EXTRASYSTOLIA					
.	.	.	.	ESCITALOPRAM	2015	YES	10	mg	ONCE
.	.	.	.	NERVOUS SYSTEM					ORAL
.	.	.	.	ESCITALOPRAM					
.	.	.	.	ANXIOUS SYNDROME					
100245	DROP	Female	69	ALLOPURINOL	2016	YES	300	MG	DAILY
.	.	.	.	MUSCULO-SKELETAL SYSTEM					ORAL
.	.	.	.	ALLOPURINOL					
.	.	.	.	HYPERURICEMIA					
.	.	.	.	LASIX	2017	YES	25	MG	DAILY
.	.	.	.	CARDIOVASCULAR SYSTEM					ORAL
.	.	.	.	FUROSEMIDE					
.	.	.	.	HYDRIC RETENTION					
100301	GEL	Female	68	OROTRE	UNK	YES	1	1	DAILY
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK				ORAL
.	.	.	.	LEKOVIT CA					
.	.	.	.	BONE DESIASE					
.	.	.	.	LEXOTAN	UNK	YES	1	1	DAILY
.	.	.	.	NERVOUS SYSTEM	UNK				ORAL
.	.	.	.	BROMAZEPAM					
.	.	.	.	ANXIUS SYNDROME					



Listing 16 (22 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100302	GEL	Male	61	METFORAL	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	METFORMIN						
.	.	.	.	DIABETES						
.	.	.	.	SIMVASTATINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	DISLIPIDEMY						
.	.	.	.	ATENOLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATENOLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	CARDIOASA	UNK	YES	100	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	CLOPIDOGREL	UNK	YES	75	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	CLOPIDOGREL						
.	.	.	.	CARDIOVASCULAR DISEASE						
.	.	.	.	PRADIF	UNK	YES	400	mg	DAILY	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES						
.	.	.	.	TAMSULOSIN						
.	.	.	.	NEPHROPATHY						
100303	DROP	Female	73	ENALAPRIL	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ENALAPRIL						
.	.	.	.	HYPERTENSION						
.	.	.	.	LOBIDIVON	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	HYPERTENSION						

Listing 16 (23 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100305	DROP	Female	85	EUTIROX	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTIROIDISM						
.	.	.	.	MODURETIC	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	MODURETIC						
.	.	.	.	HYPERTENSION						
.	.	.	.	RAMIPRIL	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	HYPERTENSION						
100306	DROP	Female	84	ACESISTEM	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	VASERETIC						
.	.	.	.	HYPERTENSION						
100307	GEL	Female	73	EUTIROX	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTIROIDISM						
100308	GEL	Female	85	COMBISARTAN	UNK	YES	1	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CO-DIOVAN						
.	.	.	.	HYPERTENSION						
100310	GEL	Female	73	ASPIRENETTA	2017	YES	100	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	SYSTEMIC THERAPY						

Listing 16 (24 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100311	GEL	Female	83	CARDIRENE	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	CITALOPRAM	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	CITALOPRAM						
.	.	.	.	ANXIUS SYNDROME						
.	.	.	.	CONDESARTAN	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CANDESARTAN						
.	.	.	.	HYPERTENSION						
.	.	.	.	CONGESCOR	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	HYPERTENSION						
-----										
100312	DROP	Female	71	BISOPROLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	EUTIROX	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTIROIDISM						

Listing 16 (25 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100313	GEL	Male	71	DIAMOX CPR	4DEC2017	YES	250	mg	ONCE	ORAL
.	.	.	.	SENSORY ORGANS						
.	.	.	.	ACETAZOLAMIDE						
.	.	.	.	BREAKAGE POSTERIORE CAPSULE						
.	.	.	.	VIGAMOX DROP	4DEC2017	YES	190	mg	3 TIMES PER DAY	OCULAR
.	.	.	.	SENSORY ORGANS						
.	.	.	.	MOXIFLOXACIN						
.	.	.	.	BREAKAGE POSTERIORE CAPSULE						
-----										
100314	DROP	Male	67	AVODART	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES						
.	.	.	.	DUTASTERIDE						
.	.	.	.	PROSTATIC HYPERTROPHY						
-----										
100315	GEL	Female	65	DEPAKIN	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	VALPROIC ACID						
.	.	.	.	ANXIUS SYNDROME						
.	.	.	.	XANAX	UNK	YES	1	#	DAILY	SUBLINGUAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	ALPRAZOLAM						
.	.	.	.	ANXIUS SYNDROME						

Listing 16 (26 of 64): Concomitant treatments

Sbj	Study	Age	Reported term/ Therapeutic area/ Preferred term/	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex (year)	Indication							
100316	DROP	Male	76	OMNIC	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES						
.	.	.	.	TAMSULOSIN						
.	.	.	.	PROSTATIC HYPERTROPHY						
.	.	.	.	PROSTANOX	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	VARIOUS						
.	.	.	.	SERENOA REPENS						
.	.	.	.	PROSTATIC HYPERTROPHY						
.	.	.	.	PROSTIDE	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES						
.	.	.	.	FINASTERIDE						
.	.	.	.	PROSTATIC HYPERTROPHY						
100317	GEL	Male	85	AVODART	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES						
.	.	.	.	DUTASTERIDE						
.	.	.	.	PROSTATIC HYPERTROPHY						
.	.	.	.	CARDIOASPIRINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	HAMODEP	UNK	YES	1	#	DAILY	ORAL
.	.	.	.							
.	.	.	.	PROSTATIC HYPERTROPHY						
.	.	.	.	XATRAL	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES						
.	.	.	.	ALFUZOSIN						
.	.	.	.	PROSTATIC HYPERTROPHY						

Listing 16 (27 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100318	GEL	Female	80	RAMIPRIL	UNK	YES	500	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	HYPERTENSION						
.	.	.	.	CARDIOASPRINA	UNK	YES	100	mg	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
100320	DROP	Male	69	BISOPROLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	CARDIOASPIRINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	PANTOPRAZOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	PANTOPRAZOLE						
.	.	.	.	GASTRIC PROTECTOR						
100321	GEL	Male	72	ATENOLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATENOLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	EUTIROX	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTIROIDISM						

Listing 16 (28 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100322	GEL	Male	80	TRIATEC	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	HYPERTENSION						
.	.	.	.	CARDIOASPIRINA		YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
100323	DROP	Female	76	SINVASTATINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SINVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMIA						
.	.	.	.	FASAVANCE	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	FOSAVANCE						
.	.	.	.	BONE DISEASE						
100325	GEL	Female	83	CARVEDILOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CARVEDILOL						
.	.	.	.	HYPERTENSION						

Listing 16 (29 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100326	DROP	Male	81	NEBIVOLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	NEBIVOLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	COUMADIN	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	WARFARIN						
.	.	.	.	ANGIOPHATHY						
.	.	.	.	KANRENOL	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CANRENOIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	IGROTAN	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CHLORTALIDONE						
.	.	.	.	HYPERTENSION						
100327	GEL	Female	73	BONVIVA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	IBANDRONIC ACID						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	DIBASE	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	COLECALCIFEROL						
.	.	.	.	OSTEOPOROSIS						



Listing 16 (30 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100328	DROP	Male	82	CARDIRENE	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	SELOKEN	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	METOPROLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	PROVISACOR	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ROSUVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMIA						
100329	GEL	Male	74	CARDIOASPIRINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	VASCULOPHATY-HIPERTENSION						
100330	DROP	Male	61	ASA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	CARDIOPHATHY						
.	.	.	.	BISOPROLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	CARDIOPHATHY						
.	.	.	.	CLOPIDOGREL	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	CLOPIDOGREL						
.	.	.	.	CARDIOPHATHY						

Listing 16 (31 of 64): Concomitant treatments

Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
100331	GEL	Female	71	STATINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	CARDIOPATHY						
100332	DROP	Male	82	KARVEZIDE	UNK	YES	150	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	KARVEA HCT						
.	.	.	.	HYPERTENSION						
.	.	.	.	ATORVASTINA	UNK	YES	20	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	VASCULOPATHY						
.	.	.	.	CARDIOASPIRINA	UNK	YES	100	mg	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	VASCULOPATHY						
.	.	.	.	LERCANIDIPINA	UNK	YES	10	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	LERCANIDIPINE						
.	.	.	.	HYPERTENSION						
.	.	.	.	METOPROLOLO	UNK	YES	100	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	METOPROLOL						
.	.	.	.	HYPERTENSION						
100333	DROP	Male	62	LENDORMIN	UNK	YES	0.25	mg	DAILY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	BROTIZOLAM						
.	.	.	.	INSOMNIA						

Listing 16 (32 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
100334	GEL	Male	72	ASA	UNK	YES	1	#	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	SOTALEX	UNK	YES	80	#	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SOTALOL						
.	.	.	.	HYPERTENSION						
100335	DROP	Female	80	APROVEL	UNK	YES	150	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	IRBESARTAN						
.	.	.	.	HYPERTENSION						
.	.	.	.	ESAMEPRAZOLO	UNK	YES	#	#	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	ESOMEPRAZOLE						
.	.	.	.	GASTRIC PROTECTOR						
100336	GEL	Female	82	MODURETIC	UNK	YES	1	#	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	MODURETIC						
.	.	.	.	HYPERTENSION						
100340	DROP	Male	83	COMBISARTAN	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CO-DIOVAN						
.	.	.	.	HYPERTENSION						

Listing 16 (33 of 64): Concomitant treatments

Sbj	Study	Sex	Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug		(year)							
100341	GEL	Male	88	AMLODIPINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMLODIPINE						
.	.	.	.	HYPERTENSION						
.	.	.	.	CARDIOASA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
100342	DROP	Female	86	BISOPROLOLO	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	CARDIOASA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
100343	GEL	Male	74	KARVEA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	IRBESARTAN						
.	.	.	.	HYPERTENSION						
.	.	.	.	SINVASTATINA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMY						

Listing 16 (34 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100346	DROP	Female	77	CARDIOASA	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS	UNK					
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	EUTIROX	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE	UNK					
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	IPOTIROIDISM						
.	.	.	.	MODURETIC	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	MODURETIC						
.	.	.	.	HYPERTENSION						
-----										
100350	DROP	Female	67	TENORMIN	UNK	YES	1	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATENOLOL						
.	.	.	.	HYPERTENSION						
-----										
100351	GEL	Female	79	TRIATEC	UNK	YES	1	#	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	RAMIPRIL						
.	.	.	.	HYPERTENSION						
-----										
100353	GEL	Female	72	TOTALIP	UNK	YES	1	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMY						
-----										
100354	GEL	Female	80	MODURETIC	UNK	YES	1	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	MODURETIC						
.	.	.	.	HYPERTENSION						

Listing 16 (35 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
100355	DROP	Female	80	ATORVASTATINA	UNK	YES	1	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMY						
-----										
100356	GEL	Male	74	ATORVASTATINA	UNK	YES	1	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMY						
.	.	.	.	BISOPROLOLO	UNK	YES	1	1	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	HYPERTENSION						

Listing 16 (36 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200101	GEL	Female	66	ADRENALIN	16JAN2018		1	ml	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	16JAN2018					
.	.	.	.	EPINEPHRINE						
.	.	.	.	DILATION						
.	.	.	.	ALPHAGAN	17JAN2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	18JAN2018					
.	.	.	.	BRIMONIDINE						
.	.	.	.	INCREASED IOP						
.	.	.	.	CEFUROXIM	16JAN2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	16JAN2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	COSOPT	17JAN2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	18JAN2018					
.	.	.	.	COSOPT						
.	.	.	.	INCREASED IOP						
.	.	.	.	DORMICUM	16JAN2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	16JAN2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	XYLONEST	16JAN2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	16JAN2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	LOKAL ANESTHESIA						
-----										
200102	DROP	Female	76	CANDERSATAN/HCT	UNK	YES	16/ 12,5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	CANDESARTAN W/HYDROCHLOROTHIAZIDE						
.	.	.	.	HYPERTENSION						

Listing 16 (37 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200103	DROP	Male	82	AMLODIPIN DEXCEL	UNK	YES	10	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK						
.	.	.	.	AMLODIPINE							
.	.	.	.	HYPERTENSION							
.	.	.	.	ARTELAC	14MAR2018		1mg/ml	Drops	AS NEEDED	OCULAR	
.	.	.	.	SENSORY ORGANS	28MAR2018						
.	.	.	.	HYPROMELLOSE							
.	.	.	.	DRY EYE							
.	.	.	.	BISOPROLOL RATIOPHARM	UNK	YES	10	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK						
.	.	.	.	BISOPROLOL							
.	.	.	.	HYPERTENSION							
.	.	.	.	BISOPROLOLHEMIFUMARAT	UNK	YES	10	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK						
.	.	.	.	BISOPROLOL							
.	.	.	.	HYPERTENSION							
.	.	.	.	CEFUROXIM	13FEB2018		1,0	ml	ONCE	OCULAR	
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	13FEB2018						
.	.	.	.	CEFUROXIME							
.	.	.	.	ANTIBIOTIC							
.	.	.	.	CORVO	UNK	YES	20	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK						
.	.	.	.	ENALAPRIL							
.	.	.	.	HYPERTENSION							
.	.	.	.	HYDROCHLOROTHIAZID	UNK	YES	25	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK						
.	.	.	.	HYDROCHLOROTHIAZIDE							
.	.	.	.	HYPERTENSION							



Listing 16 (38 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200103	DROP	Male	82	LIXIANA	23MAY2016	YES	60	mg	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS	UNK					
.	.	.	.	EDOXABAN						
.	.	.	.	HYPERTENSION						
.	.	.	.	NEVANAC GIVEN	28MAR2018		1mg/ml	Drops	3 TIMES PER DAY	OCULAR
.	.	.	.	SENSORY ORGANS	16APR2018					
.	.	.	.	NEPAFENAC						
.	.	.	.	MACULA EDEMA						
.	.	.	.	OMEGA 3	2016	YES	1	capsule	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	FISH OIL						
.	.	.	.	PREVENTION						
.	.	.	.	TAMSULOSIN	UNK	YES	0,4	mg	ONCE	ORAL
.	.	.	.	GENITO URINARY SYSTEM AND SEX HORMONES	UNK					
.	.	.	.	TAMSULOSIN						
.	.	.	.	ENLARGED PROSTATE						

Listing 16 (39 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200104	GEL	Female	78	ADRENALIN 0,05%	8MAY2018		1	ml	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	8MAY2018					
.	.	.	.	EPINEPHRINE						
.	.	.	.	PUPIL DELATION						
.	.	.	.	BETAVERT	1992	YES	12	mg	ONCE	ORAL
.	.	.	.	NERVOUS SYSTEM	UNK					
.	.	.	.	BETAHISTINE						
.	.	.	.	LABYRINTHINE VERTIGO						
.	.	.	.	CEFUROXIME	8MAY2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	8MAY2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	8MAY2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	8MAY2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	PHENYLEPHRIN-TROPICAMID	8MAY2018		3	drops	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	8MAY2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	PUPIL DILATION						
.	.	.	.	PHENYLEPHRIN-TROPICAMID	9MAY2018		1	drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	9MAY2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	PUPIL DILATION						
.	.	.	.	VIGANTOLETTEN	2015	YES	1000	IE	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK					
.	.	.	.	COLECALCIFEROL						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	XYLONEST 1%	8MAY2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	8MAY2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	LOKAL ANESTHESIA						

Listing 16 (40 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200105	GEL	Female	65	ADRENALIN	29MAY2018		1	ml	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	29MAY2018					
.	.	.	.	EPINEPHRINE						
.	.	.	.	PUPIL DILATION						
.	.	.	.	ASS 100	2010	YES	100	mg	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS	UNK					
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	ATROVASTATIN	UNK	YES	20	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	ATORVASTATIN						
.	.	.	.	HYPERCOLESTEROLEMIA						
.	.	.	.	CEFUROXIM	29MAY2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	29MAY2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	29MAY2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	29MAY2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	METROPOLOL	2010	YES	23,75	mg	TWICE PER DAY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	METOPROLOL						
.	.	.	.	HYPERTENSION						
.	.	.	.	VALSARTAN	2010	YES	40	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	VALSARTAN						
.	.	.	.	HYPERTENSION						
.	.	.	.	XYLONEST	29MAY2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	29MAY2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	LOKAL ANESTHESIA						

Listing 16 (41 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200106	DROP	Female	75	ASS 100	UNK	YES	100	mg	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS	UNK					
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	HYPERTENSION						
.	.	.	.	CEFUROXIME	26JUN2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	26JUN2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	26JUN2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	26JUN2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	FOSINORM	UNK	YES	20	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	FOSINOPRIL						
.	.	.	.	HYPERTENSION						
.	.	.	.	JANUVIA	UNK	YES	50	mg	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK					
.	.	.	.	SITAGLIPTIN						
.	.	.	.	DIABETIS						
.	.	.	.	L-THYROXIN	UNK	YES	0,075	mg	ONCE	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE	UNK					
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTHYROIDISM						

Listing 16 (42 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200106	DROP	Female	75	METFORMIN	UNK	YES	500	mg	TWICE PER DAY	ORAL	
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK						
.	.	.	.	METFORMIN							
.	.	.	.	DIABETIS							
.	.	.	.	METOPROLOL SUCCINAT TAD	UNK	YES	23,75	mg	TWICE PER DAY	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK						
.	.	.	.	METOPROLOL							
.	.	.	.	HYPERTENSION							
.	.	.	.	VIGANTOLETTEN	UNK	YES	1000	IE	ONCE	ORAL	
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK						
.	.	.	.	COLECALCIFEROL							
.	.	.	.	PREVENTION							
.	.	.	.	VITAMIN B12	UNK	YES	400	mg	ONCE	ORAL	
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS	UNK						
.	.	.	.	HYDROXOCOBALAMIN							
.	.	.	.	VITAMIN B12 DEFICIENCY							
.	.	.	.	XYLONDEST	26JUN2018		1	ml	ONCE	OCULAR	
.	.	.	.	NERVOUS SYSTEM	26JUN2018						
.	.	.	.	PRILOCAINE							
.	.	.	.	LOKAL ANESTHESIA							

Listing 16 (43 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200107	DROP	Female	54	CEFUROXIME	3JUL2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	3JUL2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	CETIRIZIN	UNK	YES	10	mg	TWICE PER DAY	ORAL
.	.	.	.	RESPIRATORY SYSTEM	UNK					
.	.	.	.	CETIRIZINE						
.	.	.	.	ALLERGICAL REACTIONS						
.	.	.	.	DORMICUM	3JUN2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	3JUL2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	DORMICUM	3JUL2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	3JUL2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	FENTANYL HXAL	UNK	YES	100	pg/h	AS NEEDED	ORAL
.	.	.	.	NERVOUS SYSTEM	UNK					
.	.	.	.	FENTANYL						
.	.	.	.	PAIN						
.	.	.	.	FENTANYL PERORAL	UNK	YES	0,2	mg	AS NEEDED	ORAL
.	.	.	.	NERVOUS SYSTEM	UNK					
.	.	.	.	FENTANYL						
.	.	.	.	PAIN						

Listing 16 (44 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200107	DROP	Female	54	FUROSEMID	UNK	YES	40	mg	AS NEEDED	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	FUROSEMIDE						
.	.	.	.	HYPERTENSION						
.	.	.	.	GLIVEC	UNK	YES	100	mg	TWICE PER DAY	ORAL
.	.	.	.	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	UNK					
.	.	.	.	IMATINIB						
.	.	.	.	SYSTEMIC MASTOCYTOSIS						
.	.	.	.	INSUMAN BASAL	UNK	YES	40-45	I.E.	3 TIMES PER DAY	SUBCUTANEOUS
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK					
.	.	.	.	INSULIN HUMAN						
.	.	.	.	DIABETIS						
.	.	.	.	LACTULOSE SIRUP	UNK	YES	1	ml	AS NEEDED	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	UNK					
.	.	.	.	LACTULOSE						
.	.	.	.	CONSTIPATION						
.	.	.	.	NITROLINGUAL AKUT SPRAY	UNK	YES	1	humb	AS NEEDED	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	GLYCERYL TRINITRATE						
.	.	.	.	ASTHMA						
.	.	.	.	PHENYLEPHRIN-TROPICAMID	4JUL2018		1	drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	4JUL2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	PUPIL DILATION						
.	.	.	.	PREDNISOLON	UNK	YES	10	mg	TWICE PER DAY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE	UNK					
.	.	.	.	PREDNISOLONE						
.	.	.	.	SYSTEMIC MASTCYTOSIS						
.	.	.	.	XYLONEST	3JUL2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	3JUL2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	LOKAL ANESTHESIA						

Listing 16 (45 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200108	GEL	Male	77	ALLOPURINOL	2008	YES	150	mg	ONCE	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	ALLOPURINOL						
.	.	.	.	ELEVATED URIC ACID LEVEL						
.	.	.	.	AMLO	2008	YES	5	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMLODIPINE						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	ASS 100	2008	YES	100	mg	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	PREVENTION						
.	.	.	.	CANDESARTAN	2008	YES	8	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	UNK					
.	.	.	.	CANDESARTAN						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	CEFUROXIM	4SEP2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	4SEP2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	4SEP2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	4SEP2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						



Listing 16 (46 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200108	GEL	Male	77	METROPOLOL	2008	YES	47,5	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	METOPROLOL						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	SIMVA	UNK	YES	40	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	SIMVASTATIN						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	THYROXIN	UNK	YES	50	microgramm	ONCE	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	HYPOTHYROIDISM						
.	.	.	.	XYLONEST 1%	4SEP2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	4SEP2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	ANESTHESIA						

Listing 16 (47 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200109	GEL	Female	84	ALENDROVIS ( ALENDRONACID)	1998	YES	70	mg	AS NEEDED	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	ALENDRONIC ACID						
.	.	.	.	OSTEOPOROSIS (FREQUENCY ONCE/WEEK)						
.	.	.	.	CALCIUM	1998	YES	500	mg	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	CALCIUM GLUCONATE						
.	.	.	.	OSTEOPOROSIS						
.	.	.	.	CEFUROXIME	20CT2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	20CT2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	20CT2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	20CT2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	INFLANEFRAN FORTE	30CT2018		1	Drop	AS NEEDED	OCULAR
.	.	.	.	SENSORY ORGANS	50CT2018					
.	.	.	.	PREDNISOLONE						
.	.	.	.	AGAINST INFLAMMATION (HOURLY)						
.	.	.	.	INFLANEFRAN FORTE	50CT2018		1	Drop	AS NEEDED	OCULAR
.	.	.	.	SENSORY ORGANS	120CT2018					
.	.	.	.	PREDNISOLONE						
.	.	.	.	AGAINST INFLAMMATION (5TIMES A DAY)						

Listing 16 (48 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200109	GEL	Female	84	INFLANEFRAN FORTE	13OCT2018		1	drop	4 TIMES PER DAY	OCULAR	
.	.	.	.	SENSORY ORGANS	19OCT2018						
.	.	.	.	PREDNISOLONE							
.	.	.	.	AGAINST INFLAMMATION							
.	.	.	.	INFLANEFRAN FORTE	20OCT2018		1	Drop	3 TIMES PER DAY	OCULAR	
.	.	.	.	SENSORY ORGANS	26OCT2018						
.	.	.	.	PREDNISOLONE							
.	.	.	.	AGAINST INFLAMMATION							
.	.	.	.	INFLANEFRAN FORTE	27OCT2018		1	Drop	TWICE PER DAY	OCULAR	
.	.	.	.	SENSORY ORGANS	2NOV2018						
.	.	.	.	PREDNISOLONE							
.	.	.	.	AGAINST INFLAMMATION							
.	.	.	.	INFLANEFRAN FORTE	3NOV2018		1	Drop	ONCE	OCULAR	
.	.	.	.	SENSORY ORGANS	9NOV2018						
.	.	.	.	PREDNISOLONE							
.	.	.	.	AGAINST INFLAMMATION							
.	.	.	.	METROPOLO	1990	YES	50	mg	TWICE PER DAY	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	METOPROLOL							
.	.	.	.	HEART RHYTHM DISTURBANCES							
.	.	.	.	MOVICOL	UNK	YES	1	bag	ONCE	ORAL	
.	.	.	.	ALIMENTARY TRACT AND METABOLISM							
.	.	.	.	MOVICOL							
.	.	.	.	CONSTIPATION							
.	.	.	.	PHENYLEPHRIN TROPICAMID	3OCT2018		1	Drop	ONCE	OCULAR	
.	.	.	.	SENSORY ORGANS	3OCT2018						
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE							
.	.	.	.	PUPIL DILATION							
.	.	.	.	RAMIPRIL	UNK	YES	2,5	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	RAMIPRIL							
.	.	.	.	HIGH BLOODPRESSURE							
.	.	.	.	SIMVASTATIN	2008	YES	20	mg	TWICE PER DAY	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	SIMVASTATIN							

. . . HIGH BLOODPRESSURE

Listing 16 (49 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200109	GEL	Female	84	VERAPAMIL	1990	YES	120	mg	TWICE PER DAY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	VERAPAMIL						
.	.	.	.	HEART RHYTHM DISTURBANCES						
.	.	.	.	XYLONEST 1%	2OCT2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	2OCT2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	ANESTHESIA						

Listing 16 (50 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200110	DROP	Male	64	AZOPT	17OCT2018	YES	1	Drop	TWICE PER DAY	OCULAR	
.	.	.	.	SENSORY ORGANS							
.	.	.	.	BRINZOLAMIDE							
.	.	.	.	ARTERY OCCLUSION AND PERFUSION							
.	.	.	.	BERODUAL N	UNK	YES	0,02-0,04	mg	AS NEEDED	ORAL	
.	.	.	.	RESPIRATORY SYSTEM							
.	.	.	.	DUOVENT							
.	.	.	.	COPD							
.	.	.	.	CEFUROXIME	9OCT2018		1	ml	ONCE	OCULAR	
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	9OCT2018						
.	.	.	.	CEFUROXIME							
.	.	.	.	ANTIBIOTIC							
.	.	.	.	DORMICUM	9OCT2018		1,5	mg	ONCE	INTRAVENOUS	
.	.	.	.	NERVOUS SYSTEM	9OCT2018						
.	.	.	.	NITRAZEPAM							
.	.	.	.	SEDATION							
.	.	.	.	HYLOGEL	21OCT2018		1	Drop	AS NEEDED	OCULAR	
.	.	.	.	SENSORY ORGANS	30OCT2018						
.	.	.	.	HYALURONIC ACID							
.	.	.	.	AS NEEDED MEANS 5 TIMES PER DAY							
.	.	.	.	INFLANEFRAN FORTE	17OCT2018		1	Drop	4 TIMES PER DAY	OCULAR	
.	.	.	.	SENSORY ORGANS	20OCT2018						
.	.	.	.	PREDNISOLONE							
.	.	.	.	ARTERY OCCLUSION							

Listing 16 (51 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200110	DROP	Male	64	INFLANEFRAIN FORTE	23OCT2018		1	Drop	TWICE PER DAY	OCULAR	
.	.	.	.	SENSORY ORGANS	30OCT2018						
.	.	.	.	PREDNISOLONE							
.	.	.	.	ARTERY OCCLUSION							
.	.	.	.	LERCANIDIPIN	UNK	YES	18,88	mg	ONCE	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	LERCANIDIPINE							
.	.	.	.	HIGH BLOODPRESSURE							
.	.	.	.	PHENYLEPHRIN-TROPICAMID	10OCT2018		1	Drop	ONCE	OCULAR	
.	.	.	.	SENSORY ORGANS	10OCT2018						
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE							
.	.	.	.	PUPIL DILATION							
.	.	.	.	RAMIPRIL	UNK	YES	5	mg	TWICE PER DAY	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	RAMIPRIL							
.	.	.	.	HIGH BLOODPRESSURE							
.	.	.	.	SPIOCTO RESPIMAT	UNK	YES	2,5	µg	TWICE PER DAY	NASAL	
.	.	.	.	RESPIRATORY SYSTEM							
.	.	.	.	TIOTROPIUM							
.	.	.	.	COPD							

Listing 16 (52 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200111	GEL	Male	73	ADRENALIN 0,05%	6NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	6NOV2018					
.	.	.	.	EPINEPHRINE						
.	.	.	.	PUPIL-DILATION						
.	.	.	.	ALKALA N	UNK	YES	3	gr	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	ALKALA N						
.	.	.	.	HEARTBURN						
.	.	.	.	ALLOPORINOL	UNK	YES	100	mg	ONCE	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	ALLOPURINOL						
.	.	.	.	GOUT						
.	.	.	.	ALPHALIPONSÄURE	UNK	YES	600	mg	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	THIOCTIC ACID						
.	.	.	.	INDISPOSITION						
.	.	.	.	BASOSYX	UNK	YES	432,5	mg	TWICE PER DAY	ORAL
.	.	.	.	VARIOUS						
.	.	.	.	GENERAL NUTRIENTS						
.	.	.	.	ACID-BASE-BALANCE						
.	.	.	.	CANDERSATAN	2017	YES	16	mg	TWICE PER DAY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CANDESARTAN						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	CEFUROXIME	6NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	6NOV2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						



Listing 16 (53 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200111	GEL	Male	73	CORNEREGEL	6NOV2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	6NOV2018					
.	.	.	.	DEXPANTHENOL						
.	.	.	.	FOREIGN BODY SENSATION						
.	.	.	.	DORMICUM	6NOV2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	6NOV2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	GRANUFINK	UNK	YES	500	mg	ONCE	ORAL
.	.	.	.	VARIOUS						
.	.	.	.	CUCURBITA PEPO						
.	.	.	.	BLADDER DISCOMFORT						
.	.	.	.	PANTOPRAZOL	UNK	YES	20	mg	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	PANTOPRAZOLE						
.	.	.	.	STOMACH PAIN						
.	.	.	.	PHENYLEPHRIN-TROPICAMID	7NOV2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	7NOV2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	PUPIL-DILATION						
.	.	.	.	Q 10 SANOMIT	UNK	YES	4	ml	4 TIMES PER DAY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	UBIDECARENONE						
.	.	.	.	Q10 DEFICIENCY						
.	.	.	.	TIMOLOL 0,5%	6NOV2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	6NOV2018					
.	.	.	.	TIMOLOL						
.	.	.	.	IOP REDUCTION						
.	.	.	.	VITAMIN B12	UNK	YES	1	ml	AS NEEDED	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	HYDROXOCOBALAMIN						
.	.	.	.	VITAMIN B12 DEFICIENCY						

Listing 16 (54 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200111	GEL	Male	73	XYLONEST	6NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	6NOV2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	ANESTHESIA						

Listing 16 (55 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200112	DROP	Male	85	CEFUROXIME	13NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	13NOV2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	13NOV2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	13NOV2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	HYLO PARIN EYE DROPS	30NOV2018		1	Drop	AS NEEDED	OCULAR
.	.	.	.	SENSORY ORGANS	5DEC2018					
.	.	.	.	HYLO PARIN						
.	.	.	.	FOREIGN BODY SENSATION, AS NEEDED MEANS 5 TIMES /D Y						
.	.	.	.	LISILICH COMP	2006	YES	20	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CARACE PLUS						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	PHENYLEPHRIN-TROPICAMID	14NOV2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	14NOV2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	PUPIL-DILATION						
.	.	.	.	XYLONEST 1%	13NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	13NOV2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	ANESTHESIA						

Listing 16 (56 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200113	DROP	Male	77	ASS 100	2013	YES	100	mg	ONCE	ORAL
.	.	.	.	BLOOD AND BLOOD FORMING ORGANS						
.	.	.	.	ACETYLSALICYLIC ACID						
.	.	.	.	CIRCULATORY DISORDER						
.	.	.	.	ATORVASTATIN	UNK	YES	10	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	ATORVASTATIN						
.	.	.	.	CHOLESTEROL						
.	.	.	.	CEFUROXIME	13NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	13NOV2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	13NOV2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	13NOV2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	ESCITALOPRAM	20OCT2017	YES	5	mg	ONCE	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	ESCITALOPRAM						
.	.	.	.	DEPRESSION						
.	.	.	.	FLOXAL	21NOV2018		1	Drop	3 TIMES PER DAY	TRANSDERMAL
.	.	.	.	SENSORY ORGANS	28DEC2018					
.	.	.	.	OFLOXACIN						
.	.	.	.	HORDEOLUM						

Listing 16 (57 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200113	DROP	Male	77	OLANZAPIN	DEC2017	YES	2,5	mg	TWICE PER DAY	ORAL	
.	.	.	.	NERVOUS SYSTEM							
.	.	.	.	OLANZAPINE							
.	.	.	.	DEPRESSION							
.	.	.	.	PHENYLEPHRIN-TROPICAMID	13NOV2018		2	Drops	ONCE	OCULAR	
.	.	.	.	SENSORY ORGANS	13NOV2018						
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE							
.	.	.	.	PUPIL-DILATION							
.	.	.	.	PHENYLEPHRIN-TROPICAMID	14NOV2018		1	Drop	ONCE	OCULAR	
.	.	.	.	SENSORY ORGANS	14NOV2018						
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE							
.	.	.	.	PUPIL-DILATION							
.	.	.	.	XYLONEST	13NOV2018		1	ml	ONCE	OCULAR	
.	.	.	.	NERVOUS SYSTEM	13NOV2018						
.	.	.	.	PRILOCAINE							
.	.	.	.	ANESTHESIA							

Listing 16 (58 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200114	DROP	Female	64	ALLOPURINOL	2008	YES	100	mg	ONCE	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	ALLOPURINOL						
.	.	.	.	GOUT						
.	.	.	.	AMLODIPIN	2008	YES	10	mg	TWICE PER DAY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	AMLODIPINE						
.	.	.	.	HIGH BLOODPRESSURE						
.	.	.	.	CEFUROXIME	27NOV2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	27NOV2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DEXAGEL	27NOV2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	27NOV2018					
.	.	.	.	DEXAMETHASONE						
.	.	.	.	ANTIFLAMATORY						
.	.	.	.	DORMICUM	27NOV2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	27NOV2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	HYDROCHLOROTIAZID	2008	YES	25	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	HYDROCHLOROTHIAZIDE						
.	.	.	.	HIGH BLOODPRESSURE						

Listing 16 (59 of 64): Concomitant treatments

=====											
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route	
Code	drug	Sex	(year)								
=====											
200114	DROP	Female	64	METFORMINHYDROCHLORID	2015	YES	1000	mg	TWICE PER DAY	ORAL	
.	.	.	.	ALIMENTARY TRACT AND METABOLISM							
.	.	.	.	METFORMIN							
.	.	.	.	DIABETIS MELLITUS							
.	.	.	.	METOPROLOL	2008	YES	200	mg	TWICE PER DAY	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	METOPROLOL							
.	.	.	.	HIGH BLOODPRESSURE							
.	.	.	.	PHENYLEPHRIN-TROPICAMID	28NOV2018		1	Drop	ONCE	OCULAR	
.	.	.	.	SENSORY ORGANS	28NOV2018						
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE							
.	.	.	.	PUPIL-DILATION							
.	.	.	.	RAMIPRIL	2008	YES	5	mg	TWICE PER DAY	ORAL	
.	.	.	.	CARDIOVASCULAR SYSTEM							
.	.	.	.	RAMIPRIL							
.	.	.	.	ARTERIAL HYPERTENSION							
.	.	.	.	SITAGUPTIN	2015	YES	50	mg	TWICE PER DAY	ORAL	
.	.	.	.	ALIMENTARY TRACT AND METABOLISM							
.	.	.	.	SITAGLIPTIN							
.	.	.	.	DIABETIS MELLITUS							
.	.	.	.	XYLONEST	27NOV2018		1	ml	ONCE	OCULAR	
.	.	.	.	NERVOUS SYSTEM	27NOV2018						
.	.	.	.	PRILOCAINE							
.	.	.	.	ANESTHESIA							

Listing 16 (60 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200115	GEL	Female	70	ADRENALIN	18DEC2018		1	ml	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	18DEC2018					
.	.	.	.	EPINEPHRINE						
.	.	.	.	DILATION						
.	.	.	.	CEFUROXIME	18DEC2018		1	ml	ONCE	OCULAR
.	.	.	.	ANTIINFECTIVES FOR SYSTEMIC USE	18DEC2018					
.	.	.	.	CEFUROXIME						
.	.	.	.	ANTIBIOTIC						
.	.	.	.	DORMICUM	18DEC2018		1,5	mg	ONCE	INTRAVENOUS
.	.	.	.	NERVOUS SYSTEM	18DEC2018					
.	.	.	.	NITRAZEPAM						
.	.	.	.	SEDATION						
.	.	.	.	NOVAMINSULFON	2017	YES	500	mg	TWICE PER DAY	ORAL
.	.	.	.	NERVOUS SYSTEM						
.	.	.	.	METAMIZOLE						
.	.	.	.	ANALGESICS						
.	.	.	.	PANTOPRACOL	2012	YES	40	mg	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	PANTOPRAZOLE						
.	.	.	.	REFLUX ESOPHAGITIS						
.	.	.	.	PEHYLEPHRINTROPICAMID	18DEC2018		2	Drops	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	18DEC2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	DILATION						



Listing 16 (61 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200115	GEL	Female	70	PHENYLEPHRINTROPICAMID	19DEC2018		1	Drop	ONCE	OCULAR
.	.	.	.	SENSORY ORGANS	19DEC2018					
.	.	.	.	PHENYLEPHRINE W/TROPICAMIDE						
.	.	.	.	DILATION						
.	.	.	.	XYLONEST	18DEC2018		1	ml	ONCE	OCULAR
.	.	.	.	NERVOUS SYSTEM	18DEC2018					
.	.	.	.	PRILOCAINE						
.	.	.	.	ANESTHESIA						

Listing 16 (62 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200202	DROP	Female	71	L-THYROXIN	2005	YES	75	microgram	DAILY	ORAL
.	.	.	.	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONE						
.	.	.	.	LEVOTHYROXINE						
.	.	.	.	THYROIDITIS						
.	.	.	.	MYDRUM (TROPICAMIDE)	18JUN2018		5	mg/ml	UNKNOWN	OCULAR
.	.	.	.	SENSORY ORGANS	18JUN2018					
.	.	.	.	TROPICAMIDE						
.	.	.	.	MYDRIATIC DRUG FOR OPERATION PREPARATION						
.	.	.	.	DICLOFENAC OPHTA SINE	6JUL2018		1	mg/ml	4 TIMES PER DAY	OCULAR
.	.	.	.	SENSORY ORGANS	24JUL2018					
.	.	.	.	DICLOFENAC						
.	.	.	.	CONJUNCTIVA HYPEREMIA						

Listing 16 (63 of 64): Concomitant treatments

=====										
Sbj	Study		Age	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
Code	drug	Sex	(year)							
=====										
200203	GEL	Male	66	BISOPROLOL	MAY2017	YES	2.5	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	BISOPROLOL						
.	.	.	.	ARTERIAL HYPERTENSION						
.	.	.	.	MYDRUM (TROPICAMIDE)	26JUN2018		unknown	drop	UNKNOWN	OCULAR
.	.	.	.	SENSORY ORGANS	26JUN2018					
.	.	.	.	TROPICAMIDE						
.	.	.	.	MYDRIATIC DRUG FOR PREPARATION						
.	.	.	.	COSOPT S	26JUN2018		unknown	drop	TWICE PER DAY	OCULAR
.	.	.	.	SENSORY ORGANS	27JUN2018					
.	.	.	.	COSOPT						
.	.	.	.	HIGH INTRAOCULAR PRESSURE (POSTOPERATIVE)						
.	.	.	.	BISOPROLOL	23AUG2018		5	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	23AUG2018					
.	.	.	.	BISOPROLOL						
.	.	.	.	NAUSEA/INCREASE OF BLOOD PRESSURE						
.	.	.	.	PANTOZOL	23AUG2018		40	mg	ONCE	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM	23AUG2018					
.	.	.	.	PANTOPRAZOLE						
.	.	.	.	HEARTBURN						
.	.	.	.	METOCLOPRAMID	3SEP2018	YES	20	drop	3 TIMES PER DAY	ORAL
.	.	.	.	ALIMENTARY TRACT AND METABOLISM						
.	.	.	.	METOCLOPRAMIDE						
.	.	.	.	HEARTBURN						
.	.	.	.	BISOPROLOL	25AUG2018		5	mg	ONCE	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM	25AUG2018					
.	.	.	.	BISOPROLOL						
.	.	.	.	NAUSEA/INCREASE OF BLOOD PRESSURE						

Sbj Code	Study drug	Sex	Age (year)	Reported term/ Therapeutic area/ Preferred term/ Indication	Start date/ End date	Ongoing	Dose	Units	Freq.	Route
200204	GEL	Male	58	HYGROTON (CHLORTALIDON)	2008	YES	25	mg	DAILY	ORAL
.	.	.	.	CARDIOVASCULAR SYSTEM						
.	.	.	.	CHLORTALIDONE						
.	.	.	.	HYPERTENSION						
.	.	.	.	ALLOPURINOL (ALLOPURINOL)	2008	YES	150	mg	DAILY	ORAL
.	.	.	.	MUSCULO-SKELETAL SYSTEM						
.	.	.	.	ALLOPURINOL						
.	.	.	.	HYPERURICEMIA						
.	.	.	.	MYDRUM (TROPICAMIDE)	3JUL2018		5	mg/ml	UNKNOWN	OCULAR
.	.	.	.	SENSORY ORGANS	3JUL2018					
.	.	.	.	TROPICAMIDE						
.	.	.	.	MYDRIATIC DRUG FOR OPERATION PREPARATION						

SAS program: L03\_List\_16.sas - SAS dataset name(s): RAND,DEMOGRAPHY,CMED\_COD

Listing 17 (1 of 6): Adverse events

Sbj code	Study drug	Sex	Age (year)	
100103		Female	70	<p>Reported term: IPERSENSIBILITY TO PRE-OPERATIVE BROMFENAC</p> <p>System Organ Class: Immune system disorders</p> <p>Preferred term : Drug hypersensitivity</p> <p>Start date: 28OCT2017</p> <p>End date: 28OCT2017</p> <p>SAE: NO</p> <p>Severity: MILD</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: OTHER</p> <p>SUSPENSION OF BROMFENAC ADMINISTRATION</p> <p>Outcome: COMPLETELY RECOVERY</p>
100313	GEL	Male	71	<p>Reported term: BREAKAGE POSTERIORE CAPSULE</p> <p>System Organ Class: Eye disorders</p> <p>Preferred term : Posterior capsule rupture</p> <p>Start date: 04DEC2017</p> <p>End date: 04DEC2017</p> <p>SAE: NO</p> <p>Severity: MODERATE</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: PRODUCT WITHDRAWAN</p> <p>Other action taken: CONCOMITANT THERAPY</p> <p>OTHER THERAPY (DIAMOX AND VIGAMOX)</p> <p>Outcome: COMPLETELY RECOVERY</p>
100337	GEL	Male	72	<p>Reported term: BREAKAGE OF THE POSTERIOR CAPSULE</p> <p>System Organ Class: Eye disorders</p> <p>Preferred term : Posterior capsule rupture</p> <p>Start date: 16MAR2018</p> <p>End date: 16MAR2018</p> <p>SAE: NO</p> <p>Severity: MILD</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: OTHER</p> <p>THE PAZ DECIDES NOT TO CONTINUE THE STUDY</p> <p>Outcome: COMPLETELY RECOVERY</p>

Listing 17 (2 of 6): Adverse events

Sbj	Study	Age	
code	drug	Sex	(year)
Preferred term : Intraocular pressure increased			
Start date: 17JAN2018			
End date: 18JAN2018			
SAE: NO			
Severity: MILD			
Study drug relat.: UNRELATED			
Action taken with study drug: NONE			
Other action taken: CONCOMITANT THERAPY			
Outcome: COMPLETELY RECOVERY			
200103	DROP	Male	82
Reported term: FOREIGN BODY FEELING IN THE LEFT EYE			
System Organ Class: Eye disorders			
Preferred term : Foreign body sensation in eyes			
Start date: 14MAR2018			
End date: 28MAR2018			
SAE: NO			
Severity: MILD			
Study drug relat.: UNRELATED			
Action taken with study drug: NONE			
Other action taken: CONCOMITANT THERAPY			
TEAR SUSTITUTE GIVEN			
Outcome: COMPLETELY RECOVERY			
200103	DROP	Male	82
Reported term: MAKULA EDEMA IN THE RIGHT EYE			
System Organ Class: Eye disorders			
Preferred term : Macular oedema			
Start date: 28MAR2018			
End date: 16APR2018			
SAE: YES			
Severity: MILD			
Study drug relat.: UNRELATED			
Action taken with study drug: NONE			
Other action taken: CONCOMITANT THERAPY			
NEVANAC GIVEN			
Outcome: COMPLETELY RECOVERY			

Listing 17 (3 of 6): Adverse events

Sbj code	Study drug	Sex	Age (year)	
200107	DROP	Female	54	<p>Reported term: ALLERGICAL REACTION ON STUDY MEDICATION System Organ Class: Immune system disorders Preferred term : Drug hypersensitivity</p> <p>Start date: 03JUL2018 End date: 05JUL2018 SAE: NO Severity: MODERATE Study drug relat.: POSSIBLY Action taken with study drug: PRODUCT WITHDRAWAN Other action taken: OTHER DEXAPOS AND DEXAGEL PRESCRIBED Outcome: COMPLETELY RECOVERY</p>
200109	GEL	Female	84	<p>Reported term: IRRITATION WITH FIBRIN REACTION System Organ Class: Injury, poisoning and procedural complications Preferred term : Fibrin deposition on lens postoperative</p> <p>Start date: 03OCT2018 End date: 10OCT2018 SAE: NO Severity: MODERATE Study drug relat.: UNLIKELY Action taken with study drug: PRODUCT WITHDRAWAN Other action taken: OTHER LOCAL CORTICOSTEROID GIVEN, HOURLY Outcome: COMPLETELY RECOVERY</p>
200110	DROP	Male	64	<p>Reported term: VASCULAR OCCLUSION System Organ Class: Vascular disorders Preferred term : Vascular occlusion</p> <p>Start date: 17OCT2018 End date: 09DEC2018 SAE: YES Severity: SEVERE Study drug relat.: UNRELATED Action taken with study drug: NONE Other action taken: OTHER PLANNED HOSPITALISATION FOR DIAGNOSTICS FOT THE 19-OCT-2018, PREDNIPOS PRESCRIBED Outcome: COMPLETELY RECOVERY</p>

Listing 17 (4 of 6): Adverse events

Sbj code	Study drug	Sex	Age (year)	
200111	GEL	Male	73	<p>Reported term: FOREIGN BODY SENSATION</p> <p>System Organ Class: Eye disorders</p> <p>Preferred term : Foreign body sensation in eyes</p> <p>Start date: 06NOV2018</p> <p>End date: 07NOV2018</p> <p>SAE: NO</p> <p>Severity: MODERATE</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: CONCOMITANT THERAPY CORNREGEL PRN</p> <p>Outcome: COMPLETELY RECOVERY</p>
200111	GEL	Male	73	<p>Reported term: INCREASED IOP</p> <p>System Organ Class: Investigations</p> <p>Preferred term : Intraocular pressure increased</p> <p>Start date: 06NOV2018</p> <p>End date: 07NOV2018</p> <p>SAE: NO</p> <p>Severity: MODERATE</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: CONCOMITANT THERAPY ADDITIONAL EYE DROPS TO LOWER DOWN THE IOP</p> <p>Outcome: COMPLETELY RECOVERY</p>
200112	DROP	Male	85	<p>Reported term: PAINFULL BODY SENSATION IN LEFT EYE</p> <p>System Organ Class: Eye disorders</p> <p>Preferred term : Eye pain</p> <p>Start date: 30NOV2018</p> <p>End date: 05DEC2018</p> <p>SAE: NO</p> <p>Severity: MILD</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: CONCOMITANT THERAPY HYLO PARIN EYE DROPS</p> <p>Outcome: COMPLETELY RECOVERY</p>



Listing 17 (5 of 6): Adverse events

Sbj code	Study drug	Sex	Age (year)	
200113	DROP	Male	77	<p>Reported term: HORDEOLUM</p> <p>System Organ Class: Infections and infestations</p> <p>Preferred term : Hordeolum</p> <p>Start date: 21NOV2018</p> <p>End date: 28DEC2018</p> <p>SAE: NO</p> <p>Severity: MILD</p> <p>Study drug relat.: UNRELATED</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: CONCOMITANT THERAPY</p> <p>FLOXAL 3 TIMES PER DA</p> <p>Outcome: COMPLETELY RECOVERY</p>
200202	DROP	Female	71	<p>Reported term: CONJUNCTIVA HYPEREMIA</p> <p>System Organ Class: Eye disorders</p> <p>Preferred term : Conjunctival hyperaemia</p> <p>Start date: 06JUL2018</p> <p>End date: .</p> <p>SAE: NO</p> <p>Severity: MILD</p> <p>Study drug relat.: UNLIKELY</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: CONCOMITANT THERAPY</p> <p>DICLOFENAC EYEDROPS</p> <p>Outcome: PERSISTENT</p>
200203	GEL	Male	66	<p>Reported term: HIGH INTRAOCULAR PRESSURE (POSTOPERATIVE)</p> <p>System Organ Class: Investigations</p> <p>Preferred term : Intraocular pressure increased</p> <p>Start date: 26JUN2018</p> <p>End date: 27JUN2018</p> <p>SAE: NO</p> <p>Severity: MILD</p> <p>Study drug relat.: UNLIKELY</p> <p>Action taken with study drug: NONE</p> <p>Other action taken: CONCOMITANT THERAPY</p> <p>TOPICAL ADMINISTRATTION OF COSOPT D GTT</p> <p>Outcome: COMPLETELY RECOVERY</p>

Listing 17 (6 of 6): Adverse events

```
=====
Sbj      Study      Age
code    drug    Sex  (year)
=====
200203 GEL      Male    66      Reported term: NAUSEA
                                System Organ Class: Gastrointestinal disorders
                                Preferred term : Nausea

                                Start date: 23AUG2018
                                End date: 25AUG2018
                                SAE: NO
                                Severity: MILD
                                Study drug relat.: UNLIKELY
                                Action taken with study drug: NONE
                                Other action taken: CONCOMITANT THERAPY
                                Outcome: COMPLETELY RECOVERY
-----
200203 GEL      Male    66      Reported term: INCREASE OF BLOOD PRESSURE
                                System Organ Class: Investigations
                                Preferred term : Blood pressure increased

                                Start date: 23AUG2018
                                End date: 25AUG2018
                                SAE: NO
                                Severity: MILD
                                Study drug relat.: UNLIKELY
                                Action taken with study drug: NONE
                                Other action taken: CONCOMITANT THERAPY
                                Outcome: COMPLETELY RECOVERY
-----
200203 GEL      Male    66      Reported term: HEARTBURN
                                System Organ Class: Gastrointestinal disorders
                                Preferred term : Dyspepsia

                                Start date: 23AUG2018
                                End date: .
                                SAE: NO
                                Severity: MODERATE
                                Study drug relat.: UNLIKELY
                                Action taken with study drug: NONE
                                Other action taken: CONCOMITANT THERAPY
                                Outcome: PERSISTENT
=====
SAS program: L03_List_17.sas - SAS dataset name(s): RAND,DEMOGRAPHY,AE_COD
```

Sbj Code	Study drug	Sex	Age (year)	Adverse event	Concomitant medication	Other	If OTHER, specify
100302	GEL	Male	61	.	.	Yes	STINGING
100335	DROP	Female	80	.	.	Yes	CLINICAL DECISION
100354	GEL	Female	80	.	.	Yes	CONJUNCTIVAL HYPEREMIA
200101	GEL	Female	66	Yes	Yes	.	
200103	DROP	Male	82	Yes	.	Yes	TEAR SUBSTITUTE
200111	GEL	Male	73	Yes	Yes	Yes	FOREIGN BODY SENSATION
200112	DROP	Male	85	Yes	Yes	.	
200202	DROP	Female	71	Yes	Yes	.	

SAS program: L03\_List\_18.sas - SAS dataset name(s): RAND,DEMOGRAPHY,UNS\_REAS